RESULT_COUNT: 1927,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
BIIB,BIIB:UW,BBG000C18861,Biogen Stock: Performance in 3Q17,2017-10-20 22:06:33 +0000,http://finance.yahoo.com/r/724bc196-648d-3cc2-bdf5-76807f48de30/biogen-stock-performance-in-3q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Biogen stock has risen ~15.4% in 3Q17, while it has risen ~31.1% year-to-date as of October 20, 2017."
BIIB,BIIB:UW,BBG000C18861,iShares U.S. Healthcare ETF Experiences Big Inflow,2017-10-20 16:02:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OF0xHcg09LQ/ishares-us-healthcare-etf-experiences-big-inflow-cm862600,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares U S Healthcare ETF Symbol IYH where we have detected an approximate 52 8 million dollar inflow that s a 2 4 increase week over week in
BIIB,BIIB:UW,BBG000C18861,"Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna",2017-10-19 13:19:01 +0000,https://finance.yahoo.com/news/zacks-market-edge-highlights-gilead-131901931.html?.tsrc=rss,"Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna"
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?,2017-10-18 13:33:01 +0000,https://finance.yahoo.com/news/biogen-biib-q3-earnings-deliver-133301308.html?.tsrc=rss,"At Biogen&apos;s (BIIB) Q3 call, investor focus will remain on Tecfidera&apos;s scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza&apos;s performance in the same quarter."
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-10-18 12:05:55 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120555620.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug",2017-10-18 11:32:11 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-exelixis-soars-113211834.html?.tsrc=rss,Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.
BIIB,BIIB:UW,BBG000C18861,Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach,2017-10-18 11:30:00 +0000,https://finance.yahoo.com/news/biogen-confirms-commitment-tackle-multiple-113000634.html?.tsrc=rss,Biogen confirms its comprehensive approach to tackle multiple sclerosis at the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment and Research in MS .
BIIB,BIIB:UW,BBG000C18861,Biogen’s stock gets a big boost from 2 upgrades a week before earnings,2017-10-18 11:13:01 +0000,http://finance.yahoo.com/r/40f402a1-8580-3ffe-a033-e6967a4ed80f/Story.aspx?guid=A168F668-B35E-11E7-B0C9-1C5A1993B863&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Biogen’s stock rallies to 2-year high after two analysts raise their ratings to buy and their price targets to at least $400.
BIIB,BIIB:UW,BBG000C18861,Biogen Could Rise 20% on Healthy Outlook,2017-10-18 10:00:00 +0000,http://finance.yahoo.com/r/cddc9372-25d9-3ca2-8c7b-9da50ac8b4be/biogen-could-rise-20-healthy-outlook?partner=YahooSA&yptr=yahoo&.tsrc=rss,Biogen shares were buoyed by strong revenue and earnings forecasts.
BIIB,BIIB:UW,BBG000C18861,Where to Find Value in Healthcare Stocks,2017-10-17 23:33:11 +0000,https://finance.yahoo.com/news/where-value-healthcare-stocks-233311502.html?.tsrc=rss,"The Biotech stocks have been on a big run in 2017, but that doesn&apos;t mean there aren&apos;t some healthcare values still out there."
BIIB,BIIB:UW,BBG000C18861,"Tuesday Sector Leaders: Healthcare, Utilities",2017-10-17 19:49:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vJK5h8nkGuo/tuesday-sector-leaders-healthcare-utilities-cm860921,The best performing sector as of midday Tuesday is the Healthcare sector higher by 0 5 Within the sector Johnson amp Johnson Symbol JNJ and Biogen Inc Symbol BIIB are two of the day s stand outs showing a gain of 3 5 and 3 2 respectively Among healthcare ETFs one ETF
BIIB,BIIB:UW,BBG000C18861,"Dow pierces 23,000 as earnings boost the blue chips higher",2017-10-17 19:44:26 +0000,https://finance.yahoo.com/news/dow-pierces-23000-earnings-boost-blue-chips-higher-194426527.html?.tsrc=rss,"The Dow (^DJI) pierces 23,000 after strong earnings beats by UnitedHealth (UNH) and Johnson & Johnson (JNJ), but quickly retreats and settles into a low volume trading range for the balance of the day.  Plus, Gary Cohn speaks to Yahoo Finance in Washington, D.C. The president’s chief economist tells us what’s open for negotiation and what’s not.  Plus, our prophecy for posterity — or as we usually call it, the look ahead — for everything you need to know about tomorrow with your favorite interlocutor. Catch The Final Round at 3:55 p.m. with Jen Rogers and Yahoo Finance’s Myles Udland and Dan Roberts."
BIIB,BIIB:UW,BBG000C18861,Stock Indexes Up Slightly; Trump Threatens Drug Firms,2017-10-17 17:51:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/keBZBMo8p6k/stock-indexes-up-slightly-trump-threatens-drug-firms-cm860855,U S stock indexes were mixed in midday action Tuesday as health insurance provider UnitedHealth UNH kept the blue chip Dow at the front of the pack The 160 Nasdaq was flat while the S amp P 500 was just under the break even line The Dow Jones industrial average
BIIB,BIIB:UW,BBG000C18861,Two positive calls on this biotech name,2017-10-17 17:37:00 +0000,https://finance.yahoo.com/video/two-positive-calls-biotech-name-173700105.html?.tsrc=rss,Stifel & Mizuho upgraded Biogen to a &quot;buy.&quot; The desk debates the calls.
BIIB,BIIB:UW,BBG000C18861,"Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments",2017-10-17 16:51:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DBQ9yp-bH-A/biogen-biomarkers-mark-way-to-alzheimers-parkinsons-treatments-cm859978,Biogen BIIB continues to drive innovation in neuroscience using biomarkers biological mechanisms and other cutting edge technologies to develop therapies to fight some of the toughest to treat diseases including MS ALS Parkinson s and Alzheimer s ibd display
BIIB,BIIB:UW,BBG000C18861,"Biogen Biomarkers Mark Way To Alzheimer&apos;s, Parkinson&apos;s Treatments",2017-10-17 15:55:37 +0000,http://finance.yahoo.com/r/557a4978-3d2d-344e-82f6-ce8791dbcb4e/biogen-biomarkers-mark-way-to-alzheimers-parkinsons-treatments?src=A00220&yptr=yahoo&.tsrc=rss,"Biogen eyes therapies for Parkinson&apos;s, Alzheimer&apos;s and more using biomarkers, biological mechanisms and other cutting-edge technologies."
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: STX, ULTA",2017-10-17 15:51:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JM-7-zp8Sso/nasdaq-100-movers-stx-ulta-cm860592,In early trading on Tuesday shares of Ulta Beauty ULTA topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 8 Year to date Ulta Beauty has lost about 21 2 of its value And the worst performing Nasdaq 100 component thus far on the day
BIIB,BIIB:UW,BBG000C18861,Should You Expect Biogen Inc (BIIB) To Continue Delivering An ROE Of 28.62%?,2017-10-17 15:51:28 +0000,https://finance.yahoo.com/news/expect-biogen-inc-biib-continue-155128478.html?.tsrc=rss,"With an ROE of 28.62%, Biogen Inc (NASDAQ:BIIB) outpaced its own industry which delivered a less exciting 15.86% over the past year. While the impressive ratio tells us that BIIBRead More..."
BIIB,BIIB:UW,BBG000C18861,"Goldman, Morgan Stanley Gain on Earnings; Spirit Airlines Flies",2017-10-17 13:49:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_Glln1iQ9kk/goldman-morgan-stanley-gain-on-earnings-spirit-airlines-flies-cm860483,Stocks are mixed this morning following earnings from Goldman Sachs GS UnitedHealth Group UNH and others Industrial production rose 0 3 in September meeting economist forecasts Stocks are mixed this morning following earnings fromGoldman SachsGoldman Sachs GS
BIIB,BIIB:UW,BBG000C18861,3 Drug Stocks Hitting 52-Week Highs: Are They Buys?,2017-10-17 11:32:00 +0000,https://finance.yahoo.com/news/3-drug-stocks-hitting-52-113200004.html?.tsrc=rss,2017 has been a great year for these drug stocks. But will their momentum taper off?
BIIB,BIIB:UW,BBG000C18861,Trump Likely To Sign Executive Order On Drug Pricing 'Any Day',2017-10-16 20:19:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CFykqmQ0Fio/trump-likely-to-sign-executive-order-on-drug-pricing-any-day-cm860295,Biotech stocks collectively inched down Monday after President Donald Trump reiterated his concerns that U S drug prices are out of control during a Cabinet meeting according to a number of reports ibd display video id 2368152 width 50 float left autostart true The president
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Monday Option Activity: FCX, BMY, BIIB",2017-10-16 19:15:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7NsuLbCZ7Y/noteworthy-monday-option-activity-fcx-bmy-biib-cm860263,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Freeport McMoran Copper amp Gold Symbol FCX where a total volume of 75 338 contracts has been traded thus far today a contract volume which is representative
BIIB,BIIB:UW,BBG000C18861,[$$] More Biotechs That Can Beat Q3 Views,2017-10-16 16:01:00 +0000,http://finance.yahoo.com/r/ee7873e5-56d9-3c93-86ec-6c7cabd0bc86/more-biotechs-that-can-beat-q3-views-1508166789?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates.  Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website."
BIIB,BIIB:UW,BBG000C18861,BIIB Crosses Above Average Analyst Target,2017-10-16 14:17:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dTnKgtfwzSg/biib-crosses-above-average-analyst-target-cm860064,In recent trading shares of Biogen Inc Symbol BIIB have crossed above the average analyst 12 month target price of 334 39 changing hands for 337 64 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation or re
BIIB,BIIB:UW,BBG000C18861,IBD Biotech Innovator Awards,2017-10-16 13:17:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kHgIl9n9Ak8/ibd-biotech-innovator-awards-cm859972,Investor s Business Daily has created the IBD Biotech Innovator Awards to recognize leading companies with groundbreaking treatments already on the market or close to final approvals Recipients of the inaugural awards are Celgene CELG Biogen BIIB
BIIB,BIIB:UW,BBG000C18861,6 Top Biotech Companies In Innovation Earn Recognition In New Awards,2017-10-16 12:01:09 +0000,http://finance.yahoo.com/r/6c7c83e3-cdcb-3b9b-a44f-7114dc6f5297/top-biotech-companies-innovation-6-biotech-stocks-recognized?src=A00220&yptr=yahoo&.tsrc=rss,Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
BIIB,BIIB:UW,BBG000C18861,Why These Biotech Players Look Poised To Crush Earnings Views,2017-10-13 22:16:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uYjC4ojl3iY/why-these-biotech-players-look-poised-to-crush-earnings-views-cm859687,Biogen BIIB Gilead Sciences GILD and Sarepta Therapeutics SRPT will build on momentum in the biotech sphere to beat Wall Street expectations for the third quarter an analyst predicted Friday ibd display video id 2359800 width 50 float
BIIB,BIIB:UW,BBG000C18861,"It's Friday the 13th, and these are 4 freaky good stocks ...",2017-10-13 21:25:00 +0000,https://finance.yahoo.com/video/friday-13th-4-freaky-good-212500541.html?.tsrc=rss,"The “Fast Money” traders share their final trades for the day including Viacom, Biogen, Square and McDonald's."
BIIB,BIIB:UW,BBG000C18861,"Stocks Up, Apple Ripe For A New Base: Will These 3 Growth Stocks Break Out?",2017-10-13 19:11:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/igtRiRkqoPs/stocks-up-apple-ripe-for-a-new-base-will-these-3-growth-stocks-break-out-cm859591,Major stock indexes staged mild gains in afternoon trading Friday as the Nasdaq composite looked poised for a third up week in a row Apple AAPL helped the cause rising more than 0 5 to 156 80 and inching ever closer to its rising 50 day moving average ibd display
BIIB,BIIB:UW,BBG000C18861,This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due,2017-10-13 15:40:46 +0000,http://finance.yahoo.com/r/26bbcb54-ea1d-3626-9031-2cf82e4cde12/top-medical-research-stock-pra-health-tests-buy-zone?src=A00220&yptr=yahoo&.tsrc=rss,Clinical research firm PRA Health Sciences is testing a new breakout move.
BIIB,BIIB:UW,BBG000C18861,Can Biotech Stay Healthy Through the End of 2017?,2017-10-13 15:18:00 +0000,http://finance.yahoo.com/r/f0e2b67c-041c-3d44-8a0a-4340fd54c1a8/can-biotech-stay-healthy-through-the-end-of-2017-1507907924?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year.  Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter.  Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a ""solid"" quarter from Bioverativ (BIVV) as well, and will also be  focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise."
BIIB,BIIB:UW,BBG000C18861,"Celgene, Biogen Are Poised to Break Out: A Technical View",2017-10-12 10:00:00 +0000,http://finance.yahoo.com/r/36734f30-43ee-3d77-a985-4c6700482d52/celgene-biogen-are-poised-break-out-technical-view?partner=YahooSA&yptr=yahoo&.tsrc=rss,"After a period of consolidation, the biotech sector is set to rise again based on technical analysis."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Amgen&apos;s Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit",2017-10-11 12:07:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-amgen-apos-120712520.html?.tsrc=rss,"With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi&apos;s win in the PCSK9 litigation."
BIIB,BIIB:UW,BBG000C18861,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 14:01:02 +0000,https://finance.yahoo.com/news/5-pharma-biotech-stocks-could-140102820.html?.tsrc=rss,Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Celgene,2017-10-10 11:37:00 +0000,http://finance.yahoo.com/r/794f27e7-d74b-327e-a833-c638d152b421/better-buy-biogen-inc-vs-celgene.aspx?yptr=yahoo&.tsrc=rss,Which one of these large-cap biotech stocks looks like a better pick right now?
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Celgene,2017-10-10 11:37:00 +0000,https://finance.yahoo.com/news/better-buy-biogen-inc-vs-113700187.html?.tsrc=rss,Which one of these large-cap biotech stocks looks like a better pick right now?
BIIB,BIIB:UW,BBG000C18861,Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit,2017-10-09 15:55:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bONhV_b-vSg/emergent-biosolutions-acquires-sanofis-smallpox-vaccine-unit-cm857001,Emergent BioSolutions Inc EBS announced that it completed the acquisition of FDA licensed smallpox vaccine s business of Sanofi SNY ACAM2000 160 The company paid an upfront payment of 97 5 million and 20 million in milestone payments The deal also includes a potential milestone
BIIB,BIIB:UW,BBG000C18861,How Did Biogen Perform in 1H17?,2017-10-09 13:13:12 +0000,http://finance.yahoo.com/r/1e3002c0-10ab-370a-bd68-f7f13ab6bd35/how-did-biogen-perform-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Biogen (BIIB) generated revenues of ~$5.9 billion compared to $5.6 billion in 1H16."
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-10-09 12:04:13 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120413954.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB.  Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $6.14 billion."
BIIB,BIIB:UW,BBG000C18861,Analysts’ Recommendations for Biogen in October 2017,2017-10-09 11:43:47 +0000,http://finance.yahoo.com/r/a07d0540-f7e6-3773-884c-51f3cbded280/analysts-recommendations-for-biogen-in-october-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn't receive any “sell” ..."
BIIB,BIIB:UW,BBG000C18861,No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock,2017-10-06 22:55:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TWZDFp5rr5c/no-side-effects-to-this-bullish-trade-on-celgene-corporation-celg-stock-cm856576,InvestorPlace Stock Market News Stock Advice amp Trading Tips Yesterday Celgene Corporation NASDAQ CELG caught a downgrade and the stock fell 4 on the headline Money fled to Biogen Inc NASDAQ BIIB which caught the opposing upgrade Source Wikimedia
BIIB,BIIB:UW,BBG000C18861,5 Stocks to Buy As They Drive the Market Melt Up,2017-10-06 22:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SRsXay-euqo/5-stocks-to-buy-as-they-drive-the-market-melt-up-cm856546,InvestorPlace Stock Market News Stock Advice amp Trading Tips There s no other way to say this The market is in full melt up mode Everyday feels the same a low volume low volatility surge with minimal fuss or drama Is this what heaven feels like Source Shutterstock Still
BIIB,BIIB:UW,BBG000C18861,Intercept Dives Along With Ocaliva Prescriptions On FDA Warning,2017-10-06 21:41:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PAZ8yobg6_s/intercept-dives-along-with-ocaliva-prescriptions-on-fda-warning-cm856365,Intercept Pharmaceuticals ICPT toppled Friday on a report outlining a 25 dip in prescriptions of liver disease drug Ocaliva the week the Food and Drug Administration warned doctors of overdose related deaths ibd display video id 2327695 width 50 float
BIIB,BIIB:UW,BBG000C18861,"Notable Friday Option Activity: GDOT, BIIB, CRM",2017-10-06 20:43:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FDMC4xi82nY/notable-friday-option-activity-gdot-biib-crm-cm856461,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Green Dot Corp Symbol GDOT where a total of 1 903 contracts have traded so far representing approximately 190 300 underlying shares That amounts to about 47 7 of GDOT s
BIIB,BIIB:UW,BBG000C18861,Bernstein analyst breaks down his best biotech picks,2017-10-06 17:20:00 +0000,https://finance.yahoo.com/video/bernstein-analyst-breaks-down-best-172000371.html?.tsrc=rss,"Ronny Gal, Bernstein senior analyst, discusses his top biotech picks to buy ahead of earnings."
BIIB,BIIB:UW,BBG000C18861,Why Biogen and L Brands Rose on October 5,2017-10-06 17:06:00 +0000,http://finance.yahoo.com/r/2556accc-1e7f-3803-95ee-1f10042876ae/biogen-inc-l-brands-move-higher-october-5?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Biogen (BIIB) was one of the top gainers in the S&P 500 on October 5. After trading with mixed sentiment in the first three trading days of the week, Biogen opened higher on Thursday."
BIIB,BIIB:UW,BBG000C18861,Life (Science) Lessons: The Hows And Whos To Play Biotech,2017-10-06 15:09:49 +0000,https://finance.yahoo.com/news/life-science-lessons-hows-whos-150949582.html?.tsrc=rss,"Biotech is booming. After particularly rough endings to 2015 and 2016, iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has had “a rockstar of a year,” and the last two weeks, in particular, have ..."
BIIB,BIIB:UW,BBG000C18861,No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock,2017-10-06 13:37:37 +0000,https://finance.yahoo.com/news/no-side-effects-bullish-trade-133737087.html?.tsrc=rss,"Yesterday, Celgene Corporation (NASDAQ:CELG) caught a downgrade and the stock fell 4% on the headline.  To do this, I use CELG options instead of trading its underlying equity.  Click to Enlarge Fundamentally, Celgene is not cheap."
BIIB,BIIB:UW,BBG000C18861,[$$] Get Back Into Biogen,2017-10-06 11:59:00 +0000,http://finance.yahoo.com/r/ecf23d6c-becf-37e5-99ed-6f00934ea14a/get-back-into-biogen-1507291167?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biogen (BIIB:Nasdaq)  By Morgan Stanley ($314.92, Oct. 5, 2017) We are upgrading Biogen to Overweight from Equal-weight and raising the price target to $375 from $311, as we believe the base business is proving more durable than expected with Ocrevus share loss slower than expected.  Business development provides upside optionality while Alzheimer’s remains the key, must-own catalyst.  Biogen (BIIB) has been a complicated story with uncertainty about its base business, which is facing potential market share and pricing pressure offset by a Phase 3 Alzheimer’s catalyst that could make all its potential issues disappear."
BIIB,BIIB:UW,BBG000C18861,"Stocks Hold Gains As Microsoft, Amazon.com Aid The Nasdaq",2017-10-05 20:49:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jV-Md-H7Eus/stocks-hold-gains-as-microsoft-amazoncom-aid-the-nasdaq-cm855961,The stock market s morning advance stalled at midday but the main indexes were holding most of the day s gains in afternoon trading Thursday ibd display video id 2327695 width 50 float left autostart true The Nasdaq composite and S amp P 500 were an hour away from making it eight
BIIB,BIIB:UW,BBG000C18861,Netflix Breaks Out While Homebuilders Add To Rally,2017-10-05 19:30:25 +0000,http://finance.yahoo.com/r/ac3b19e0-4982-37f2-b883-d80b0dff498c/netflix-breaks-out-homebuilders-rally?src=A00220&yptr=yahoo&.tsrc=rss,Netflix made a record high Thursday as the stock broke out past a new buy point in energetic trading.
BIIB,BIIB:UW,BBG000C18861,"Catabasis' DMD Candidate Slows Disease Progression, Stock Up",2017-10-05 17:48:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OD5R5R9SzV0/catabasis-dmd-candidate-slows-disease-progression-stock-up-cm855887,Catabasis Pharmaceuticals Inc CATB announced data from a phase II study which showed that its pipeline candidate edasalonexent substantially slowed disease progression in male children with Duchenne muscular dystrophy DMD The company is planning to initiate a phase III study on
BIIB,BIIB:UW,BBG000C18861,ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status,2017-10-05 17:48:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ccG5twBHj8Q/acadias-antipsychotic-drug-gets-breakthrough-therapy-status-cm855879,ACADIA Pharmaceuticals Inc ACAD announced the initiation of a phase III study HARMONY for evaluating its antipsychotic drug Nuplazid for the treatment of hallucinations and delusions associated with dementia related psychosis The FDA also granted Breakthrough Therapy Designation to
BIIB,BIIB:UW,BBG000C18861,"Biotech: Buy Biogen, Sell Celgene",2017-10-05 17:29:00 +0000,http://finance.yahoo.com/r/7a026254-dd84-3bd8-ac9e-d2d6c01899e0/biotech-buy-biogen-sell-celgene-1507224573?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Morgan Stanley's Matthew Harrison and his team take a look at biotech today, writing that investors should buy Biogen (BIIB) rather than Celgene (CELG).  Harrison upgraded Biogen to Overweight from Equal Weight, and raised his price target from $311 to $375, writing that the company's base business is more durable than he anticipated, as its multiple sclerosis treatment, Ocrevus, is losing market share more slowly than expected.  In addition, he sees Spinraza, Biogen's spinal muscular atrophy drug, as worth potentially $4 billion, a fact that's under-appreciated by the market, and writes that the company's Alzheimer's business ""remains the key, must-own catalyst."
BIIB,BIIB:UW,BBG000C18861,Ligand (LGND) Signs Deal to Acquire Crystal Bioscience,2017-10-05 16:51:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HWgvJ2S8PhA/ligand-lgnd-signs-deal-to-acquire-crystal-bioscience-cm855836,Ligand Pharmaceuticals Incorporated LGND inked a deal to acquire Crystal Bioscience Inc for 25 million in cash The company will also pay an additional 10 5 million to the shareholders of Crystal Bioscience on success based milestones Additionally Crystal Bioscience will share
BIIB,BIIB:UW,BBG000C18861,"Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says",2017-10-05 15:59:00 +0000,http://finance.yahoo.com/r/d7e75893-54a5-3119-928d-09542c59ad2c/celgene-and-biogen-analyst-moves-are-useless-jim-cramer-says.html?puc=yahoov&cm_ven=YAHOOV&yptr=yahoo&.tsrc=rss,"Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves ""useless."""
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: CELG, NCLH",2017-10-05 15:50:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-_3ZIh9IOWw/nasdaq-100-movers-celg-nclh-cm855762,In early trading on Thursday shares of Norwegian Cruise Line Holdings topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 8 Year to date Norwegian Cruise Line Holdings registers a 36 6 gain And the worst performing Nasdaq 100 component thus
BIIB,BIIB:UW,BBG000C18861,"Catabasis&apos; DMD Candidate Slows Disease Progression, Stock Up",2017-10-05 15:47:03 +0000,https://finance.yahoo.com/news/catabasis-apos-dmd-candidate-slows-154703511.html?.tsrc=rss,Catabasis&apos; (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.
BIIB,BIIB:UW,BBG000C18861,3 Biotechs to Buy Ahead of Q3 Earnings,2017-10-05 15:45:00 +0000,http://finance.yahoo.com/r/cd0a82b5-88f1-31bc-bf3e-51c9bcf75909/3-biotechs-to-buy-ahead-of-q3-earnings-1507218301?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"With third-quarter earnings season just around the corner, Bernstein's Aaron (Ronny) Gal and his team take a look at the biotech sector with an eye toward upcoming reports.  As for specific stocks, he has Outperform ratings on Biogen (BIIB), Allergan (AGN) and Mylan (MYL).  Allergan reminded us EPS should be similar to 2Q17 ($4.02) and with hurricanes probably come close (BERN: $4.04, -4c)."
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Tech stocks power Wall St indexes to fresh record-highs,2017-10-05 15:19:25 +0000,https://finance.yahoo.com/news/us-stocks-tech-stocks-power-151925955.html?.tsrc=rss,"The three main U.S. indexes climbed to fresh record-highs for the fourth day in a row on Thursday, fueled by gains in technology stocks including Netflix, Microsoft and Amazon.com. Nine of the 11 major ..."
BIIB,BIIB:UW,BBG000C18861,11.7% of OVLC Holdings Seeing Recent Insider Buys,2017-10-05 14:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qps1meyMhL8/117-of-ovlc-holdings-seeing-recent-insider-buys-cm855631,A look at the weighted underlying holdings of the Guggenheim U S Large Cap Optimized Volatility ETF OVLC shows an impressive 11 7 of holdings on a weighted basis have experienced insider buying within the past six months Biogen Inc Symbol BIIB which makes up 1 26 of
BIIB,BIIB:UW,BBG000C18861,Biogen shares jump after Morgan Stanley upgrades company on its Alzheimer’s drugs,2017-10-05 14:35:49 +0000,http://finance.yahoo.com/r/1a582efe-559f-3728-b028-effe730ae353/104754532?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104754532&yptr=yahoo&.tsrc=rss,"Morgan Stanley raises its rating for Biogen shares to overweight from equal-weight, citing the potential of its Alzheimer's therapy pipeline."
BIIB,BIIB:UW,BBG000C18861,Cramer's Stop Trading: Celgene is not a sell,2017-10-05 13:55:00 +0000,https://finance.yahoo.com/video/cramers-stop-trading-celgene-not-135500674.html?.tsrc=rss,CNBC's Jim Cramer explains why he is watching shares of Celgene after Morgan Stanley downgraded the stock.
BIIB,BIIB:UW,BBG000C18861,"Biogen's stock surges after Morgan Stanley boosts rating, price target",2017-10-05 13:53:31 +0000,http://finance.yahoo.com/r/d5aa7f4b-b0b0-3dd2-9a56-a99104942ad5/Story.aspx?guid=EFF9CEC4-D2D0-4BA0-A9A9-063AADD557F9&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Biogen Inc. ran up 3.4% in morning trade Thursday, enough to make it the third-biggest gainer within the S&P 500 , after the biotechnology company was upgraded at Morgan Stanley, which cited ..."
BIIB,BIIB:UW,BBG000C18861,"Nasdaq Leads Stocks Higher; Microsoft, Biogen Upgraded",2017-10-05 13:41:47 +0000,http://finance.yahoo.com/r/b2277d20-8a36-30f0-a32f-99be45368bbb/stock-futures-positive-blue-chip-biotech-leaders-get-upgrades?src=A00220&yptr=yahoo&.tsrc=rss,The Nasdaq charged to another new high at Thursday&apos;s open.
BIIB,BIIB:UW,BBG000C18861,"Morning Movers: Constellation Brands Jumps, Biogen Bounces, Celgene Slips",2017-10-05 12:47:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JiyjL6DFtl0/morning-movers-constellation-brands-jumps-biogen-bounces-celgene-slips-cm855551,Stocks look set for a higher open today ahead of U S jobless claims data this morning Stocks look set for a higher open today ahead of U S jobless claims data this morning Agence France Presse Getty Images Agence France Presse Getty Images S amp P 500 futures have ticked
BIIB,BIIB:UW,BBG000C18861,Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy,2017-10-05 11:30:00 +0000,https://finance.yahoo.com/news/biogen-spinraza-nusinersen-data-show-113000239.html?.tsrc=rss,Biogen presented new data demonstrating that earlier initiation of treatment with SPINRAZA® may improve motor function outcomes in infants and children with spinal muscular atrophy .
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. (BIIB) Is Climbing On Spinraza Data,2017-10-05 09:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mnb234ZoEPU/biogen-inc-biib-is-climbing-on-spinraza-data-20171005-00725,Biogen Inc. (BIIB) Is Climbing On Spinraza Data
BIIB,BIIB:UW,BBG000C18861,"How Mylan&apos;s MS-Generic Approval Caused Teva, Momenta To Plunge",2017-10-04 20:11:23 +0000,http://finance.yahoo.com/r/9a253306-8f9d-37cf-9280-59d6bf351019/how-mylans-ms-generic-approval-caused-teva-momenta-to-plunge?src=A00220&yptr=yahoo&.tsrc=rss,"Never count out Mylan, an analyst said Wednesday, after the FDA approved its generic versions of Teva&apos;s Copaxone."
BIIB,BIIB:UW,BBG000C18861,Emergent Completes Acquisition of Anthrax Drug Raxibacumab,2017-10-04 18:32:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TtRalZISAbE/emergent-completes-acquisition-of-anthrax-drug-raxibacumab-cm855360,Emergent BioSolutions Inc EBS announced that it has closed the acquisition of anthrax monoclonal antibody raxibacumab from GlaxoSmithkline plc GSK In December 2012 160 raxibacumab was approved of by the FDA for the treatment and prophylaxis of inhalational anthrax Going forward
BIIB,BIIB:UW,BBG000C18861,"Celsion's Immunotherapy Candidate Impresses, Stock Surges",2017-10-04 18:31:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y0NlXvYIEQw/celsions-immunotherapy-candidate-impresses-stock-surges-cm855349,Celsion Corporation CLSN announced results from phase Ib study OVATION evidently showing biological activity of its immunotherapy candidate GEN1 in advanced ovarian cancer patients Celsion is developing the candidate for newly diagnosed patients who will be administered in
BIIB,BIIB:UW,BBG000C18861,Why Biotech's Rally May Push These 8 Stocks Even Higher,2017-10-04 18:00:00 +0000,http://finance.yahoo.com/r/151ef30b-bce6-3c91-a407-1cffd796237b/why-biotechs-rally-may-push-these-8-stocks-even-higher?partner=YahooSA&yptr=yahoo&.tsrc=rss,Biotech stocks remain sharply undervalued even after a summer rally and should surge higher
BIIB,BIIB:UW,BBG000C18861,"Notable ETF Outflow Detected - VHT, AGN, TMO, BIIB",2017-10-04 16:31:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L51yqJ1BAF8/notable-etf-outflow-detected-vht-agn-tmo-biib-cm855242,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Health Care ETF Symbol VHT where we have detected an approximate 30 8 million dollar outflow that s a 0 4 decrease week over week from 46 477 345
BIIB,BIIB:UW,BBG000C18861,Emergent Completes Acquisition of Anthrax Drug Raxibacumab,2017-10-04 16:11:04 +0000,https://finance.yahoo.com/news/emergent-completes-acquisition-anthrax-drug-161104515.html?.tsrc=rss,"Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline."
BIIB,BIIB:UW,BBG000C18861,Allergan's Botox Gets FDA Nod for Forehead Line Treatment,2017-10-04 15:36:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zEQs0CtzZpk/allergans-botox-gets-fda-nod-for-forehead-line-treatment-cm855190,Allergan plc AGN announced that the FDA has approved its Botox Cosmetic product for a third indication temporary improvement of moderate to severe forehead lines in appearance associated with frontalis muscle activity in adults So far this year Allergan s share price has slipped 0
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: JD, MYL",2017-10-04 15:31:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qSP6uLtnCJ4/nasdaq-100-movers-jd-myl-cm855144,In early trading on Wednesday shares of Mylan MYL topped the list of the day s best performing components of the Nasdaq 100 index trading up 17 6 Year to date Mylan registers a 0 3 gain And the worst performing Nasdaq 100 component thus far on the day is JD com JD
BIIB,BIIB:UW,BBG000C18861,"Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen",2017-10-04 13:34:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i6zC0CNgIP4/zackscom-featured-highlights-include-article-texas-instruments-applied-materials-pepsico-cbre-group-and-biogen-cm855129,For Immediate Release Chicago IL October 4 2017 Stocks in this week s article Texas Instruments Incorporated 160 Nasdaq 160 TXN 160 Free Report Applied Materials Inc 160 Nasdaq 160 AMAT 160 Free Report Pepsico Inc 160 NYSE 160 PEP 160
BIIB,BIIB:UW,BBG000C18861,Amgen Enters Into an Immuno-Oncology Partnership With CytomX,2017-10-04 13:11:01 +0000,https://finance.yahoo.com/news/amgen-enters-immuno-oncology-partnership-131101519.html?.tsrc=rss,Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.
BIIB,BIIB:UW,BBG000C18861,"Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen",2017-10-04 12:03:12 +0000,https://finance.yahoo.com/news/zacks-com-featured-highlights-article-120312334.html?.tsrc=rss,"Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen"
BIIB,BIIB:UW,BBG000C18861,"After Strong Q3, Vetr Issues Hold Downgrade On Biogen",2017-10-04 11:54:08 +0000,https://finance.yahoo.com/news/strong-q3-vetr-issues-hold-115408183.html?.tsrc=rss,"The Vetr crowd downgraded its rating on Biogen Inc. (NASDAQ: BIIB ) from 4 stars (Buy), issued 26 days ago, to 3 stars (Hold). Crowd sentiment at the time of the downgrade was split, with 50 percent of ..."
BIIB,BIIB:UW,BBG000C18861,"Why PTC Therapeutics, Inc. Dropped Today",2017-10-03 22:54:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pHPtsLq4kqc/why-ptc-therapeutics-inc-dropped-today-cm854888,What happened PTC Therapeutics NASDAQ PTCT 160 fell 10 9 on Tuesday after disclosing data 160 for RG7916 in patients with Type 2 and Type 3 spinal muscular atrophy SMA So what It s been a roller coaster for PTC Therapeutics falling last week after FDA
BIIB,BIIB:UW,BBG000C18861,"Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up",2017-10-03 22:53:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ahvnlmb7kz0/endocyte-inks-deal-for-prostate-cancer-candidate-shares-up-cm854887,Shares of Endocyte Inc ECYT have soared more than 150 on Oct 2 after it acquired an exclusive worldwide license to develop and commercialize ABX GmbH s phase III ready prostate cancer candidate 177Lu PSMA 617 Also the share price increased more than 50 in pre market trading on Oct
BIIB,BIIB:UW,BBG000C18861,"AveXis Flies, But PTC Sinks On Spinal Muscular Atrophy Data",2017-10-03 20:55:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wPwyx787e2M/avexis-flies-but-ptc-sinks-on-spinal-muscular-atrophy-data-cm854822,AveXis AVXS touched a record high Tuesday but PTC Therapeutics PTCT plunged by double digits as each biotech presented updates on their spinal muscular atrophy programs during the World Muscle Society annual meeting ibd display video id 2326188 width
BIIB,BIIB:UW,BBG000C18861,"Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy",2017-10-03 18:55:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1o3nQu3AGgY/mallinckrodt-neuroprotexeon-team-up-for-inhalation-therapy-cm854767,Mallinckrodt plc MNK announced that it has entered into a licensing agreement with NeuroproteXeon The agreement relates to the development and commercialization of NeuroproteXeon s investigational pharmaceutical grade xenon gas for inhalation therapy The therapy is being evaluated to
BIIB,BIIB:UW,BBG000C18861,5 Top ROE Stocks to Buy as Markets Snub Geopolitical Threats,2017-10-03 14:59:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ncIi3FQ51xI/5-top-roe-stocks-to-buy-as-markets-snub-geopolitical-threats-cm854569,The U S equity market maintained a steady momentum rebuffing geopolitical threats related to North Korean missile tests and deadly terrorist attacks in the home soil in Las Vegas As investors reposed their faith in riskier bets like equities courtesy of strengthening dollar and sell off
BIIB,BIIB:UW,BBG000C18861,Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA,2017-10-03 14:56:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/duZla6ZlWGM/allergans-snda-for-anti-infective-avycaz-accepted-by-fda-cm854524,Allergan plc AGN announced that a supplemental New Drug Application sNDA for its anti infective drug Avycaz has been accepted and granted priority review by the FDA We remind investors that Avycaz is currently approved for the treatment of complicated urinary tract infections
BIIB,BIIB:UW,BBG000C18861,"After Intepirdine Flunked in Alzheimer’s Disease, Is Axovant Sciences a Buy?",2017-10-03 13:53:00 +0000,http://finance.yahoo.com/r/17827451-5f51-30d8-a1e1-9eeb3552696c/after-intepirdine-flunked-in-alzheimers-disease-is.aspx?yptr=yahoo&.tsrc=rss,The biotech&apos;s shares lost more than 70% of their value after intepirdine failed in a phase III trail.
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern",2017-10-03 13:51:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_ef0AP2e22U/the-zacks-analyst-blog-highlights-procter-gamble-petrochina-biogen-accenture-and-norfolk-southern-cm854477,For Immediate Release Chicago IL October 03 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the
BIIB,BIIB:UW,BBG000C18861,Allergan&apos;s sNDA for Anti-Infective Avycaz Accepted by FDA,2017-10-03 13:50:01 +0000,https://finance.yahoo.com/news/allergan-apos-snda-anti-infective-135001236.html?.tsrc=rss,Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.
BIIB,BIIB:UW,BBG000C18861,3 Top-Ranked Big Biotech Stocks to Buy Now,2017-10-03 13:30:01 +0000,https://finance.yahoo.com/news/3-top-ranked-big-biotech-133001290.html?.tsrc=rss,"With biotech stocks on a tear, here we have picked three of the biggest biotech companies which look well poised for growth and can be added to one&apos;s portfolio"
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern",2017-10-03 12:19:12 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-procter-121912587.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern"
BIIB,BIIB:UW,BBG000C18861,Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults,2017-10-03 00:45:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_1_yjMXC6TM/novo-nordisks-fiasp-gets-fda-nod-for-diabetes-in-adults-cm854287,Novo Nordisk NVO announced that the FDA has approved its fast acting mealtime insulin aspart Fiasp for the treatment of adults with diabetes The FDA approval was based on results from a phase III study showing that Fiasp improved overall blood sugar HbA1c and post meal sugar
BIIB,BIIB:UW,BBG000C18861,"Top Stock Reports for Procter & Gamble, PetroChina & Biogen",2017-10-02 23:48:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ersGm0FK304/top-stock-reports-for-procter-gamble-petrochina-biogen-cm854295,Monday October 2 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Procter amp Gamble PG PetroChina PTR and Biogen BIIB These research reports have been hand
BIIB,BIIB:UW,BBG000C18861,"Top Stock Reports for Procter & Gamble, PetroChina & Biogen",2017-10-02 23:47:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bT26eOWwriI/top-stock-reports-for-procter-gamble-petrochina-biogen-cm854293,Monday October 2 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Procter amp Gamble PG PetroChina PTR and Biogen BIIB These research reports have been hand
BIIB,BIIB:UW,BBG000C18861,4 Biotech Stocks (and 1 ETF) to Buy As They Bolt Higher,2017-10-02 23:46:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YC71v8n_SPQ/4-biotech-stocks-and-1-etf-to-buy-as-they-bolt-higher-cm854290,InvestorPlace Stock Market News Stock Advice amp Trading Tips U S equities are continuing their recent push higher on Monday led once again by the performance of small cap stocks in the Russell 2000 From its mid August low the index is up more than 11 in an impressive near
BIIB,BIIB:UW,BBG000C18861,Lilly (LLY) Makes Leadership Changes to Executive Positions,2017-10-02 22:19:10 +0000,https://finance.yahoo.com/news/lilly-lly-makes-leadership-changes-221910705.html?.tsrc=rss,Eli Lilly and Company (LLY) makes some executive appointments for various departments.
BIIB,BIIB:UW,BBG000C18861,"Top Stock Reports for Procter & Gamble, PetroChina & Biogen",2017-10-02 21:25:09 +0000,https://finance.yahoo.com/news/top-stock-reports-procter-gamble-212509076.html?.tsrc=rss,"Top Stock Reports for Procter & Gamble, PetroChina & Biogen"
BIIB,BIIB:UW,BBG000C18861,"Top Stock Reports for Procter & Gamble, PetroChina & Biogen",2017-10-02 20:56:08 +0000,https://finance.yahoo.com/news/top-stock-reports-procter-gamble-205608395.html?.tsrc=rss,"Top Stock Reports for Procter & Gamble, PetroChina & Biogen"
BIIB,BIIB:UW,BBG000C18861,"Congressman urges President Trump to take action on $90,000 multiple sclerosis drug",2017-10-01 21:11:18 +0000,http://finance.yahoo.com/r/69bc074f-1fd4-3092-b66e-5f5cc1753b35/Story.aspx?guid=418093E6-A454-11E7-BDF5-7DD5423393CF&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"U.S. prices of Zinbryta are higher than those in other countries, including 2.8 times higher than Norway and Denmark and 3.8 times higher than Switzerland."
BIIB,BIIB:UW,BBG000C18861,"Notable Friday Option Activity: BIIB, RJF, TSN",2017-09-29 18:33:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IFmNQzhE40Q/notable-friday-option-activity-biib-rjf-tsn-cm853214,Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in Biogen Inc Symbol BIIB where a total of 7 266 contracts have traded so far representing approximately 726 600 underlying shares That amounts to about 54 9 of BIIB s average
BIIB,BIIB:UW,BBG000C18861,Biotech stocks plunge after FDA makes it easier for public to search for drug side effects,2017-09-29 17:24:41 +0000,https://finance.yahoo.com/news/biotech-stocks-plunge-fda-makes-172441898.html?.tsrc=rss,"Sarepta Therapeutics, Ionis Pharmaceuticals, Biogen and Acadia Pharmaceuticals all traded lower after investors found reports on their drugs on a database."
BIIB,BIIB:UW,BBG000C18861,Biotech stocks plunge after FDA makes it easier for public to search for drug side effects,2017-09-29 17:24:41 +0000,http://finance.yahoo.com/r/872ed6f8-3d88-30f7-8bc5-feeeca9eba73/104741133?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104741133&yptr=yahoo&.tsrc=rss,"Sarepta Therapeutics, Ionis Pharmaceuticals, Biogen and Acadia Pharmaceuticals all traded lower after investors found reports on their drugs on a database."
BIIB,BIIB:UW,BBG000C18861,"Biogen: Shares Hit By Similar Fears Hitting Sarepta; Analyst Calls Pullback ""Inappropriate""",2017-09-29 16:43:00 +0000,http://finance.yahoo.com/r/ffc009a8-4b17-3ad0-b0e6-1d4a9ee3e2f9/biogen-share-hit-by-similar-fears-hitting-sarepta-analyst-calls-pullback-inappropriate-1506703448?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"A new tool became available today that makes the FDA’s adverse event reporting system far more user-friendly.  Now at just below $304 a share, Biogen’s stock is almost flat after earlier falling almost 2% to $303 a share.  Ionis Pharmaceuticals (IONS), the smaller drug maker that licensed Spinraza to Biogen last year, has not been so fortunate."
BIIB,BIIB:UW,BBG000C18861,FDA makes side effect database searchable,2017-09-29 16:39:00 +0000,https://finance.yahoo.com/video/fda-makes-side-effect-database-163900753.html?.tsrc=rss,CNBC's Meg Tirrell reports on biotech stocks taking a hit after the FDA makes a searchable database for side effects.
BIIB,BIIB:UW,BBG000C18861,Why Amgen's Drug Win Sent AbbVie Stock Into The Stratosphere,2017-09-28 21:34:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6RgH0tGmS00/why-amgens-drug-win-sent-abbvie-stock-into-the-stratosphere-cm852720,AbbVie ABBV launched to a record high Thursday after it settled a patent dispute with Amgen AMGN that will require the No 1 biotech to pay AbbVie royalties on sales of its Humira copycat ibd display video id 2322998 width 50 float left autostart true By
BIIB,BIIB:UW,BBG000C18861,"Biotechs Beating The Market, But Are They In Buy Range?",2017-09-28 19:42:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_heWsI7EUBo/biotechs-beating-the-market-but-are-they-in-buy-range-cm852774,Biotechs continue to outmuscle the broader stock market as both nonleveraged and leveraged exchange traded 160 funds are showing healthy gains ibd display video id 2323711 width 50 float left autostart true Despite 160 a recent pullback iShares Nasdaq Biotechnology
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-09-27 12:04:42 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120442600.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB.  Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $8.72 billion."
BIIB,BIIB:UW,BBG000C18861,"AKBA Hits New 52-week High, PMD Launches Hair Test, Mateon Runs Out Of FOCUS",2017-09-27 02:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iHRH0_v2eew/akba-hits-new-52week-high-pmd-launches-hair-test-mateon-runs-out-of-focus-20170927-00063,"AKBA Hits New 52-week High, PMD Launches Hair Test, Mateon Runs Out Of FOCUS"
BIIB,BIIB:UW,BBG000C18861,"Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017",2017-09-26 20:01:00 +0000,https://finance.yahoo.com/news/biogen-report-third-quarter-2017-200100860.html?.tsrc=rss,"Biogen Inc. today announced it will report third quarter 2017 financial results on Tuesday, October 24, 2017, before the financial markets open."
BIIB,BIIB:UW,BBG000C18861,"MOAT, OILU: Big ETF Outflows",2017-09-26 16:54:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xA8ADToyjOs/moat-oilu-big-etf-outflows-cm851170,Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel the biggest outflow was seen in the Morningstar Wide Moat ETF where 4 450 000 units were destroyed or a 12 2 decrease week over week Among the largest underlying components of MOAT in
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-09-26 12:04:36 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120436830.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,Is Biogen Inc. (BIIB) a Great Stock for Value Investors?,2017-09-25 15:53:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wOF-oqGsqU0/is-biogen-inc-biib-a-great-stock-for-value-investors-cm850380,Value investing is easily one of the most popular ways to find great stocks in any market environment After all who wouldn t want to find stocks that are either flying under the radar and are compelling buys or offer up tantalizing discounts when compared to fair value One way to find
BIIB,BIIB:UW,BBG000C18861,Is Biogen Inc. (BIIB) a Great Stock for Value Investors?,2017-09-25 13:40:01 +0000,https://finance.yahoo.com/news/biogen-inc-biib-great-stock-134001491.html?.tsrc=rss,Lets put Biogen Inc.(BIIB) stock into this equation and find out if it is a good choice for value-oriented investors right now.
BIIB,BIIB:UW,BBG000C18861,"Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area",2017-09-25 13:23:00 +0000,https://finance.yahoo.com/news/biogen-appoints-camille-lee-svp-132300100.html?.tsrc=rss,"Biogen announced the appointment of Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective today."
BIIB,BIIB:UW,BBG000C18861,Today's Research Reports on Stocks to Watch: Juno Therapeutics and Biogen,2017-09-22 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000470.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 22, 2017 / Shares of Biogen tumbled on Thursday after receiving a downgrade from Raymond James that took it down two notches from ""strong buy"" to ""market ..."
BIIB,BIIB:UW,BBG000C18861,"Gilead, Amgen, and Biogen May Lift Biotech Higher",2017-09-22 10:00:00 +0000,http://finance.yahoo.com/r/b1da5a4a-985a-3c39-87ae-67c0297baa75/gilead-amgen-and-biogen-may-lift-biotech-higher?partner=YahooSA&yptr=yahoo&.tsrc=rss,These drug juggernauts could bolster the entire biotechnology sector as we head toward year-end.
BIIB,BIIB:UW,BBG000C18861,"Today&apos;s charts: Tesla, AMD developing new AI chip; Blue Apron shares gain; Biogen downgrade; Amazon expands in New York",2017-09-21 15:22:10 +0000,https://finance.yahoo.com/news/todays-charts-tesla-amd-developing-new-ai-chip-blue-apron-shares-gain-biogen-downgrade-amazon-expands-new-york-152210837.html?.tsrc=rss,"Tesla (TSLA) is teaming up with AMD (AMD) to develop its own AI chip for self-driving cars, according to a report by CNBC.  Jefferies analyst Mark Lipacis wrote it’s a “critical win” for AMD.  On the other hand, Nvidia (NVDA) shares are falling on the news, since a partnership with AMD would make Tesla less reliant on the company."
BIIB,BIIB:UW,BBG000C18861,Biogen: Buy or Hold?,2017-09-21 15:09:00 +0000,http://finance.yahoo.com/r/bb42814d-1dda-3818-96a6-b64fc0c43dc1/biogen-buy-or-hold-1506006585?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Just as one analyst goes bullish on Biogen (BIIB), another has moved to the sidelines.  Earlier today, Raymond James analyst Laura Chico cut her rating on the stock by two notches, from a Strong Buy to a Market Perform (skipping over Outperform entirely) and lowered her price target from $329 a share to $319 a share.  Chico sees continued headwinds for Biogen’s all-important multiple sclerosis drug franchise as a rival drug from Roche (RHHBY) gains market share."
BIIB,BIIB:UW,BBG000C18861,"Today's charts: Tesla, AMD developing new AI chip; Blue Apron shares gain; Biogen drops on downgrade",2017-09-21 15:03:26 +0000,https://finance.yahoo.com/video/todays-charts-tesla-amd-developing-150326058.html?.tsrc=rss,"Yahoo Finance's Seana Smith is tracking AMD, Nvidia, Blue Apron and Biogen in intraday trading on Thursday."
BIIB,BIIB:UW,BBG000C18861,"Morning Movers: Calgon Carbon Surges, Biogen Slips, AMD Gains",2017-09-21 13:25:00 +0000,http://finance.yahoo.com/r/eabf0e33-4649-3d79-98c5-849a47a9950e/morning-movers-calgon-carbon-surges-biogen-slips-amd-gains-1506000344?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"U.S. stocks look set for a mixed open Thursday after the Federal Reserve made an announcement that marked the end to quantitative easing data showed jobless claims fell in September. On Wednesday, the ..."
BIIB,BIIB:UW,BBG000C18861,Biogen's stock falls after Raymond James cuts rating by two notches,2017-09-21 13:06:08 +0000,http://finance.yahoo.com/r/86385755-e262-3d70-9be1-8fedfc7853e1/Story.aspx?guid=8D6FB59E-B6EE-498E-B154-03BF3F57D479&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Biogen Inc. fell 0.6% in light premarket trade Thursday, after the biotechnology company was downgraded by two notches at Raymond James, which cited continued headwinds for the multiple sclerosis ..."
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-09-21 12:04:40 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120440413.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,Biogen Spinoff Bioverativ Is A Buy,2017-09-20 14:51:56 +0000,https://finance.yahoo.com/news/biogen-spinoff-bioverativ-buy-145156624.html?.tsrc=rss,Analysts at Argus Research turned bullish on Bioverativ Inc (NASDAQ: BIVV ) as the company could establish itself as a profitable biotech within the hemophilia and blood disorders space. The firm's Jasper ...
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-09-20 12:04:54 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120454450.html?.tsrc=rss,"This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB.  Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $1.03 billion."
BIIB,BIIB:UW,BBG000C18861,"Sorry Qualcomm, Inc. (QCOM) Stock Bears, It Has Bottomed!",2017-09-19 20:36:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BkKrJNl-kGc/sorry-qualcomm-inc-qcom-stock-bears-it-has-bottomed-cm848027,InvestorPlace Stock Market News Stock Advice amp Trading Tips Any way you slice it risks still abound for Qualcomm Inc NASDAQ QCOM But if the price chart is an accurate and forward looking indicator QCOM bulls are in good position for the first time in a very long while
BIIB,BIIB:UW,BBG000C18861,Profit From the Biogen Inc (BIIB) Stock Dip!,2017-09-19 19:36:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xZtO6Y2voJI/profit-from-the-biogen-inc-biib-stock-dip-cm847993,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB stock had a fantastic start to September with a 15 rally But in the past few days of trading it gave back about one third of it Source Biogen via YouTube Clearly this is a
BIIB,BIIB:UW,BBG000C18861,Think Before You Chase Nvidia Corporation (NVDA) Stock’s Momentum,2017-09-19 19:36:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-SDdQLkkp1w/think-before-you-chase-nvidia-corporation-nvda-stocks-momentum-cm847990,InvestorPlace Stock Market News Stock Advice amp Trading Tips Nvidia Corporation NASDAQ NVDA has certainly been on a monster rally over the past year rising nearly 200 Nvidia is the best performing stock in the S amp P 500 over the past 52 weeks In the past two years
BIIB,BIIB:UW,BBG000C18861,Play the Support Test in VanEck Vectors Gold Miners ETF (GDX),2017-09-19 19:35:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0ZNWnZAgyo4/play-the-support-test-in-vaneck-vectors-gold-miners-etf-gdx-cm847986,InvestorPlace Stock Market News Stock Advice amp Trading Tips A critical test looms for gold prices which should determine the fate of the VanEck Vectors Gold Miners ETF NYSEARCA GDX GDX and the yellow metal are tied at the hip just like conjoined twins And that makes
BIIB,BIIB:UW,BBG000C18861,Profit From the Biogen Inc (BIIB) Stock Dip!,2017-09-19 14:41:19 +0000,https://finance.yahoo.com/news/profit-biogen-inc-biib-stock-144119228.html?.tsrc=rss,"Biogen Inc (NASDAQ:BIIB) stock had a fantastic start to September with a 15% rally.  Clearly, this is a momentum stock, so it will never give us a clear signal for entry.  More often than not, traders tend to overshoot with the price action of momentum stocks."
BIIB,BIIB:UW,BBG000C18861,Apple Leads 7 Top Stocks Holding In Buy Range,2017-09-19 11:01:21 +0000,http://finance.yahoo.com/r/352304b8-fbd3-38e1-8748-2b15e4a79c56/apple-microsoft-lead-7-top-stocks-holding-in-buy-range-sp-500-futures?src=A00220&yptr=yahoo&.tsrc=rss,"With the market grinding higher, some breakouts struggle. But Apple, Microsoft, Biogen, Alexion Pharmaceuticals, Wynn Resorts and Electronic Arts are holding in buy zones after breaking out several days or weeks ago."
BIIB,BIIB:UW,BBG000C18861,"Gilead Sciences: Is The Kite Deal Too Little, Too Late?",2017-09-18 15:35:00 +0000,http://finance.yahoo.com/r/f671e14c-d4a0-3468-acf7-c08c5badbf8d/gilead-sciences-is-the-kite-deal-too-little-too-late-1505748947?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Last month, Gilead Sciences (GILD) made big news when it announced the acquisition of Kite Pharma (KITE).  For the most part, analysts were bullish on the deal, with the noted exception being Leerink's Geoffrey Porges and Bradley Canino.  The pair penned a note late last month explaining why they were not excited by Gilead’s latest purchase."
BIIB,BIIB:UW,BBG000C18861,Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?,2017-09-18 14:39:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_bwsKgVau78/billionaire-george-soros-fund-bought-these-3-pharma-stocks-should-you-cm847017,Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets As such the quarterly 13F filings of his namesake fund Soros Fund Management are must read material for any serious investor The latest
BIIB,BIIB:UW,BBG000C18861,Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?,2017-09-16 12:03:00 +0000,http://finance.yahoo.com/r/29feae24-c8ef-371c-86aa-b23e5176bdff/which-of-these-5-will-be-the-best-selling-drug-wor.aspx?yptr=yahoo&.tsrc=rss,All five of these drugs have a genuine shot at $10 billion or more in annual sales in 2020.
BIIB,BIIB:UW,BBG000C18861,"IBB, BIIB, REGN, ALXN: ETF Inflow Alert",2017-09-15 16:38:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jp7jqBjHZBY/ibb-biib-regn-alxn-etf-inflow-alert-cm846357,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Nasdaq Biotechnology ETF Symbol IBB where we have detected an approximate 448 1 million dollar inflow that s a 4 8 increase week over week
BIIB,BIIB:UW,BBG000C18861,Biosimilar 2017 Progress Report: Stocks in Focus,2017-09-14 21:01:09 +0000,https://finance.yahoo.com/news/biosimilar-2017-progress-report-stocks-210109959.html?.tsrc=rss,The biosimilar space remains in the spotlight as a number of regulatory decisions are pending.
BIIB,BIIB:UW,BBG000C18861,4 Biotech Stocks for the Long-Term,2017-09-13 18:35:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p0qq_jnkZAc/4-biotech-stocks-for-the-long-term-cm845299,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biotech is one those sectors that can absolutely kill it compared to the broad market or get killed when times are tough Biotech stocks have been a favorite of fast money too since it moves faster than
BIIB,BIIB:UW,BBG000C18861,4 Biotech Stocks for the Long-Term,2017-09-13 14:05:30 +0000,https://finance.yahoo.com/news/4-biotech-stocks-long-term-140530574.html?.tsrc=rss,"Biotech stocks have been a favorite of fast money, too, since it moves faster than the Standard & Poor’s 500 – in both directions.  Some stocks, such as Vertex Pharmaceuticals (NASDAQ:VRTX), are already up triple-digit percentages this year.  Or, they may be emerging from long trading ranges where uncertainty previously ruled."
BIIB,BIIB:UW,BBG000C18861,"Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 14, 2017",2017-09-13 13:29:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j02vgkvA6ug/gilead-sciences-inc-gild-ex-dividend-date-scheduled-for-september-14-2017-cm844884,Gilead Sciences Inc GILD will begin trading ex dividend on September 14 2017 A cash dividend payment of 0 52 per share is scheduled to be paid on September 28 2017 Shareholders who purchased GILD prior to the ex dividend date are eligible for the cash dividend payment This marks
BIIB,BIIB:UW,BBG000C18861,What Is Biogen Inc’s (BIIB) Share Price Doing?,2017-09-12 12:49:17 +0000,https://finance.yahoo.com/news/biogen-inc-biib-share-price-124917381.html?.tsrc=rss,"Let’s talk about the popular Biogen Inc (NASDAQ:BIIB). The company’s shares View our latest analysis for Biogen What’s the opportunity in BIIB? According to my valuation model, the stock isRead More..."
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-09-12 12:06:32 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120632801.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,"Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical",2017-09-12 11:30:00 +0000,https://finance.yahoo.com/news/biogen-appoints-sanjay-jariwala-svp-113000700.html?.tsrc=rss,"Biogen announced today the appointment of Dr. Sanjay Jariwala as Senior Vice President, Worldwide Medical."
BIIB,BIIB:UW,BBG000C18861,BIIB January 2020 Options Begin Trading,2017-09-11 17:37:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/40o9YCJxtsM/biib-january-2020-options-begin-trading-cm843868,Investors in Biogen Inc Symbol BIIB saw new options become available today for the January 2020 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 858 days until expiration the newly available contracts represent
BIIB,BIIB:UW,BBG000C18861,Why Biogen Stock Raced Higher In August,2017-09-11 14:38:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bgvJnQM_6uU/why-biogen-stock-raced-higher-in-august-cm843618,What happened Biotech titan Biogen NASDAQ BIIB saw its shares rise by 8 73 last month according to data from S amp P Global Market Intelligence This healthy march northward was sparked by an encouraging clinical update for the biotech s early stage Alzheimer s disease
BIIB,BIIB:UW,BBG000C18861,Biogen Reaches Analyst Target Price,2017-09-11 14:37:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/soU78ezWXNY/biogen-reaches-analyst-target-price-cm843603,In recent trading shares of Biogen Inc Symbol BIIB have crossed above the average analyst 12 month target price of 324 61 changing hands for 326 33 share When a stock reaches the target an analyst has set the analyst logically has two ways to react downgrade on valuation or re
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-09-11 14:10:17 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-141017535.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,Why Biogen Stock Raced Higher In August,2017-09-11 13:33:00 +0000,http://finance.yahoo.com/r/0bcbc6d9-2c43-3195-8299-9d87eeeae63b/why-biogen-stock-raced-higher-in-august.aspx?yptr=yahoo&.tsrc=rss,Biogen&apos;s stock gets a bump from its promising Alzheimer&apos;s disease drug candidate in August.
BIIB,BIIB:UW,BBG000C18861,What’s Gilead Sciences’ Valuation?,2017-09-11 12:36:46 +0000,http://finance.yahoo.com/r/47c215a5-9292-3017-a7cb-0781a98329b0/whats-gilead-sciences-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
BIIB,BIIB:UW,BBG000C18861,Biogen To Present At Morgan Stanley Conference; Webcast At 11:05 AM ET,2017-09-11 10:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pGAZUufc94k/biogen-to-present-at-morgan-stanley-conference-webcast-at-1105-am-et-20170911-00753,Biogen To Present At Morgan Stanley Conference; Webcast At 11:05 AM ET
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-09-08 14:22:10 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-142210394.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,"Despite biotech's epic run, these names are still a barga...",2017-09-07 21:52:00 +0000,https://finance.yahoo.com/video/despite-biotechs-epic-run-names-215200237.html?.tsrc=rss,CNBC's Meg Tirrell reports on what's driving the biotech sector to a possible breakout. The “Fast Money” traders weigh in.
BIIB,BIIB:UW,BBG000C18861,AbbVie Submits NDA for Endometriosis Candidate to the FDA,2017-09-07 16:54:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J_4ps9YXxWQ/abbvie-submits-nda-for-endometriosis-candidate-to-the-fda-cm842394,AbbVie Inc ABBV and partner Neurocrine Biosciences announced that the new drug application NDA for their pipeline candidate elagolix has been submitted to the FDA AbbVie is looking to get elagolix approved as an oral medicine for the management of pain associated with endometriosis
BIIB,BIIB:UW,BBG000C18861,Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference,2017-09-06 20:01:00 +0000,https://finance.yahoo.com/news/biogen-present-morgan-stanley-15th-200100866.html?.tsrc=rss,"Biogen Inc. announced today that it will present at the Morgan Stanley 15th Annual Global Healthcare Conference. The webcast will be live on Monday, September 11, 2017 at 11:05 a.m."
BIIB,BIIB:UW,BBG000C18861,Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study,2017-09-06 16:54:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WfIumkgNKjU/novartis-nvs-ms-drug-gilenya-positive-in-long-term-study-cm841759,Novartis AG NVS announced positive top line results from the phase III study PARADIGMS The study evaluated the safety and efficacy of oral once daily Gilenya in children and adolescents aged 10 17 with multiple sclerosis MS The flexible duration up to two years double
BIIB,BIIB:UW,BBG000C18861,These 4 Biotechs Just Moved Into Buy Zones; Is This Giant Next?,2017-09-01 11:45:46 +0000,http://finance.yahoo.com/r/3177b128-03e5-3556-8021-991ed8c0fd9f/these-4-biotechs-just-moved-into-buy-zones-sp-500-futures?src=A00220&yptr=yahoo&.tsrc=rss,Several biotech stocks broke out Thursday as the Nasdaq composite and other major averages approached all-time highs. Celgene could be next.
BIIB,BIIB:UW,BBG000C18861,Featured Company News - Ionis Earns Regulatory Milestone Payment from Biogen for SPINRAZA,2017-09-01 11:00:00 +0000,https://finance.yahoo.com/news/featured-company-news-ionis-earns-110000042.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / September 1, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) (""Ionis""), ..."
BIIB,BIIB:UW,BBG000C18861,"Thursday Sector Leaders: Healthcare, Energy",2017-08-31 19:48:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i1t9oVX6pk4/thursday-sector-leaders-healthcare-energy-cm839908,Looking at the sectors faring best as of midday Thursday shares of Healthcare companies are outperforming other sectors higher by 1 4 Within that group Biogen Inc Symbol BIIB and Celgene Corp Symbol CELG are two large stocks leading the way showing a gain of 3 8 and 3
BIIB,BIIB:UW,BBG000C18861,5 Biotech Stocks That Are Breaking Higher,2017-08-31 00:48:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9gpEQanX48/5-biotech-stocks-that-are-breaking-higher-cm839469,InvestorPlace Stock Market News Stock Advice amp Trading Tips U S equities are continuing to melt higher on Wednesday as fears over the North Korean missile strike earlier in the week are fading amid a fresh focus on possible tax reform legislation Source Shutterstock Also we
BIIB,BIIB:UW,BBG000C18861,Biogen Alzheimer's Drug Shows Promise in Long-Term Study,2017-08-29 17:52:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MV4uBZiaT8g/biogen-alzheimers-drug-shows-promise-in-long-term-study-cm838739,Biogen Inc BIIB announced data from a long term study on its Alzheimer s disease AD candidate aducanumab Data from the study showed a continued benefit in the rate of amyloid decline over a two three year period in patients with prodromal or mild Alzheimer s disease when treated
BIIB,BIIB:UW,BBG000C18861,"Company News For August 29, 2017",2017-08-29 16:52:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KFvtvNnOH0Y/company-news-for-august-29-2017-cm838672,160 160 160 160 160 160 160 160 Shares of Expedia Inc EXPE declined 4 5 after the company s Chief Executive Officer Dara Khosrowshahi announced that he would be joining Uber as CEO 160 160 160 160 160 160 160 160 Biogen Inc s BIIB shares surged 2
BIIB,BIIB:UW,BBG000C18861,Biogen Alzheimer&apos;s Drug Shows Promise in Long-Term Study,2017-08-29 15:29:03 +0000,https://finance.yahoo.com/news/biogen-alzheimer-apos-drug-shows-152903612.html?.tsrc=rss,"Biogen (BIIB) announced data from a long-term study on its Alzheimer&apos;s disease candidate, aducanumab, which showed continued benefit in the rate of amyloid decline."
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-08-29 12:03:20 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120320508.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,Trade of the Day: Biogen Inc (BIIB) Stock Is Coiling,2017-08-29 11:38:31 +0000,https://finance.yahoo.com/news/trade-day-biogen-inc-biib-113831214.html?.tsrc=rss,"Biotechnology stocks as represented by the&#160;iShares Nasdaq Biotechnology Index (ETF)&#160;(NASDAQ:IBB) rallied about 1.9% on Monday on the back of merger and acquisition activity in the space. While the recent bounce in biotech land has largely taken place in sync, shares of&#160;Biogen Inc&#160;(NASDAQ:BIIB) through the lens of technical analysis and in my eye are showing a tight chart pattern and thus a great way to define risk for a breakout trade setup.Source: Biogen via YouTube"
BIIB,BIIB:UW,BBG000C18861,S&P 500 Futures Fall Sharply On North Korea Launch,2017-08-29 11:00:29 +0000,http://finance.yahoo.com/r/5afca1d8-6e28-397b-9a54-0e25973377ad/s-these-4-stocks-show-why-buy-points-are-key?src=A00220&yptr=yahoo&.tsrc=rss,"Stock futures fell late Monday after North Korea fired a missile over Japan. Tesla, Apple chipmaker Skyworks, SPDR Gold Shares ETF and Biogen all showed the importance of proper buy points."
BIIB,BIIB:UW,BBG000C18861,Biogen&apos;s Alzheimer&apos;s Drug Shows Promise — Could It Break Out?,2017-08-28 20:35:20 +0000,http://finance.yahoo.com/r/6e291dce-1312-35ef-a165-be56499baae9/biogens-alzheimers-drug-shows-promise-could-it-break-out?src=A00220&yptr=yahoo&.tsrc=rss,Biogen stock neared a buy point after its Alzheimer&apos;s treatment showed promise at the two-year and three-year marks.
BIIB,BIIB:UW,BBG000C18861,"Monday Sector Leaders: Healthcare, Technology & Communications",2017-08-28 19:48:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DPSOuixqWJg/monday-sector-leaders-healthcare-technology-communications-cm838141,The best performing sector as of midday Monday is the Healthcare sector higher by 0 6 Within that group Biogen Inc Symbol BIIB and Illumina Inc Symbol ILMN are two of the day s stand outs showing a gain of 2 9 and 2 5 respectively Among healthcare ETFs one ETF following the
BIIB,BIIB:UW,BBG000C18861,Vanguard Russell 1000 ETF -- Insider Buying Index Registering 11.9%,2017-08-28 14:48:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1zasyEWn-XI/vanguard-russell-1000-etf-insider-buying-index-registering-119-cm837848,A look at the weighted underlying holdings of the Vanguard Russell 1000 ETF Symbol VONE shows an impressive 11 9 of holdings on a weighted basis have experienced insider buying within the past six months Biogen Inc Symbol BIIB which makes up 0 26 of the Vanguard Russell 1000
BIIB,BIIB:UW,BBG000C18861,​Head of Biogen's copycat drug unit leaves to join Scangos startup,2017-08-28 14:35:08 +0000,http://finance.yahoo.com/r/798b8d2f-ea48-32c3-957d-a4a64e4b3dac/head-of-biogens-copycat-drug-unit-leaves-to-join.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"The head of a Biogen division that makes biosimilars — cheaper, knockoff versions of popular biologic drugs — has left the Cambridge firm to become the chief operating officer of a startup led by former Biogen CEO George Scangos.  Alpna Seth, who spent nearly two decades at Biogen (BIIB), including the last three years as senior vice president and global head of the biosimilars unit in Switzerland, left the company sometime in July and joined San Francisco-based Vir Biotechnology earlier this month, according to her LinkedIn page.  Scangos took the top job at Vir immediately after being replaced as Biogen’s CEO in January by Michel Vounatsos."
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-08-28 12:02:53 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120253601.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,"Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira(R), Approved in the European Union",2017-08-28 11:40:00 +0000,https://finance.yahoo.com/news/featured-company-news-imraldi-r-114000738.html?.tsrc=rss,"Research Desk Line-up: ObsEva Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biogen Inc. ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab,2017-08-28 11:30:00 +0000,https://finance.yahoo.com/news/biogen-reports-data-phase-1b-113000757.html?.tsrc=rss,"Biogen  today announced results from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease."
BIIB,BIIB:UW,BBG000C18861,Consider This Before You Buy Biogen,2017-08-27 13:49:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Hhknfltu1tY/consider-this-before-you-buy-biogen-cm837624,Biogen NASDAQ BIIB is the leading maker of medicine used to treat multiple sclerosis However new drugs from Roche Holdings NASDAQOTH RHHBY and Celgene Corp NASDAQ CELG threaten its dominance and add pressure to the company to diversify itself A new
BIIB,BIIB:UW,BBG000C18861,Consider This Before You Buy Biogen,2017-08-27 12:01:00 +0000,http://finance.yahoo.com/r/56dc560a-f1bc-34e4-a5ad-15262c996ca5/consider-this-before-you-buy-biogen.aspx?yptr=yahoo&.tsrc=rss,New drugs that compete against Biogen&apos;s franchise of top-selling multiple sclerosis medicine pose a threat to Biogen&apos;s revenue.
BIIB,BIIB:UW,BBG000C18861,Biogen's Humira Biosimilar Imraldi Gets Approval in EU,2017-08-25 17:39:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xKYeaXhAoXs/biogens-humira-biosimilar-imraldi-gets-approval-in-eu-cm837281,Biogen Inc BIIB announced that its biosimilar version of AbbVie Inc s ABBV top selling blockbuster drug Humira has been approved by the European Commission The biosimilar will be marketed by the trade name of Imraldi Imraldi or SB5 will be used for a whole range of indications
BIIB,BIIB:UW,BBG000C18861,Steven Cohen Plunges Into Opioid Replacement Maker Pacira,2017-08-25 17:38:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W_ltYRVvVhk/steven-cohen-plunges-into-opioid-replacement-maker-pacira-cm837322,Steven Cohen Trades Portfolio founder of Point72 Asset Management made a 1098 increase to his holding of Pacira Pharmaceuticals PCRX he revealed this week Steven Cohen Trades Portfolio founder of Point72 Asset Management made a 1098 increase to his holding of
BIIB,BIIB:UW,BBG000C18861,Biogen&apos;s Humira Biosimilar Imraldi Gets Approval in EU,2017-08-25 15:13:03 +0000,https://finance.yahoo.com/news/biogen-apos-humira-biosimilar-imraldi-151303489.html?.tsrc=rss,"Biogen Inc.&apos;s (BIIB) biosimilar version of AbbVie&apos;s top-selling blockbuster drug, Humira has been approved by the European Commission."
BIIB,BIIB:UW,BBG000C18861,"Samsung, Biogen version of AbbVie's Humira approved in Europe",2017-08-25 04:00:26 +0000,https://finance.yahoo.com/news/samsung-biogen-version-abbvies-humira-040026914.html?.tsrc=rss,"A biosimilar version of AbbVie Inc's  blockbuster arthritis drug Humira, produced by a joint  venture of Biogen Inc and Samsung Biologics  , was approved by European Union regulators, the  partners said on Thursday.  The new drug, Imraldi, marks the third European Commission  approval for ""biosimilar"" versions from the joint venture,  Samsung Bioepis, of drugs in a class known as TNF inhibitors."
BIIB,BIIB:UW,BBG000C18861,"ADMS Soars On FDA Nod, EARS Gets An Earful, Thumbs Up For BIIB's Humira Biosim",2017-08-25 02:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r3NZwQRzQNs/adms-soars-on-fda-nod-ears-gets-an-earful-thumbs-up-for-biibs-humira-biosim-20170825-00064,"ADMS Soars On FDA Nod, EARS Gets An Earful, Thumbs Up For BIIB's Humira Biosim"
BIIB,BIIB:UW,BBG000C18861,"Samsung, Biogen version of AbbVie's Humira approved in Europe",2017-08-25 00:57:18 +0000,https://finance.yahoo.com/news/samsung-biogen-version-abbvies-humira-005718433.html?.tsrc=rss,"Biogen Inc's version of AbbVie  Inc's blockbuster arthritis drug Humira has been  approved by European Union regulators, Biogen and joint venture  partner Samsung Biologics said on Thursday.  The new drug, Imraldi, marks the third European Commission  approval for ""biosimilar"" versions from joint venture Samsung  Bioepis of drugs in a class known as TNF inhibitors."
BIIB,BIIB:UW,BBG000C18861,"IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union",2017-08-24 23:05:00 +0000,https://finance.yahoo.com/news/imraldi-biogen-adalimumab-biosimilar-referencing-230500752.html?.tsrc=rss,"The European Commission granted a marketing authorization for IMRALDI® , an adalimumab biosimilar referencing Humira®.1"
BIIB,BIIB:UW,BBG000C18861,How Ionis’s Spinraza Performed in 2Q17,2017-08-24 13:07:27 +0000,http://finance.yahoo.com/r/4f296d01-ca19-352d-b283-29f87a894c1f/how-ioniss-spinraza-performed-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Ionis Pharmaceuticals' (IONS) Spinraza (Nusinersen) is a drug designed for the treatment of patients with spinal muscular atrophy (or SMA).
BIIB,BIIB:UW,BBG000C18861,"Orbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells Centene ...",2017-08-23 22:37:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8srIcgQhMh4/orbimed-advisors-llc-buys-cigna-corp-clovis-oncology-inc-gilead-sciences-inc-sells-centene-cm836259,Orbimed Advisors Llc New Purchases CI CLVS EVHC JUNO IOVA IART CTIC NVUS ARGX VRNA Added Positions GILD MYL BIIB ALNY REGN CELG IMMU JNJ GBT NVRO Reduced Positions HCA PFE SHPG BMY AET INCY IRWD BMRN AGN BSX Sold Out CNC
BIIB,BIIB:UW,BBG000C18861,Ionis Reports Revenue Growth in 2Q17,2017-08-23 22:06:44 +0000,http://finance.yahoo.com/r/a55daf7e-39ad-3321-94f3-079a0c439d02/ionis-reports-revenue-growth-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Ionis (IONS) is a biopharmaceutical company that develops and commercializes RNA-targeted therapies.
BIIB,BIIB:UW,BBG000C18861,Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much,2017-08-23 21:38:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S2vukS9Itr8/heres-the-simple-reason-why-multiple-sclerosis-drugs-cost-so-much-cm836219,Two members of the U S House of Representatives Committee on Oversight and Government Reform want to know why the prices of multiple sclerosis MS drugs are so high Rep 160 Elijah Cummings D Md and Rep Peter Welch D Vt have sent letters to seven drugmakers including
BIIB,BIIB:UW,BBG000C18861,Here&apos;s the Simple Reason Why Multiple Sclerosis Drugs Cost So Much,2017-08-23 19:42:00 +0000,http://finance.yahoo.com/r/843de9e1-1673-3c66-ada0-7b593133212b/heres-the-simple-reason-why-multiple-sclerosis-dru.aspx?yptr=yahoo&.tsrc=rss,"It&apos;s not just Biogen, Teva, and other drugmakers. It&apos;s the entire system."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe",2017-08-23 13:42:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rTLUDBHEcDc/biotech-stock-roundup-eu-label-expansion-for-alexion-biib-facing-drug-price-probe-cm835901,Alexion Pharmaceuticals ALXN got a boost with the EU approving its key revenue driver Soliris for an additional indication Meanwhile Biogen BIIB was in the news with an investigation being launched into the rising prices of multiple sclerosis MS drugs The investigation has been launched
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe",2017-08-23 11:56:11 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-eu-label-115611574.html?.tsrc=rss,Key highlights include regulatory approvals for companies like Alexion (ALXN) and Ironwood while Biogen is one of the companies facing an investigation into the pricing of multiple sclerosis drugs.
BIIB,BIIB:UW,BBG000C18861,How Allergan’s International Segment Performed in 2Q17,2017-08-23 11:37:09 +0000,http://finance.yahoo.com/r/c09cbf72-70b9-3692-b2d7-35fb6772ed1b/how-allergans-international-segment-performed-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Allergan’s (AGN) international business includes total revenues from the sales of branded products as well as aesthetics products outside the US markets.
BIIB,BIIB:UW,BBG000C18861,ETF Topper: Biotechnology Isn't Totally on the Outs,2017-08-22 21:29:00 +0000,http://finance.yahoo.com/r/3e7342d6-43f8-3f07-8edb-cf07ee16b19c/etf-topper-biotechnology-isnt-totally-on-the-outs-1503437394?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Technology stocks led the S&P 500 on Tuesday, but in exchange-traded fund land, those tracking biotech stocks were the real winners. The SPDR S&P Biotech ETF (XBI) and First Trust NYSE Arca Biotechnology ..."
BIIB,BIIB:UW,BBG000C18861,How Allergan’s US Specialized Therapeutics Segment Performed in 2Q17,2017-08-22 13:07:36 +0000,http://finance.yahoo.com/r/9215aa76-8b09-3de4-a49c-1ed56baa2894/how-allergans-us-specialized-therapeutics-segment-performed-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"The US Specialized Therapeutics segment reported revenues of $1.7 billion in 2Q17, a 15.2% increase as compared to $1.5 billion during 2Q16."
BIIB,BIIB:UW,BBG000C18861,Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why,2017-08-21 15:45:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zk1JPQZtteU/biogen-6-other-multiple-sclerosis-drug-stocks-in-focus-heres-why-cm834684,Drug pricing is back in the news with an investigation being launched by Rep Elijah E Cummings and Rep Peter Welch into the skyrocketing prices of multiple sclerosis MS drugs MS an unpredictable and often disabling disease of the central nervous system CNS interrupts the flow
BIIB,BIIB:UW,BBG000C18861,Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here&apos;s Why,2017-08-21 13:31:01 +0000,https://finance.yahoo.com/news/biogen-6-other-multiple-sclerosis-133101020.html?.tsrc=rss,"Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis (""MS"") drugs."
BIIB,BIIB:UW,BBG000C18861,"[$$] Biogen Treads Tricky Path Between Politicians, Investors",2017-08-21 04:23:11 +0000,http://finance.yahoo.com/r/90dcf9f2-02d1-3ea2-9244-241308dba6ad/biogen-treads-tricky-path-between-politicians-investors-1503067399?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Biogen is taking a political risk with aggressive multiple sclerosis drug pricing, but the company is under pressure to boost its share price."
BIIB,BIIB:UW,BBG000C18861,"[$$] Biogen Treads Tricky Path Between Politicians, Investors",2017-08-18 22:24:25 +0000,http://finance.yahoo.com/r/90dcf9f2-02d1-3ea2-9244-241308dba6ad/biogen-treads-tricky-path-between-politicians-investors-1503067399?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Biogen is taking a political risk with aggressive multiple sclerosis drug pricing, but the company is under pressure to boost its share price."
BIIB,BIIB:UW,BBG000C18861,"Orbimed Advisors Llc Buys Cigna Corp, Clovis Oncology Inc, Gilead Sciences Inc, Sells Centene ...",2017-08-18 19:37:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/quy__G9HnE0/orbimed-advisors-llc-buys-cigna-corp-clovis-oncology-inc-gilead-sciences-inc-sells-centene-cm834160,Orbimed Advisors Llc New Purchases CI CLVS EVHC JUNO IOVA IART CTIC NVUS ARGX VRNA Added Positions GILD MYL BIIB ALNY REGN CELG IMMU JNJ GBT NVRO Reduced Positions HCA PFE SHPG BMY AET INCY IRWD BMRN AGN BSX Sold Out CNC
BIIB,BIIB:UW,BBG000C18861,We Did The Math OEF Can Go To $119,2017-08-18 14:39:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4dZPpcSBiAs/we-did-the-math-oef-can-go-to-119-cm833927,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BIIB,BIIB:UW,BBG000C18861,"Notable Thursday Option Activity: DE, NVDA, BIIB",2017-08-17 19:39:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DwGowL90UCo/notable-thursday-option-activity-de-nvda-biib-cm833498,Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in Deere amp Co Symbol DE where a total of 22 127 contracts have traded so far representing approximately 2 2 million underlying shares That amounts to about 118 7 of DE s
BIIB,BIIB:UW,BBG000C18861,What's Up With Biogen?,2017-08-17 17:16:00 +0000,http://finance.yahoo.com/r/0f0f3ef4-c8a2-3bab-9696-e925af74bb1b/whats-up-with-biogen-1502990176?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Biogen (BIIB) are falling today, which in itself isn’t hard to fathom given that the broader biotech sector is in decline. The iShares Nasdaq Biotechnology ETF (IBB) has dropped more than 1.1% ..."
BIIB,BIIB:UW,BBG000C18861,Today's Research Reports on Stocks to Watch: Biogen Inc. and MannKind Corporation,2017-08-17 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000413.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 17, 2017 / Biogen saw its market cap increase over $1 billion in Wednesday trading after Goldman Sachs took a big bet on the company by adding it to its ""conviction ..."
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-08-17 12:02:40 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120240328.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,Race For A New Alzheimer's Drug,2017-08-17 07:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lbkiaxnPQ74/race-for-a-new-alzheimers-drug-20170817-00301,Race For A New Alzheimer's Drug
BIIB,BIIB:UW,BBG000C18861,Goldman Sachs Bet on Biogen’s Potential Landmark Alzheimer’s Drug Props Up Stock,2017-08-16 18:30:11 +0000,https://finance.yahoo.com/news/goldman-sachs-bet-biogen-potential-183011242.html?.tsrc=rss,Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.
BIIB,BIIB:UW,BBG000C18861,​Biogen gains $1B in value after Goldman Sachs touts Alzheimer’s drug,2017-08-16 16:40:14 +0000,http://finance.yahoo.com/r/2c5cbd26-7333-303f-a469-a9c56322d3b2/biogen-gains-1b-in-value-after-goldman-sachs.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen Inc. gained more than $1 billion in market value Wednesday morning after Goldman Sachs, one of the world’s largest investment banks, added the drug developer to its closely-watched Equity Conviction List.  Goldman Sachs analysts Terence Flynn and Cameron Bradshaw issued a research note this morning announcing that Cambridge-based Biogen (BIIB) was added to the list, which is essentially a strong recommendation to general investors to buy stock in a certain company.  In their research note, Flynn and Bradshaw pointed specifically to Biogen’s experimental drug to treat Alzheimer’s disease, called aducanumab, as a prime reason for the company’s inclusion on the list."
BIIB,BIIB:UW,BBG000C18861,"Noteworthy ETF Inflows: TQQQ, GOOG, AMGN, BIIB",2017-08-16 16:34:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dICcupno64A/noteworthy-etf-inflows-tqqq-goog-amgn-biib-cm832828,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares UltraPro QQQ Symbol TQQQ where we have detected an approximate 55 6 million dollar inflow that s a 2 9 increase week over week in outstanding
BIIB,BIIB:UW,BBG000C18861,Goldman has a new favorite biotech because of potential Alzheimer's blockbuster,2017-08-16 14:51:25 +0000,http://finance.yahoo.com/r/78a41c65-4d67-3e65-baed-7da90ec45fe5/104656053?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104656053&yptr=yahoo&.tsrc=rss,"Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a 'blockbuster' drug."
BIIB,BIIB:UW,BBG000C18861,Goldman has a new favorite biotech because of potential A...,2017-08-16 14:46:00 +0000,https://finance.yahoo.com/video/goldman-favorite-biotech-because-potential-144600305.html?.tsrc=rss,Research analyst Terence Flynn added Biogen to Goldman Sachs' Americas Conviction List on optimism its Alzheimer's drug may be the first to successfully slow the progression of the disease.
BIIB,BIIB:UW,BBG000C18861,Biogen: Goldman Has Conviction!,2017-08-16 14:08:00 +0000,http://finance.yahoo.com/r/7b7787d2-935f-3328-9c2a-a0daa604d2bf/biogen-goldman-has-conviction-1502892539?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biogen (BIIB) has had a good, though not great year. Is it time to add it to your portfolio? Shares of Biogen have gained 11.5% so far this year, and while that's better than the S&P 500's 10.3% rise during ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List,2017-08-16 14:07:00 +0000,http://finance.yahoo.com/r/5fe4954b-c660-3d0f-873d-6f33167ee4f2/biogen-shares-climb-after-goldman-adds-it-to-conviction-buy-list.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"'Biogen has a relatively under-leverage balance sheet, and we expect  and US cash to grow.'"
BIIB,BIIB:UW,BBG000C18861,Biogen Added To Goldman's Conviction List On Alzheimer's Promise,2017-08-16 13:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9PMXYzNCCGY/biogen-added-to-goldmans-conviction-list-on-alzheimers-promise-20170816-00814,Biogen Added To Goldman's Conviction List On Alzheimer's Promise
BIIB,BIIB:UW,BBG000C18861,Goldman has a new favorite biotech because of potential Alzheimer&apos;s blockbuster,2017-08-16 13:18:07 +0000,https://finance.yahoo.com/news/goldman-favorite-biotech-because-potential-131807843.html?.tsrc=rss,"Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a &apos;blockbuster&apos; drug."
BIIB,BIIB:UW,BBG000C18861,Goldman Sachs adds Biogen to its Americas Conviction List,2017-08-16 13:12:17 +0000,http://finance.yahoo.com/r/8e00eb0c-ce8c-3548-b361-95e2f913959b/Story.aspx?guid=A99F3B5D-8FB7-4421-9783-F6EBC0DEB453&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Goldman Sachs added Biogen Inc. to its Americas Conviction List on Wednesday. Biogen shares surged as much as 1.4% in premarket trade Wednesday. Biogen was previously upgraded to buy in late July by Goldman. ...
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-08-16 12:02:24 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120224602.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,"What You See, and What You Get: The Neurology of Perception",2017-08-16 00:35:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pvFLqj7qJNY/what-you-see-and-what-you-get-the-neurology-of-perception-cm832527,1 00 Neuroscience The 4 Theaters Of The Brain 5 00 Investors Train Their Brains to Trade Assumption and Perception 10 00 Neurology Is The New Oncology The Boom In Brain Sciences 14 00 Biotech Companies With Breakthrough
BIIB,BIIB:UW,BBG000C18861,Pfizer’s Declining-Revenue Products in 2Q17,2017-08-15 11:36:43 +0000,http://finance.yahoo.com/r/6a6eb8be-826d-366f-89b1-e22fdcc5e854/pfizers-declining-revenue-products-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,We discussed the products that contribute to the growth of Pfizer’s (PFE) revenues in 2Q17. Let's now take a look at the products that have impacted revenue growth in 2Q17.
BIIB,BIIB:UW,BBG000C18861,"Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2017",2017-08-14 13:15:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LymzjUiVA4Y/amgen-inc-amgn-ex-dividend-date-scheduled-for-august-15-2017-cm831525,Amgen Inc AMGN will begin trading ex dividend on August 15 2017 A cash dividend payment of 1 15 per share is scheduled to be paid on September 08 2017 Shareholders who purchased AMGN prior to the ex dividend date are eligible for the cash dividend payment This marks the 3rd quarter
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-08-12 12:02:38 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120238714.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,"Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs",2017-08-11 21:36:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0PNx02wL43U/ionis-pharmaceuticals-inc-growing-royalties-an-advancing-pipeline-and-getting-back-rights-to-some-drugs-cm831170,Ionis Pharmaceuticals NASDAQ IONS reported second quarter earnings earlier this week and then followed up on Friday with a disclosure that it s getting full rights back to two of its drugs inotersen and IONIS FB LRx after GlaxoSmithKline NYSE GSK decided not to license
BIIB,BIIB:UW,BBG000C18861,"Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs",2017-08-11 20:07:00 +0000,http://finance.yahoo.com/r/b38182a2-d547-3c08-9cb1-25d62313a97b/ionis-pharmaceuticals-inc-growing-royalties-advanc.aspx?yptr=yahoo&.tsrc=rss,"A solid second quarter from the biotech, with growing royalties on Spinraza and two more drugs to be reviewed by regulators, and it regained full rights to two drugs after its partner declined to license them."
BIIB,BIIB:UW,BBG000C18861,"IHS Markit Score downgrades Biogen Inc to 60 out of 100, ranking positively in only one out of three available IHS Markit categories.",2017-08-10 12:04:07 +0000,https://finance.yahoo.com/news/ihs-markit-score-downgrades-biogen-120407575.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene,2017-08-10 11:00:00 +0000,https://finance.yahoo.com/news/agtc-files-investigational-drug-application-110000947.html?.tsrc=rss,"GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 10, 2017-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ..."
BIIB,BIIB:UW,BBG000C18861,AGTC Files IND For Treatment Of X-Linked Retinitis Pigmentosa - Quick Facts,2017-08-10 07:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TgULh4DCXh8/agtc-files-ind-for-treatment-of-xlinked-retinitis-pigmentosa--quick-facts-20170810-00399,AGTC Files IND For Treatment Of X-Linked Retinitis Pigmentosa - Quick Facts
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix",2017-08-09 15:40:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j905mtG3lQI/the-zacks-analyst-blog-highlights-biogen-activision-cigna-kraft-heinz-and-equinix-cm829435,For Immediate Release Chicago IL August 09 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix",2017-08-09 13:52:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-biogen-135201910.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix"
BIIB,BIIB:UW,BBG000C18861,See what the IHS Markit Score report has to say about Biogen Inc.,2017-08-09 12:04:07 +0000,https://finance.yahoo.com/news/see-ihs-markit-score-report-120407825.html?.tsrc=rss,Biogen Inc NASDAQ/NGS:BIIB
BIIB,BIIB:UW,BBG000C18861,"Top Analyst Reports for Biogen, Activision & Cigna",2017-08-08 23:35:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3wt9BzRcg-M/top-analyst-reports-for-biogen-activision-cigna-cm829130,Tuesday August 8 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Biogen BIIB Activision ATVI and Cigna CI These research reports have been hand picked from the
BIIB,BIIB:UW,BBG000C18861,"Top Analyst Reports for Biogen, Activision & Cigna",2017-08-08 20:33:08 +0000,https://finance.yahoo.com/news/top-analyst-reports-biogen-activision-203308206.html?.tsrc=rss,"Top Analyst Reports for Biogen, Activision & Cigna"
BIIB,BIIB:UW,BBG000C18861,"ETFs with exposure to Biogen, Inc. : August 8, 2017",2017-08-08 20:05:51 +0000,http://finance.yahoo.com/r/e891c2c9-7ab0-33d6-a77e-a64bbca69af4/etfs-with-exposure-to-biogen-inc-august-8-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biogen, Inc. Here are 5 ETFs with the largest exposure to BIIB-US. Comparing the performance and risk of Biogen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
BIIB,BIIB:UW,BBG000C18861,"Apple, Microsoft Lift Dow To 11th Win; 2 Equity Plays Near Buy",2017-08-08 18:34:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lwr-yGc7kvo/apple-microsoft-lift-dow-to-11th-win-2-equity-plays-near-buy-cm828656,Stocks were holding slim gains in late afternoon trading Tuesday as Apple AAPL and Microsoft MSFT 160 lifted 160 the Dow Jones industrial average to its 11th straight win ibd display video id 2070780 width 50 float left autostart true PowerShares QQQ
BIIB,BIIB:UW,BBG000C18861,"Noteworthy ETF Inflows: VHT, TMO, BIIB, AET",2017-08-08 16:38:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EyVak8WlIPU/noteworthy-etf-inflows-vht-tmo-biib-aet-cm828859,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Health Care ETF Symbol VHT where we have detected an approximate 40 6 million dollar inflow that s a 0 6 increase week over week in outstanding
BIIB,BIIB:UW,BBG000C18861,Dow Guns For 11th Straight; Moat-Protected Stocks In Buy Zone?,2017-08-08 15:36:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T-e1BdtRpFE/dow-guns-for-11th-straight-moat-protected-stocks-in-buy-zone-cm828656,Several equity ETFs are testing support at their 50 day moving average lines as the market continues to trade near record levels ibd display video id 2070020 width 50 float left autostart true Among the latest to take the dip VanEck Vectors Morningstar Wide Moat
BIIB,BIIB:UW,BBG000C18861,"PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y",2017-08-07 22:36:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ycxx52tGzN8/pdl-biopharma-pdli-q2-earnings-beat-revenues-rise-yy-cm828395,PDL BioPharma Inc PDLI reported earnings of 26 cents per share in the second quarter of 2017 surpassing both the Zacks Consensus Estimate and the year ago earnings of 9 cents per share The company generated total revenue of 143 8 million in the quarter significantly skyrocketing
BIIB,BIIB:UW,BBG000C18861,These 3 Biotechs Just Crushed Analyst Expectations,2017-08-07 15:41:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0b7j7jeHDs4/these-3-biotechs-just-crushed-analyst-expectations-cm828104,Earnings season is under way and biotech business appears to be booming But it takes more than just a good quarter to know if a biotech is poised for sustainable long term growth With many companies issuing conservative profit forecasts at the start of the year second quarter
BIIB,BIIB:UW,BBG000C18861,These 3 Biotechs Just Crushed Analyst Expectations,2017-08-07 13:31:00 +0000,http://finance.yahoo.com/r/fcd2ee6f-6d51-37f6-972d-03160858cd3c/these-3-biotechs-just-crushed-analyst-expectations.aspx?yptr=yahoo&.tsrc=rss,"But before you invest in any of them, you should read this."
BIIB,BIIB:UW,BBG000C18861,See Which Of The Latest 13F Filers Holds Biogen,2017-08-04 18:58:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sVOrm9zMH9U/see-which-of-the-latest-13f-filers-holds-biogen-cm827442,At Holdings Channel we have reviewed the latest batch of the 24 most recent 13F filings for the 06 30 2017 reporting period and noticed that Biogen Inc Symbol BIIB was held by 10 of these funds When hedge fund managers appear to be thinking alike we find it is a good idea to take a
BIIB,BIIB:UW,BBG000C18861,AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa,2017-08-03 20:01:00 +0000,https://finance.yahoo.com/news/agtc-announces-u-fda-orphan-200100019.html?.tsrc=rss,"GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 03, 2017-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ..."
BIIB,BIIB:UW,BBG000C18861,Is a Beat in Store for Ionis (IONS) This Earnings Season?,2017-08-01 23:54:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Hfio6F2Weyw/is-a-beat-in-store-for-ionis-ions-this-earnings-season-cm825363,We expect Ionis Pharmaceuticals Inc IONS to beat expectations when it reports second quarter 2017 results on Aug 8 Last quarter the company delivered a positive earnings surprise of 130 In fact it has pulled off a positive surprise in three of the trailing four quarters recording
BIIB,BIIB:UW,BBG000C18861,Is a Beat in Store for Ionis (IONS) This Earnings Season?,2017-08-01 21:48:09 +0000,https://finance.yahoo.com/news/beat-store-ionis-ions-earnings-214809440.html?.tsrc=rss,"Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2."
BIIB,BIIB:UW,BBG000C18861,3 ETFs to Watch Out for on Biotech Earnings,2017-08-01 04:26:04 +0000,https://finance.yahoo.com/news/3-etfs-watch-biotech-earnings-042604658.html?.tsrc=rss,Major players in the biotech space reported their second quarter 2017 results.
BIIB,BIIB:UW,BBG000C18861,7 Explosive Healthcare Stocks to Buy Now,2017-07-31 23:54:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/02-UkV_z2Ig/7-explosive-healthcare-stocks-to-buy-now-cm824622,InvestorPlace Stock Market News Stock Advice amp Trading Tips The healthcare sector along with its many sub industries has taken a leadership role in the market again in 2017 The strength in the sector can be attributed to a few things First the sector
BIIB,BIIB:UW,BBG000C18861,"Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences",2017-07-31 13:00:00 +0000,https://finance.yahoo.com/news/biogen-appoints-anabella-villalobos-senior-130000388.html?.tsrc=rss,"Biogen  today announced the appointment of Anabella Villalobos, Ph.D., as senior vice president, Biotherapeutic & Medicinal Sciences . Dr. Villalobos will lead Biogen’s BTMS organization in the delivery of high-quality, differentiated molecules to the clinic."
BIIB,BIIB:UW,BBG000C18861,"Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line",2017-07-28 20:59:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0jE04gEgUTs/acorda-acor-q2-earnings-miss-estimates-revenues-in-line-cm823637,Acorda Therapeutics Inc ACOR reported adjusted earnings of 6 cents per share in the second quarter of 2017 including the impact of stock based compensation expenses compared with a loss of 41 cents per share in the year ago quarter Acorda s shares have lost more than 3 on
BIIB,BIIB:UW,BBG000C18861,"Notable ETF Inflow Detected - VHT, LLY, TMO, BIIB",2017-07-28 15:57:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/30OvFeGcSz8/notable-etf-inflow-detected-vht-lly-tmo-biib-cm823222,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Health Care ETF Symbol VHT where we have detected an approximate 33 3 million dollar inflow that s a 0 5 increase week over week in outstanding
BIIB,BIIB:UW,BBG000C18861,Abarca Health Announces Innovative Value-Based Contract With Biogen For Multiple Sclerosis Therapies,2017-07-28 14:00:00 +0000,https://finance.yahoo.com/news/abarca-health-announces-innovative-value-140000136.html?.tsrc=rss,"The agreement is the first to apply value-based contracts to cover Medicaid patients in the United States.  SAN JUAN, Puerto Rico, July 28, 2017 /PRNewswire/ -- Abarca Health, a pharmacy benefit management (PBM) and technology company that serves more than two million lives across the nation, has signed a value-based reimbursement contract with Biogen Inc. (BIIB) for select products in Biogen's leading multiple sclerosis (MS) portfolio.  The agreement places accountability on Biogen to deliver safety, efficacy, and value for the patients who receive these life-impacting therapies and for the payers who finance them."
BIIB,BIIB:UW,BBG000C18861,Biogen’s Biosimilars Witnessed High Growth in 2Q17,2017-07-28 13:08:36 +0000,http://finance.yahoo.com/r/e581d10f-be6d-30de-b342-487ae2597ba2/biogens-biosimilars-witnessed-high-growth-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Biogen’s (BIIB) biosimilars franchise reported revenue of ~$91 million, compared to $31 million in 2Q16."
BIIB,BIIB:UW,BBG000C18861,Biogen’s Spinraza Saw High Growth in 2Q17,2017-07-28 11:40:00 +0000,http://finance.yahoo.com/r/51f62d42-7dde-3af4-a469-b957680b74bb/biogens-spinraza-saw-high-growth-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Biogen’s (BIIB) Spinraza generated revenue of ~$203 million, compared to $47 million in 1Q17."
BIIB,BIIB:UW,BBG000C18861,How Did Biogen’s Multiple Sclerosis Drugs Perform in 2Q17?,2017-07-27 22:05:43 +0000,http://finance.yahoo.com/r/4be77983-d401-3e2f-9073-5b45d5585118/how-did-biogens-multiple-sclerosis-drugs-perform-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Biogen’s (BIIB) Tecfidera generated revenue of ~$1.1 billion, which reflected a ~13% rise year-over-year (or YoY) and a ~16% rise quarter-over-quarter."
BIIB,BIIB:UW,BBG000C18861,Biogen’s Interferons Witnessed Steady Growth in 2Q17,2017-07-27 20:35:43 +0000,http://finance.yahoo.com/r/8023c043-d1a8-36c3-bf3b-04af7f785ad9/biogens-interferons-witnessed-steady-growth-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Biogen’s (BIIB) net revenue from the sale of interferons amounted to ~$691 million, a 5% fall year-over-year (or YoY) and a ~7% rise quarter-over-quarter."
BIIB,BIIB:UW,BBG000C18861,How Did Biogen Perform in 2Q17?,2017-07-27 19:00:06 +0000,http://finance.yahoo.com/r/4cec35d5-8945-3cb1-b9b6-8fb9ae3982a3/how-did-biogen-perform-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Biogen (BIIB) generated revenue of ~$3.1 billion, a 6% rise year-over-year (or YoY) and a 9% rise quarter-over-quarter."
BIIB,BIIB:UW,BBG000C18861,Abarca Health And Biogen Announces Innovative Value-Based Contract For Multiple Sclerosis Therapies,2017-07-27 18:41:00 +0000,https://finance.yahoo.com/news/abarca-health-biogen-announces-innovative-184100730.html?.tsrc=rss,"The agreement is the first to apply value-based contracts to cover patients in Puerto Rico.  SAN JUAN, Puerto Rico, July 27, 2017 /PRNewswire/ -- Abarca Health, a pharmacy benefit management (PBM) and technology company that serves more than two million lives across the nation, has signed a value-based reimbursement contract with Biogen Inc. (BIIB) for select products in Biogen's leading multiple sclerosis (MS) portfolio.  The agreement places accountability on Biogen to deliver safety, efficacy, and value for the patients who receive these life-impacting therapies and for the payers who finance them."
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. :BIIB-US: Earnings Analysis: Q2, 2017 By the Numbers : July 27, 2017",2017-07-27 16:06:43 +0000,http://finance.yahoo.com/r/62cb2ec6-e4fe-38b5-9158-f2555a2b54ec/biogen-inc-biib-us-earnings-analysis-q2-2017-by-the-numbers-july-27-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Biogen, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Biogen, Inc. – Amgen Inc. and Johnson & Johnson (AMGN-US and JNJ-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 2,727.90 million, Net Earnings ... Read more
<b>(Read more...)</b>"
BIIB,BIIB:UW,BBG000C18861,Today's Research Reports on Trending Tickers: Biogen Inc. and Pluristem Therapeutics Inc.,2017-07-27 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-trending-tickers-120000551.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 27, 2017 / U.S. markets continued to reach record highs Wednesday as upbeat earnings from bellwether companies, such as Boeing Co. and AT&T Inc., continue to boost investor ..."
BIIB,BIIB:UW,BBG000C18861,Corporate News Blog - Alpine Immune Sciences Goes Public on NASDAQ; Announces the Completion of an Immuno-Oncology Merger with Nivalis Therapeutics,2017-07-27 11:10:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-alpine-immune-111000775.html?.tsrc=rss,"Research Desk Line-up: Biogen Post Earnings Coverage LONDON, UK / ACCESSWIRE / July 27, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Nivalis Therapeutics, ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Inc Wants to Be the &quot;Fastest-Growing Large-Cap Biotech Company&quot;,2017-07-26 21:58:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BDeXT9wEtSc/biogen-inc-wants-to-be-the-fastest-growing-large-cap-biotech-company-cm822075,Biogen NASDAQ BIIB started 160 the biotech earnings season off with a bang generating enough revenue for the company to have confidence to increase its revenue guidance for the year Earnings weren t nearly as hot but Biogen has a good excuse one time investments in the company
BIIB,BIIB:UW,BBG000C18861,"Market Close Report: Historical high reached as NASDAQ Composite Index closes at 6,422.75.",2017-07-26 20:49:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_7nhgE1Q1sg/market-close-report-historical-high-reached-as-nasdaq-composite-index-closes-at-642275-cm822041,Wednesday s session closes with the NASDAQ Composite Index reaching a historical high The index closed at 6 422 75 up 10 58 for the day The index had a previous high 6412 1735 on 07 25 2017 The total shares traded for the NASDAQ was over 2 2 billion Declining stocks led advancers by 1 05 to
BIIB,BIIB:UW,BBG000C18861,Biogen Inc Wants to Be the &quot;Fastest-Growing Large-Cap Biotech Company&quot;,2017-07-26 20:21:00 +0000,http://finance.yahoo.com/r/869d901e-b0dd-33d1-b64e-ea7048a89580/biogen-inc-wants-to-be-the-fastest-growing-large-c.aspx?yptr=yahoo&.tsrc=rss,"After a solid second quarter, management lays out plans for future growth."
BIIB,BIIB:UW,BBG000C18861,"Let’s Hear It for Biogen Inc (BIIB) Drug Spinraza’s Blockbuster Potential, Raves Cowen Top Analyst",2017-07-26 17:48:05 +0000,https://finance.yahoo.com/news/let-hear-biogen-inc-biib-174805204.html?.tsrc=rss,"Coming off its successful launch of Spinraza, the first drug approved to treat children and adults with spinal muscular atrophy (SMA), Biogen Inc (NASDAQ:BIIB) released second quarter revenues yesterday.  Tecfidera, Rituxan and Gazyva, Avonex and Plegridy all outclassed consensus, while Plegridy and Tysabri fell in line with the Street."
BIIB,BIIB:UW,BBG000C18861,The biotech Goldman Sachs loves,2017-07-26 17:33:00 +0000,https://finance.yahoo.com/video/biotech-goldman-sachs-loves-173300453.html?.tsrc=rss,Is this entire sector set to break out?
BIIB,BIIB:UW,BBG000C18861,Biogen: Now That's More Like It!,2017-07-26 15:00:00 +0000,http://finance.yahoo.com/r/aa8fb3f9-82f1-38ea-af58-c3d16cd01f5e/biogen-now-thats-more-like-it-1501081225?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Yesterday, shares of Biogen (BIIB) finished lower on the day despite the fact that it reported Street-beating earnings. Today, they're gaining what they should have yesterday after Goldman Sachs upgraded ..."
BIIB,BIIB:UW,BBG000C18861,"19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug",2017-07-26 14:09:43 +0000,https://finance.yahoo.com/news/19-upside-predicted-biogen-goldman-140943380.html?.tsrc=rss,"Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB ) from Neutral to Buy and raised its price target to $338 on the strength of the pharmaceutical company’s Alzheimer’s drug, Aducanumab. Analyst Terence Flynn ..."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug",2017-07-26 14:03:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/02xDNr1AwQk/biotech-stock-roundup-amgen-biogen-top-q2-estimates-update-on-incyte-ra-drug-cm821419,Key biotech stocks Amgen AMGN and Biogen BIIB reported second quarter results yesterday both companies surpassed earnings and sales estimates There were several other key updates as well from companies like Incyte INCY and The Medicines Co MDCO 160 Recap of the Week s
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug",2017-07-26 12:15:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-amgen-biogen-121512704.html?.tsrc=rss,Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.
BIIB,BIIB:UW,BBG000C18861,Biogen shares surge 2% after upgrade to buy at Goldman Sachs,2017-07-26 12:15:06 +0000,http://finance.yahoo.com/r/44dca47c-e469-344a-ad05-5a87d2cbf8be/Story.aspx?guid=466EF0D2-3A8F-4A78-823B-B43ED7796783&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Biogen Inc. shares surged as much as 2% in premarket trade Wednesday after the company was upgraded to buy at Goldman Sachs and its price target was raised by nearly 20% to $338. Biogen shares closed at ...
BIIB,BIIB:UW,BBG000C18861,"Lgt Capital Partners Ltd. Buys Dr Pepper Snapple Group Inc, UnitedHealth Group Inc, Starbucks ...",2017-07-26 10:56:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uWY7Q_948jI/lgt-capital-partners-ltd-buys-dr-pepper-snapple-group-inc-unitedhealth-group-inc-starbucks-cm821357,Lgt Capital Partners Ltd New Purchases DPS C Added Positions UNH SBUX AKAM BIIB CL MS CELG AMG VZ NDAQ Reduced Positions AWK MRK CERN AQN MCD ISRG DVMT AAPL MAS Sold Out INDA TGNA WFM CARS New Purchases DPS C
BIIB,BIIB:UW,BBG000C18861,Validea Warren Buffett Strategy Daily Upgrade Report,2017-07-26 08:57:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JQGUurmTEh4/validea-warren-buffett-strategy-daily-upgrade-report-cm821338,The following are today s upgrades for Validea s Patient Investor model based on the published strategy of Warren Buffett This strategy seeks out firms with long term predictable profitability and low debt that trade at reasonable valuations The following are today s upgrades for Validea
BIIB,BIIB:UW,BBG000C18861,​Biogen to ‘streamline operations’ and invest more in R&D,2017-07-26 02:10:11 +0000,http://finance.yahoo.com/r/299d42d2-9ccf-3eeb-9af3-9386fdfa68ac/biogen-to-streamline-operations-and-invest-more.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"While announcing record-breaking quarterly revenues and raising its forecast for full-year revenue, Biogen said Tuesday that it plans to “streamline its operations” in order to prioritize spending on developing and commercializing its drugs.  The statement was included in Biogen’s (BIIB) second quarter earnings release as part of a corporate strategy update.  The company also announced a ""new priority for capital deployment"" through increased business development activity, suggesting plans to increase merger activity in coming months."
BIIB,BIIB:UW,BBG000C18861,Biogen tops Street 2Q forecasts,2017-07-26 01:48:11 +0000,https://finance.yahoo.com/news/biogen-tops-street-2q-forecasts-104102429.html?.tsrc=rss,"On a per-share basis, the Cambridge, Massachusetts-based company said it had net income of $4.07. Earnings, adjusted for one-time gains and costs, came to $5.04 per share. The results surpassed Wall Street ..."
BIIB,BIIB:UW,BBG000C18861,Alphabet Did Nothing to Push S&P 500 and Nasdaq to Fresh Records,2017-07-26 00:00:00 +0000,http://finance.yahoo.com/r/ba747480-0a0f-33d4-95b6-9c68ebc847fa/earnings-wave-pushes-s-amp-p-500-and-nasdaq-to-fresh-records.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Wall Street at records.
BIIB,BIIB:UW,BBG000C18861,Edited Transcript of BIIB earnings conference call or presentation 25-Jul-17 12:00pm GMT,2017-07-25 23:57:07 +0000,https://finance.yahoo.com/news/edited-transcript-biib-earnings-conference-235707814.html?.tsrc=rss,Q2 2017 Biogen Inc Earnings Call
BIIB,BIIB:UW,BBG000C18861,Milan Prosecutor Investigates Biogen' Interactions With Healthcare Providers,2017-07-25 21:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g1K4-wc9OTE/milan-prosecutor-investigates-biogen-interactions-with-healthcare-providers-20170725-01741,Milan Prosecutor Investigates Biogen' Interactions With Healthcare Providers
BIIB,BIIB:UW,BBG000C18861,Biogen Says It's Under Investigation by Milan Prosecutor,2017-07-25 21:08:52 +0000,http://finance.yahoo.com/r/dbbe7eac-5ca3-3927-8627-e6895f9d804c/biogen-says-it-s-under-investigation-by-milan-prosecutor?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Biogen Inc. said its interactions with health-care providers in Italy are under investigation by a prosecutor in Milan.
BIIB,BIIB:UW,BBG000C18861,"Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up",2017-07-25 21:04:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o7FJP-Y9Nm4/biogen-biib-tops-q2-earnings-sales-spinraza-sales-up-cm821209,Biogen Inc BIIB a well known name in the multiple sclerosis MS market surpassed expectations both for earnings and sales in the second quarter of 2017 The drugmaker also raised its revenue guidance for 2017 as sales of its newest drug Spinraza spinal muscular atrophy
BIIB,BIIB:UW,BBG000C18861,This Biotech Nearly Tripled Street Expectations For One Key Drug,2017-07-25 20:49:40 +0000,http://finance.yahoo.com/r/c945cb02-af73-34ea-b3fc-ecdaf61d506a/biogen-rockets-on-consensus-smashing-q2-sales-profits?src=A00220&yptr=yahoo&.tsrc=rss,"Biogen popped early Tuesday after its spinal drug nearly tripled expectations in the second quarter, leading to a 4% guidance boost."
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen's Short-Term Pain To Yield Long-Term Gain,2017-07-25 20:06:00 +0000,http://finance.yahoo.com/r/c9ab8bdd-64d2-3c38-a1aa-60615201029e/biogens-short-term-pain-to-yield-long-term-gain-1501013196?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biogen announced better-than-expected second-quarter results and raised its forecast, yet shares surrendered this morning’s early gains.  In short, Biogen said it will reinvest more in the business and repurchase fewer shares.  Biogen (BIIB) said it earned $5.04 a share on revenue that rose 6.4%, to $3.08 billion."
BIIB,BIIB:UW,BBG000C18861,"Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up",2017-07-25 18:37:06 +0000,https://finance.yahoo.com/news/biogen-biib-tops-q2-earnings-183706708.html?.tsrc=rss,Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.
BIIB,BIIB:UW,BBG000C18861,Biogen: Where'd My Gains Go?,2017-07-25 18:30:00 +0000,http://finance.yahoo.com/r/aa6e273c-2c2c-3732-9f9b-26b5c1d8b910/biogen-whered-my-gains-go-1501007422?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Shares of Biogen (BIIB) traded up as much as 2.5% this morning after reporting earnings. Later they were down as much as 1.6%. Now they're up slightly on the day. What's going on? It's not Biogen's earnings. ...
BIIB,BIIB:UW,BBG000C18861,"Notable Tuesday Option Activity: CTRN, PCRX, BIIB",2017-07-25 17:00:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dn_4WYn1GQA/notable-tuesday-option-activity-ctrn-pcrx-biib-cm820983,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Citi Trends Inc Symbol CTRN where a total of 2 000 contracts have traded so far representing approximately 200 000 underlying shares That amounts to about 172 2 of CTRN s
BIIB,BIIB:UW,BBG000C18861,Wal-Mart Stores Inc (WMT) Stock Is Perking Up!,2017-07-25 16:57:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/41N0SD-kIfY/wal-mart-stores-inc-wmt-stock-is-perking-up-cm821067,InvestorPlace Stock Market News Stock Advice amp Trading Tips One of the quickest ways to identify what s moving on the Street is to sort your watch list by percentage change I did just that after Monday s trading and discovered that Wal Mart Stores Inc NYSE WMT shares
BIIB,BIIB:UW,BBG000C18861,Eli Lilly beats on earnings as stock dips,2017-07-25 16:55:00 +0000,https://finance.yahoo.com/video/eli-lilly-beats-earnings-stock-165500597.html?.tsrc=rss,CNBC's Meg Tirrell reports on Eli Lilly beating on earnings as the stock dips almost 4% and Biogen pops on an earnings beat.
BIIB,BIIB:UW,BBG000C18861,Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite,2017-07-25 16:35:00 +0000,http://finance.yahoo.com/r/7727bfd0-5fdc-33bd-855e-e3afca0bdc8c/biotech-movers-novavax-falls-again-after-new-data-on-rsv-vaccine-fails-to-excite.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Novavax, Medicines Co. and Biogen were among the biotech stock movers in premarket trading on July 25."
BIIB,BIIB:UW,BBG000C18861,"After strong quarter, Biogen rolls out growth strategy",2017-07-25 16:24:04 +0000,https://finance.yahoo.com/news/biogen-revenue-rises-6-4-104505993.html?.tsrc=rss,"Strong sales for its spinal muscular atrophy (SMA) drug, Spinraza, also spurred the U.S. drugmaker to raise its 2017 profit and revenue forecasts.  Spinraza could become one of the company's ""largest commercial assets, shifting the center of gravity for Biogen beyond MS"", CEO Michel Vounatsos said in a post-earnings conference call."
BIIB,BIIB:UW,BBG000C18861,"Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed",2017-07-25 16:08:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XznaTXdlKG4/lilly-lly-q2-earnings-top-baricitinib-re-filing-delayed-cm821037,Eli Lilly and Company LLY reported second quarter 2017 adjusted earnings per share of 1 11 which beat the Zacks Consensus Estimate of 1 04 by 6 7 Earnings rose 29 from the year ago quarter backed by volume driven pharma sales growth and higher profits Revenues Beat Quarterly
BIIB,BIIB:UW,BBG000C18861,"3 Stocks to Watch on Tuesday: Alphabet Inc (GOOGL), Biogen Inc (BIIB) and Michael Kors Holdings Ltd (KORS)",2017-07-25 15:56:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oK-scisMYm0/3-stocks-to-watch-on-tuesday-alphabet-inc-googl-biogen-inc-biib-and-michael-kors-holdings-ltd-kors-cm820958,InvestorPlace Stock Market News Stock Advice amp Trading Tips Despite a 0 4 move higher 160 from tech stocks helped by Apple Inc NASDAQ AAPL and Amazon com Inc NASDAQ AMZN U S equities suffered a broader down day Monday The
BIIB,BIIB:UW,BBG000C18861,"S&P 500 Hits All-Time High, Alphabet's Fall Pressures Nasdaq",2017-07-25 14:50:00 +0000,http://finance.yahoo.com/r/a36abb45-cfcf-3126-b286-ac2fab8477f3/s-amp-p-500-hits-intraday-high-but-alphabet-weighs-on-nasdaq.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Stocks are mixed.
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Tops Q2 Earnings and Revenue,2017-07-25 14:07:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O8jQXe_Y9b4/biogen-biib-tops-q2-earnings-and-revenue-cm820675,Cambridge MA based 160 Biogen Inc BIIB one of the world s leading biotechnology companies focuses on therapeutic areas including neurology and immunology The company is best known for its multiple sclerosis MS franchise comprising treatments like Avonex Tysabri Tecfidera and
BIIB,BIIB:UW,BBG000C18861,Dow Climbs As These Blue Chips Beat; Alphabet Drags On Nasdaq,2017-07-25 13:43:36 +0000,http://finance.yahoo.com/r/1e32a0a4-f5f0-3508-9ea9-bb238d997824/dow-futures-higher-as-cat-utx-beat-alphabet-drags-on-nasdaq?src=A00220&yptr=yahoo&.tsrc=rss,"Stocks were divided at the start bell Tuesday as opening gains from Caterpillar and McDonald&apos;s hoisted the Dow, and the Nasdaq was under early pressure from Alphabet and Seagate Technologies."
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Caterpillar, McDonald's to lift S&P, Dow at open",2017-07-25 12:55:23 +0000,https://finance.yahoo.com/news/us-stocks-caterpillar-mcdonalds-lift-125523439.html?.tsrc=rss,"The S&P and the Dow looked set to open  higher on Tuesday, helped by strong earnings from Caterpillar  and McDonald's, but Google-parent Alphabet may weigh on the  tech-heavy Nasdaq.  Caterpillar's shares rose 5.4 percent in premarket  trading after the company reported quarterly results that  smashed expectations and raised its full-year outlook for the  second time this year."
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Tops Q2 Earnings and Revenue,2017-07-25 12:17:12 +0000,https://finance.yahoo.com/news/biogen-biib-tops-q2-earnings-121712917.html?.tsrc=rss,Biogen (BIIB) reported better-than expected earnings in the second quarter of 2017 with revenue beating estimates.
BIIB,BIIB:UW,BBG000C18861,"3 Stocks to Watch on Tuesday: Alphabet Inc (GOOGL), Biogen Inc (BIIB) and Michael Kors Holdings Ltd (KORS)",2017-07-25 11:45:52 +0000,https://finance.yahoo.com/news/3-stocks-watch-tuesday-alphabet-114552334.html?.tsrc=rss,"Despite a 0.4% move higher from tech stocks, helped by Apple Inc. (NASDAQ:AAPL) and Amazon.com, Inc. (NASDAQ:AMZN), U.S. equities suffered a broader down day Monday.  Making moves this morning on their latest quarterly results are Alphabet Inc (NASDAQ:GOOGL) and Biogen Inc (NASDAQ:BIIB), though Michael Kors Holdings Ltd (NYSE:KORS) is also making waves via a big-name buyout in the fashion space.  Alphabet’s second attempt to sustain a run above $1,000 per share has hit a snag, as the company’s second-quarter earnings report failed to impress investors enough to keep GOOGL stock on the rise."
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Dow, S&P futures higher; Alphabet weighs down Nasdaq",2017-07-25 11:16:23 +0000,https://finance.yahoo.com/news/us-stocks-dow-p-futures-111623662.html?.tsrc=rss,"S&P and Dow futures were higher on  Tuesday, with the earnings season gaining momentum and ahead of  a two-day Federal Reserve meeting, while a fall in Google-parent  Alphabet weighed on Nasdaq futures.  * Shares of Alphabet were down 2.5 percent in  premarket trading, after the tech giant noted that costs were  rising faster than sales and warned that expenses would remain  high as more searches shift to mobile devices."
BIIB,BIIB:UW,BBG000C18861,"Biogen stock surges nearly 6% on Q2 profit, revenue beats",2017-07-25 11:11:38 +0000,http://finance.yahoo.com/r/cb6887c4-f15f-3804-9de7-bf1bb590c4ec/Story.aspx?guid=029C3249-F717-4AD3-8E6B-2B49A6DA91C7&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Biogen Inc. shares surged 5.8% in premarket trade Tuesday after the company reported second-quarter profit and revenue beats. Earnings for the latest quarter fell to $863 million, or $4.07 per share, from ..."
BIIB,BIIB:UW,BBG000C18861,"Earnings Reaction History: Biogen Idec, 58.3% Follow-Through Indicator, 5.3% Sensitive",2017-07-25 10:37:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wNDHCN1OYOs/earnings-reaction-history-biogen-idec-583-follow-through-indicator-53-sensitive-cm820620,Expected Earnings Release 07 25 2017 PremarketExpected Earnings Release 07 25 2017 Premarket Avg Extended Hours Dollar Volume 74 988 907Avg Extended Hours Dollar Volume 74 988 907 Biogen Idec BIIB is due to issue its quarterly earnings report in the upcoming extended hours
BIIB,BIIB:UW,BBG000C18861,"Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance",2017-07-25 10:30:00 +0000,https://finance.yahoo.com/news/biogen-reports-record-quarterly-revenues-103000250.html?.tsrc=rss,"Biogen Inc. today reported second quarter 2017 financial results, including:"
BIIB,BIIB:UW,BBG000C18861,Investor Network: Biogen Inc. to Host Earnings Call,2017-07-25 10:00:00 +0000,https://finance.yahoo.com/news/investor-network-biogen-inc-host-100000686.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / July 25, 2017 / Biogen Inc. (NASDAQ: BIIB ) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, July 25, 2017 at 8:00 AM Eastern Time. ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Q2 17 Earnings Conference Call At 8:00 AM ET,2017-07-25 07:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rQEldhAF_vo/biogen-q2-17-earnings-conference-call-at-800-am-et-20170725-00374,Biogen Q2 17 Earnings Conference Call At 8:00 AM ET
BIIB,BIIB:UW,BBG000C18861,Biogen Lifts FY17 Forecast As Q2 Results Top Estimates - Quick Facts,2017-07-25 06:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sWz5R4kLWjM/biogen-lifts-fy17-forecast-as-q2-results-top-estimates--quick-facts-20170725-00316,Biogen Lifts FY17 Forecast As Q2 Results Top Estimates - Quick Facts
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Q2 Income Falls 6%,2017-07-25 06:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aSvQj5-bG-o/biogen-inc-q2-income-falls-6-20170725-00268,Biogen Inc. Q2 Income Falls 6%
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Q2 Income Falls 6%,2017-07-25 06:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-049SXWoNHE/biogen-inc-q2-income-falls-6%25-20170725-00268,Biogen Inc. Q2 Income Falls 6%
BIIB,BIIB:UW,BBG000C18861,Biotechs Find Strength In Numbers In Treating Multiple Sclerosis,2017-07-24 20:45:02 +0000,http://finance.yahoo.com/r/06e1cfaf-3d8c-3f7d-9983-b0d05eb22cd0/new-ms-drugs-threaten-biogen-novartis-dominance?src=A00220&yptr=yahoo&.tsrc=rss,"Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen."
BIIB,BIIB:UW,BBG000C18861,"Pre-Market Earnings Report for July 25, 2017 :  MMM, MCD, UTX, LLY, DD, CAT, BIIB, GM, KMB, HCA, PCAR, TROW",2017-07-24 20:16:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l4RSMTtytQY/pre-market-earnings-report-for-july-25-2017-mmm-mcd-utx-lly-dd-cat-biib-gm-kmb-hca-pcar-trow-cm820506,The following companies are expected to report earnings prior to market open on 07 25 2017 Visit our Earnings Calendar for a full list of expected earnings releases 3M Company MMM is reporting for the quarter ending June 30 2017 The diversified
BIIB,BIIB:UW,BBG000C18861,Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations,2017-07-24 20:15:00 +0000,https://finance.yahoo.com/news/alisha-alaimo-appointed-svp-biogen-201500749.html?.tsrc=rss,"Biogen announced today the appointment of Alisha A. Alaimo to Senior Vice President of US Therapeutic Operations, where she will lead sales and marketing, market access, patient services and commercial operations and strategy."
BIIB,BIIB:UW,BBG000C18861,Biogen Earnings Preview: Analysis,2017-07-24 16:07:00 +0000,http://finance.yahoo.com/r/99a4bfb0-9025-3519-98ec-0e9f84c65026/biogen-earnings-preview-analysis?partner=YahooSA&yptr=yahoo&.tsrc=rss,Revenue and earnings probably declined in the latest quarter
BIIB,BIIB:UW,BBG000C18861,2 Ways To Trade This Week's Healthcare Earnings,2017-07-24 15:51:55 +0000,https://finance.yahoo.com/news/2-ways-trade-weeks-healthcare-155155577.html?.tsrc=rss,View more earnings on CURE See more from Benzinga Focusing On An Alternative To S&P 500 ETFs A New ETF For Low Vol ETFs © 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved....
BIIB,BIIB:UW,BBG000C18861,"Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN",2017-07-24 13:05:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/na8HBi0HD_Y/big-pharma-q2-earnings-releases-on-jul-25-lly-biib-amgn-cm820000,The second quarter reporting cycle seems to have gotten off to a good start with an abundance of positive surprises particularly on the revenue front Meanwhile earnings and revenue growth also bettered expectations As of Jul 21 2017 97 S amp P 500 members accounting for 28 1 of
BIIB,BIIB:UW,BBG000C18861,"Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN",2017-07-24 12:16:12 +0000,https://finance.yahoo.com/news/big-pharma-q2-earnings-releases-121612693.html?.tsrc=rss,Three pharma giants are set to report second-quarter results on Jul 25. Let&apos;s see how things are shaping up for this quarter.
BIIB,BIIB:UW,BBG000C18861,These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet,2017-07-23 13:04:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HIqLPfhEpfU/these-5-drugs-could-be-worth-45-billion-and-theyre-not-even-on-the-market-yet-cm819829,45 billion for five experimental drugs That s how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now The firm calculated the net present value the current value of potential future sales of all the experimental drugs
BIIB,BIIB:UW,BBG000C18861,These 5 Drugs Could Be Worth $45 Billion -- and They&apos;re Not Even on the Market Yet,2017-07-23 11:27:00 +0000,http://finance.yahoo.com/r/cd7be451-95ee-3e17-9e89-8b2c3babf417/these-5-drugs-could-be-worth-45-billion-and-theyre.aspx?yptr=yahoo&.tsrc=rss,"Biogen, Johnson & Johnson, Lilly, AbbVie, and Celgene could have huge winners on their hands in the near future."
BIIB,BIIB:UW,BBG000C18861,Will Gilead Beat 2Q Earnings? Perhaps…But Does It Matter?,2017-07-21 17:38:00 +0000,http://finance.yahoo.com/r/160bc290-317e-38d7-a838-bece487a56a4/will-gilead-beat-2q-earnings-perhapsbut-does-it-matter-1500658730?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Is Gilead Sciences (GILD) poised for a beat next week?  Guggenheim analyst Tony Butler sees Gilead earning $2.15 a share, a penny above the consensus forecast compiled by sell-side analyst, with operating revenue of $6.54 billion beating the $6.31 billion expected by the Street.  Butler’s estimates for the full 2017 calendar year are also above consensus, with per-share earnings of $8.28 on operating revenue of $25.4 billion."
BIIB,BIIB:UW,BBG000C18861,7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods,2017-07-21 17:15:00 +0000,http://finance.yahoo.com/r/7d0c7a23-fc9a-31ef-962e-9fb56ff24aab/jana-partners-to-put-whole-foods-amazon-deal-windfall-to-use.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here are the activist investor's next potential targets.
BIIB,BIIB:UW,BBG000C18861,"ITOT, TMO, COST, BIIB: ETF Inflow Alert",2017-07-20 16:04:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X3aH2rPzxBU/itot-tmo-cost-biib-etf-inflow-alert-cm818733,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Core S amp P Total U S Stock Market ETF Symbol ITOT where we have detected an approximate 67 9 million dollar inflow that s a 0 7 increase week
BIIB,BIIB:UW,BBG000C18861,Biotech Stocks On Verge Of Next Major Move Up,2017-07-19 18:30:00 +0000,http://finance.yahoo.com/r/74265b46-fc00-3b3b-8947-f074312d4fd1/biotech-stocks-verge-next-major-move?partner=YahooSA&yptr=yahoo&.tsrc=rss,A biotech breakout may be fueled by positive medical data and earnings
BIIB,BIIB:UW,BBG000C18861,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?,2017-07-19 16:08:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bMMoAQYV5F4/can-biogen-biib-keep-the-earnings-streak-alive-in-q2-cm818132,Biogen Inc BIIB a well known name in the multiple sclerosis MS market will report second quarter 2017 results on Jul 25 before the market opens Last quarter the company delivered a positive earnings surprise of 4 63 Biogen s shares have declined 0 4 this year so far while the
BIIB,BIIB:UW,BBG000C18861,The Best Stock in Massachusetts: Biogen,2017-07-19 14:10:15 +0000,https://finance.yahoo.com/news/best-stock-massachusetts-biogen-201005507.html?.tsrc=rss,We analyzed publicly traded companies based in the Bay State to identify the best stock in Massachusetts to buy now.
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs",2017-07-19 14:06:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vPIIyQZEiWc/biotech-stock-roundup-vertex-boosted-by-cf-data-fda-nod-for-gilead-puma-drugs-cm818047,Key highlights this week include impressive data from Vertex s VRTX cystic fibrosis CF pipeline while companies like Gilead GILD and Puma PBYI got FDA approval for their hepatitis C virus HCV and breast cancer treatments respectively 160 Recap of the Week s Most Important
BIIB,BIIB:UW,BBG000C18861,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?,2017-07-19 13:52:01 +0000,https://finance.yahoo.com/news/biogen-biib-keep-earnings-streak-135201093.html?.tsrc=rss,"At Biogen&apos;s (BIIB) Q2 call, investor focus will remain on Tecfidera&apos;s scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza&apos;s performance in Q2."
BIIB,BIIB:UW,BBG000C18861,These 2 Drug Giants In Buy Range Just Beat Earnings Views,2017-07-18 20:16:52 +0000,http://finance.yahoo.com/r/6344fe91-679f-3ff1-a7bd-fccb051748d0/novartis-tops-earnings-views-dows-johnson-johnson-on-tap?src=A00220&yptr=yahoo&.tsrc=rss,Novartis reported smaller earnings and revenue declines for Q2 than expected. Johnson & Johnson topped on earnings but fell just shy on revenue.
BIIB,BIIB:UW,BBG000C18861,"Agree To Purchase Biogen At $200, Earn 4% Using Options",2017-07-18 17:01:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uHp2v2cdiTY/agree-to-purchase-biogen-at-200-earn-4-using-options-cm817574,Investors eyeing a purchase of Biogen Inc Symbol BIIB stock but cautious about paying the going market price of 281 89 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the January 2019 put
BIIB,BIIB:UW,BBG000C18861,Insiders Buy the Holdings of BBH ETF,2017-07-18 15:06:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xdPe9pnjzXU/insiders-buy-the-holdings-of-bbh-etf-cm817379,A look at the weighted underlying holdings of the Biotech ETF BBH shows an impressive 11 2 of holdings on a weighted basis have experienced insider buying within the past six months Biogen Inc Symbol BIIB which makes up 5 86 of the Biotech ETF BBH has seen 2 directors
BIIB,BIIB:UW,BBG000C18861,AveXis Inc.: Buy at the High?,2017-07-18 14:04:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aAv3kl7RMO8/avexis-inc-buy-at-the-high-cm817311,In the time it takes most newborns to sprout their first teeth AveXis Inc NASDAQ AVXS looks ready to sink its teeth into the biotech industry Since its market debut in early 2016 stellar clinical trial results for its lead candidate have propelled the stock about 349
BIIB,BIIB:UW,BBG000C18861,AveXis Inc.: Buy at the High?,2017-07-18 12:42:00 +0000,http://finance.yahoo.com/r/236791dc-f58c-3189-9d37-9137d2327500/avexis-inc-buy-at-the-high.aspx?yptr=yahoo&.tsrc=rss,"Stellar clinical-trial results have pushed AveXis Inc. stock to an all-time high. Is the stock still a buy at recent prices, or should you wait for a pullback?"
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Monday Option Activity: VHC, AGN, BIIB",2017-07-17 20:48:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V7Jv8djLPiM/noteworthy-monday-option-activity-vhc-agn-biib-cm817130,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in VirnetX Holding Corp Symbol VHC where a total volume of 1 970 contracts has been traded thus far today a contract volume which is representative of approximately 197
BIIB,BIIB:UW,BBG000C18861,&apos;Stars Align&apos; For These Biotechs To Crush Earnings Consensus,2017-07-17 18:30:52 +0000,http://finance.yahoo.com/r/35ed523a-9bbf-398d-99b0-595e5cdb347f/stars-align-for-these-biotechs-to-crush-earnings-consensus?src=A00220&yptr=yahoo&.tsrc=rss,"Regeneron and Gilead are most likely to beat Wall Street views for second-quarter sales and profits, an analyst said Monday."
BIIB,BIIB:UW,BBG000C18861,Biogen aims to block Tecfidera generics with flurry of lawsuits,2017-07-17 17:55:10 +0000,http://finance.yahoo.com/r/2a3bffa3-3664-3ae1-89fa-eaa2fce7780d/biogen-aims-to-block-tecfidera-generics-with.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen is moving aggressively to protect its lucrative multiple sclerosis franchise, filing patent lawsuits against more than two dozen companies to prevent them from selling generic versions of blockbuster drug Tecfidera.  Cambridge-based Biogen (BIIB) filed 26 different lawsuits in federal court between June 26 and June 30.  The complaints accuse scores of drugmakers, including Mylan Pharmaceuticals and Novartis unit Sandoz, of infringing patents on Tecfidera through their efforts to market generic versions of the drug."
BIIB,BIIB:UW,BBG000C18861,Biogen Breaks Above 200-Day Moving Average - Bullish for BIIB,2017-07-17 16:48:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0uss9ECe8L0/biogen-breaks-above-200-day-moving-average-bullish-for-biib-cm816956,In trading on Monday shares of Biogen Inc Symbol BIIB crossed above their 200 day moving average of 281 35 changing hands as high as 284 20 per share Biogen Inc shares are currently trading up about 1 1 on the day The chart below shows the one year performance of BIIB shares versus
BIIB,BIIB:UW,BBG000C18861,[$$] Biotechs in Focus Ahead of Earnings,2017-07-17 15:15:00 +0000,http://finance.yahoo.com/r/622b6d9d-e661-32f7-87f9-7dae41ef33e0/biotechs-in-focus-ahead-of-earnings-1500304501?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse  Heading into the quarter, Biogen and Alexion Pharmaceuticals are in focus in our coverage universe.  Key products of focus for the quarter include Regeneron’s (REGN) newly launched Dupixent, Biogen/Ionis Pharmaceuticals’ (IONS) Spinraza now in its second full quarter and Alexion’s (ALXN) Soliris."
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Celgene Corporation,2017-07-16 17:45:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VAg_BBig36g/better-buy-biogen-inc-vs-celgene-corporation-cm816588,Biogen NASDAQ BIIB and Celgene NASDAQ CELG have ranked among the most successful biotech stocks of the past decade Biogen stock has soared more than 430 in the last 10 years while Celgene s share price has jumped more than 340 But which of these two biotech stocks is
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Celgene Corporation,2017-07-16 15:42:00 +0000,http://finance.yahoo.com/r/224aa79f-c4a4-30f8-ab8c-4fcdbb4c497e/better-buy-biogen-inc-vs-celgene-corporation-2.aspx?yptr=yahoo&.tsrc=rss,Which big biotech stock wins in a head-to-head matchup between Biogen and Celgene?
BIIB,BIIB:UW,BBG000C18861,Could Q2 Surprise Spike This Beleaguered Biotech&apos;s Stock?,2017-07-14 18:37:55 +0000,http://finance.yahoo.com/r/fa266e36-c89c-33f0-9814-ea0bafc11d0c/could-q2-surprise-spike-this-beleaguered-biotechs-stock?src=A00220&yptr=yahoo&.tsrc=rss,"A key hepatitis C drug from Gilead could top Wall Street&apos;s Q2 expectations, but investors want to hear more about potential M&A activity."
BIIB,BIIB:UW,BBG000C18861,Expect A Strong Quarter From Biogen: Instinet,2017-07-14 14:59:00 +0000,http://finance.yahoo.com/r/356766a0-727c-3444-ba35-cfe1d6a92524/expect-a-strong-quarter-from-biogen-instinet-1500044368?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biogen (BIIB) will report earnings on Tuesday, and Instinet's Christopher Marai and his team are upbeat about the results.  Marai reiterated a Buy rating and $355 price target on Biogen Friday, and tweaked his sales and earnings estimates higher as well."
BIIB,BIIB:UW,BBG000C18861,Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®),2017-07-14 11:30:00 +0000,https://finance.yahoo.com/news/biogen-present-data-alzheimers-association-113000412.html?.tsrc=rss,"Biogen will present data from its Alzheimer’s disease programs at the Alzheimer's Association International Conference® 2017 in London, July 16 - 20, 2017."
BIIB,BIIB:UW,BBG000C18861,"Top Stock Reports for Boeing, AbbVie & U.S. Bancorp",2017-07-14 05:45:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Hsw6i41Zbj4/top-stock-reports-for-boeing-abbvie-us-bancorp-cm815957,Thursday July 13 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Boeing BA AbbVie ABBV and U S Bancorp USB These research reports have been hand picked from
BIIB,BIIB:UW,BBG000C18861,How Biogen Inc. Makes Most of Its Money,2017-07-13 22:47:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nh5otBT6xLE/how-biogen-inc-makes-most-of-its-money-cm815900,Biogen NASDAQ BIIB recorded 2 38 billion in product revenue in the first quarter a nice haul for a large biotech but 40 of its sales came from its top selling multiple sclerosis drug Tecfidera Drug First
BIIB,BIIB:UW,BBG000C18861,"Top Stock Reports for Boeing, AbbVie & U.S. Bancorp",2017-07-13 21:54:09 +0000,https://finance.yahoo.com/news/top-stock-reports-boeing-abbvie-215409254.html?.tsrc=rss,"Top Stock Reports for Boeing, AbbVie & U.S. Bancorp"
BIIB,BIIB:UW,BBG000C18861,How Biogen Inc. Makes Most of Its Money,2017-07-13 20:39:00 +0000,http://finance.yahoo.com/r/1ee33b05-82c6-306a-af03-b3aba0ae6ca8/how-biogen-inc-makes-most-of-its-money.aspx?yptr=yahoo&.tsrc=rss,A concentrated revenue source puts the biotech in need of diversification.
BIIB,BIIB:UW,BBG000C18861,The Math Shows BBH Can Go To $140,2017-07-12 14:44:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j6F-eEB6c8c/the-math-shows-bbh-can-go-to-140-cm814932,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BIIB,BIIB:UW,BBG000C18861,3 Red-Hot Biotech Stocks That Could Get Even Hotter,2017-07-11 14:23:00 +0000,https://finance.yahoo.com/news/video-3-biotech-stocks-double-135500082.html?.tsrc=rss,An analyst weighs in.
BIIB,BIIB:UW,BBG000C18861,"Amgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios",2017-07-10 19:46:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NYgpkAGO3LI/amgen-inc-amgn-stock-is-the-cure-for-ailing-portfolios-cm814066,InvestorPlace Stock Market News Stock Advice amp Trading Tips As violent as the biotech sector has been for the past twelve months stocks like Amgen Inc NASDAQ AMGN have been resilient in setting new highs While the range is flat overall AMGN stock
BIIB,BIIB:UW,BBG000C18861,What Drove Biogen Stock in 2Q17?,2017-07-10 18:35:56 +0000,http://finance.yahoo.com/r/b7c9013f-c5a1-374b-8cd5-bbee6eb2ea30/what-drove-biogen-stock-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017."
BIIB,BIIB:UW,BBG000C18861,Three Biotechs That Look Best Positioned Ahead Of Q2 Earnings,2017-07-10 18:19:00 +0000,http://finance.yahoo.com/r/ab19172b-5cc6-3d8b-8986-608cbd9193a7/three-biotechs-that-look-best-positioned-ahead-of-q2-earnings-1499710784?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Morgan Stanley’s Matthew Harrison and his team have a second-quarter preview for the biotech sector out Monday, with potentially better-than-expected results from a number of high-profile players.  Harrison writes that the second-quarter reports will be dominated by strategic updates form Alexion Pharmaceuticals (ALXN) and Biogen (BIIB), as well as the potential for Gilead Sciences (GILD) for the first time in a number of quarters.  While he expects Amgen (AMGN), Celgene (CELG), and Vertex (VRTX) to report largely in-line earnings, while he sees a “broadly positive” for the sector as a whole, with Biogen, Gilead, and Regeneron (REGN) as best positioned going into earnings season, although he maintained Equal Weight ratings on them."
BIIB,BIIB:UW,BBG000C18861,"BIB, BIIB, REGN, VRTX: ETF Outflow Alert",2017-07-10 16:46:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1VGbs7NDB8I/bib-biib-regn-vrtx-etf-outflow-alert-cm813872,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares Ultra Nasdaq Biotechnology Symbol BIB where we have detected an approximate 70 4 million dollar outflow that s a 14 8 decrease week over week
BIIB,BIIB:UW,BBG000C18861,"Amgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios",2017-07-10 15:31:46 +0000,https://finance.yahoo.com/news/amgen-inc-amgn-stock-cure-153146609.html?.tsrc=rss,"As violent as the biotech sector has been for the past twelve months, stocks like Amgen, Inc. (NASDAQ:AMGN) have been resilient in setting new highs.  While the range is flat overall, AMGN stock has had several +/- 25% moves in recent months.  Most of the headlines are not specific to AMGN stock, but rather caused by politicians."
BIIB,BIIB:UW,BBG000C18861,Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs,2017-07-10 11:30:00 +0000,https://finance.yahoo.com/news/biogen-appoints-amy-chevalier-efantis-113000756.html?.tsrc=rss,"Biogen announced today the appointment of Amy Chevalier Efantis as Vice President of Government Affairs, effective July 17."
BIIB,BIIB:UW,BBG000C18861,3 Hot Biotech Stocks Ready for the Sector’s Next Breakout,2017-07-06 15:50:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qmh4wSz1ycA/3-hot-biotech-stocks-ready-for-the-sectors-next-breakout-cm812546,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biotech stocks and pharmaceutical stocks have been in the political crosshairs for more than a year The threat of government controls left the group attractively valued into 2017 but the potential for headline risks has
BIIB,BIIB:UW,BBG000C18861,Bright spots in biotech,2017-07-05 17:54:00 +0000,https://finance.yahoo.com/video/bright-spots-biotech-175400830.html?.tsrc=rss,CNBC's Seema Mody reports on some highs in the biotechnology sector.
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Cara Plunges on Study Data, Regulatory Updates & More",2017-07-05 13:48:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TlttQR7dBQo/biotech-stock-roundup-cara-plunges-on-study-data-regulatory-updates-more-cm811794,It s been a pretty slow week for the biotech sector with not too many major updates being provided Among key news Cara Therapeutics CARA saw its shares declining on mixed data on its experimental pain treatment Meanwhile companies like BioMarin BMRN and Acorda ACOR provided
BIIB,BIIB:UW,BBG000C18861,3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher,2017-07-05 13:46:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5x339JXJ0wQ/3-reasons-sizzling-hot-bioverativ-stock-can-go-even-higher-cm811671,Some spinoffs work really well while others don t So far Biogen s NASDAQ BIIB spinoff of Bioverativ NASDAQ BIVV at the beginning of the year definitely seems to be working well Bioverativ stock is up more than 25 year to date well ahead of Biogen and many other
BIIB,BIIB:UW,BBG000C18861,Why Gilead Stock Is Back in the Game,2017-07-05 13:00:00 +0000,http://finance.yahoo.com/r/d07b66e9-6360-345e-ab2d-57f97ccdeb3b/why-gilead-stock-back-game?partner=YahooSA&yptr=yahoo&.tsrc=rss,President Trump’s softening stance on pharma has allowed biotechs like Gilead to regain some traction.
BIIB,BIIB:UW,BBG000C18861,3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher,2017-07-05 12:03:00 +0000,http://finance.yahoo.com/r/e1939db5-86f8-399f-8c03-f7f3a1d9fa3b/3-reasons-sizzling-hot-bioverativ-stock-can-go-eve.aspx?yptr=yahoo&.tsrc=rss,Biogen spinoff Bioverativ is on a roll that doesn&apos;t seem likely to slow down anytime soon.
BIIB,BIIB:UW,BBG000C18861,3 Best-Performing Stocks in June,2017-07-03 14:47:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z3qgs2BQpj0/3-best-performing-stocks-in-june-cm811117,June was a quiet month for the S amp P 500 The famous index ended the month down less than 1 from where it started However not every company from the index had muted returns In fact three stocks Signet Jewelers Limited NYSE SIG Alexion Pharmaceuticals
BIIB,BIIB:UW,BBG000C18861,Finding Value in Biotech?,2017-07-03 14:14:00 +0000,http://finance.yahoo.com/r/d634d985-bc32-34a9-a642-02f4d895aef6/finding-value-in-biotech-1499091291?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biotech stocks are often considered among the faster-growing stocks in the market. But a number of them--Amgen (AMGN) Biogen (BIIB), and Gilead Sciences (GILD), for instance--are part of the Russell 1000 ..."
BIIB,BIIB:UW,BBG000C18861,3 Charts That Show Why to Buy Gilead Sciences Stock Now,2017-07-02 16:36:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_NELil938dk/3-charts-that-show-why-to-buy-gilead-sciences-stock-now-cm810960,Probably every investor interested in biotech knows all of the challenges facing Gilead Sciences NASDAQ GILD Its once high flying stock has been beaten down over the last couple of years as sales plunged for its hepatitis C franchise However over the last month Gilead
BIIB,BIIB:UW,BBG000C18861,4 Reasons the AveXis Inc. Rally Could Continue,2017-07-01 17:42:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4clvVsXPdbo/4-reasons-the-avexis-inc-rally-could-continue-cm810889,AveXis Inc NASDAQ AVXS shareholders have enjoyed a 103 gain over the past year and a stunning 333 gain since the clinical stage biotech made its debut as a publicly traded company in early 2016 Despite the terrific run up there are at least four reasons the rally could
BIIB,BIIB:UW,BBG000C18861,4 Reasons the AveXis Inc. Rally Could Continue,2017-07-01 15:41:00 +0000,http://finance.yahoo.com/r/e0ad6191-1382-3bc8-8502-56079da6115d/4-reasons-the-avexis-inc-rally-could-continue.aspx?yptr=yahoo&.tsrc=rss,AveXis Inc. stock has more than doubled over the past year. Here&apos;s why it could climb even further.
BIIB,BIIB:UW,BBG000C18861,Can Regeneron Hit $540?,2017-06-30 13:25:00 +0000,http://finance.yahoo.com/r/d84fecc2-687a-323b-9212-265bb68bbc7b/can-regeneron-hit-540-1498829120?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The broader biotech sector has pulled back since hitting a new high earlier this month. And like most of its brethren, Regeneron Pharmaceuticals (REGN) has fallen as well, though at a faster pace. Since ..."
BIIB,BIIB:UW,BBG000C18861,What Analysts Recommend for Biogen in June 2017,2017-06-30 11:36:20 +0000,http://finance.yahoo.com/r/108372c7-4128-32e2-a7a9-5f5be5553bac/what-analysts-recommend-for-biogen-in-june-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth."
BIIB,BIIB:UW,BBG000C18861,U.S. IRS probes drug company-funded patient assistance charity,2017-06-29 16:18:01 +0000,https://finance.yahoo.com/news/u-irs-probes-drug-company-161801396.html?.tsrc=rss,"The U.S. Internal Revenue  Service is probing whether a patient-assistance charity wrongly  gave a benefit to its pharmaceutical company donors by returning  most of the money they donated as payments for drugs they make,  court papers show.  The inquiry focuses on Good Days, which operates a co-pay  assistance program that it says since 2003 has provided more  than $1 billion in assistance to patients to buy expensive drugs  for chronic and terminal diseases.  The Texas-based charity, previously known as Chronic Disease  Fund Inc, has since February filed several lawsuits in federal  courts in three states and the District of Columbia to quash  summonses the IRS served on drug companies that donated to it."
BIIB,BIIB:UW,BBG000C18861,Seeking Value in Biotech: Bioverativ,2017-06-29 16:14:18 +0000,https://finance.yahoo.com/news/seeking-value-biotech-bioverativ-161418096.html?.tsrc=rss,Spinoff logs 35% revenue growth in 1st quarter
BIIB,BIIB:UW,BBG000C18861,Biogen’s Interferon Therapies Could Witness Modest Fall in 2017,2017-06-29 14:37:13 +0000,http://finance.yahoo.com/r/11101971-e378-365a-998e-f564656b3ff5/biogens-interferon-therapies-could-witness-modest-fall-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod",2017-06-29 14:07:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jAAJmwPsq4w/biotech-stock-roundup-eu-nod-for-regeneron-ra-drug-portola-soars-on-fda-nod-cm809914,Biotech stocks have been in the news recently with expectations remaining high that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected Meanwhile companies like Portola PTLA and Regeneron REGN provided regulatory updates
BIIB,BIIB:UW,BBG000C18861,Spinraza May Significantly Boost Biogen’s Revenue Growth,2017-06-29 13:08:08 +0000,http://finance.yahoo.com/r/30f72d22-fe74-3c58-b580-8dd5ff559d45/spinraza-may-significantly-boost-biogens-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Spinraza (nusinersen) is a biologic drug indicated for the treatment of spinal muscular atrophy (or SMA).
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod",2017-06-29 12:40:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-eu-nod-124012930.html?.tsrc=rss,Key highlights in the biotech sector include FDA approval for Portola&apos;s (PTLA) anticoagulant and EU approval for Regeneron&apos;s rheumatoid arthritis (RA) drug.
BIIB,BIIB:UW,BBG000C18861,Biosimilars Could Boost Biogen’s Revenue in 2017,2017-06-29 11:43:29 +0000,http://finance.yahoo.com/r/bc91bdce-3a49-37bf-adff-0c6c6c44207e/biosimilars-could-boost-biogens-revenue-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Biogen’s (BIIB) biosimilar portfolio generated revenues of ~$101 million."
BIIB,BIIB:UW,BBG000C18861,New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity,2017-06-29 11:30:00 +0000,https://finance.yahoo.com/news/data-reaffirm-clinically-meaningful-benefit-113000354.html?.tsrc=rss,"Biogen will present robust efficacy and safety data from Phase 2 and 3 SPINRAZA® studies at the Cure SMA 2017 Annual SMA Conference in Orlando, Fl, June 29 – July 2, 2017."
BIIB,BIIB:UW,BBG000C18861,Tysabri Could Boost Biogen’s Revenue Growth,2017-06-28 21:35:43 +0000,http://finance.yahoo.com/r/a25c516c-1927-3469-aeea-3d6d525c3eb7/tysabri-could-boost-biogens-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Biogen’s (BIIB) Tysabri reported revenues of around $2.0 billion, which is ~4% growth year-over-year (or YoY)."
BIIB,BIIB:UW,BBG000C18861,How Biogen’s Tecfidera Is Expected to Perform in 2017,2017-06-28 20:06:12 +0000,http://finance.yahoo.com/r/da72bffc-688b-37fd-983c-b75fa870df5b/how-biogens-tecfidera-is-expected-to-perform-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Biogen’s (BIIB) Tecfidera reported revenues of ~$4.0 billion, which reflected ~9% growth year-over-year (or YoY)."
BIIB,BIIB:UW,BBG000C18861,What’s in Biogen’s Clinical Pipeline?,2017-06-28 18:35:22 +0000,http://finance.yahoo.com/r/09672885-6c50-3c32-9a07-27046d1807e6/whats-in-biogens-clinical-pipeline?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Currently, Biogen is conducting 13 clinical studies in early phases and expects promising results from those trials."
BIIB,BIIB:UW,BBG000C18861,Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs,2017-06-28 11:30:00 +0000,https://finance.yahoo.com/news/biogen-appoints-catherine-steele-senior-113000434.html?.tsrc=rss,"Biogen announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17."
BIIB,BIIB:UW,BBG000C18861,"Like Biogen, this Fidelity-backed startup is targeting a deadly infant disease",2017-06-28 11:20:12 +0000,http://finance.yahoo.com/r/05cb6d2f-de43-3efc-8e7d-267322abdc66/like-biogen-this-fidelity-backed-startup-is.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Since being launched in 2014 with financing from Fidelity and other prominent investors, Cambridge-based Scholar Rock has been developing a drug that is designed to block a protein that limits muscle growth.  On Wednesday, the privately-held, 40-employee company revealed for the first time which disease it plans to target: spinal muscular atrophy, or SMA, a leading genetic cause of death in infants.  There was no approved treatment for SMA until December 2016, when the FDA green-lighted Biogen's (BIIB) Spinraza."
BIIB,BIIB:UW,BBG000C18861,2 Pharma Buyout Targets That May Surprise You,2017-06-27 12:08:00 +0000,http://finance.yahoo.com/r/843a6f38-6ac1-3950-96fb-797be2623bf5/2-biopharma-buyout-targets-that-may-surprise-you.aspx?yptr=yahoo&.tsrc=rss,"When the M&A bonanza picks up again, Biogen and Bristol-Myers Squibb may be the first to go. Here&apos;s why."
BIIB,BIIB:UW,BBG000C18861,"Noteworthy ETF Outflows: JKD, MO, BIIB, ANTM",2017-06-26 16:52:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zVF-lTxhKqk/noteworthy-etf-outflows-jkd-mo-biib-antm-cm808178,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Morningstar Large Cap ETF Symbol JKD where we have detected an approximate 125 9 million dollar outflow that s a 12 8 decrease week over week
BIIB,BIIB:UW,BBG000C18861,Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold,2017-06-23 13:54:36 +0000,https://finance.yahoo.com/news/deutsche-banks-big-pharma-3-135436967.html?.tsrc=rss,"Biotech stocks have been on a tear in the past week, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) up 8.8 percent. However, despite the run-up, Deutsche Bank sees more upside ahead for ..."
BIIB,BIIB:UW,BBG000C18861,"Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use",2017-06-23 11:55:00 +0000,https://finance.yahoo.com/news/biogen-imraldi-adalimumab-biosimilar-candidate-115500873.html?.tsrc=rss,"The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for IMRALDI® , an adalimumab biosimilar candidate referencing Humira®.1 The positive opinion will now be referred to the European Commission , which grants marketing authorization for medicines in the European Union ."
BIIB,BIIB:UW,BBG000C18861,InPlay from Briefing.com,2017-06-23 09:53:44 +0000,https://finance.yahoo.com/news/inplay-briefing-com-125529772.html?.tsrc=rss,InPlay from Briefing.com
BIIB,BIIB:UW,BBG000C18861,Biogen's IMRALDI Granted Positive Opinion By Europe's CHMP,2017-06-23 08:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JqeIgm0TWtk/biogens-imraldi-granted-positive-opinion-by-europes-chmp-20170623-00294,Biogen's IMRALDI Granted Positive Opinion By Europe's CHMP
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : June 22, 2017",2017-06-22 20:53:14 +0000,http://finance.yahoo.com/r/7b65a97b-8c99-380f-a75e-514caef421ed/biogen-inc-value-analysis-nasdaqbiib-june-22-2017?yptr=yahoo&.tsrc=rss,"Categories:  Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Biogen, Inc. a score of 84. Our analysis is based on comparing Biogen, Inc. with the following peers – Amgen Inc., Celgene Corporation, Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Pfizer Inc., Sanofi Sponsored ADR, Acorda Therapeutics, Inc., Sangamo Therapeutics, Inc. and Bio-Rad Laboratories, Inc. Class ... Read more
<b>(Read more...)</b>"
BIIB,BIIB:UW,BBG000C18861,Futures: These 2 Big Breakouts Highlight New Market Leadership,2017-06-22 10:48:59 +0000,http://finance.yahoo.com/r/fdb36375-5029-3e80-af82-34b9bdcfc6eb/these-2-big-breakouts-highlight-new-market-leadership-sp-500-futures?src=A00220&yptr=yahoo&.tsrc=rss,"Nasdaq 100 futures edged higher Thursday morning as Oracle surged on strong earnings. On Wednesday, Celgene broke out as biotechs and business software increasingly lead the market rally."
BIIB,BIIB:UW,BBG000C18861,5 Biotech Stocks That Are Roaring Back to Life,2017-06-22 00:19:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fUGdfB4IjU4/5-biotech-stocks-that-are-roaring-back-to-life-cm806624,InvestorPlace Stock Market News Stock Advice amp Trading Tips While the broad market drifts lower in trading on Wednesday for the second day biotech stocks and pharma stocks are blasting to the upside in a rare show of strength amid a week of weakness Source Shutterstock
BIIB,BIIB:UW,BBG000C18861,7 Healthcare Stocks to Buy Now,2017-06-21 22:19:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PCltdn2YVU4/7-healthcare-stocks-to-buy-now-cm806577,InvestorPlace Stock Market News Stock Advice amp Trading Tips With the benefit of perfect hindsight the middle of 2015 represented a high tide in healthcare investing Source Shutterstock While the sector overall has recovered this year the Health Care SPDR ETF NYSEARCA
BIIB,BIIB:UW,BBG000C18861,Update: Wall Street Weighed Down By Oil Declines as Health Stocks Lift Nasdaq,2017-06-21 20:59:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mCtcAJUOrXw/update-wall-street-weighed-down-by-oil-declines-as-health-stocks-lift-nasdaq-cm806535,Another day of selling in oil pushed the S amp P 500 and the Dow Jones Industrial Average into the red for a second straight session while gains in health stocks helped the Nasdaq Composite buck the weaker trend Another day of selling in oil pushed the S P 500 and the Dow Jones Industrial
BIIB,BIIB:UW,BBG000C18861,[$$] Pharma recovers composure as price concerns ease,2017-06-21 20:26:08 +0000,"http://finance.yahoo.com/r/d675286f-a701-3df6-8510-e41a4f5b29ae/c175dd92-5696-11e7-80b6-9bfa4c1f83d2,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The Nasdaq Biotechnology Index enjoyed one of its best rallies since the US election on Wednesday, helping a broad rise for the healthcare sector, as investors bet that Donald Trump's administration will ..."
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Wednesday Option Activity: CMG, BIIB, AAPL",2017-06-21 20:22:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/prWPND31tEY/noteworthy-wednesday-option-activity-cmg-biib-aapl-cm806494,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Chipotle Mexican Grill Inc Symbol CMG where a total volume of 28 349 contracts has been traded thus far today a contract volume which is representative of approximately 2
BIIB,BIIB:UW,BBG000C18861,Biotech Breakouts: Biogen Spinoff Bioverativ In Buy Zone,2017-06-21 20:11:47 +0000,http://finance.yahoo.com/r/17bbe4ed-20d2-3541-9615-008ca8ad3ace/biotech-breakouts-biogen-spin-off-bioverativ-in-buy-zone?src=A00220&yptr=yahoo&.tsrc=rss,"Bioverativ shows rising price performance, earning an upgrade to its IBD Relative Strength Rating."
BIIB,BIIB:UW,BBG000C18861,Amgen An Undervalued Industry Leader,2017-06-21 19:00:00 +0000,http://finance.yahoo.com/r/32350ffa-bf78-341a-9966-7802574a289f/amgen-an-undervalued-industry-leader?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Given the company’s industry leading position, solid fundamentals and attractive stock valuation, we view it as a preferable alternative to traditional competitors in its industry."
BIIB,BIIB:UW,BBG000C18861,Amgen: In Defense of A Pipeline,2017-06-21 14:35:00 +0000,http://finance.yahoo.com/r/b0c77884-5a47-3ae4-8b7a-cfad798fb9ad/amgen-in-defense-of-a-pipeline-1498055757?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Critics complain that Amgen’s pipeline is bereft of exciting possibilities.  Meanwhile, Amgen’s genetics-based R&D approach hasn’t delivered any homeruns yet, what with sputtering sales of its cholesterol drug Repatha and safety issues surrounding the experimental osteoporosis drug romosozumab."
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : June 21, 2017",2017-06-21 12:08:35 +0000,http://finance.yahoo.com/r/57c045c7-c278-3a5c-9163-d258e574b303/biogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-biib-us-june-21-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Biogen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more
<b>(Read more...)</b>"
BIIB,BIIB:UW,BBG000C18861,"Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017",2017-06-20 20:01:00 +0000,https://finance.yahoo.com/news/biogen-report-second-quarter-2017-200100570.html?.tsrc=rss,"Biogen Inc. today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open."
BIIB,BIIB:UW,BBG000C18861,Updates on the Adcetris and Opdivo Combination,2017-06-20 19:36:10 +0000,http://finance.yahoo.com/r/d1dfdee6-b40d-3a1a-8523-e64daa81bf20/updates-adcetris-opdivo-combination?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Bristol-Myers Squibb and Seattle Genetics are evaluating a combination of Opdivo with Adcetris to treat refractory or relapsed classical Hodgkin Lymphoma.
BIIB,BIIB:UW,BBG000C18861,Biotech Stock With 50% Profit Margin Nears Buy Zone,2017-06-20 15:31:24 +0000,http://finance.yahoo.com/r/10091ed6-bb82-3292-bdfa-4cfdc5ef8fa1/biotech-stock-with-50-profit-margin-nears-buy-zone?src=A00220&yptr=yahoo&.tsrc=rss,"On Tuesday, Celgene got an upgrade for its IBD SmartSelect Composite Rating from 94﻿﻿ ﻿to 97."
BIIB,BIIB:UW,BBG000C18861,"Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer",2017-06-20 11:30:00 +0000,https://finance.yahoo.com/news/biogen-appoints-ginger-gregory-executive-113000941.html?.tsrc=rss,"Biogen announced today the appointment of Ginger Gregory, PhD, as Executive Vice President, Chief Human Resources Officer, effective July 17."
BIIB,BIIB:UW,BBG000C18861,5 Most Profitable Big Pharma Stocks on the Market Right Now,2017-06-20 11:27:00 +0000,http://finance.yahoo.com/r/003646c7-280d-3ef3-b660-d57cff7b2db6/5-most-profitable-big-pharma-stocks-on-the-market.aspx?yptr=yahoo&.tsrc=rss,"Looking for big pharma stocks with big-time profit margins? Check out Gilead Sciences, Amgen, Novartis, Biogen, and Bristol-Myers Squibb."
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Wall St hits record highs on strong technology, health stocks",2017-06-19 20:28:08 +0000,https://finance.yahoo.com/news/us-stocks-wall-st-hits-202808991.html?.tsrc=rss,"U.S. stocks rose on Monday,  with the S&P 500 and the Dow  hitting record highs with growth  sectors such as technology in favor again as investors appeared  to regain confidence in the economy after upbeat comments from  Federal Reserve officials.  Nasdaq's biotechnology index rose 2.5 percent in its  biggest one-day gain since February while the S&P's healthcare  index had a record-high close."
BIIB,BIIB:UW,BBG000C18861,"Monday Sector Leaders: Healthcare, Technology & Communications",2017-06-19 20:19:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LDwVCsxHcsc/monday-sector-leaders-healthcare-technology-communications-cm805314,Looking at the sectors faring best as of midday Monday shares of Healthcare companies are outperforming other sectors up 1 3 Within the sector PerkinElmer Inc Symbol PKI and Biogen Inc Symbol BIIB are two large stocks leading the way showing a gain of 5 9 and 4 0
BIIB,BIIB:UW,BBG000C18861,The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It,2017-06-19 19:16:20 +0000,https://finance.yahoo.com/news/near-term-setup-biogen-positive-191620402.html?.tsrc=rss,"While risks to the stock still remain, UBS has upgraded Biogen Inc (NASDAQ: BIIB ) from Sell to Neutral and has raised its price target for the stock from $262 to $270. At this point, the risks are fully ..."
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Wall St at record highs on technology, health stocks strength",2017-06-19 19:02:55 +0000,https://finance.yahoo.com/news/us-stocks-wall-st-record-190255181.html?.tsrc=rss,"U.S. stocks rose on Monday,  with the S&P 500 and the Dow Jones Industrial Average hitting  record highs helped by a technology sector rebound and strength  in healthcare and financial stocks.  Nasdaq's biotechnology index rose 2.5 percent and was  on track for its biggest one-day gain since February helped by  stocks including Biogen Inc and Clovis Oncology  while the S&P's healthcare index hit a record  high."
BIIB,BIIB:UW,BBG000C18861,"Biogen's stock jumps after UBS boosts rating, price target",2017-06-19 18:43:32 +0000,http://finance.yahoo.com/r/0cb065f6-e165-30c2-aaba-c9b002f27948/Story.aspx?guid=FA81EF9A-198B-47BC-82F0-1E2AF4440796&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Biogen Inc. ran up 3.9% in afternoon trade Monday, to turn positive on the year, after UBS backed away from its bearish rating on the belief valuation may have bottomed. Analyst Carter Gould ..."
BIIB,BIIB:UW,BBG000C18861,Picks of Steel,2017-06-19 18:15:00 +0000,https://finance.yahoo.com/video/picks-steel-181500605.html?.tsrc=rss,Big names and big movers in the blitz.
BIIB,BIIB:UW,BBG000C18861,Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress,2017-06-19 15:52:00 +0000,http://finance.yahoo.com/r/54313d39-be8d-393c-a2b4-edfa6d37f38d/biogen-upgraded-at-ubs-on-alzheimer-s-clinical-trial-progress.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Positive clinical trial results and newly priced-in competition breed some optimism for UBS Analyst Carter Gould.
BIIB,BIIB:UW,BBG000C18861,"Biogen: ""The Underperformance Stops Here""",2017-06-19 15:11:00 +0000,http://finance.yahoo.com/r/05671a65-d2e2-3e72-886c-753d7d8245b3/biogen-the-underperformance-stops-here-1497885096?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"It was more than three months ago when UBS warned investors to exit Biogen (BIIB), initiating coverage on the drug maker at a Sell and predicting the shares would fall to $260 a share.  Analyst Carter Gould’s prediction came to bear.  As of Friday’s close, Biogen’s share price had fallen to just under $252, a more than 14% decline since he set his sell rating on March 8."
BIIB,BIIB:UW,BBG000C18861,Will These Cutting-Edge Cancer Killers Reignite The Biotech Rally?,2017-06-19 14:19:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cugF5S2JfJk/will-these-cutting-edge-cancer-killers-reignite-the-biotech-rally-cm803947,The biotech industry always a highly technical conundrum for investors might currently pose an even greater challenge 160 and offer even greater opportunities than usual Early industry innovators like Amgen AMGN Biogen BIIB and Gilead
BIIB,BIIB:UW,BBG000C18861,Do You Really Want to Love Your Medicines?,2017-06-19 13:02:48 +0000,https://finance.yahoo.com/news/really-want-love-medicines-130248477.html?.tsrc=rss,Far-fetched but pharma marketers are giving it a try
BIIB,BIIB:UW,BBG000C18861,"Morning Movers: Valeant Jumps, U.S. Steel Gains, Biogen Rises",2017-06-19 12:56:00 +0000,http://finance.yahoo.com/r/2f4c4b08-c675-36d8-b93a-6ca77b793203/morning-movers-valeant-jumps-u-s-steel-gains-biogen-rises-1497877005?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Stocks look set for a higher open this morning as tech stocks look set to rebound. S&P 500 futures have risen 0.3%, while Dow Jones Industrial Average futures have advanced 0.3%. Nasdaq Composite futures ..."
BIIB,BIIB:UW,BBG000C18861,Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why,2017-06-16 20:20:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7qExo5y8fJA/nektar-nktr-stock-rallied-almost-50-this-year-heres-why-cm804556,Shares of Nektar Therapeutics NKTR are up almost 46 7 this year so far outperforming the Zacks classified Medical Drugs industry s registered increase of 3 during this period Let s analyze the factors that led to the rally San Francisco CA based Nektar Therapeutics is
BIIB,BIIB:UW,BBG000C18861,Biotech Stocks To Watch And Pharma Industry News,2017-06-16 17:06:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
BIIB,BIIB:UW,BBG000C18861,Bear of the Day: Bioverativ (BIVV),2017-06-16 14:12:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SE_Sop_Ep6o/bear-of-the-day-bioverativ-bivv-cm804367,Bioverativ BIVV is a biotechnology company focused on the discovery and commercialization of innovative therapies for the treatment of hemophilia and other rare blood disorders The company was spun off from Biogen BIIB in February of this year and reported its first full quarter as
BIIB,BIIB:UW,BBG000C18861,"​Accenture, 1QBit partner for drug discovery through quantum computing",2017-06-16 01:19:00 +0000,http://finance.yahoo.com/r/1d122c0d-4b24-30bb-96f6-75f789b1bda0/accenture-1qbit-partner-for-drug-discovery-through-quantum-computing/#ftag=YHFb1d24ec?yptr=yahoo&.tsrc=rss,Accenture and quantum computing startup 1QBit have partnered with pharmaceutical giant Biogen to develop a quantum-enabled molecular comparison application for drug discovery.
BIIB,BIIB:UW,BBG000C18861,Don’t Be Scared of Biogen Inc (BIIB) Stock,2017-06-15 18:11:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cJJTbSsumKs/dont-be-scared-of-biogen-inc-biib-stock-cm804035,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB stock has had a choppy few months It has been ping ponging back and forth by 15 in either direction as political rhetoric weighs on biotechs Politicians have used
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug",2017-06-15 12:26:12 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-management-changes-122612497.html?.tsrc=rss,Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead&apos;s HIV regimen.
BIIB,BIIB:UW,BBG000C18861,Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects,2017-06-15 12:02:00 +0000,http://finance.yahoo.com/r/a82be746-82c1-37ba-b128-6f560a31e3ac/cfo-departure-signals-biogen-isn-t-about-to-be-sold.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Paul Clancy's move to another biotech firm could mean that there's nothing imminent in terms of Biogen being bought out, says Mizuho analyst Salim Syed."
BIIB,BIIB:UW,BBG000C18861,How analysts are interpreting Biogen's management shakeup,2017-06-15 02:10:09 +0000,http://finance.yahoo.com/r/2d53371e-3114-3161-b715-58ba15d52608/how-analysts-are-interpreting-biogens-management.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"A string of departures from Biogen’s executive team this year has raised a pressing question among market analysts: Is the state’s largest independent drugmaker looking to make a deal?  Since getting a new CEO in January in Michel Vounatsos, Biogen (BIIB) has lost three top executives — technology head Adriana Karaboutis, human resources chief Kenneth DiPietro and chief financial officer Paul Clancy, who announced Tuesday that he will soon join Alexion Pharmaceuticals.  Meanwhile, Biogen remains without a chief scientific officer after Spyros Artavanis-Tsakonas changed titles to part-time visiting scientist."
BIIB,BIIB:UW,BBG000C18861,The Hot Stock: Alexion Pharmaceuticals Jumps 9.3%,2017-06-14 21:46:00 +0000,http://finance.yahoo.com/r/7be35edb-7b12-3601-ae16-0804aae7315a/the-hot-stock-alexion-pharmaceuticals-jumps-9-3-1497476801?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Alexion Pharmaceuticals (ALXN) soared to the top of the S&P 500 today after it poached Biogen's (BIIB) CFO. Alexion Pharmaceuticals gained 9.3% to $118.00 today, while the S&P 500 dipped 0.1% to 2,437.92. ..."
BIIB,BIIB:UW,BBG000C18861,Biogen and Anadarko slump while H&R Block and Southern rise,2017-06-14 21:27:54 +0000,https://finance.yahoo.com/news/biogen-anadarko-slump-while-h-212754636.html?.tsrc=rss,"Stocks that moved substantially or traded heavily Wednesday: Biogen Inc., down 8.05 to $253.37 The drugmaker's chief financial officer is leaving to take the same role at Alexion Pharmaceuticals. H&R Block ..."
BIIB,BIIB:UW,BBG000C18861,"Market Close Report: NASDAQ Composite index closes at 6,194.89 down -25.48 points",2017-06-14 20:48:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KkTBYZ5dMw4/market-close-report-nasdaq-composite-index-closes-at-619489-down-2548-points-cm803544,Wednesday s session closes with the NASDAQ Composite Index at 6 194 89 The total shares traded for the NASDAQ was over 1 95 billion Declining stocks led advancers by 1 39 to 1 ratio There were 1212 advancers and 1689 decliners for the day On the NASDAQ Stock Exchange 43 stocks reached a 52
BIIB,BIIB:UW,BBG000C18861,Is Defecting CFO A Glutton For Punishment By Moving To Alexion?,2017-06-14 20:16:17 +0000,http://finance.yahoo.com/r/9922fe85-159f-343e-8398-6dc740bdcab0/alexion-gets-a-new-finance-chief-from-rival-biogen-shares-rise?src=A00220&yptr=yahoo&.tsrc=rss,"Alexion Pharmaceuticals&apos; newest executive must have an appetite for punishment, by defecting from Biogen, an analyst suggested Wednesday"
BIIB,BIIB:UW,BBG000C18861,Alexion Stock Soars After It Poaches Biogen CFO,2017-06-14 20:16:00 +0000,http://finance.yahoo.com/r/8a41a6a3-168f-323b-a460-88c40e4bff8d/alexion-soars-after-biogen-cfo-joins-company-alxn-biib?partner=YahooSA&yptr=yahoo&.tsrc=rss,Alexion shares climbed more than 9% amid news that it had poached Biogen CFO Paul Clancy.
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Wednesday Option Activity: AAPL, BIIB, CMG",2017-06-14 19:07:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jA8bGIdQ8_I/noteworthy-wednesday-option-activity-aapl-biib-cmg-cm803457,Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in Apple Inc Symbol AAPL where a total of 208 518 contracts have traded so far representing approximately 20 9 million underlying shares That amounts to about 70 9 of AAPL s
BIIB,BIIB:UW,BBG000C18861,[$$] Alexion Even Stronger After Adding Biogen CFO,2017-06-14 18:02:00 +0000,http://finance.yahoo.com/r/09bbad32-62fa-3044-b8e9-17d3b55e03e3/alexion-even-stronger-after-adding-biogen-cfo-1497463351?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When news broke late Tuesday that Biogen’s much respected chief financial officer Paul Clancy was leaving the company, investors quickly sold the biotech giant’s stock.  Clancy’s departure, though a loss for Biogen (ticker:ticker:NasdaqGS:BIIB), is a big gain for Alexion Pharmaceuticals (ALXN).  The same veteran executive who helped lead Biogen through a turnaround will assume the CFO post at Alexion on July 31, replacing Dave Anderson, who plans to leave come August."
BIIB,BIIB:UW,BBG000C18861,One of Stephanie Link's picks jumps 10 percent,2017-06-14 17:31:00 +0000,https://finance.yahoo.com/video/one-stephanie-links-picks-jumps-173100515.html?.tsrc=rss,Big moves in today's Halftime blitz - Alexion jumps big.
BIIB,BIIB:UW,BBG000C18861,"Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data",2017-06-14 16:22:00 +0000,http://finance.yahoo.com/r/ba2a0bf1-25c9-35ee-b612-3ed19c375493/biotech-movers-epizyme-alexion-xbiotech.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14."
BIIB,BIIB:UW,BBG000C18861,"Biogen Loses Top Executive Again, CFO Clancy to Join Alexion",2017-06-14 16:08:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HXG_C03QQGI/biogen-loses-top-executive-again-cfo-clancy-to-join-alexion-cm803299,Biogen Inc s BIIB chief financial officer CFO for the last 10 years Paul Clancy is joining Alexion Pharmaceuticals Inc ALXN next month Shares of Alexion were up 3 7 in after hours trading on Tuesday while Biogen s shares declined 1 3 This year Biogen s shares have declined 9 9
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: BIIB, ALXN",2017-06-14 16:08:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6bndhbihqqU/nasdaq-100-movers-biib-alxn-cm803320,In early trading on Wednesday shares of Alexion Pharmaceuticals topped the list of the day s best performing components of the Nasdaq 100 index trading up 7 2 Year to date Alexion Pharmaceuticals has lost about 5 4 of its value And the worst performing Nasdaq 100 component thus far
BIIB,BIIB:UW,BBG000C18861,"3 Stocks to Watch on Wednesday: Ford Motor Company (F), Alexion Pharmaceuticals, Inc. (ALXN) and H & R Block Inc (HRB)",2017-06-14 16:06:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tY-3JMZtj7I/3-stocks-to-watch-on-wednesday-ford-motor-company-f-alexion-pharmaceuticals-inc-alxn-and-h-r-block-inc-hrb-cm803370,InvestorPlace Stock Market News Stock Advice amp Trading Tips U S markets bounced back on Tuesday thanks to tech stocks recovery from 160 a dismal Monday Friday slide The 160 S amp P 500 Index 160 was 0 5 better the 160 Dow Jones Industrial Average
BIIB,BIIB:UW,BBG000C18861,Biogen: Oops…There Goes Another Executive,2017-06-14 15:54:00 +0000,http://finance.yahoo.com/r/6c95217c-2754-3565-b772-86568682fe84/biogen-oopsthere-goes-another-executive-1497455672?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Biogen (BIIB) is losing its chief financial officer...to another drug maker. The company announced late Tuesday that CFO Paul Clancy will depart next month to take a post at another drug company.  Which ...
BIIB,BIIB:UW,BBG000C18861,"Biogen Loses Top Executive Again, CFO Clancy to Join Alexion",2017-06-14 14:31:02 +0000,https://finance.yahoo.com/news/biogen-loses-top-executive-again-143102983.html?.tsrc=rss,"Biogen Inc.&apos;s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month."
BIIB,BIIB:UW,BBG000C18861,Alexion Pharmaceuticals Adds New CFO From Biogen,2017-06-14 13:15:28 +0000,https://finance.yahoo.com/news/alexion-pharmaceuticals-adds-cfo-biogen-131528115.html?.tsrc=rss,Shares of Alexion Pharmaceuticals saw a handy gain early on Wednesday after the company announced that there would be changes in its leadership.
BIIB,BIIB:UW,BBG000C18861,Morning Movers: Alexion Climbs on Biogen Hire; H&R Block Jumps,2017-06-14 12:31:00 +0000,http://finance.yahoo.com/r/c774a429-b20d-3a9d-81a2-d772720f16d8/morning-movers-alexion-climbs-on-biogen-hire-h-r-block-jumps-1497443482?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Stocks look set for a higher open this morning ahead of the Fed's announcement on interest rates this afternoon. S&P 500 futures have advanced 0.1%, while Dow Jones Industrial Average futures have risen ..."
BIIB,BIIB:UW,BBG000C18861,"Early movers: BA, MAT, ANTM, BIIB, HRB, TM & more",2017-06-14 12:13:24 +0000,https://finance.yahoo.com/news/early-movers-ba-mat-antm-121324923.html?.tsrc=rss,These are the stocks posting the largest moves before the bell.
BIIB,BIIB:UW,BBG000C18861,"3 Stocks to Watch on Wednesday: Ford Motor Company (F), Alexion Pharmaceuticals, Inc. (ALXN) and H & R Block Inc (HRB)",2017-06-14 12:03:54 +0000,https://finance.yahoo.com/news/3-stocks-watch-wednesday-ford-120354186.html?.tsrc=rss,"Ford Motor Company (NYSE:F), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and H & R Block Inc (NYSE:HRB) are all in the spotlight Wednesday morning.  F shares are trying to keep up a slow recovery amid news that Ford has made some inroads on the electric vehicle front — in Germany.  Germany’s Deutsche Post DHL Group — better known under its simpler delivery brand, DHL — has signed Ford up as a components supplier as it builds out its line of StreetScooter electric delivery vans."
BIIB,BIIB:UW,BBG000C18861,"Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations",2017-06-14 11:30:00 +0000,https://finance.yahoo.com/news/jean-paul-kress-appointed-evp-113000972.html?.tsrc=rss,"Biogen announced today the appointment of Jean-Paul Kress, MD, as Executive Vice President and President, International, and Head of Global Therapeutic Operations, effective June 19."
BIIB,BIIB:UW,BBG000C18861,Alexion Pharma Appoints Biogen Executive Paul Clancy As CFO,2017-06-13 23:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4NySnA0IseE/alexion-pharma-appoints-biogen-executive-paul-clancy-as-cfo-20170613-01392,Alexion Pharma Appoints Biogen Executive Paul Clancy As CFO
BIIB,BIIB:UW,BBG000C18861,Biogen CFO Paul Clancy To Step Down,2017-06-13 23:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DGRtAjzmCXI/biogen-cfo-paul-clancy-to-step-down-20170613-01385,Biogen CFO Paul Clancy To Step Down
BIIB,BIIB:UW,BBG000C18861,Biogen CFO Bolts to Alexion,2017-06-13 22:05:00 +0000,http://finance.yahoo.com/r/a3a5cef0-c131-3613-b49d-0afea82fe621/biogen-cfo-bolts-to-alexion.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Chief accounting officer Greg Covino will serve as Biogen's interim principal financial officer while the firm searches for a new finance chief.
BIIB,BIIB:UW,BBG000C18861,Alexion names Biogen's Paul Clancy as CFO,2017-06-13 21:46:55 +0000,https://finance.yahoo.com/news/alexion-names-biogens-paul-clancy-204706819.html?.tsrc=rss,"Alexion Pharmaceuticals Inc on Tuesday named Biogen Inc's Chief Financial Officer Paul Clancy as its finance head, effective July 31. Clancy will succeed Dave Anderson, who will remain with Alexion until ..."
BIIB,BIIB:UW,BBG000C18861,Biogen exodus continues as CFO set to join Alexion,2017-06-13 21:05:09 +0000,http://finance.yahoo.com/r/5ca5a7ba-ff68-3722-871c-1d7e1ad762df/biogen-exodus-continues-as-cfo-set-to-join-alexion.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen, one of the state's largest drugmakers, has seen its leadership ranks dwindle in recent years, fueling speculation about a potential takeover.  Biogen (BIIB) said in a release Tuesday afternoon that chief financial officer Paul Clancy will leave ""to join another biopharmaceutical company."" Moments later, New Haven, Connecticut-based Alexion Pharmaceuticals (ALXN) announced that Clancy had accepted a job as its CFO.  Earlier this year, Adriana Karaboutis left her post as executive vice president of technology, business solutions and corporate affairs."
BIIB,BIIB:UW,BBG000C18861,Alexion hires Biogen executive to serve as its CFO,2017-06-13 20:45:33 +0000,http://finance.yahoo.com/r/46eee632-df8c-30b5-9181-4cf94c345dbd/Story.aspx?guid=5A8B9180-2A94-4E6E-AC06-CF221B400CA3&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Shares of Alexion Pharmaceuticals Inc. rose more than 2% late Tuesday after the company announced the hiring of the former Biogen Inc. chief financial officer as its CFO. Paul J. Clancy will join Alexion ...
BIIB,BIIB:UW,BBG000C18861,Biogen Announces Management Change,2017-06-13 20:15:00 +0000,https://finance.yahoo.com/news/biogen-announces-management-change-201500302.html?.tsrc=rss,"Biogen announced today that Paul Clancy, Executive Vice President, Finance & Chief Financial Officer  will leave the organization to join another biopharmaceutical company."
BIIB,BIIB:UW,BBG000C18861,"Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for June 14, 2017",2017-06-13 13:18:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O94S0bthOXk/gilead-sciences-inc-gild-ex-dividend-date-scheduled-for-june-14-2017-cm802537,Gilead Sciences Inc GILD will begin trading ex dividend on June 14 2017 A cash dividend payment of 0 52 per share is scheduled to be paid on June 29 2017 Shareholders who purchased GILD prior to the ex dividend date are eligible for the cash dividend payment This represents an 10
BIIB,BIIB:UW,BBG000C18861,Celgene&apos;s Next Blockbuster: What You Need to Know,2017-06-13 11:24:00 +0000,http://finance.yahoo.com/r/a394d239-7bf0-3fc3-8101-ca8a60bcafdd/celgenes-next-blockbuster-what-you-need-to-know.aspx?yptr=yahoo&.tsrc=rss,Could Celgene&apos;s newest drug finally get this company the respect it deserves?
BIIB,BIIB:UW,BBG000C18861,Insiders Buy the Holdings of VONE ETF,2017-06-12 15:29:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UrtS5PC_aXc/insiders-buy-the-holdings-of-vone-etf-cm802006,A look at the weighted underlying holdings of the Vanguard Russell 1000 ETF VONE shows an impressive 11 3 of holdings on a weighted basis have experienced insider buying within the past six months Biogen Inc Symbol BIIB which makes up 0 24 of the Vanguard Russell 1000 ETF
BIIB,BIIB:UW,BBG000C18861,How Ionis Pharmaceuticals’ Spinraza Performed in 1Q17,2017-06-12 14:37:08 +0000,http://finance.yahoo.com/r/47f8fc45-4d26-347b-ad0c-6f95a0077ae4/how-ionis-pharmaceuticals-spinraza-performed-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Ionis’s (IONS) Spinraza (nusinersen) is a drug designed for the treatment of patients with SMA (spinal muscular atrophy). SMA is a severe genetic disease affecting the nervous system and voluntary…
BIIB,BIIB:UW,BBG000C18861,2 Reasons Why Biogen's Shares Slumped in May,2017-06-09 12:28:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a4CVlQ_-1eU/2-reasons-why-biogens-shares-slumped-in-may-cm801005,What happened Biotech titan Biogen NASDAQ BIIB had a rough time last month as a pair of unrelated issues helped send its shares down by 8 58 according to data from S amp P Global Market Intelligence First off the biotech industry as a whole took a step back in
BIIB,BIIB:UW,BBG000C18861,2 Reasons Why Biogen&apos;s Shares Slumped in May,2017-06-09 11:22:00 +0000,http://finance.yahoo.com/r/876cc1bc-b71e-3c5d-8370-6bf32160dffc/2-reasons-why-biogens-shares-slumped-in-may.aspx?yptr=yahoo&.tsrc=rss,A pair of unrelated issues helped send the large-cap biotech&apos;s shares down by 8.58% over the month -- only one of them company-specific.
BIIB,BIIB:UW,BBG000C18861,Breakout Watch: Top Funds Buy This Biotech IPO With 196% Growth,2017-06-08 15:13:45 +0000,http://finance.yahoo.com/r/065afe91-4c92-3ea9-95c7-a34b76d933bd/breakout-watch-top-funds-buy-biotech-ipo-biogen-spinoff-bioverativ-196-growth?src=A00220&yptr=yahoo&.tsrc=rss,Top fund managers have been buying shares in Biogen spinoff and 2017 IPO Bioverativ. Is it getting ready to breakout from its first post-IPO base?
BIIB,BIIB:UW,BBG000C18861,IPO Stock News And Analysis: Find Today&apos;s Top New Issues,2017-06-07 20:33:05 +0000,http://finance.yahoo.com/r/45cab0b3-73ce-3b0d-8c0e-ebbd4c5e71b2/ipo-stock-news-and-analysis-find-todays-top-new-issues?src=A00220&yptr=yahoo&.tsrc=rss,"Get the latest news on recent and upcoming IPOs, filings for new issues, and today’s top-performing IPO stocks."
BIIB,BIIB:UW,BBG000C18861,Biogen Annual Meeting Of Stockholders At 9:00 AM ET,2017-06-07 08:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QAn-8McJJVU/biogen-annual-meeting-of-stockholders-at-900-am-et-20170607-00424,Biogen Annual Meeting Of Stockholders At 9:00 AM ET
BIIB,BIIB:UW,BBG000C18861,3 Stocks That Could Be Life-Changers,2017-06-06 18:19:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4OLNBDeMGBM/3-stocks-that-could-be-life-changers-cm799568,A stock that provides a market beating return over the long run can be financially life changing NVIDIA NASDAQ NVDA Biogen NASDAQ BIIB and JPMorgan Chase NYSE JPM all have that potential NVIDIA and Biogen could also be life changing in other ways with
BIIB,BIIB:UW,BBG000C18861,3 Stocks That Could Be Life-Changers,2017-06-06 16:28:00 +0000,http://finance.yahoo.com/r/3f925a42-2878-3ea2-a4a2-13b0aeace759/3-stocks-that-could-be-life-changers.aspx?yptr=yahoo&.tsrc=rss,Both financially and in a greater sense.
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharmaceuticals Inc. Swooned 6% in May,2017-06-06 15:18:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YHozFnRDJ_U/why-ionis-pharmaceuticals-inc-swooned-6-in-may-cm799396,What happened Shares of Ionis Pharmaceuticals NASDAQ IONS 160 a commercial stage biotech focused on RNA targeted therapeutics dropped 160 6 in May according to data from S amp P Global Market Intelligence So what Here s a look back at the key events
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharmaceuticals Inc. Swooned 6% in May,2017-06-06 14:13:00 +0000,http://finance.yahoo.com/r/15a06ce6-ff3a-32c0-967b-6c533fe919b8/why-ionis-pharmaceuticals-inc-swooned-6-in-may.aspx?yptr=yahoo&.tsrc=rss,Some downbeat news from a Phase 3 trial overshadowed all the good news that was delivered during the month.
BIIB,BIIB:UW,BBG000C18861,Biogen Inc (BIIB) Stock Can Help You Earn Income From Thin Air,2017-06-05 19:01:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bHrIuXyfjsk/biogen-inc-biib-stock-can-help-you-earn-income-from-thin-air-cm798955,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB stock has had a rough couple of months sliding 15 since March The earnings reception was less than ideal from Wall Street Source Biogen via YouTube The stock price move is a
BIIB,BIIB:UW,BBG000C18861,Is This Biotech IPO And Biogen Spinoff About To Break Out?,2017-06-05 16:40:38 +0000,http://finance.yahoo.com/r/08d166e7-efdf-3927-b177-b91b16630e72/is-this-biotech-ipo-and-biogen-spinoff-about-to-break-out?src=A00220&yptr=yahoo&.tsrc=rss,"Bioverativ shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 85."
BIIB,BIIB:UW,BBG000C18861,Biogen/Ionis Spinraza Granted Marketing Authorization in EU,2017-06-02 21:31:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VqAARWqJAyQ/biogenionis-spinraza-granted-marketing-authorization-in-eu-cm798223,Biogen Inc BIIB announced granting of marketing authorization to its marketed drug Spinraza nusinersen by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy SMA This is the first approved treatment in the European Union
BIIB,BIIB:UW,BBG000C18861,"Notable Friday Option Activity: LEN, BIIB, RRC",2017-06-02 20:31:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/agfYY2MJxeI/notable-friday-option-activity-len-biib-rrc-cm798207,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Lennar Corp Symbol LEN where a total volume of 8 313 contracts has been traded thus far today a contract volume which is representative of approximately 831 300
BIIB,BIIB:UW,BBG000C18861,Biogen/Ionis Spinraza Granted Marketing Authorization in EU,2017-06-02 19:58:07 +0000,https://finance.yahoo.com/news/biogen-ionis-spinraza-granted-marketing-195807505.html?.tsrc=rss,Biogen Inc. (BIIB) announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy.
BIIB,BIIB:UW,BBG000C18861,Biotech ETF Experiences Big Outflow,2017-06-02 16:33:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IECsP51pPQk/biotech-etf-experiences-big-outflow-cm798041,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Biotech ETF Symbol BBH where we have detected an approximate 11 7 million dollar outflow that s a 1 8 decrease week over week from 5 596 503 to 5 496
BIIB,BIIB:UW,BBG000C18861,"Biogen, Ionis Stocks Pop After Europe Approves $125,000 Drug",2017-06-01 20:15:36 +0000,http://finance.yahoo.com/r/59ef2a2f-51c6-368f-b310-3e607dcf3e82/biogen-ionis-stocks-pop-after-europe-approves-125000-drug?src=A00220&yptr=yahoo&.tsrc=rss,Biogen and Ionis stocks popped Thursday after the European Commission approved an application for their costly spinal disease drug Spinraza.
BIIB,BIIB:UW,BBG000C18861,Biogen rare infant disease drug Spinraza approved in E.U.,2017-06-01 13:50:12 +0000,http://finance.yahoo.com/r/3b803dae-43c9-3bcc-9b0d-d865ad3a978c/biogen-rare-infant-disease-drug-spinraza-approved.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Back in December, Biogen’s Spinraza became the first drug approved by the FDA to treat spinal muscular atrophy, a top genetic cause of death in infants.  Now, the Cambridge-based company has repeated that feat in Europe.  Biogen (BIIB) said Thursday that the European Commission has approved Spinraza, meaning it will become the first drug available in the European Union for SMA patients."
BIIB,BIIB:UW,BBG000C18861,"Bridge With Buffett And Thorp, And Five Stocks That Could Follow Suit",2017-06-01 13:16:00 +0000,http://finance.yahoo.com/r/8630cc6d-cfbb-3d3a-bd53-9f0dad8d4626/bridge-with-buffett-and-thorp-and-five-stocks-that-could-follow-suit?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Like bridge, you do better in the market if you get more information, sooner, and put it to better use."
BIIB,BIIB:UW,BBG000C18861,Analysts’ Views on Alexion Pharmaceuticals and Its Peers,2017-06-01 11:37:57 +0000,http://finance.yahoo.com/r/e1db19d2-3c1c-38ec-bbff-b2549505a088/analysts-views-alexion-pharmaceuticals-peers?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 21 analysts analyzing Alexion Pharmaceuticals, six analysts recommended a “strong buy” and 11 analysts recommended a “buy.”"
BIIB,BIIB:UW,BBG000C18861,SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy,2017-06-01 11:30:00 +0000,https://finance.yahoo.com/news/spinraza-nusinersen-approved-european-union-113000919.html?.tsrc=rss,"The European Commission has granted a marketing authorization for SPINRAZA® for the treatment of 5q spinal muscular atrophy , Biogen announced today.1 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases.2 SPINRAZA is the first approved treatment in the European Union for SMA, a leading genetic cause of death in infants that is marked by progressive, debilitating ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Reports Marketing Authorization For SPINRAZA In European Union,2017-06-01 07:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZMRTHko0o7g/biogen-reports-marketing-authorization-for-spinraza-in-european-union-20170601-00404,Biogen Reports Marketing Authorization For SPINRAZA In European Union
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Gilead Sciences Inc.,2017-05-31 22:33:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aJsziSrcuyQ/better-buy-biogen-inc-vs-gilead-sciences-inc-cm797100,Two big biotechs have been big busts for investors so far in 2017 Shares of Biogen NASDAQ BIIB and Gilead Sciences NASDAQ GILD are both down year to date with Gilead s shareholders experiencing the worse pain Should long term investors consider either one of
BIIB,BIIB:UW,BBG000C18861,Biogen Announces Webcast of Virtual Annual Meeting of Stockholders,2017-05-31 21:00:00 +0000,https://finance.yahoo.com/news/biogen-announces-webcast-virtual-annual-210000038.html?.tsrc=rss,"Biogen Inc. announced today that the webcast of the Company's 2017 Annual Meeting of Stockholders will be held on Wednesday, June 7, 2017 at 9:00 a.m. Eastern Daylight Time."
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Gilead Sciences Inc.,2017-05-31 20:22:00 +0000,http://finance.yahoo.com/r/f0204389-56b8-3bb2-a42a-a7a3ff1671bb/better-buy-biogen-inc-vs-gilead-sciences-inc.aspx?yptr=yahoo&.tsrc=rss,"If you could only buy Biogen or Gilead Sciences stock, which would it be? Here&apos;s how the biotechs stack up."
BIIB,BIIB:UW,BBG000C18861,Big Pharma Stock Earns Relative Strength Rating Upgrade,2017-05-31 16:49:33 +0000,http://finance.yahoo.com/r/d5150fcd-d9f1-32a1-9524-ca1e2796c73e/roche-earns-relative-strength-rating-upgrade?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Roche shows improving technical performance. Will it continue?
BIIB,BIIB:UW,BBG000C18861,5 Drug Stocks in Focus on World MS Day,2017-05-31 16:36:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WraSAmDK038/5-drug-stocks-in-focus-on-world-ms-day-cm796902,Since 2009 World MS Day is officially marked on the last Wednesday of May with events and campaigns focused on bringing the worldwide multiple sclerosis MS community together and raising awareness about the disease Life with MS This World MS Day the theme is Life with MS
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture",2017-05-31 15:37:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fanSA1Js9pg/the-zacks-analyst-blog-highlights-unitedhealth-group-union-pacific-biogen-united-technologies-and-accenture-cm796835,For Immediate Release Chicago IL May 31 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BIIB,BIIB:UW,BBG000C18861,5 Drug Stocks in Focus on World MS Day,2017-05-31 14:08:02 +0000,https://finance.yahoo.com/news/5-drug-stocks-focus-world-140802344.html?.tsrc=rss,"Life with MS -- this world MS day, here&apos;s a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market."
BIIB,BIIB:UW,BBG000C18861,Celgene's Stock May Be Incredibly Overvalued Right Now -- Here's Why,2017-05-31 13:33:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mHlfqeeLba8/celgenes-stock-may-be-incredibly-overvalued-right-now-heres-why-cm796644,Celgene NASDAQ CELG has long garnered one of the richest valuations among large cap biotechs and for good reason The long and short of it is that Celgene has been able to post industry leading levels of revenue growth year after year thanks to its unmatched ability to churn out
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture",2017-05-31 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-unitedhealth-133001221.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: UnitedHealth Group, Union Pacific, Biogen, United Technologies and Accenture"
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for UnitedHealth Group, Union Pacific & Biogen",2017-05-30 23:30:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ODYARUMB6xE/top-research-reports-for-unitedhealth-group-union-pacific-biogen-cm796529,Tuesday May 30 2017 Today s Research Daily features new research reports on 16 major stocks including UnitedHealth Group Inc UNH Union Pacific Corporation UNP and Biogen Inc BIIB You can see all of today s research reports here gt gt
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for UnitedHealth Group, Union Pacific & Biogen",2017-05-30 21:29:09 +0000,https://finance.yahoo.com/news/top-research-reports-unitedhealth-group-212909946.html?.tsrc=rss,"Top Research Reports for UnitedHealth Group, Union Pacific & Biogen"
BIIB,BIIB:UW,BBG000C18861,Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?,2017-05-30 17:34:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LcBRmkMKcJ4/are-nektars-nktr-key-drugs-set-to-drive-growth-in-2017-cm796322,On May 29 2017 we issued an updated report on Nektar Therapeutics NKTR Nektar Therapeutics is a biopharmaceutical company focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms Nektar s shares have
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug",2017-05-30 13:37:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4TE2mSDzGdM/biotech-stock-roundup-puma-soars-on-advisory-panel-vote-priority-review-for-kite-drug-cm795997,While Puma s PBYI shares soared on a positive recommendation from an FDA advisory panel for the company s breast cancer treatment neratinib companies like Inovio INO and BioCryst BCRX also saw their shares gaining on positive data Recap of the Week s Most Important Stories
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug",2017-05-30 11:49:11 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-puma-soars-114911555.html?.tsrc=rss,Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.
BIIB,BIIB:UW,BBG000C18861,UPDATE 1-Deadly brain infection in German MS patient prompts Roche investigation,2017-05-28 10:51:33 +0000,https://finance.yahoo.com/news/1-deadly-brain-infection-german-105133114.html?.tsrc=rss,"A person in Germany treated with  Roche Holding AG’s new multiple sclerosis drug Ocrevus  has been diagnosed with an often-deadly brain infection after  switching from another medication earlier this year, the Swiss  drugmaker said on Wednesday.  Roche said it was investigating a case of Progressive  Multifocal Leukoencephalopathy (PML) in a patient previously  being treated for three years with Biogen Inc's Tysabri  and who had received a single dose of Ocrevus in April.  Roche is trying to determine the source of the illness but  MS drugs that suppress the immune system can increase the risk  of serious infections."
BIIB,BIIB:UW,BBG000C18861,Which Biotechs Benefit Most Under Trump&apos;s Tax Reform Vision?,2017-05-27 12:00:55 +0000,http://finance.yahoo.com/r/cc324037-f97e-3ba0-8f24-1c7e7820a122/which-biotechs-benefit-most-under-trumps-tax-reform-vision?src=A00220&yptr=yahoo&.tsrc=rss,"Regeneron, Gilead and Biogen will benefit the most among biotechs under Trump&apos;s proposed tax reform, a measure that would cut the corporate tax rate by 20%."
BIIB,BIIB:UW,BBG000C18861,Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer,2017-05-26 15:36:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vsyv3bnPbkk/merck-mrk-buys-rights-to-anti-tau-antibody-for-alzheimer-cm795236,Merck amp Co Inc MRK announced that it has bought exclusive worldwide license from Teijin Pharma for the development manufacture and commercialization of an investigational preclinical anti tau antibody Merck sees potential in the development and commercialization of the candidate for
BIIB,BIIB:UW,BBG000C18861,Merck (MRK) Buys Rights to Anti-tau Antibody for Alzheimer,2017-05-26 13:42:01 +0000,https://finance.yahoo.com/news/merck-mrk-buys-rights-anti-134201797.html?.tsrc=rss,"Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody."
BIIB,BIIB:UW,BBG000C18861,Stock Exchange: Time to reconsider health care?,2017-05-26 12:31:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SgaY6HFjiwg/stock-exchange-time-to-reconsider-health-care-cm795011,By Jeff Miller ByJeff Miller Each week the Stock Exchange highlights the results from different technical trading methods We also provide contrast and often dissent from a fundamental analyst It is always interesting when we find a pick where multiple methods agree This week the
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?,2017-05-26 09:32:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SiGZlYOepeE/biogen-biib-down-95-since-earnings-report-can-it-rebound-cm794962,It has been about a month since the last earnings report for Biogen Inc BIIB Shares have lost about 9 5 in that time frame underperforming the market Will the recent negative trend continue leading up to the stock s next earnings release or is it due for a breakout Before we dive
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Down 9.5% Since Earnings Report: Can It Rebound?,2017-05-26 07:53:07 +0000,https://finance.yahoo.com/news/biogen-biib-down-9-5-075307573.html?.tsrc=rss,BIIB reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
BIIB,BIIB:UW,BBG000C18861,​Another top Biogen executive stepping down,2017-05-25 16:35:08 +0000,http://finance.yahoo.com/r/4ce596a3-33aa-33b8-a1a5-0e3caa9386cc/another-top-biogen-executive-stepping-down.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen, the state’s largest local drug company by market cap and headcount, is about to lose yet another top executive. Kenneth DiPietro plans to step down as executive vice president of human resources ..."
BIIB,BIIB:UW,BBG000C18861,Biogen's Fampyra Conditional Approval Converted to Standard,2017-05-25 15:37:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ade6PoDiyPc/biogens-fampyra-conditional-approval-converted-to-standard-cm794575,Biogen Inc BIIB announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis MS patients in the EU has been converted to a standard marketing approval As part of the conditional approval received in 2011 Biogen was required
BIIB,BIIB:UW,BBG000C18861,Short Sellers Raise the Stakes in Major Biotechs,2017-05-25 13:50:14 +0000,https://finance.yahoo.com/news/short-sellers-raise-stakes-major-135014512.html?.tsrc=rss,"The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed."
BIIB,BIIB:UW,BBG000C18861,Biogen&apos;s Fampyra Conditional Approval Converted to Standard,2017-05-25 13:16:01 +0000,https://finance.yahoo.com/news/biogen-apos-fampyra-conditional-approval-131601907.html?.tsrc=rss,Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
BIIB,BIIB:UW,BBG000C18861,"Jeff Ubben Buys 1, Sells 1 in 1st Quarter",2017-05-25 11:30:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aeqRQZV8Gus/jeff-ubben-buys-1-sells-1-in-1st-quarter-cm794320,Jeff Ubben Trades Portfolio s ValueAct Holdings bought Bioverativ Inc BIVV and sold Allison Transmission Holdings Inc ALSN during the first quarter Jeff Ubben Trades Portfolio s ValueAct Holdings boughtBioverativ Inc Bioverativ Inc BIVV and
BIIB,BIIB:UW,BBG000C18861,Deadly brain infection in German MS patient prompts Roche investigation,2017-05-24 21:44:24 +0000,https://finance.yahoo.com/news/deadly-brain-infection-german-ms-214424143.html?.tsrc=rss,"A person in Germany treated with  Roche Holding AG’s new multiple sclerosis drug Ocrevus  has been diagnosed with an often-deadly brain infection after  switching from another medication earlier this year, the Swiss  drugmaker said on Wednesday.  Roche said it was investigating a case of Progressive  Multifocal Leukoencephalopathy (PML) in a patient previously  being treated for three years with Biogen Inc’s Tysabri  and who had received a single dose of Ocrevus in February.  Roche is trying to determine the source of the illness but  MS drugs that suppress the immune system can increase the risk  of serious infections."
BIIB,BIIB:UW,BBG000C18861,Biogen Spinoff Bioverativ Squares Off With Roche After $400 Million Buy,2017-05-24 20:15:49 +0000,http://finance.yahoo.com/r/bbbd61ec-6fd3-3d64-ad46-10bf044f9144/biogen-spin-bioverativ-squares-off-with-roche-after-400-million-buy?src=A00220&yptr=yahoo&.tsrc=rss,Bioverativ stock popped Wednesday after the Biogen spinoff announced a $400 million acquisition of True North Therapeutics.
BIIB,BIIB:UW,BBG000C18861,"Notable Wednesday Option Activity: JNJ, C, BIIB",2017-05-24 19:33:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tYC2TtAH9WI/notable-wednesday-option-activity-jnj-c-biib-cm794102,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Johnson amp Johnson Symbol JNJ where a total volume of 22 555 contracts has been traded thus far today a contract volume which is representative of approximately 2 3
BIIB,BIIB:UW,BBG000C18861,Roche investigating case of patient illness after taking MS drug,2017-05-24 19:02:02 +0000,https://finance.yahoo.com/news/roche-investigating-case-patient-illness-190202944.html?.tsrc=rss,"A person in Germany treated with  Roche’s new multiple sclerosis drug Ocrevus has been  diagnosed with an often-deadly brain infection after switching  from another medication earlier this year, the Swiss drugmaker  said on Wednesday.  Roche said it was investigating a case of Progressive  Multifocal Leukoencephalopathy (PML) in a patient previously  being treated for three years with Biogen Inc’s Tysabri  and who had received a single dose of Ocrevus in February.  Roche said the case of the rare brain disease that is  usually fatal or disabling was reported as a carry-over from  Tysabri, also known as natalizumab, by the physician who had  been treating the patient."
BIIB,BIIB:UW,BBG000C18861,InPlay from Briefing.com,2017-05-24 08:42:59 +0000,https://finance.yahoo.com/news/inplay-briefing-com-115750752.html?.tsrc=rss,InPlay from Briefing.com
BIIB,BIIB:UW,BBG000C18861,Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS,2017-05-24 05:30:00 +0000,https://finance.yahoo.com/news/biogen-fampyra-granted-standard-marketing-053000351.html?.tsrc=rss,"The European Commission has granted a standard marketing authorization for FAMPYRA for walking improvement in people with multiple sclerosis , Biogen announced today."
BIIB,BIIB:UW,BBG000C18861,Biogen's FAMPYRA Granted MA In EU For Improvement Of Walking In People With MS,2017-05-24 01:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2IVOzOwS6D4/biogens-fampyra-granted-ma-in-eu-for-improvement-of-walking-in-people-with-ms-20170524-00039,Biogen's FAMPYRA Granted MA In EU For Improvement Of Walking In People With MS
BIIB,BIIB:UW,BBG000C18861,Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment,2017-05-22 12:20:00 +0000,http://finance.yahoo.com/r/55a65a32-06d6-396c-8528-9c69e880932b/celgene-stock-rises-premarket-on-positive-late-stage-test-results-for-multiple-sclerosis-treatment.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The trial enrolled 1,313 RMS patients in 21 countries for two years of study."
BIIB,BIIB:UW,BBG000C18861,Why Long-Term Investors Should Prefer Celgene Over Biogen,2017-05-21 14:12:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0RBZh9VOoFM/why-long-term-investors-should-prefer-celgene-over-biogen-cm792329,Biogen NASDAQ BIIB has enjoyed some good news lately The spinal muscular atrophy drug that it licensed from Ionis Pharmaceuticals NASDAQ IONS won U S regulatory approval in December and the launch appears to be going well The spin off of its hemophilia business into
BIIB,BIIB:UW,BBG000C18861,Why Long-Term Investors Should Prefer Celgene Over Biogen,2017-05-21 13:03:00 +0000,http://finance.yahoo.com/r/2ff19d64-8e8c-3158-85ca-17db1ef47b08/why-long-term-investors-should-prefer-celgene-over.aspx?yptr=yahoo&.tsrc=rss,Biogen isn&apos;t a bad biotech stock pick. But Celgene is better. Here&apos;s why.
BIIB,BIIB:UW,BBG000C18861,"Amgen, Gilead, Biogen Won&apos;t Lead The Biotech Boom — So Who Will?",2017-05-19 20:30:36 +0000,http://finance.yahoo.com/r/43448f46-ab61-3261-87b4-c50ada16e8c5/amgen-gilead-biogen-wont-lead-the-biotech-boom-so-who-will?src=A00220&yptr=yahoo&.tsrc=rss,"Regeneron, Vertex and Alexion look likely to catch the next wave in biotech and start a boom, an analyst says."
BIIB,BIIB:UW,BBG000C18861,5 Reasons Big Biotech Could Gain 25%-30%,2017-05-19 17:09:00 +0000,http://finance.yahoo.com/r/de60de58-e525-3cc6-80bf-38f0a88cd4ca/5-reasons-big-biotech-could-gain-25-30-1495213782?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Leerink analyst Geoffrey Porges sees a light at the end of the tunnel for Big Biotech.  In a note published today, he predicted that the stocks in his coverage area could shake off the doldrums, and climb 25% to 30% in the next year, if “the group captures a re-rating back to the long term average relative multiple, and our generally positive view of the near and long term revenue and earnings outlook materializes.” That coverage universe includes AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Amgen (AMGN), Biogen (BIIB), Celgene (CELG), Gilead Sciences (GILD), Regeneron (REGN) and Vertex (VRTX).  The smaller companies in the group offer the profile of earlier legions of biotech companies, whereas the mature companies in the group (GILD [MP], AMGN [MP], BIIB[MP]) face more near term downside than upside."
BIIB,BIIB:UW,BBG000C18861,Why Stay Bullish On Gilead,2017-05-19 16:02:00 +0000,http://finance.yahoo.com/r/482217aa-20b1-35d8-ad6b-7095e61a0a71/why-stay-bullish-on-gilead-1495209758?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"There’s no shortage of investors who have lost confidence in Gilead Sciences (GILD). Hopes of better news were shattered by its most recent earnings report. And so far, the company has not delivered a ..."
BIIB,BIIB:UW,BBG000C18861,"Noteworthy ETF Outflows: VV, BIIB, PYPL, DHR",2017-05-18 16:12:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zjUysPCKKvI/noteworthy-etf-outflows-vv-biib-pypl-dhr-cm791275,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Large Cap ETF Symbol VV where we have detected an approximate 18 9 million dollar outflow that s a 0 2 decrease week over week from 85 207 747
BIIB,BIIB:UW,BBG000C18861,Biogen has acquired Remedy Pharma's stroke medication for $120 mln,2017-05-18 13:28:28 +0000,http://finance.yahoo.com/r/f5e4e914-4a56-3776-9d5c-8b477550399e/Story.aspx?guid=62A529EA-42CF-4DBE-B369-DEBA8820A12E&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Biogen Inc. said early Thursday that it has acquired a stroke medication from privately-held Remedy Pharmaceuticals for $120 million. The deal may also include additional milestone payments and royalties, ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Acquires Remedy Pharmaceuticals’ Late-Stage Drug CIRARA™,2017-05-18 13:00:00 +0000,https://finance.yahoo.com/news/biogen-acquires-remedy-pharmaceuticals-stage-130000897.html?.tsrc=rss,"Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving treatments to people affected by central nervous system diseases and injuries, today announced that Biogen completed an asset purchase of its Phase 3 candidate, CIRARA."
BIIB,BIIB:UW,BBG000C18861,Biogen Buys Remedy Pharma' Late-Stage Drug CIRARA,2017-05-18 09:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R2ILskU3C6k/biogen-buys-remedy-pharma-latestage-drug-cirara-20170518-00720,Biogen Buys Remedy Pharma' Late-Stage Drug CIRARA
BIIB,BIIB:UW,BBG000C18861,Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference,2017-05-17 20:01:00 +0000,https://finance.yahoo.com/news/biogen-present-bernstein-33rd-annual-200100404.html?.tsrc=rss,"Biogen Inc. announced today that it will present at the Bernstein 33rd Annual Strategic Decisions Conference. The webcast will be live on Wednesday, May 31, 2017 at 3:00 p.m."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal",2017-05-17 13:18:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VWR-nTULKG0/biotech-stock-roundup-biogen-inks-deal-to-boost-pipeline-sangamo-soars-on-pfizer-deal-cm790465,Biogen BIIB was in the news this week not only for an agreement that will boost its pipeline but also for a favorable decision in a securities litigation Meanwhile Sangamo s SGMO shares skyrocketed on a collaboration with Pfizer 160 Recap of the Week s Most Important
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal",2017-05-17 11:53:11 +0000,https://finance.yahoo.com/news/biotech-stock-roundup-biogen-inks-115311547.html?.tsrc=rss,Quite a few deals were announced this week including by companies like Biogen (BIIB).
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Buys Stroke Candidate Cirara for $120M,2017-05-16 21:16:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xCEMajf_3ew/biogen-biib-buys-stroke-candidate-cirara-for-120m-cm790187,Biogen Inc BIIB announced the acquisition of New York based private pharma company Remedy Pharmaceuticals phase III candidate Cirara for an upfront payment of 120 million Cirara is being evaluated for the treatment of large hemispheric stroke LHI Shares were up almost 1 5 on Monday
BIIB,BIIB:UW,BBG000C18861,This Fund’s Picks Gained 200% In A Year And Why No One Knows About It,2017-05-16 20:51:01 +0000,http://finance.yahoo.com/r/04c47290-fb3c-36dd-bc6c-e564cc4eecee/this-funds-picks-gained-200-in-a-year-and-why-no-one-knows-about-it-581306?yptr=yahoo&.tsrc=rss,"You probably haven’t heard of Alex Denner‘s Sarissa Capital Management, which is a shame, as the fund is coming off a first-quarter in which its stock picks in companies valued at $1 billion or more delivered weighted average returns of 53.2%, pushing its 1-year returns to an even 200%. With the media paying most of […]"
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Buys Stroke Candidate Cirara for $120M,2017-05-16 19:24:07 +0000,https://finance.yahoo.com/news/biogen-biib-buys-stroke-candidate-192407430.html?.tsrc=rss,"Biogen Inc. (BIIB) announced the acquisition of Remedy Pharmaceuticals&apos; phase III candidate, Cirara for the treatment of large hemispheric stroke (LHI)."
BIIB,BIIB:UW,BBG000C18861,Want to Get in on Biotech? Check Out These 3 Stocks,2017-05-16 14:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-WF7wU0S0y0/want-to-get-in-on-biotech-check-out-these-3-stocks-cm789802,Biotechnology has been one of the hottest areas for investors over the last five years due to the advent of multiple game changing new medicines and the ever expanding human population that s putting a tremendous amount of pressure on healthcare systems worldwide That said there
BIIB,BIIB:UW,BBG000C18861,Biogen wins dismissal of investor suit over Tecfidera patient death,2017-05-16 13:20:02 +0000,http://finance.yahoo.com/r/4faa7e1e-f13f-3611-8caf-e8466d3f138b/biogen-wins-dismissal-of-investor-suit-over.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"A federal appeals court in Boston has dismissed a suit claiming that Biogen and its top executives misled investors about how the 2014 death of a patient on Tecfidera would impact sales of the blockbuster multiple sclerosis drug.  The First Circuit Court of Appeals in Boston on Friday upheld a lower court’s decision to dismiss the case, which stems from Biogen’s (BIIB) disclosure in October 2014 that a patient who had taken Tecfidera for more than four years in a clinical trial had died of a rare brain disease.  Biogen changed the drug’s label to reflect the death in December 2014."
BIIB,BIIB:UW,BBG000C18861,"Biogen nabs stroke treatment for $120M, eyeing late-stage trial",2017-05-16 13:17:36 +0000,http://finance.yahoo.com/r/d0cffe08-9b2f-399e-92cc-9d8b01f557df/biogen-nabs-stroke-treatment-for-120m-eyeing-late.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen said Monday it will acquire an experimental stroke treatment from a New York biotech for $120 million, as the Cambridge company builds out its arsenal of late-stage neuroscience drugs.  Biogen (BIIB) said it would pay $120 million upfront to Remedy Pharmaceuticals for Cirara, a treatment that's now in trials for a severe kind of stroke called large hemispheric infarction, or LHI, in which brain swelling often leads to death.  Privately-held Remedy will share the development costs for Cirara in LHI stroke, and could receive milestone payments and royalties."
BIIB,BIIB:UW,BBG000C18861,John Paulson Takes A Shine To Telecom,2017-05-15 21:59:10 +0000,http://finance.yahoo.com/r/36dda89a-f3e7-3c3c-b3df-b2bef394c4e3/paulson0515?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Hedge-fund billionaire John Paulson bought new positions in telecommunications operators T-Mobile US Inc. and Dish Network Corp. in the first quarter, according to securities filings Monday."
BIIB,BIIB:UW,BBG000C18861,"Notable Monday Option Activity: RTN, BIIB, MON",2017-05-15 19:15:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OFB3swgIdio/notable-monday-option-activity-rtn-biib-mon-cm789442,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Raytheon Co Symbol RTN where a total volume of 9 145 contracts has been traded thus far today a contract volume which is representative of approximately 914 500
BIIB,BIIB:UW,BBG000C18861,Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke,2017-05-15 11:30:00 +0000,https://finance.yahoo.com/news/biogen-acquires-remedy-pharmaceuticals-cirara-113000390.html?.tsrc=rss,"Biogen announced today that it has completed an asset purchase of Remedy Pharmaceuticals’ Phase 3 candidate, CIRARA™ . The target indication for CIRARA is large hemispheric infarction , a severe form of ischemic stroke where brain swelling often leads to a disproportionately large share of stroke-related morbidity and mortality."
BIIB,BIIB:UW,BBG000C18861,"​Biogen loses chief scientific officer, but agrees to fund his Harvard lab",2017-05-14 22:10:09 +0000,http://finance.yahoo.com/r/fa98353f-8b77-35fa-9566-fd32865a82bf/biogen-loses-chief-scientific-officer-but-agrees.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"A prominent Harvard Medical School professor has quietly left his post as the chief scientific officer of Biogen, but will still receive research funding from the Cambridge biotech.  Biogen (BIIB) disclosed in its proxy statement last month that Spyros Artavanis-Tsakonas, who was named permanent CSO in 2013, is now serving in the more limited role of part-time “visiting scientist.” According to the filing, Biogen reached an agreement with Harvard in January under which it will pay the university $1.7 million per year, including $1 million to fund research at Artavanis-Tsakonas’ lab into neurodegenerative diseases."
BIIB,BIIB:UW,BBG000C18861,"Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 15, 2017",2017-05-12 14:34:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3tDyfKDzZKE/amgen-inc-amgn-ex-dividend-date-scheduled-for-may-15-2017-cm788498,Amgen Inc AMGN will begin trading ex dividend on May 15 2017 A cash dividend payment of 1 15 per share is scheduled to be paid on June 08 2017 Shareholders who purchased AMGN prior to the ex dividend date are eligible for the cash dividend payment This represents an 15 increase
BIIB,BIIB:UW,BBG000C18861,10 Growth Stocks at Reasonable Prices,2017-05-12 10:00:00 +0000,http://finance.yahoo.com/r/4206692e-58e5-39a6-a86e-79f405a76252/article.aspx?id=808397&SR=Yahoo&yptr=yahoo&.tsrc=rss,We examined the 500-plus holdings in the Morningstar US Growth Index and found some stocks with decent growth prospects at reasonable valuations.
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Inc.'s First Royalties Roll In,2017-05-11 21:02:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bqni9gNdiZE/ionis-pharmaceuticals-incs-first-royalties-roll-in-cm788134,Ionis Pharmaceuticals NASDAQ IONS released first quarter earnings on May 9 but the most interesting number sales of Spinraza was already known since Ionis partner Biogen NASDAQ BIIB disclosed sales of 47 million a few weeks ago Ionis Pharmaceuticals
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Inc.&apos;s First Royalties Roll In,2017-05-11 19:45:00 +0000,http://finance.yahoo.com/r/554262f4-d100-3bc1-91b9-6245c3160721/ionis-pharmaceuticals-incs-first-royalties-roll-in.aspx?yptr=yahoo&.tsrc=rss,The biotech books its first quarter of royalties from Spinraza with more to come.
BIIB,BIIB:UW,BBG000C18861,Biogen Enters Oversold Territory (BIIB),2017-05-11 18:02:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2aQ_xBOdSwo/biogen-enters-oversold-territory-biib-cm788029,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
BIIB,BIIB:UW,BBG000C18861,Edited Transcript of BIIB earnings conference call or presentation 25-Apr-17 12:30pm GMT,2017-05-11 13:01:05 +0000,http://finance.yahoo.com/news/edited-transcript-biib-earnings-conference-122541471.html?.tsrc=rss,Q1 2017 Biogen Inc Earnings Call
BIIB,BIIB:UW,BBG000C18861,iShares Russell 1000 Growth ETF Experiences Big Outflow,2017-05-10 16:03:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q6cqqz4aatM/ishares-russell-1000-growth-etf-experiences-big-outflow-cm787213,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Russell 1000 Growth ETF Symbol IWF where we have detected an approximate 158 7 million dollar outflow that s a 0 4 decrease week over week
BIIB,BIIB:UW,BBG000C18861,"BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience",2017-05-10 13:00:00 +0000,http://finance.yahoo.com/news/bioxcel-therapeutics-inc-bti-launched-130000524.html?.tsrc=rss,"BRANFORD, Conn., May 10, 2017-- BioXcel Corporation, a privately held biopharmaceutical company pioneering the integration of big data analytics and machine learning-based artificial intelligence with ..."
BIIB,BIIB:UW,BBG000C18861,Richard Pzena Invests in 3 Health Care Companies,2017-05-09 19:05:14 +0000,http://finance.yahoo.com/news/richard-pzena-invests-3-health-171820932.html?.tsrc=rss,Guru releases 1st-quarter portfolio
BIIB,BIIB:UW,BBG000C18861,IYH's Underlying Holdings Could Mean 10% Gain Potential,2017-05-09 15:03:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1dsf7ebdaZY/iyhs-underlying-holdings-could-mean-10-gain-potential-cm786393,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BIIB,BIIB:UW,BBG000C18861,4 Drug Stocks Poised to Beat this Earnings Season,2017-05-08 21:24:09 +0000,http://finance.yahoo.com/news/4-drug-stocks-poised-beat-212409778.html?.tsrc=rss,M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.
BIIB,BIIB:UW,BBG000C18861,"ETFs with exposure to Biogen, Inc. : May 8, 2017",2017-05-08 20:12:22 +0000,http://finance.yahoo.com/r/4ed72608-fadb-3b81-9757-1ab55276c068/etfs-with-exposure-to-biogen-inc-may-8-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biogen, Inc. Here are 5 ETFs with the largest exposure to BIIB-US. Comparing the performance and risk of Biogen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
BIIB,BIIB:UW,BBG000C18861,BioMarin: Is Profitability On The Horizon?,2017-05-08 18:57:00 +0000,http://finance.yahoo.com/r/cc0a47e1-94b4-33a2-b154-c473e610724a/biomarin-is-profitability-on-the-horizon-1494269871?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When will BioMarin Pharmaceuticals (BMRN) turn a profit? The drug maker specializes in therapies for rare diseases, and already markets a handful of medications that generated revenue of $1.12 billion ..."
BIIB,BIIB:UW,BBG000C18861,Why Biogen Inc. Shareholders Have Something to Worry About,2017-05-07 17:42:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/STF-IIMh8BU/why-biogen-inc-shareholders-have-something-to-worry-about-cm785518,Biogen NASDAQ BIIB has gotten off to a great start in 2017 in some respects The biotech launched promising new spinal muscular atrophy drug SMA Spinraza The Committee for Medicinal Products for Human Use CHMP recommended approval for Spinraza in Europe Biogen 160 spun off
BIIB,BIIB:UW,BBG000C18861,Why Biogen Inc. Shareholders Have Something to Worry About,2017-05-07 15:42:00 +0000,http://finance.yahoo.com/r/848426c6-bbd4-38c5-977d-fb06cc61ded7/why-biogen-inc-shareholders-have-something-to-worr.aspx?yptr=yahoo&.tsrc=rss,"Biogen has a great thing going with Spinraza, but there are big questions for its multiple sclerosis franchise and pipeline prospects."
BIIB,BIIB:UW,BBG000C18861,"Huge Hedge Fund, Biotech and Technology Trades Highlight Insider Buying: Apollo Global, Biogen, Twitter, DDR and More",2017-05-07 14:15:19 +0000,http://finance.yahoo.com/news/huge-hedge-fund-biotech-technology-141519387.html?.tsrc=rss,"With the markets once again bumping up against and trading around all-time highs, we were somewhat surprised to see as much insider buying as we did last week."
BIIB,BIIB:UW,BBG000C18861,Weekly Top Insider Buys Highlights,2017-05-06 02:49:55 +0000,http://finance.yahoo.com/news/weekly-top-insider-buys-highlights-024955984.html?.tsrc=rss,"Largest transactions were for Salesforce.com, Synchrony Financial, American Airlines Group and Biogen"
BIIB,BIIB:UW,BBG000C18861,"Friday Sector Laggards: Healthcare, Financial",2017-05-05 20:25:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bAz58qwobME/friday-sector-laggards-healthcare-financial-cm785211,The worst performing sector as of midday Friday is the Healthcare sector showing a 0 3 loss Within that group Biogen Inc Symbol BIIB and Incyte Corporation Symbol INCY are two large stocks that are lagging showing a loss of 2 8 and 2 2 respectively Among healthcare ETFs one
BIIB,BIIB:UW,BBG000C18861,"Notable Friday Option Activity: BIIB, NWL, NKE",2017-05-05 19:26:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yJ0jQ71oZjo/notable-friday-option-activity-biib-nwl-nke-cm785170,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Biogen Inc Symbol BIIB where a total volume of 7 448 contracts has been traded thus far today a contract volume which is representative of approximately 744 800
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson",2017-05-05 15:29:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nrd4Be2QLng/the-zacks-analyst-blog-highlights-exxon-mobil-jpmorgan-union-pacific-biogen-and-becton-dickinson-cm784938,For Immediate Release Chicago IL May 05 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog include
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson",2017-05-05 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-exxon-133001890.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Exxon Mobil, JPMorgan, Union Pacific, Biogen and Becton Dickinson"
BIIB,BIIB:UW,BBG000C18861,[$$] Big Sales by Biogen CFO Don't Deter Buying,2017-05-05 11:40:00 +0000,http://finance.yahoo.com/r/3551767a-10f3-35bc-adc6-570bd375f80b/big-sales-by-biogen-cfo-dont-deter-buying-1493984458?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Clancy, who has served as CFO for nearly a decade, recently slashed his holdings by 65% by selling more than $5.75 million in shares of the biotech, which is probably best known for multiple sclerosis treatments such as Tysabri.  The sales, made on March 13 and April 25, are somewhat distressing to investors as they mark Clancy’s first since September 2013, and they also come at a trying time for Biogen.  Why didn’t Biogen simply sell the operation for needed cash?"
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for May 4, 2017",2017-05-05 05:19:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_fH3ijcgfZ0/top-research-reports-for-may-4-2017-cm784691,Thursday May 4 2017 Today s Research Daily features new research reports on 16 major stocks including Exxon Mobil XOM JPMorgan JPM and Union Pacific UNP Exxon Mobil shares tracked the S amp P 500 index through year end 2016 but have lagged the broader index as well as the peer
BIIB,BIIB:UW,BBG000C18861,What's in the Cards for Ionis (IONS) this Earnings Season?,2017-05-04 17:12:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N2InhMPVO8E/whats-in-the-cards-for-ionis-ions-this-earnings-season-cm784322,Ionis Pharmaceuticals Inc IONS is scheduled to report first quarter 2017 results on May 9 Last quarter the company recorded a positive earnings surprise of 265 Let s see how things are shaping up for this announcement Ionis share price has increased 0 4 year to date compared with
BIIB,BIIB:UW,BBG000C18861,"Insiders Are Loading Up on Twitter, Biogen & More",2017-05-04 17:00:00 +0000,http://finance.yahoo.com/r/79b5cf68-8c9e-3493-a32c-be90bd8b9064/insiders-are-loading-up-on-twitter-biogen-amp-more.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Insiders at Twitter, Biogen and three other companies have been snapping up shares of their own stock lately."
BIIB,BIIB:UW,BBG000C18861,What&apos;s in the Cards for Ionis (IONS) this Earnings Season?,2017-05-04 14:56:02 +0000,http://finance.yahoo.com/news/apos-cards-ionis-ions-earnings-145602165.html?.tsrc=rss,"Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report first-quarter 2017 results on May 9. Last quarter, the company recorded a positive earnings surprise of 265%. Let&apos;s see how things are shaping up for this announcement."
BIIB,BIIB:UW,BBG000C18861,What's Behind Ionis Pharmaceuticals' 20% Rally In April,2017-05-04 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wMhgkgqm32U/whats-behind-ionis-pharmaceuticals-20-rally-in-april-cm783948,What happened Shares of Ionis Pharmaceuticals NASDAQ IONS 160 rallied 20 in April according to S amp P Global Market Intelligence following news that sales of Spinraza are off to a solid start and that it had inked a collaboration deal to develop therapeutics for use
BIIB,BIIB:UW,BBG000C18861,What&apos;s Behind Ionis Pharmaceuticals&apos; 20% Rally In April,2017-05-04 11:00:00 +0000,http://finance.yahoo.com/r/231ff4a0-f036-32d3-8ac6-7890a7765eb1/whationis-pharmaceuticals-dropped-187-in-march.aspx?yptr=yahoo&.tsrc=rss,Better-than-expected sales of a newly launched drug and an intriguing new partner in China sent shares soaring last month.
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. -- Moody's revised Biogen's outlook to stable; affirms Baa1,2017-05-03 20:29:12 +0000,http://finance.yahoo.com/r/5559c7d9-467c-3b84-a16e-31161bf03c8a/viewresearchdoc.aspx?docid=PR_365977&WT.mc_id=AM~WWFob29fRmluYW5jZV9TQl9SYXRpbmcgTmV3c19BbGxfRW5n~20170503_PR_365977&yptr=yahoo&.tsrc=rss,"Rating Action: Moody's revised Biogen's outlook to stable; affirms Baa1. Global Credit Research- 03 May 2017. New York, May 03, 2017-- Moody's Investors Service affirmed the Baa1 senior unsecured ratings ..."
BIIB,BIIB:UW,BBG000C18861,Morningstar Wide Moat ETF -- Insider Buying Index Registering 12.0%,2017-05-03 19:49:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iBN4Sqm23yo/morningstar-wide-moat-etf-insider-buying-index-registering-120-cm783635,A look at the weighted underlying holdings of the Morningstar Wide Moat ETF Symbol MOAT shows an impressive 12 0 of holdings on a weighted basis have experienced insider buying within the past six months TransDigm Group Inc Symbol TDG which makes up 2 43 of the Morningstar Wide
BIIB,BIIB:UW,BBG000C18861,"Neighborhood Health Plan changes course, will cover Biogen drug for all patients",2017-05-02 22:55:08 +0000,http://finance.yahoo.com/r/f6d4411e-4c34-347b-a929-63264db50277/neighborhood-health-plan-changes-course-will-cover.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Citing new clinical data presented last week by Cambridge drugmaker Biogen, the health insurance plan run by Partners HealthCare says it’s changing its policy and will now pay for a newly approved drug intended to treat all patients with the rare genetic disease, spinal muscular atrophy.  In an email to the Boston Business Journal today, Neighborhood Health Plan Chief Medical Officer Dr. Anton Dodek confirmed that the company decided to pay for the drug, called Spinraza, for all patients with SMA.  “Based on new evidence presented last week during the annual meeting of the American Academy of Neurology, Neighborhood Health Plan is in the process of changing its prescription drug policy to cover Spinraza for all spinal muscular atrophy patients,” said Dodek."
BIIB,BIIB:UW,BBG000C18861,"Tuesday 5/2 Insider Buying Report: BIIB, WWD",2017-05-02 16:29:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1OCRfv8aJcg/tuesday-52-insider-buying-report-biib-wwd-cm782748,Bargain hunters are wise to pay careful attention to insider buying because although there are many various reasons for an insider to sell a stock presumably the only reason they would use their hard earned dollars to make a purchase is that they expect to make money Today we look at
BIIB,BIIB:UW,BBG000C18861,"Notable ETF Outflow Detected - BIB, BIIB, REGN, ILMN",2017-05-02 16:28:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lS110Dmg4BQ/notable-etf-outflow-detected-bib-biib-regn-ilmn-cm782766,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares Ultra Nasdaq Biotechnology Symbol BIB where we have detected an approximate 12 6 million dollar outflow that s a 3 1 decrease week over week
BIIB,BIIB:UW,BBG000C18861,Neurotrope Alzheimer's drug data fails to impress; shares crater,2017-05-01 14:33:39 +0000,http://finance.yahoo.com/news/neurotrope-alzheimers-drug-data-fails-111008321.html?.tsrc=rss,"Neurotrope Inc's shares more than  halved after data from a small trial on the company's  Alzheimer's drug failed to impress investors, the latest in a  series of setbacks in the quest for an effective treatment for  the memory-robbing disease.  A total of 113 patients completed the study and Neurotrope  said the higher 40 microgram (mcg) dose showed ""very modest  efficacy"".  Statistical significance in late-stage trials is typically  defined by a p-value of 0.05 or less, but this was more an  exploratory mid-stage study and the data is encouraging, Chief  Scientific Officer Daniel Alkon said on a call with analysts."
BIIB,BIIB:UW,BBG000C18861,Biogen Pursuing Investigational Candidates in Alzheimer’s Disease,2017-05-01 13:06:32 +0000,http://finance.yahoo.com/r/b1369a99-c704-3a47-871c-17523c40e875/biogen-pursuing-multiple-investigational-candidates-alzheimers-disease?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.
BIIB,BIIB:UW,BBG000C18861,Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17,2017-05-01 11:36:30 +0000,http://finance.yahoo.com/r/7dc82359-d379-3ecd-a025-2ae1472f9a2a/biogen-developed-targeted-marketing-strategy-spinraza-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities."
BIIB,BIIB:UW,BBG000C18861,"ETFs with exposure to Biogen, Inc. : April 28, 2017",2017-04-28 19:45:17 +0000,http://finance.yahoo.com/r/2828af43-cabb-339d-8805-3d4f56193c5a/etfs-with-exposure-to-biogen-inc-april-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biogen, Inc. Here are 5 ETFs with the largest exposure to BIIB-US. Comparing the performance and risk of Biogen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
BIIB,BIIB:UW,BBG000C18861,What&apos;s Worrying Me About Biogen,2017-04-28 18:20:00 +0000,http://finance.yahoo.com/r/356d311a-a849-33cc-aea6-e75a8baaf6fc/whats-worrying-me-about-biogen.aspx?yptr=yahoo&.tsrc=rss,Biogen could struggle to maintain its market-leading position in multiple sclerosis over the next two years.
BIIB,BIIB:UW,BBG000C18861,"Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss",2017-04-28 16:30:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lrdX_JOthGY/acorda-acor-q1-loss-wider-than-expected-revenues-miss-cm781214,Acorda Therapeutics Inc ACOR reported loss of 25 cents per share in the first quarter of 2017 including the impact of stock based compensation expenses wider than the Zacks Consensus Estimate of a loss of 16 cents The company had reported a gain of 9 cents per share in the year ago
BIIB,BIIB:UW,BBG000C18861,Biogen Has Developed a Robust Access Strategy for Spinraza,2017-04-28 14:36:53 +0000,http://finance.yahoo.com/r/cba05e79-4a3f-3338-8df3-b0e1e43c19ed/biogen-developed-robust-access-strategy-spinraza?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Biogen’s (BIIB) Spinraza earned revenues of $47.0 million, of which $46.0 million were from the US market."
BIIB,BIIB:UW,BBG000C18861,Biogen’s Spinraza Witnessed Robust Patient Demand in 1Q17,2017-04-28 13:06:56 +0000,http://finance.yahoo.com/r/e6760315-f100-3ed8-9319-0ab4f7aecf27/spinraza-witnessed-robust-patient-demand-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Spinraza, Biogen’s (BIIB) SMA (spinal muscular atrophy) therapy, was approved by the FDA (U.S. Food and Drug Administration) on December 23, 2016."
BIIB,BIIB:UW,BBG000C18861,These 7 Drugmakers Relied on Price Hikes for 100% of Their Earnings Growth in 2016,2017-04-28 12:02:00 +0000,http://finance.yahoo.com/r/fd720da2-c405-315d-af88-671123b30b69/these-7-drugmakers-relied-on-price-hikes-for-100-o.aspx?yptr=yahoo&.tsrc=rss,"If President Trump cracks down on drug price inflation, these pharma and biotech offenders could be in big trouble."
BIIB,BIIB:UW,BBG000C18861,How Biogen’s Tysabri and Zinbryta Performed in 1Q17,2017-04-28 11:37:35 +0000,http://finance.yahoo.com/r/ed66e7f4-5d01-372b-a5f2-0b5a90e550d0/tysabri-zinbryta-performed-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets."
BIIB,BIIB:UW,BBG000C18861,Mixed bag for biotech earnings,2017-04-27 21:16:00 +0000,http://finance.yahoo.com/video/mixed-bag-biotech-earnings-211600318.html?.tsrc=rss,CNBC's Meg Tirrell reports the latest from the Vertex Pharmaceuticals earnings call. The &quot;Fast Money&quot; traders weigh in on trading the pharma and biotech space.
BIIB,BIIB:UW,BBG000C18861,"Better Buy: Ionis Pharmaceuticals, Inc. vs. bluebird bio",2017-04-27 17:31:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cylZBQVTC6o/better-buy-ionis-pharmaceuticals-inc-vs-bluebird-bio-cm780433,The most promising biotechs have productive platforms and are pioneering new approaches to treating conditions difficult to address with conventional therapies Two that fit that bill are Ionis Pharmaceuticals NASDAQ IONS and bluebird bio NASDAQ BLUE Which one represents
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. :BIIB-US: Earnings Analysis: Q1, 2017 By the Numbers : April 27, 2017",2017-04-27 15:02:46 +0000,http://finance.yahoo.com/r/83025a4c-6335-387b-b068-31908320be02/biogen-inc-biib-us-earnings-analysis-q1-2017-by-the-numbers-april-27-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Biogen, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Biogen, Inc. – Johnson & Johnson (JNJ-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 2,480.50 million, Net Earnings of USD 747.60 million. Gross ... Read more
<b>(Read more...)</b>"
BIIB,BIIB:UW,BBG000C18861,Biogen Still Dominated the Multiple Sclerosis Market in 1Q17,2017-04-27 14:39:07 +0000,http://finance.yahoo.com/r/02b1246d-5330-36e6-ab70-d228ce546c25/biogen-continued-dominate-multiple-sclerosis-market-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Biogen witnessed a slight contraction in demand for its MS products in the US market in 1Q17 on a quarter-over-quarter basis.
BIIB,BIIB:UW,BBG000C18861,Analysts’ Recommendations for Biogen in 1Q17,2017-04-27 13:08:44 +0000,http://finance.yahoo.com/r/eaaac98e-9975-3136-bbb0-fa8ec282f11c/analysts-recommendations-biogen-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Biogen (BIIB) currently holds a 38.0% share of the global MS market. In 1Q17, the company reported revenues of around $2.2 billion for its MS franchise"
BIIB,BIIB:UW,BBG000C18861,Biogen Reports Strong Revenue Growth in 1Q17,2017-04-27 11:39:42 +0000,http://finance.yahoo.com/r/80ef9d55-040c-360e-bdf5-78e97c21b4be/biogen-reported-strong-revenue-growth-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Biogen (BIIB) reported its 1Q17 results on April 25, 2017. Its revenues were about $2.8 billion, which is a YoY (year-over-year) rise of about 3.0%."
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Earnings: New Drug Sparks Life,2017-04-26 20:44:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Eeo4tNXG9JM/biogen-inc-earnings-new-drug-sparks-life-cm779825,Biogen NASDAQ BIIB reported first quarter earnings on Tuesday resulting in investors excited about the potential for Spinraza its new spinal muscular atrophy drug developed with Ionis Pharmaceuticals NASDAQ IONS but tolerating ho hum sales growth of its multiple
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Earnings: New Drug Sparks Life,2017-04-26 19:55:00 +0000,http://finance.yahoo.com/r/e5dadf3f-8c8a-38c8-98bc-e213aefa2b44/biogen-inc-earnings-new-drug-sparks-life.aspx?yptr=yahoo&.tsrc=rss,Spinraza launch is off to a good start.
BIIB,BIIB:UW,BBG000C18861,"​Hyde Park boy with rare disease wins appeal, will receive Biogen drug",2017-04-26 18:55:06 +0000,http://finance.yahoo.com/r/6beabebc-2cef-3a25-88ab-8fb3a2c6ff32/hyde-park-boy-with-rare-disease-wins-appeal-will.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Doug Hansen of Hyde Park said he has won his appeal of a coverage decision by Neighborhood Health Plan, overturning the health insurance company's refusal to pay for an expensive new drug by Biogen to treat his 11-year-old son, Tyler.  Tyler Hansen has spinal muscular atrophy, a very rare disease that that reduces ability to control voluntary muscle movement.  The first-ever drug to treat the disease, called Spinraza and marketed by Cambridge-based Biogen (BIIB), was just approved by the Food and Drug Administration in December, and Tyler was prescribed the drug in early February."
BIIB,BIIB:UW,BBG000C18861,"Stock Market News for April 26, 2017",2017-04-26 14:26:02 +0000,http://finance.yahoo.com/news/stock-market-news-april-26-142602220.html?.tsrc=rss,"Benchmarks finished in the green on Tuesday, following the release of strong earnings reports and as expectation for possible tax reform grew"
BIIB,BIIB:UW,BBG000C18861,"Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY",2017-04-26 14:08:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J5LPdt37ifM/pharma-stocks-q1-earnings-roster-for-apr-27-celg-abbv-bmy-cm779340,Things are certainly looking up as we get into the thick of the Q1 earnings season By the end of this week approximately half of the S amp P 500 Index would be reporting making the picture clearer As of Apr 21 95 S amp P 500 members accounting for 24 9 of the index s total
BIIB,BIIB:UW,BBG000C18861,Better Buy: Amgen Inc. vs. Biogen,2017-04-26 13:05:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aE32V7j-Nzs/better-buy-amgen-inc-vs-biogen-cm779256,If you re looking for unusually high returns on your capital biotechnology remains a fairly safe bet even despite its monstrous run up over the past five years The growing and aging global population after all is expected to drive an ever increasing demand for the biologically
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : April 26, 2017",2017-04-26 12:42:56 +0000,http://finance.yahoo.com/r/f850b2a1-ab20-3ac6-88f6-76b69aee2d1c/biogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-biib-us-april-26-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Biogen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more
<b>(Read more...)</b>"
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug",2017-04-26 12:18:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-biogen-gains-121812290.html?.tsrc=rss,Focus this week remained on Biogen&apos;s (BIIB) first quarter results which surpassed expectations.
BIIB,BIIB:UW,BBG000C18861,Today's Research Reports on Stocks to Watch: Lockheed Martin and Biogen,2017-04-26 11:30:00 +0000,http://finance.yahoo.com/news/todays-research-reports-stocks-watch-113000163.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / April 26, 2017 / Biogen topped earnings estimates after its $125,000 spinal muscular atrophy drug kicked off the year with a great start but Lockheed Martin fails to impress ..."
BIIB,BIIB:UW,BBG000C18861,Better Buy: Amgen Inc. vs. Biogen,2017-04-26 11:20:00 +0000,http://finance.yahoo.com/r/840e080b-f8f2-3af5-beda-17f4620e575a/better-buy-amgen-inc-vs-biogen.aspx?yptr=yahoo&.tsrc=rss,Which biotech is the better stock?
BIIB,BIIB:UW,BBG000C18861,Spinraza's Fast Start Puts Ionis on a Path to Profit,2017-04-25 23:06:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HNX1EJwEmkQ/spinrazas-fast-start-puts-ionis-on-a-path-to-profit-cm779130,Ionis Pharmaceuticals NASDAQ IONS collaboration partner Biogen NASDAQ BIIB reported first quarter financial results earlier today and in that report it disclosed that sales of Ionis and Biogen s Spinraza totaled 47 million during its first quarter on the market
BIIB,BIIB:UW,BBG000C18861,Spinraza&apos;s Fast Start Puts Ionis on a Path to Profit,2017-04-25 21:42:00 +0000,http://finance.yahoo.com/r/b43eabd7-5f30-3c54-ac61-ecd0e4abf331/spinrazas-fast-start-puts-ionis-on-a-path-to-profi.aspx?yptr=yahoo&.tsrc=rss,A strong start for the spinal muscular atrophy drug Spinraza could help Ionis Pharmaceuticals deliver pro forma profit in 2017.
BIIB,BIIB:UW,BBG000C18861,"Biogen Earnings Top As $125,000 Drug Starts Well",2017-04-25 20:45:00 +0000,http://finance.yahoo.com/r/1434781e-a11d-319f-946c-8340bc6b85c4/biogen-reports-tuesday-could-stock-pop-on-125000-drug?src=A00220&yptr=yahoo&.tsrc=rss,"Biogen reported better-than-expected first-quarter earnings and revenue, with a solid start to its $125,000 Spinraza drug."
BIIB,BIIB:UW,BBG000C18861,Biogen and Alzheimer’s: There’s a Fundamental Problem Here,2017-04-25 20:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/90-5yAatAas/biogen-and-alzheimers-theres-a-fundamental-problem-here-cm778976,Back in 2015 biotech juggernaut Biogen NASDAQ BIIB made headlines on the news that its investigational Alzheimer s disease AD treatment aducanumab showed strong efficacy in an early stage clinical trial This devastating disease affects millions of Americans and the scope of
BIIB,BIIB:UW,BBG000C18861,Biogen Inc (BIIB) Stock Pops on Strong Q1 Earnings,2017-04-25 20:02:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e5SEpIVuOXQ/biogen-inc-biib-stock-pops-on-strong-q1-earnings-cm779017,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB stock was up on Tuesday following the release of its earnings report for the first quarter of 2017 Biogen Inc reported earnings per share of 5 20 during the
BIIB,BIIB:UW,BBG000C18861,Biogen and Alzheimer’s: There’s a Fundamental Problem Here,2017-04-25 19:01:00 +0000,http://finance.yahoo.com/r/dac343b2-d600-36a4-847a-3ae178d75197/biogen-and-alzheimers-theres-a-fundamental-problem.aspx?yptr=yahoo&.tsrc=rss,Biogen&apos;s &quot;moonshot&quot; will likely end in failure
BIIB,BIIB:UW,BBG000C18861,"Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong",2017-04-25 17:10:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QW-LKRiHXB0/biogen-biib-q1-earnings-sales-top-spinraza-sales-strong-cm778866,Biogen Inc BIIB reported better than expected results in the first quarter of 2017 The company surpassed expectations both for earnings and sales Shares of Biogen rose more almost 5 in pre market trading in response to the strong results However we note that Biogen s
BIIB,BIIB:UW,BBG000C18861,"Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down",2017-04-25 17:09:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YP7nF9VrEV8/lilly-lly-tops-q1-earnings-misses-sales-shares-down-cm778822,Eli Lilly and Company LLY reported first quarter 2017 adjusted earnings per share of 98 cents which beat the Zacks Consensus Estimate of 96 cents by 2 1 Earnings rose 18 from the year ago quarter backed by volume driven pharma sales growth and higher profits Including a
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: ESRX, BIIB",2017-04-25 17:06:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AvoUu-8rUVc/nasdaq-100-movers-esrx-biib-cm778819,In early trading on Tuesday shares of Biogen BIIB topped the list of the day s best performing components of the Nasdaq 100 index trading up 5 0 Year to date Biogen registers a 2 5 gain And the worst performing Nasdaq 100 component thus far on the day is Express Scripts
BIIB,BIIB:UW,BBG000C18861,"Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong",2017-04-25 14:46:02 +0000,http://finance.yahoo.com/news/biogen-biib-q1-earnings-sales-144602594.html?.tsrc=rss,Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
BIIB,BIIB:UW,BBG000C18861,Biogen: Stuck in a Rut?,2017-04-25 14:22:00 +0000,http://finance.yahoo.com/r/6b5c2a60-a816-3904-a557-ce4f585e5910/biogen-stuck-in-a-rut?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Biogen (BIIB) are soaring today after the biotech giant released earnings today. Despite the big gain, shares of Biogen look stuck in a rut. There's no doubt that Biogen delivered everything ..."
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Beats on Q1 Earnings and Revenue,2017-04-25 14:08:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YCpXS8OQqvc/biogen-biib-beats-on-q1-earnings-and-revenue-cm778645,Cambridge MA based Biogen Inc BIIB one of the world s leading biotechnology companies focuses on therapeutic areas including neurology and immunology The company is best known for its multiple sclerosis MS franchise comprising treatments like Avonex Tysabri Tecfidera and
BIIB,BIIB:UW,BBG000C18861,"Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers",2017-04-25 13:59:00 +0000,http://finance.yahoo.com/r/8ee32597-e077-3174-8214-37e725e3c597/endo-pops-after-parkinson-s-tests-idexx-continues-fall-biogen-higher-tuesday-s-biotech-movers.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Biogen's new spine disease drug outperformed expectations during its commercial debut.
BIIB,BIIB:UW,BBG000C18861,​Biogen shares jump as launch of new drug beats expectations,2017-04-25 13:51:40 +0000,http://finance.yahoo.com/r/4e07e1fd-3e21-31ab-a187-a12ab7a9984c/biogen-shares-jump-as-launch-of-new-drug-beats.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen said Tuesday that its recently-approved drug for a rare infant disease had generated far more revenue in the first quarter of 2017 than analysts expected, lifting shares of the Cambridge biotech.  Biogen (BIIB) reported $47 million in first quarter sales of Spinraza, which in December became the first drug approved to treat spinal muscular atrophy, a leading genetic cause of death in infants.  Shares of Biogen rose about 4 percent in pre-market trading as of 8:45 a.m., potentially adding more than $2 billion to the company’s market cap."
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Nasdaq breaches 6,000 mark for first time ever",2017-04-25 13:50:23 +0000,http://finance.yahoo.com/news/us-stocks-nasdaq-breaches-6-135023976.html?.tsrc=rss,"The Nasdaq breached the 6,000 mark for  the first time ever on Tuesday, spurred by a raft of strong  corporate earnings and President Donald Trump's promise of a  major tax reform plan.  The tech-heavy Nasdaq rose as much as 0.4 percent to hit a  record level of 6,007.72 helped by gains in Biogen and  Apple."
BIIB,BIIB:UW,BBG000C18861,Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch,2017-04-25 13:34:00 +0000,http://finance.yahoo.com/r/a75d9d39-6798-3531-8ed3-ce3413756f9e/biogen-spine-disease-drug-sales-strong-in-first-quarter-since-commercial-launch.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Biogen adjusted profit rose in the first quarter on a small increase in total revenue. Sales of the biotech company's multiple sclerosis drugs remain flat.
BIIB,BIIB:UW,BBG000C18861,"Health Care Sector Update for 04/25/2017: BIIB, ESRX, JNJ, PFE, ABT, MRK, AMGN",2017-04-25 13:04:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MHe5sOu469A/health-care-sector-update-for-04252017-biib-esrx-jnj-pfe-abt-mrk-amgn-cm778440,Top Health Care stocks Top Health Care stocks JNJ 01 JNJ 01 PFE 1 PFE 1 ABT 2 5 ABT 2 5 MRK flatMRK flat AMGN 0 8 AMGN 0 8 Health care shares were mostly higher in pre market trade Tuesday Health care shares were mostly higher in pre market trade Tuesday In health
BIIB,BIIB:UW,BBG000C18861,Biogen's Excellent Q1 Bodes Well for Biotech,2017-04-25 12:58:00 +0000,http://finance.yahoo.com/r/29f80396-9673-33da-b217-04f135c02e39/biogens-excellent-q1-bodes-well-biotech?partner=YahooSA&yptr=yahoo&.tsrc=rss,Biogen's very strong quarterly results should power further gains for the broader biotech sector.
BIIB,BIIB:UW,BBG000C18861,Morning Movers: More Stocks Than I Know What To Do With!,2017-04-25 12:50:00 +0000,http://finance.yahoo.com/r/c10d992a-cced-3416-bf27-d06444a8f530/morning-movers-more-stocks-than-i-know-what-to-do-with-with?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Stocks look set to continue their rally following yesterday's big gains. S&P 500 futures have risen 0.3%, while Dow Jones Industrial Average futures have gained 0.7%. Nasdaq Composite futures have advanced ..."
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Beats on Q1 Earnings and Revenue,2017-04-25 12:36:12 +0000,http://finance.yahoo.com/news/biogen-biib-beats-q1-earnings-123612336.html?.tsrc=rss,BIIB???s first quarter 2017 earnings were better-than expected. The company posted earnings of $5.20 per share while our consensus called for EPS of $4.97.
BIIB,BIIB:UW,BBG000C18861,Earnings Preview: What To Expect From Amgen On Wednesday,2017-04-25 12:26:00 +0000,http://finance.yahoo.com/r/6a67680c-8416-3d1c-bee2-025915d66950/earnings-preview-what-to-expect-from-amgen-on-wednesday?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Amgen is expected to earn $3.00/share on $5.65 billion in revenue. Meanwhile, the so-called Whisper number is $3.09"
BIIB,BIIB:UW,BBG000C18861,Biogen Surges After Sales of Drug for Deadly Muscle Disease Beat Estimates,2017-04-25 11:15:27 +0000,http://finance.yahoo.com/r/8a0b50fa-4b0c-3e26-ade8-924cd83a8cd2/biogen-jumps-as-deadly-muscle-disease-drug-sales-beat-estimates?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Biogen Inc. surged the most this year as its new therapy for a rare and deadly muscle disease started strong in its first full quarter, bolstering chances the drug will become a blockbuster."
BIIB,BIIB:UW,BBG000C18861,"Biogen stock rises after first-quarter earnings, profit beat",2017-04-25 11:14:04 +0000,http://finance.yahoo.com/r/acd3b64a-e8cd-3a5b-84b5-b933739c787a/Story.aspx?guid=10E7CFF8-838D-4650-9627-D1DBCAC31C18&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Biogen Inc. shares rose as much as 4.8% in premarket trade Tuesday after the company reported a first-quarter earnings and profit beat. Earnings for the latest quarter declined to $747.6 million, or $3.46 ..."
BIIB,BIIB:UW,BBG000C18861,Drugmaker Biogen's revenue rises 3 percent,2017-04-25 11:10:55 +0000,http://finance.yahoo.com/news/drugmaker-biogens-revenue-rises-3-111055585.html?.tsrc=rss,"Biogen Inc reported a 3 percent rise in quarterly revenue, helped by higher-than-expected sales of its newly launched spinal muscular atrophy drug, Spinraza. However, net income attributable fell to $747.6 ..."
BIIB,BIIB:UW,BBG000C18861,Biogen tops Street 1Q forecasts,2017-04-25 11:08:49 +0000,http://finance.yahoo.com/news/biogen-tops-street-1q-forecasts-110849592.html?.tsrc=rss,"The Cambridge, Massachusetts-based company said it had net income of $3.46 per share. Earnings, adjusted for one-time gains and costs, came to $5.20 per share. The results surpassed Wall Street expectations. ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Reports First Quarter 2017 Revenues of $2.8 Billion,2017-04-25 10:59:00 +0000,http://finance.yahoo.com/news/biogen-reports-first-quarter-2017-105900884.html?.tsrc=rss,"Biogen Inc. today reported first quarter 2017 financial results, including:"
BIIB,BIIB:UW,BBG000C18861,"Earnings Reaction History: Biogen Idec, 58.3% Follow-Through Indicator, 5.0% Sensitive",2017-04-25 10:23:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ISj0EBvTAvM/earnings-reaction-history-biogen-idec-583-follow-through-indicator-50-sensitive-cm778380,Expected Earnings Release 04 25 2017 PremarketExpected Earnings Release 04 25 2017 Premarket Avg Extended Hours Dollar Volume 78 767 991Avg Extended Hours Dollar Volume 78 767 991 Biogen Idec BIIB is due to issue its quarterly earnings report in the upcoming extended hours
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. (BIIB) Is Up Sharply On Better Than Expected Q1 Earnings,2017-04-25 09:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lm0QTfZr-S4/biogen-inc-biib-is-up-sharply-on-better-than-expected-q1-earnings-20170425-01033,Biogen Inc. (BIIB) Is Up Sharply On Better Than Expected Q1 Earnings
BIIB,BIIB:UW,BBG000C18861,Biogen Q1 17 Earnings Conference Call At 8:30 AM ET,2017-04-25 07:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l0D3Lb0URlc/biogen-q1-17-earnings-conference-call-at-830-am-et-20170425-00511,Biogen Q1 17 Earnings Conference Call At 8:30 AM ET
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Q1 Earnings Climb 7%,2017-04-25 07:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8Y9vPS_kIRU/biogen-inc-q1-earnings-climb-7-20170425-00433,Biogen Inc. Q1 Earnings Climb 7%
BIIB,BIIB:UW,BBG000C18861,Pricey rare disease drug’s launch will be likely focus of Biogen earnings,2017-04-24 20:28:16 +0000,http://finance.yahoo.com/r/2500ea9f-eb5e-3e25-84ba-de5ab59923ad/Story.aspx?guid=4C2E2C0C-26C5-11E7-B1CB-9E0646962565&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Spinraza’s price tag — up to $750,000 in the first year — has attracted criticism."
BIIB,BIIB:UW,BBG000C18861,"Pre-Market Earnings Report for April 25, 2017 :  KO, MMM, MCD, LLY, LMT, DD, BIIB, CAT, SPGI, VLO, GLW, BHI",2017-04-24 20:12:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jSF4oKh--Bs/pre-market-earnings-report-for-april-25-2017-ko-mmm-mcd-lly-lmt-dd-biib-cat-spgi-vlo-glw-bhi-cm778233,The following companies are expected to report earnings prior to market open on 04 25 2017 Visit our Earnings Calendar for a full list of expected earnings releases Coca Cola Company KO is reporting for the quarter ending March 31 2017 The
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Monday Option Activity: AAPL, ISRG, BIIB",2017-04-24 20:04:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/luLHw5eIsxI/noteworthy-monday-option-activity-aapl-isrg-biib-cm778185,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Apple Inc Symbol AAPL where a total volume of 283 612 contracts has been traded thus far today a contract volume which is representative of approximately 28 4
BIIB,BIIB:UW,BBG000C18861,Biotech: 3 Things to Focus on as Biogen and Amgen Report,2017-04-24 18:49:00 +0000,http://finance.yahoo.com/r/bc3f182c-86e8-32ab-ad6a-7c198da54bdb/biotech-3-things-to-focus-on-as-biogen-and-amgen-report?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Top holdings Biogen (BIIB) and Amgen (AMGN) have gained 1.95% and 1.56% ahead of earnings results, respectively.  Alliance Bernstein analyst Ronny Gal has an Outperform rating on Biogen with a price target of $310, implying an upside of 12% from its recent price of $277.  Gal details three things to watch for when Biogen reports tomorrow:  MS sales."
BIIB,BIIB:UW,BBG000C18861,"Make Biogen Inc (BIIB) Stock Pay You, Even With No Dividend",2017-04-24 18:03:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/781vMELpOTU/make-biogen-inc-biib-stock-pay-you-even-with-no-dividend-cm778114,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB has been awfully kind to us in 2017 Oh sure the stock price is awful down 3 amid an up market but we ve been successfully able to squeeze profits out of BIIB stock despite its
BIIB,BIIB:UW,BBG000C18861,"Monday’s Vital Data: Apple Inc. (AAPL), Visa Inc (V) and Micron Technology, Inc (MU)",2017-04-24 18:02:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pHIleSJHC7E/mondays-vital-data-apple-inc-aapl-visa-inc-v-and-micron-technology-inc-mu-cm778108,InvestorPlace Stock Market News Stock Advice amp Trading Tips U S stock futures are running higher this morning as Wall Street heaves a sigh of relief following the first round of French elections Investors were concerned about a potential runoff between two anti
BIIB,BIIB:UW,BBG000C18861,3 Key Factors to Look Out for in Biogen's Q1 Results,2017-04-24 15:07:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3dEaTYIH2ds/3-key-factors-to-look-out-for-in-biogens-q1-results-cm777766,This week earnings season for the pharma and biotech sector will start in earnest with several major companies scheduled to report results Biotech major Biogen Inc BIIB is one of the companies that will be reporting results tomorrow A look at Biogen s earnings track record shows
BIIB,BIIB:UW,BBG000C18861,3 Key Factors to Look Out for in Biogen&apos;s Q1 Results,2017-04-24 13:06:01 +0000,http://finance.yahoo.com/news/3-key-factors-look-biogen-130601603.html?.tsrc=rss,"With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue."
BIIB,BIIB:UW,BBG000C18861,"Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales",2017-04-24 12:50:00 +0000,http://finance.yahoo.com/r/1873916d-c181-340b-aa2f-5c5eba101a3f/biogen-hopes-new-spine-drug-data-convinces-insurers-to-loosen-patient-access-boost-sales.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"When Biogen reports first-quarter earnings Tuesday, investors will be looking to see if Spinraza sales match or exceed $16 million consensus."
BIIB,BIIB:UW,BBG000C18861,"Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS",2017-04-24 12:04:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AixDPKrsJNM/drug-stocks-q1-earnings-releases-on-apr-25-lly-biib-nvs-cm777652,As the Q1 earnings season gets in full swing this week we believe this quarter is on track to see the highest growth in almost three years As of Apr 21 2017 95 S amp P 500 members accounting for 24 9 of the index s total market capitalization reported results according to the
BIIB,BIIB:UW,BBG000C18861,TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment,2017-04-24 11:30:00 +0000,http://finance.yahoo.com/news/tecfidera-tysabri-data-demonstrate-improved-113000722.html?.tsrc=rss,"Biogen announced new real-world data that show treatment with its leading multiple sclerosis therapies, TECFIDERA® and TYSABRI® , early in the course of the disease may improve outcomes for people living with relapsing MS."
BIIB,BIIB:UW,BBG000C18861,Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy,2017-04-24 11:30:00 +0000,http://finance.yahoo.com/news/final-phase-3-study-data-113000581.html?.tsrc=rss,"Biogen will present Phase 3 end of study SPINRAZA® data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor function in children with later-onset spinal muscular atrophy compared to untreated children."
BIIB,BIIB:UW,BBG000C18861,"Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS",2017-04-24 09:52:09 +0000,http://finance.yahoo.com/news/drug-stocks-q1-earnings-releases-095209011.html?.tsrc=rss,"As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years."
BIIB,BIIB:UW,BBG000C18861,"Biogen: TECFIDERA, TYSABRI Data Show Improved Outcomes With Early MS Treatment",2017-04-24 07:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yTWaIRxGTdQ/biogen-tecfidera-tysabri-data-show-improved-outcomes-with-early-ms-treatment-20170424-00389,"Biogen: TECFIDERA, TYSABRI Data Show Improved Outcomes With Early MS Treatment"
BIIB,BIIB:UW,BBG000C18861,3 Stocks That Growth Investors Should Love,2017-04-23 17:03:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8DunDjcPMc/3-stocks-that-growth-investors-should-love-cm777595,If you re a growth investor you love revenue growth You love earnings growth And most of all you love share price growth There are three stocks that should check off all of these boxes in the days ahead Celgene NASDAQ CELG Ionis Pharmaceuticals NASDAQ IONS
BIIB,BIIB:UW,BBG000C18861,3 Stocks That Growth Investors Should Love,2017-04-23 15:01:00 +0000,http://finance.yahoo.com/r/2fceb37f-e2ae-3054-b3cb-31e9d6321287/3-stocks-that-growth-investors-should-love.aspx?yptr=yahoo&.tsrc=rss,"Impressive growth could be in store for biotech stocks Celgene, Ionis, and Vertex."
BIIB,BIIB:UW,BBG000C18861,"Street Watches To See If $125,000 Drug Boosts Biogen&apos;s Results",2017-04-21 20:13:54 +0000,http://finance.yahoo.com/r/ecf53783-ebba-363a-bae3-da92f0670785/will-biogens-q1-spinraza-revenue-be-a-slam-dunk-or-resounding-flop?src=A00220&yptr=yahoo&.tsrc=rss,Wall Street will be keyed in Tuesday to Biogen&apos;s earnings for a first look at whether payer pushback hindered sales of Spinraza.
BIIB,BIIB:UW,BBG000C18861,Biogen Says It's Back and Ready for ‘Highly Active’ Dealmaking,2017-04-21 18:38:48 +0000,http://finance.yahoo.com/news/biogen-says-back-ready-highly-183848730.html?.tsrc=rss,Biogen Inc. is ready to make some deals.
BIIB,BIIB:UW,BBG000C18861,Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy,2017-04-21 18:00:00 +0000,http://finance.yahoo.com/news/biogen-spinraza-nusinersen-receives-positive-180000065.html?.tsrc=rss,Biogen today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorization for SPINRAZA® to treat patients with spinal muscular atrophy .
BIIB,BIIB:UW,BBG000C18861,What to expect from biotech,2017-04-20 21:53:00 +0000,http://finance.yahoo.com/video/expect-biotech-215300900.html?.tsrc=rss,CNBC's Meg Tirrell discusses what healthcare investors should expect from the biotech sector. With the &quot;Fast Money&quot; traders.
BIIB,BIIB:UW,BBG000C18861,What's in Store for Biogen (BIIB) this Earnings Season?,2017-04-20 16:05:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F0-Me36YjRo/whats-in-store-for-biogen-biib-this-earnings-season-cm776417,Biogen Inc BIIB a well known name in the multiple sclerosis MS market will report first quarter 2017 results on Apr 25 before the market opens Last quarter the company delivered a positive earnings surprise of 1 41 Biogen s shares rose 4 this year so far while the Zacks
BIIB,BIIB:UW,BBG000C18861,Marijuana Stocks: A 4/20 Special,2017-04-20 14:37:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FyVbCOq46TU/marijuana-stocks-a-420-special-cm776404,"Marijuana stocks (Shutterstock photo)    Today is April 20th. Now, for those readers of a certain age or who have led a somewhat sheltered existence, this means nothing, but many will understand that today, 4/20, is a logical day to talk about one of the fastest growing businesses in the U.S.: Marijuana."
BIIB,BIIB:UW,BBG000C18861,What&apos;s in Store for Biogen (BIIB) this Earnings Season?,2017-04-20 14:16:02 +0000,http://finance.yahoo.com/news/apos-store-biogen-biib-earnings-141602122.html?.tsrc=rss,"Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens."
BIIB,BIIB:UW,BBG000C18861,Innoviva director vote drama hands last-minute loss to Sarissa,2017-04-20 13:42:12 +0000,http://finance.yahoo.com/news/innoviva-director-vote-drama-hands-134212274.html?.tsrc=rss,"Shareholders of Innoviva Inc.  handed a narrow victory to the U.S. respiratory drug  company, according to a person close to the matter, as its fight  against activist hedge fund Sarissa Capital saw several last  minute twists and turns.  Innoviva shareholders supported the company's three director  nominees at the annual meeting, according to the person who has  access to the preliminary voting totals.  Sarissa had nominated three of its own directors, after  months of pressuring changes at the company."
BIIB,BIIB:UW,BBG000C18861,Activist Sarissa says Innoviva backed out of proxy settlement deal,2017-04-20 02:09:01 +0000,http://finance.yahoo.com/news/activist-sarissa-says-innoviva-backed-020901838.html?.tsrc=rss,"Activist hedge fund Sarissa Capital  Management LP said on Wednesday that U.S. respiratory drug  company Innoviva Inc reneged on a proxy settlement deal  that was struck earlier in the day.  Sarissa, run by former Carl Icahn protege Alex Denner, said  in a statement that Innoviva had accepted an offer to settle the  proxy contest ahead of the shareholder vote scheduled for  Thursday by adding two Sarissa-nominated directors to the board."
BIIB,BIIB:UW,BBG000C18861,Gilead Sciences: Who's Frustrated Now?,2017-04-19 15:42:00 +0000,http://finance.yahoo.com/r/bda188a0-b14b-3d9a-9c65-d366c2bb23bc/gilead-sciences-whos-frustrated-now?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Last month, I urged investors to stay away from  Gilead Sciences (GILD), arguing that it had, in effect, become a value trap (even if I didn't use those exact words.  Barclays analyst Geoff Meacham and team note that ""investors seem increasingly more frustrated"" with not only Gilead, but with Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) as well."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed",2017-04-19 14:06:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ElHVpLVTn4U/biotech-stock-roundup-fda-crl-hits-incyte-pipeline-setbacks-weigh-on-oncomed-cm775728,The FDA s complete response letter CRL for Incyte INCY and Lilly s experimental rheumatoid arthritis RA treatment was the big news in the biotech sector while OncoMed OMED continued to be hit by more pipeline setbacks Recap of the Week s Most Important Stories CRL for Incyte s
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed",2017-04-19 11:57:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-fda-crl-115711490.html?.tsrc=rss,Incyte&apos;s (INCY) shares were hit by the FDA&apos;s complete response letter (CRL) for the company&apos;s rheumatoid arthritis drug.
BIIB,BIIB:UW,BBG000C18861,"Commit To Buy Biogen At $140, Earn 2.6% Using Options",2017-04-18 19:03:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/toJjbhEJgJE/commit-to-buy-biogen-at-140-earn-26-using-options-cm775438,Investors eyeing a purchase of Biogen Inc Symbol BIIB stock but cautious about paying the going market price of 270 09 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the January 2019 put
BIIB,BIIB:UW,BBG000C18861,Bristol-Myers and Nordic Ink Biomarker Collaboration Deal,2017-04-18 15:04:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wlQYLxuerIg/bristol-myers-and-nordic-ink-biomarker-collaboration-deal-cm775248,Bristol Myers Squibb Company BMY recently announced that it has inked a collaboration agreement with Nordic Bioscience a Danish company specializing in biomarker technologies The partnership will focus on developing translational biomarkers and diagnostics for the evaluation of non
BIIB,BIIB:UW,BBG000C18861,Biogen to unveil new data supporting broad use of infant disease drug,2017-04-18 14:55:09 +0000,http://finance.yahoo.com/r/12bf77e1-ea16-3175-91b6-3ebbba9ae7b3/biogen-to-unveil-new-data-supporting-broad-use-of.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen said Tuesday that it plans to unveil new data next week supporting the broad effectiveness of its FDA-approved drug for a rare infant disease.  Cambridge-based Biogen (BIIB) said it would present the data during the American Academy of Neurology’s annual meeting in Boston, which begins Saturday.  The data is from one Phase 2 study and one Phase 3 study of Spinraza, the first drug approved in the U.S. to treat spinal muscular atrophy, a leading genetic cause of death in infants."
BIIB,BIIB:UW,BBG000C18861,The 7 Most Expensive Prescription Drugs in the World,2017-04-18 11:54:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IztSKJxo6yM/the-7-most-expensive-prescription-drugs-in-the-world-cm774991,Image source Getty Images Imagine buying a Ferrari 488 Spider and a Porsche 911 Carrera e very year You d spend more than the costs of those two sports cars if you had to pay the average wholesale price for the costliest prescription drugs The highest priced
BIIB,BIIB:UW,BBG000C18861,Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress,2017-04-18 11:30:00 +0000,http://finance.yahoo.com/news/biogen-highlights-advances-neurology-research-113000653.html?.tsrc=rss,Biogen will present data from its portfolio of treatments and investigational therapies for people with serious neurological and neurodegenerative diseases at the 69th annual meeting of the American Academy of Neurology in Boston .
BIIB,BIIB:UW,BBG000C18861,Biogen to License Alzheimer Candidate from Bristol-Myers,2017-04-17 15:57:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NLW4lr-fHFQ/biogen-to-license-alzheimer-candidate-from-bristol-myers-cm774651,Biogen Inc BIIB recently announced that it has inked a deal to buy worldwide rights for Bristol Myers Squibb s BMY anti tau antibody BMS 986168 for an upfront payment of 300 million Biogen sees significant potential in the development and commercialization of BMS 986168 for
BIIB,BIIB:UW,BBG000C18861,Biogen to License Alzheimer Candidate from Bristol-Myers,2017-04-17 13:37:01 +0000,http://finance.yahoo.com/news/biogen-license-alzheimer-candidate-bristol-133701144.html?.tsrc=rss,"Biogen Inc. (BIIB) recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb&apos;s (BMY) anti-tau antibody, BMS-986168, for an upfront payment of $300 million."
BIIB,BIIB:UW,BBG000C18861,How Biogen&apos;s Takeover Prospects Soured In Mere Months,2017-04-14 13:51:24 +0000,http://finance.yahoo.com/r/0f608109-e937-3acc-86e6-c22f9ff1e49b/merck-allergan-lilly-miss-on-biogen-but-ma-could-be-around-corner?src=A00220A&yptr=yahoo&.tsrc=rss,"Potential Biogen acquirers are now likely waiting until 2020, when Biogen is expected to unveil late-stage Alzheimer&apos;s data."
BIIB,BIIB:UW,BBG000C18861,Biogen Snaps Up A 'Rare Find' From BMS: Instinet,2017-04-14 13:38:00 +0000,http://finance.yahoo.com/r/98546180-9c65-3ed6-9f6f-d3560f2e9e35/biogen-snaps-up-a-rare-find-from-bms-instinet?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Biogen will pay $300 million up front fro the drug, which targets Progressive Supernuclear Palsy (PSP), and may also  make potential milestone payments of up to $410 million.  and his team reiterated a Buy rating and $355 price target on the stock following the news.  They write that the deal could ultimately reach some $1.26 billion in value depending on royalty payments."
BIIB,BIIB:UW,BBG000C18861,Could Bristol&apos;s Drug Help Biogen Take AbbVie In Alzheimer&apos;s?,2017-04-13 20:40:07 +0000,http://finance.yahoo.com/r/ed6cad67-1e28-35ff-bb51-82f8dac19d03/could-bristols-drug-help-biogen-take-abbvie-in-alzheimers?src=A00220A&yptr=yahoo&.tsrc=rss,Biogen is licensing Bristol&apos;s palsy drug with a $2 billion market opportunity and the potential to pivot into Alzheimer&apos;s.
BIIB,BIIB:UW,BBG000C18861,Biogen pays $300M to Bristol-Myers for another potential Alzheimer's drug,2017-04-13 14:20:11 +0000,http://finance.yahoo.com/r/b521f09f-f0df-3a61-bc03-4e8422dfc877/biogen-pays-300m-to-bristol-myers-for-another.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Biogen is beefing up its Alzheimer’s pipeline, agreeing to pay $300 million to license an experimental drug from Bristol-Myers Squibb that the Cambridge biotech plans to quickly push into mid-stage studies.  Biogen (BIIB) said Thursday that it will give New York-based Bristol-Myers Squibb (BMY) an upfront payment of $300 million, plus up to $410 million in additional milestone payments and royalties in exchange for full rights to BMS-986168.  The drug targets a type of protein, called tau, that forms deposits in the brain linked to Alzheimer’s disease."
BIIB,BIIB:UW,BBG000C18861,"Biotech Movers: Synergy, Biogen, Insys",2017-04-13 13:21:00 +0000,http://finance.yahoo.com/r/80393725-d8f1-3ae3-b1a8-600304f7fae3/biotech-movers-synergy-biogen-insys.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday."
BIIB,BIIB:UW,BBG000C18861,"Bristol-Myers to license two drugs to Biogen, Roche",2017-04-13 12:29:25 +0000,http://finance.yahoo.com/news/bristol-myers-license-two-drugs-115641596.html?.tsrc=rss,"Bristol-Myers Squibb Co said on  Thursday it would license two of its drugs to Biogen Inc  and Roche Holding AG for an upfront fee of $470  million.  Bristol will license its experimental neurodegenerative  disorder drug, BMS-986168, to Biogen as a treatment for  progressive supranuclear palsy, which is characterized by brain  cell damage."
BIIB,BIIB:UW,BBG000C18861,Bristol-Myers to get $470 million upfront for license deals with Biogen and Roche,2017-04-13 11:11:31 +0000,http://finance.yahoo.com/r/8b10fcdf-9246-32b7-b5d1-abefe001e485/Story.aspx?guid=B543BBBA-425E-483C-9AA2-2813639E94BB&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Bristol-Myers Squibb Co. said Thursday it entered into license deals with Biogen Inc. and Roche, in which it will receive a combined $470 million in upfront payments and up to $615 million in potential ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb,2017-04-13 11:00:00 +0000,http://finance.yahoo.com/news/biogen-licenses-phase-2-anti-110000184.html?.tsrc=rss,"Biogen  today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer’s disease and progressive supranuclear palsy , from Bristol-Myers Squibb ."
BIIB,BIIB:UW,BBG000C18861,"Bristol-Myers To Get $470 Mln Upfront From Licensing Deals With Biogen, Roche",2017-04-13 07:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4mbND805XYM/bristolmyers-to-get-470-mln-upfront-from-licensing-deals-with-biogen-roche-20170413-00286,"Bristol-Myers To Get $470 Mln Upfront From Licensing Deals With Biogen, Roche"
BIIB,BIIB:UW,BBG000C18861,How These Biotechs Could Save The Drug Sector In Q1 — Or Not,2017-04-12 16:51:42 +0000,http://finance.yahoo.com/r/095712cc-355d-3dd3-9c11-7756d0ae978c/how-these-biotechs-could-save-or-tank-the-drug-sector-in-q1?src=A00220A&yptr=yahoo&.tsrc=rss,Biotech investors will likely be keyed in on launches of Biogen&apos;s Spinraza and Regeneron&apos;s Dupixent as first-quarter results roll around.
BIIB,BIIB:UW,BBG000C18861,"[$$] Celgene, Biogen to Gain From Higher Prices",2017-04-12 15:25:00 +0000,http://finance.yahoo.com/r/6be67c46-3434-347a-8fd1-d7fbd3320773/celgene-biogen-to-gain-from-higher-prices-1492010746?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse  Heading into earnings, we think Biogen, Alexion Pharmaceuticals and Gilead Sciences will be in focus.  Key products of focus are Spinraza (Biogen (BIIB)/Ionis Pharmaceuticals (IONS)), Soliris (Alexion (ALXN)) and Harvoni (Gilead (GILD)).  Interestingly, we think numbers look low for Gilead hepatitis C virus (HCV) and we see potential for a beat this quarter."
BIIB,BIIB:UW,BBG000C18861,Don't Get Your Hopes Up For Biotech's Q1 Earnings,2017-04-12 14:13:00 +0000,http://finance.yahoo.com/r/2bdd40e0-1e70-316a-a95a-680207edf458/dont-get-your-hopes-up-for-biotechs-q1-earnings?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"More detail from the note: Biogen’s (BIIB) Spinraza is likely to be scrutinized given the once-high expectations for the drug and the recent structural challenges noted in linking diagnosed patients to treatment.  Investor’s will also be attempting to assess how much damage Ocrevus may do to Biogen’s own multiple sclerosis business unit.  For Amgen (AMGN) and REGN, investors will be asking about changes in reimbursement, patient access and starts for the PCSK9 class, after the recent FOURIER results."
BIIB,BIIB:UW,BBG000C18861,Post Earnings Coverage as NeuroDerm Reported FY16 Results,2017-04-12 12:15:00 +0000,http://finance.yahoo.com/news/post-earnings-coverage-neuroderm-reported-121500483.html?.tsrc=rss,"Upcoming AWS Coverage on Biogen Post-Earnings Results LONDON, UK / ACCESSWIRE / April 12, 2017 / Active Wall St. announces its post-earnings coverage on NeuroDerm Ltd. (NASDAQ: NDRM ). The Company released ..."
BIIB,BIIB:UW,BBG000C18861,First Quarter Earnings Preview: Biotech Heavyweights,2017-04-12 10:00:00 +0000,http://finance.yahoo.com/r/e948fb33-532b-35ac-a297-8a0db0e59a70/first-quarter-earnings-preview-biotech-heavyweights?partner=YahooSA&yptr=yahoo&.tsrc=rss,"The March quarter earnings season is getting underway soon, get ahead of the game with our biotech earnings preview."
BIIB,BIIB:UW,BBG000C18861,Roche Just Scored One of the Biggest Pharma Wins of 2017,2017-04-10 18:55:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpgBvFeZSCg/roche-just-scored-one-of-the-biggest-pharma-wins-of-2017-cm772292,Swiss drugmaker Roche Holdings NASDAQOTH RHHBY got a nod from the FDA for its multiple sclerosis drug Ocrevus at the end of March triggering hope from MS sufferers and dread from competitors Investors had expected the development which is likely to pay off in a big way A
BIIB,BIIB:UW,BBG000C18861,Roche Just Scored One of the Biggest Pharma Wins of 2017,2017-04-10 17:04:00 +0000,http://finance.yahoo.com/r/9bd48012-a39c-32b6-a357-e56b345b0f9f/roche-just-scored-one-of-the-biggest-pharma-wins-o.aspx?yptr=yahoo&.tsrc=rss,Approval of a new multiple sclerosis drug paves the way for a new blockbuster.
BIIB,BIIB:UW,BBG000C18861,AbbVie's Elagolix Meets Primary Endpoint in Phase II Study,2017-04-10 16:55:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fo3PwiBWt88/abbvies-elagolix-meets-primary-endpoint-in-phase-ii-study-cm772211,AbbVie Inc ABBV along with Neurocrine Biosciences Inc NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids The data from the study were presented at the
BIIB,BIIB:UW,BBG000C18861,"3 Big Stock Charts for Friday: Biogen Inc (BIIB), American Airlines Group Inc (AAL) and Cisco Systems, Inc. (CSCO)",2017-04-07 20:55:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UogAdnwKIho/3-big-stock-charts-for-friday-biogen-inc-biib-american-airlines-group-inc-aal-and-cisco-systems-inc-csco-cm771628,InvestorPlace Stock Market News Stock Advice amp Trading Tips We continue to see some fractures in the market from a technical perspective as the number of companies that are trading below their respective 50 day moving averages in the S amp P 500 is on the rise What
BIIB,BIIB:UW,BBG000C18861,"How Roche&apos;s &apos;Game Changer&apos; Drug Will Chip Away At Biogen, Novartis",2017-04-07 20:45:41 +0000,http://finance.yahoo.com/r/78c37551-1175-3e20-a519-36e95b7aaead/how-roches-game-changer-drug-will-chip-away-at-biogen-novartis?src=A00220A&yptr=yahoo&.tsrc=rss,Roche&apos;s Ocrevus will be a &quot;game changer&quot; in multiple sclerosis and looks likely to chip away at 3%-4% of Biogen&apos;s sales.
BIIB,BIIB:UW,BBG000C18861,Why Roche's New Drug Is Bad News For Biogen,2017-04-07 17:34:00 +0000,http://finance.yahoo.com/r/6ea5bb51-5630-3f66-9a72-56237da69fb9/why-roches-new-drug-is-bad-news-for-biogen?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The market is up today, but shares of Biogen (BIIB) are down.  The biotech giant dropped 1.1% to just over $268 a share after analysts at Leerink cut their price target from $300 to $290.  Granted, shaving $10 off a $300 price target doesn’t seem like much of a shift in sentiment."
BIIB,BIIB:UW,BBG000C18861,"​Biogen multiple sclerosis drug sales could fall $900M by 2020, analyst predicts",2017-04-07 15:40:12 +0000,http://finance.yahoo.com/r/d7f74ac6-b735-3721-8913-975e8580f9ed/biogen-multiple-sclerosis-drug-sales-could-fall.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Annual revenue from Biogen’s multiple sclerosis treatments could decline $900 million by 2020 — more than 10 percent — amid increased competition from Roche’s potential blockbuster Ocrevus and other drugs, according to an analyst.  Leerink Partners analyst Geoffrey Porges made the prediction in a note on Friday morning, citing conversations with physicians at large MS treatment centers who collectively oversee more than 16,000 patients, some of whom take drugs sold by Biogen (BIIB).  According to Porges, the specialists indicated that Ocrevus, which was approved by the FDA on March 28 , will primarily cut into sales of Biogen’s Tysabri and its top-selling drug Tecfidera."
BIIB,BIIB:UW,BBG000C18861,"Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline",2017-04-06 15:56:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6FzIEtVW7vg/acorda-acor-to-reduce-workforce-focus-on-product-pipeline-cm770742,Acorda Therapeutics Inc ACOR recently announced plans to reduce its workforce by approximately 20 The workforce reduction which is expected to be completed in Apr 2017 is part of the company s strategy to significantly lower its operating expenses The company expects this move
BIIB,BIIB:UW,BBG000C18861,"Wednesday Sector Laggards: Utilities, Healthcare",2017-04-05 19:53:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8Li658fRAuE/wednesday-sector-laggards-utilities-healthcare-cm770364,The worst performing sector as of midday Wednesday is the Utilities sector higher by 0 2 Within the sector Sempra Energy Symbol SRE and AES Corp Symbol AES are two of the day s laggards showing a loss of 1 0 and 0 6 respectively Among utilities ETFs one ETF following the
BIIB,BIIB:UW,BBG000C18861,Peek Under The Hood: BBH Has 14% Upside,2017-04-05 13:24:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZMqfUqllHww/peek-under-the-hood-bbh-has-14-upside-cm769995,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BIIB,BIIB:UW,BBG000C18861,Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market,2017-04-04 21:40:00 +0000,http://finance.yahoo.com/r/30ea8855-c236-3950-97e6-19ce7a5805fd/abbvie-is-a-total-return-play-here-s-why.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
BIIB,BIIB:UW,BBG000C18861,"Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight",2017-04-03 20:43:32 +0000,http://www.investors.com/news/technology/acorda-biogen-stocks-topple-as-rivalries-from-these-companies-loom/?src=A00220A,"Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight"
BIIB,BIIB:UW,BBG000C18861,"Acorda, Forward, Biogen Fall On Multiple Sclerosis Drug Fight",2017-04-03 20:43:32 +0000,http://finance.yahoo.com/r/ee6c74a7-9552-31a9-9003-fd3830c27c95/acorda-biogen-stocks-topple-as-rivalries-from-these-companies-loom?src=A00220A&yptr=yahoo&.tsrc=rss,"Acorda, Forward and Biogen stocks continued to feel the fallout Monday of several FDA and district court decisions in MS."
BIIB,BIIB:UW,BBG000C18861,3 Biotech Trades for the Faux Doomsday Scenario,2017-04-03 20:36:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2Wcb-zyXb3A/3-biotech-trades-for-the-faux-doomsday-scenario-cm769273,InvestorPlace Stock Market News Stock Advice amp Trading Tips Even under normal circumstances healthcare and biotech stocks are prone to making headlines They ve been a political punching bag for more than a year now First Hillary Clinton vowed to rein in the sector policies
BIIB,BIIB:UW,BBG000C18861,"Snap Started At Hold, Kite Pharma Can't Stay Aloft, Accenture Cut",2017-04-03 20:19:57 +0000,http://finance.yahoo.com/r/b5da2e04-a313-31e0-81b1-9b38fc8905f2/snap-started-at-hold-suntrust-upgraded-to-buy-accenture-downgraded?src=A00220A&yptr=yahoo&.tsrc=rss,"Snapchat parent got a hold rating, while Accenture was downgraded. Kite initially soared on a bullish analyst note and trial data, but that didn't last."
BIIB,BIIB:UW,BBG000C18861,"Snap Started At Hold, Kite Pharma Can't Stay Aloft, Accenture Cut",2017-04-03 20:19:57 +0000,http://www.investors.com/news/technology/snap-started-at-hold-suntrust-upgraded-to-buy-accenture-downgraded/?src=A00220A,"Snap Started At Hold, Kite Pharma Can't Stay Aloft, Accenture Cut"
BIIB,BIIB:UW,BBG000C18861,"Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge",2017-04-03 15:40:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IXaeHaZgOXk/acordas-acor-ms-drug-patents-invalidated-shares-plunge-cm769055,Acorda Therapeutics Inc s ACOR shares were down almost 21 5 after the U S District Court for the District of Delaware invalidated four patents of its key multiple sclerosis drug Ampyra thereby making way for generic versions of the drug The company is likely to appeal the ruling
BIIB,BIIB:UW,BBG000C18861,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them,2017-04-02 11:23:00 +0000,http://finance.yahoo.com/r/58ac3440-3f9d-385a-ad3a-27f1c34c8411/5-deadliest-diseases-in-the-us-and-the-top-drugs-p.aspx?yptr=yahoo&.tsrc=rss,Promising treatments could be on the way to address the diseases causing the most American deaths.
BIIB,BIIB:UW,BBG000C18861,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them,2017-04-02 11:23:00 +0000,https://www.fool.com/investing/2017/04/02/5-deadliest-diseases-in-the-us-and-the-top-drugs-p.aspx,5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them
BIIB,BIIB:UW,BBG000C18861,Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today,2017-03-31 22:59:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LdEP_7J0dS0/why-acorda-therapeutics-inc-and-forward-pharma-as-got-crushed-today-cm768586,What happened Forward Pharma NASDAQ FWP ended the day down 19 9 while Acorda Therapeutics NASDAQ ACOR didn t fare any better down 21 5 after investors received word that the companies had lost separate patent battles So what A U S patent board ruled
BIIB,BIIB:UW,BBG000C18861,Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today,2017-03-31 21:14:00 +0000,https://www.fool.com/investing/2017/03/31/why-acorda-therapeutics-inc-and-forward-pharma-as.aspx,Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today
BIIB,BIIB:UW,BBG000C18861,Why Acorda Therapeutics Inc and Forward Pharma A/S Got Crushed Today,2017-03-31 21:14:00 +0000,http://finance.yahoo.com/r/5627c38f-c5a6-37de-8897-e452b0f4ea3d/why-acorda-therapeutics-inc-and-forward-pharma-as.aspx?yptr=yahoo&.tsrc=rss,Patent battles end poorly for both companies.
BIIB,BIIB:UW,BBG000C18861,"Acorda, Forward Stocks Plunge On Multiple Sclerosis Court Rulings",2017-03-31 20:25:50 +0000,http://finance.yahoo.com/r/09909821-5673-3a9d-a71f-325c394098ca/acorda-forward-stocks-plunge-on-multiple-sclerosis-court-rulings?src=A00220A&yptr=yahoo&.tsrc=rss,Acorda and Forward stocks plunged midday Friday on court decisions related to multiple sclerosis drugs Ampyra and Tecfidera.
BIIB,BIIB:UW,BBG000C18861,"Acorda, Forward Stocks Plunge On Multiple Sclerosis Court Rulings",2017-03-31 20:25:50 +0000,http://www.investors.com/news/technology/acorda-forward-stocks-plunge-on-multiple-sclerosis-court-rulings/?src=A00220A,"Acorda, Forward Stocks Plunge On Multiple Sclerosis Court Rulings"
BIIB,BIIB:UW,BBG000C18861,Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher,2017-03-31 20:09:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jFkCS-rqvI4/mid-afternoon-market-update-dow-drops-50-points-trc-companies-shares-spike-higher-cm768552,Toward the end of trading Friday the Dow traded down 0 24 percent to 20 678 49 while the NASDAQ rose 0 07 percent to 5 918 43 The S amp P also fell dropping 0 10 percent to 2 365 79 Leading and Lagging Sectors Friday afternoon the utilities sector proved to be a source
BIIB,BIIB:UW,BBG000C18861,Two biotech stocks plunge after losing patent fights,2017-03-31 19:57:45 +0000,http://finance.yahoo.com/news/two-biotech-stocks-plunge-losing-195745085.html?.tsrc=rss,"According to a filing from the U.S. Patent and Trademark Office, Forward Pharma has been interfering with Biogen."
BIIB,BIIB:UW,BBG000C18861,Two biotech stocks plunge after losing patent fights,2017-03-31 19:57:45 +0000,http://www.cnbc.com/id/104377361?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104377361,Two biotech stocks plunge after losing patent fights
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Friday Option Activity: PX, BIIB, EXPE",2017-03-31 18:59:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rpjyZU8aZrI/noteworthy-friday-option-activity-px-biib-expe-cm768471,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Praxair Inc Symbol PX where a total volume of 10 865 contracts has been traded thus far today a contract volume which is representative of approximately 1 1 million
BIIB,BIIB:UW,BBG000C18861,​Biogen wins another big Tecfidera patent case,2017-03-31 18:45:06 +0000,http://finance.yahoo.com/r/f1d0bb86-5505-3c34-81fb-4fb94d94afa3/biogen-wins-another-round-in-tecfidera-patent.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"For the second time in as many weeks, Biogen has prevailed in a high-stakes legal dispute over patents on its blockbuster multiple sclerosis treatment Tecfidera.  The U.S. Patent Trial and Appeal Board on Friday rejected a bid by Danish biotech Forward Pharma (FWP) to invalidate the patents.  A ruling in favor of Forward Pharma would have forced Biogen (BIIB) to pay a 10 percent royalty on sales of Tecfidera beginning in 2021."
BIIB,BIIB:UW,BBG000C18861,​Biogen wins another big Tecfidera patent case,2017-03-31 18:45:06 +0000,http://www.bizjournals.com/boston/news/2017/03/31/biogen-wins-another-round-in-tecfidera-patent.html?ana=yahoo,​Biogen wins another big Tecfidera patent case
BIIB,BIIB:UW,BBG000C18861,Biogen wins Tecfidera U.S. patent dispute with Forward Pharma,2017-03-31 17:02:22 +0000,http://finance.yahoo.com/news/biogen-wins-tecfidera-u-patent-170222978.html,Biogen wins Tecfidera U.S. patent dispute with Forward Pharma
BIIB,BIIB:UW,BBG000C18861,Biogen wins Tecfidera U.S. patent dispute with Forward Pharma,2017-03-31 17:02:22 +0000,http://finance.yahoo.com/news/biogen-wins-tecfidera-u-patent-170222978.html?.tsrc=rss,"A U.S. patent board on Friday ruled  against Danish drugmaker Forward Pharma A/S, finding  Biogen's patents on its blockbuster multiple sclerosis drug  Tecfidera to be valid.  The ruling by the U.S. Patent Trial and Appeal Board (PTAP)  frees Bigoen Inc from future royalty payments to  Forward and sent the Danish firm's shares down nearly 20  percent.  Biogen shares were up 1.4 percent."
BIIB,BIIB:UW,BBG000C18861,Acorda Therapy tanks,2017-03-31 16:41:00 +0000,http://finance.yahoo.com/video/acorda-therapy-tanks-164100690.html?.tsrc=rss,"Shares of Acorda were hit today after a District Court invalidated four patents for Ampyra, which represents 95 percent of the company's revenue. CNBC's Meg Tirrell reports."
BIIB,BIIB:UW,BBG000C18861,Acorda Therapy tanks,2017-03-31 16:41:00 +0000,http://finance.yahoo.com/video/acorda-therapy-tanks-164100690.html,Acorda Therapy tanks
BIIB,BIIB:UW,BBG000C18861,"Biogen stock rises, Forward Pharma halted down 20% after patent ruling",2017-03-31 16:27:01 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=95C9BE47-291E-4653-A90E-4244EC2D31CE&siteid=yhoof2,"Biogen stock rises, Forward Pharma halted down 20% after patent ruling"
BIIB,BIIB:UW,BBG000C18861,"Biogen stock rises, Forward Pharma halted down 20% after patent ruling",2017-03-31 16:27:01 +0000,http://finance.yahoo.com/r/f57b248b-70a4-3d80-9219-abbc3c682497/Story.aspx?guid=95C9BE47-291E-4653-A90E-4244EC2D31CE&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Shares of Biogen Inc. rose Friday, while Forward Pharma A/S shares were halted after falling almost 20%, after Biogen was reported to have won a patent ruling. The U.S. Patent Office ruled in favor of ..."
BIIB,BIIB:UW,BBG000C18861,Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient,2017-03-31 16:15:35 +0000,http://finance.yahoo.com/news/forward-pharma-falls-biogen-patent-161535412.html,Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient
BIIB,BIIB:UW,BBG000C18861,Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient,2017-03-31 16:15:35 +0000,http://finance.yahoo.com/news/forward-pharma-falls-biogen-patent-161535412.html?.tsrc=rss,Forward Pharma A/S (NASDAQ: FWP ) plummeted 30 percent Friday on news of Biogen Inc (NASDAQ: BIIB )’s patent victory over the active ingredient in their competing multiple sclerosis treatments. Biogen ...
BIIB,BIIB:UW,BBG000C18861,Forward Pharma plunges on patent ruling,2017-03-31 16:10:00 +0000,http://finance.yahoo.com/video/forward-pharma-plunges-patent-ruling-161000765.html,Forward Pharma plunges on patent ruling
BIIB,BIIB:UW,BBG000C18861,Forward Pharma plunges on patent ruling,2017-03-31 16:10:00 +0000,http://finance.yahoo.com/video/forward-pharma-plunges-patent-ruling-161000765.html?.tsrc=rss,CNBC's Meg Tirrell reports on the latest market action in the bio-tech sector.
BIIB,BIIB:UW,BBG000C18861,Novartis Expects to Launch 5 Key Biosimilars by 2020,2017-03-31 14:36:35 +0000,http://marketrealist.com/2017/03/novartis-expects-launch-five-key-biosimilars-2020/?utm_source=yahoo&utm_medium=feed,Novartis Expects to Launch 5 Key Biosimilars by 2020
BIIB,BIIB:UW,BBG000C18861,Can Vertex Keep Climbing?,2017-03-31 13:43:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/31/can-vertex-keep-climbing/?mod=yahoobarrons&ru=yahoo,Can Vertex Keep Climbing?
BIIB,BIIB:UW,BBG000C18861,Can Vertex Keep Climbing?,2017-03-31 13:43:00 +0000,http://finance.yahoo.com/r/cf2e536b-1ade-35e3-b21f-ebc410f8910e/can-vertex-keep-climbing?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Vertex Pharmaceuticals (VRTX) has had a great week.  The drug maker released stellar late-stage clinical trial data late Tuesday for its new cystic fibrosis drug, and its share price has surged more than 20% in response.  The drug maker already markets the only two disease-modifying treatments available for cystic fibrosis, a deadly genetic disorder."
BIIB,BIIB:UW,BBG000C18861,BUZZ-AC Immune Ltd: Drops on block sale,2017-03-31 13:21:48 +0000,http://uk.finance.yahoo.com/news/buzz-ac-immune-ltd-drops-132148843.html,"[Reuters - UK Focus] - ** Shares of Swiss biotech AC Immune down 6.7 pct to $10.79 in light premarket trading on block sale ** Sources say Jefferies re-offered 1.9 mln shares at $11, roughly 5-pct discount to stock's $11.57 ..."
BIIB,BIIB:UW,BBG000C18861,Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis,2017-03-29 23:58:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aO2vfQdgtgg/roches-ocrevus-wins-fda-approval-for-2-forms-of-sclerosis-cm767520,Roche Holdings AG RHHBY announced that the FDA has approved Ocrevus ocrelizumab as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis Roche s share price shows that the company has outperformed the Zacks classified industry year to date
BIIB,BIIB:UW,BBG000C18861,Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis,2017-03-29 21:43:00 +0000,http://finance.yahoo.com/r/36179ddf-16a9-34dc-902f-3222745852a4/roches-ocrevus-wins-fda-approval-2-forms-sclerosis?partner=YahooSA&yptr=yahoo&.tsrc=rss,Roche Holdings AG RHHBY announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis. Roche’s share price ...
BIIB,BIIB:UW,BBG000C18861,Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis,2017-03-29 21:43:00 +0000,http://www.investopedia.com/partner/zacks/roches-ocrevus-wins-fda-approval-2-forms-sclerosis/?partner=YahooSA,Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis
BIIB,BIIB:UW,BBG000C18861,Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen,2017-03-29 20:31:10 +0000,http://www.investors.com/news/technology/roche-multiple-sclerosis-drug-ok-bittersweet-for-beleaguered-biogen/?src=A00220A,Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen
BIIB,BIIB:UW,BBG000C18861,Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen,2017-03-29 20:31:10 +0000,http://finance.yahoo.com/r/a9342fb0-d98e-3ad6-bfba-023f6a3af4b0/roche-multiple-sclerosis-drug-ok-bittersweet-for-beleaguered-biogen?src=A00220A&yptr=yahoo&.tsrc=rss,"The FDA's approval of a multiple sclerosis drug from Roche is likely to be bittersweet for Biogen, analysts said Wednesday."
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: BIIB, VRTX",2017-03-29 15:59:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I6RUKJaugCg/nasdaq-100-movers-biib-vrtx-cm767233,In early trading on Wednesday shares of Vertex Pharmaceuticals VRTX topped the list of the day s best performing components of the Nasdaq 100 index trading up 24 6 Year to date Vertex Pharmaceuticals registers a 51 7 gain And the worst performing Nasdaq 100 component thus far
BIIB,BIIB:UW,BBG000C18861,U.S. approves Roche drug that targets severe form of MS,2017-03-29 13:26:30 +0000,http://finance.yahoo.com/news/u-approves-roche-drug-targets-132630507.html,"[Reuters] - Roche's multiple sclerosis (MS) drug Ocrevus won U.S. approval, putting the potential blockbuster back on track after a brief delay and giving a lift to patients with a form of the disease that until now had no approved treatment. The drug, also known as ocrelizumab and administered via infusion, becomes the first U.S. Food and Drug Administration-approved medicine for the primary progressive form of the neurological disease (PPMS). Ocrevus, to have a list price of $65,000 annually, undercutting rival Merck's Rebif by a quarter, is also approved to treat the most common form of MS, known as relapsing-remitting multiple sclerosis (RRMS)."
BIIB,BIIB:UW,BBG000C18861,UPDATE 2-Roche MS drug Ocrevus approved by FDA after 3-month delay,2017-03-29 09:40:36 +0000,http://finance.yahoo.com/news/roche-ms-drug-ocrevus-approved-011425630.html,"[Reuters] - The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS)."
BIIB,BIIB:UW,BBG000C18861,"Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen",2017-03-29 00:45:00 +0000,https://www.thestreet.com/story/14062067/1/roche-wins-fda-backing-for-new-multiple-sclerosis-therapy-competition-could-crimp-biogen.html?puc=yahoo&cm_ven=YAHOO,"Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen"
BIIB,BIIB:UW,BBG000C18861,"Biotech ETFs Defy Trump Tweets To Rally, But What Can Send Them Higher?",2017-03-28 19:58:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e42gGD59Z5k/biotech-etfs-defy-trump-tweets-to-rally-but-what-can-send-them-higher-cm766850,The largest biotech ETFs served up a reminder in March 160 that 160 investors in this high growth industry should expect 160 a bumpy ride They hit their best levels in a year early on then took a nasty tumble 160 before bouncing back smartly from those losses On Tuesday
BIIB,BIIB:UW,BBG000C18861,Could International Laggards Come Out as Winners?,2017-03-28 13:07:07 +0000,http://marketrealist.com/2017/03/international-laggards-winners-medium-term/?utm_source=yahoo&utm_medium=feed,Could International Laggards Come Out as Winners?
BIIB,BIIB:UW,BBG000C18861,Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases,2017-03-28 11:30:00 +0000,http://uk.finance.yahoo.com/news/biogen-present-data-13th-international-113000907.html,Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases
BIIB,BIIB:UW,BBG000C18861,"Biogen to Report First Quarter 2017 Financial Results on April 25, 2017",2017-03-27 20:01:00 +0000,http://finance.yahoo.com/news/biogen-report-first-quarter-2017-200100385.html,"[Business Wire] - Biogen Inc. today announced it will report first quarter 2017 financial results on Tuesday, April 25, 2017, before the financial markets open."
BIIB,BIIB:UW,BBG000C18861,Short Interest Pulls Back in Major Biotechs,2017-03-27 14:30:30 +0000,http://finance.yahoo.com/news/short-interest-pulls-back-major-143030456.html,Short Interest Pulls Back in Major Biotechs
BIIB,BIIB:UW,BBG000C18861,Cytokinetics SMA Drug Did Well in Early Study,2017-03-22 19:10:00 +0000,http://www.investopedia.com/news/cytokinetics-sma-drug-did-well-early-study-cytk/?partner=YahooSA,Cytokinetics SMA Drug Did Well in Early Study
BIIB,BIIB:UW,BBG000C18861,Could Biogen Spinoff Bleed This Biotech In Hemophilia?,2017-03-22 16:53:28 +0000,http://www.investors.com/news/technology/could-biogen-spinoff-bleed-this-biotech-in-hemophilia/?src=A00220A,Could Biogen Spinoff Bleed This Biotech In Hemophilia?
BIIB,BIIB:UW,BBG000C18861,Recent Developments for Ionis Pharmaceuticals,2017-03-22 14:37:19 +0000,http://marketrealist.com/2017/03/recent-developments-ionis-pharmaceuticals/?utm_source=yahoo&utm_medium=feed,Recent Developments for Ionis Pharmaceuticals
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results",2017-03-22 14:09:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/veBMJx2G_Gg/biotech-stock-roundup-amgen-down-on-repatha-data-nektar-surges-on-pain-results-cm764070,Biotech stocks were hit by the release of the Budget Blueprint for 2018 which could require companies to shell out higher fees for regulatory reviews Moreover the budget proposes a reduction of 5 8 billion in the National Institutes of Health s NIH spending Other key updates include Amgen
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results",2017-03-22 12:33:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-amgen-down-123312736.html,"Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results"
BIIB,BIIB:UW,BBG000C18861,A Look at Ionis Pharmaceuticals’ Spinraza,2017-03-22 11:37:25 +0000,http://marketrealist.com/2017/03/a-look-at-ionis-pharmaceuticals-spinraza/?utm_source=yahoo&utm_medium=feed,A Look at Ionis Pharmaceuticals’ Spinraza
BIIB,BIIB:UW,BBG000C18861,[$$] Two Cheers for Biogen’s Court Victory,2017-03-22 04:07:16 +0000,https://www.wsj.com/articles/two-cheers-for-biogens-court-victory-1490115155?ru=yahoo?mod=yahoo_itp,[$$] Two Cheers for Biogen’s Court Victory
BIIB,BIIB:UW,BBG000C18861,Billionaires' Best Healthcare Stock Picks of 2017 (So Far),2017-03-21 21:09:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZGJWbPLlDBU/billionaires-best-healthcare-stock-picks-of-2017-so-far-cm763781,Billionaire investors didn t amass their fortunes by picking horrible stocks While you wouldn t want to blindly copy these successful investors it certainly doesn t hurt to watch which stocks they choose and how those stocks perform I looked at the portfolios of several of
BIIB,BIIB:UW,BBG000C18861,Biogen Wins Tecfidera Patent Case,2017-03-21 20:43:00 +0000,http://www.investopedia.com/news/biogen-wins-tecfidera-patent-case-biib/?partner=YahooSA,Biogen Wins Tecfidera Patent Case
BIIB,BIIB:UW,BBG000C18861,"Health Care Sector Update for 03/21/2017: BIIB,PTIE,AXSM",2017-03-21 20:26:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/36lzZRVa4rI/health-care-sector-update-for-03212017-biibptieaxsm-cm763758,Top Health Care StocksTop Health Care Stocks JNJ 0 58 JNJ 0 58 PFE 0 29 PFE 0 29 MRK 0 33 MRK 0 33 ABT 0 45 ABT 0 45 AMGN 1 55 AMGN 1 55 Health care stocks resisted much of the steeper declines most sectors experienced today with the NYSE Health Care Index falling about 0 5
BIIB,BIIB:UW,BBG000C18861,Biogen Stock Pops After Judge Upholds Critical Drug Patent,2017-03-21 20:04:31 +0000,http://www.investors.com/news/technology/biogen-pops-after-judge-upholds-tecfidera-patent-will-ma-buzz-return/?src=A00220A,Biogen Stock Pops After Judge Upholds Critical Drug Patent
BIIB,BIIB:UW,BBG000C18861,Biogen wins patent decision,2017-03-21 18:13:00 +0000,http://finance.yahoo.com/video/biogen-wins-patent-decision-181300448.html,Biogen wins patent decision
BIIB,BIIB:UW,BBG000C18861,Biogen: Did Someone Say Biotech Stocks are Falling?,2017-03-21 17:44:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/21/biogen-did-someone-say-biotech-stocks-are-falling/?mod=yahoobarrons&ru=yahoo,Biogen: Did Someone Say Biotech Stocks are Falling?
BIIB,BIIB:UW,BBG000C18861,[$$] Two Cheers for Biogen's Court Victory,2017-03-21 16:52:39 +0000,https://www.wsj.com/articles/two-cheers-for-biogens-court-victory-1490115155?mod=yahoo_hs,[$$] Two Cheers for Biogen's Court Victory
BIIB,BIIB:UW,BBG000C18861,Biogen wins ruling in Tecfidera IP case; shares rise,2017-03-21 16:26:12 +0000,http://finance.yahoo.com/news/biogen-wins-ruling-tecfidera-ip-162612781.html,Biogen wins ruling in Tecfidera IP case; shares rise
BIIB,BIIB:UW,BBG000C18861,Biogen prevails in dispute over key Tecfidera patent,2017-03-21 15:45:08 +0000,http://www.bizjournals.com/boston/news/2017/03/21/biogen-prevails-in-dispute-over-key-tecfidera.html?ana=yahoo,Biogen prevails in dispute over key Tecfidera patent
BIIB,BIIB:UW,BBG000C18861,3 Biotech Stocks That Are Broker Favorites,2017-03-21 15:11:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nu2Z5LqTpbM/3-biotech-stocks-that-are-broker-favorites-cm763530,Biotech stocks which have been showing signs of recovery this year slipped last week following the release of the Budget Blueprint for 2018 Amgen s AMGN data on its PCSK9 inhibitor Repatha and a couple of analyst downgrades for Biogen BIIB Budget Calls for Higher Fees Even
BIIB,BIIB:UW,BBG000C18861,3 Biotech Stocks That Are Broker Favorites,2017-03-21 13:25:01 +0000,http://finance.yahoo.com/news/3-biotech-stocks-broker-favorites-132501079.html,3 Biotech Stocks That Are Broker Favorites
BIIB,BIIB:UW,BBG000C18861,"Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics",2017-03-21 13:07:00 +0000,https://www.fool.com/investing/2017/03/21/better-buy-ionis-pharmaceuticals-inc-vs-juno-thera.aspx,"Better Buy: Ionis Pharmaceuticals, Inc. vs. Juno Therapeutics"
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : March 21, 2017",2017-03-21 12:17:16 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-biib-us-march-21-2017/,"Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : March 21, 2017"
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. (BIIB) Has Suddenly Spiked To The Upside,2017-03-21 10:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-tXKPzAIfyk/biogen-inc-biib-has-suddenly-spiked-to-the-upside-20170321-00760,Biogen Inc. (BIIB) Has Suddenly Spiked To The Upside
BIIB,BIIB:UW,BBG000C18861,European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details,2017-03-20 08:24:00 +0000,https://www.thestreet.com/story/14050566/1/european-stocks-drift-lower-deutsche-bank-falls-on-rights-issue-details.html?puc=yahoo&cm_ven=YAHOO,European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details
BIIB,BIIB:UW,BBG000C18861,European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade,2017-03-20 07:00:00 +0000,https://www.thestreet.com/story/14050477/1/european-stocks-set-for-mixed-open-dollar-slumps-in-quiet-asia-trade.html?puc=yahoo&cm_ven=YAHOO,European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
BIIB,BIIB:UW,BBG000C18861,Alkermes Starts Phase III Study to Treat Multiple Sclerosis,2017-03-18 00:05:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c525OZEiOp4/alkermes-starts-phase-iii-study-to-treat-multiple-sclerosis-cm762484,Alkermes plc ALKS announced the initiation of a new phase III study of pipeline candidate ALKS 8700 ALKS 8700 is a monomethyl fumarate MMF prodrug which is being developed for the treatment of multiple sclerosis The trial is a randomized five week head to head phase III study which
BIIB,BIIB:UW,BBG000C18861,Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis,2017-03-17 21:44:00 +0000,https://www.thestreet.com/story/14049515/1/week-in-review-stocks-post-small-gains-after-fed-pulls-trigger-on-third-hike-since-crisis.html?puc=yahoo&cm_ven=YAHOO,Week in Review: Stocks Post Small Gains After Fed Pulls Trigger on Third Hike Since Crisis
BIIB,BIIB:UW,BBG000C18861,AveXis Inc Stock Is Spiking Again Today -- Here's Why,2017-03-17 17:06:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8XeRZwRxVLo/avexis-inc-stock-is-spiking-again-today-heres-why-cm762301,What happened Shares of AveXis Inc NASDAQ AVXS a clinical stage biotech company developing gene therapies are adding to a tremendous run up this year with a 16 8 gain as of 11 30 a m EDT during Friday s session Yesterday afternoon the company included phase 1 trial data
BIIB,BIIB:UW,BBG000C18861,"Stock Market News for March 17, 2017",2017-03-17 16:08:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/soErufQC3hw/stock-market-news-for-march-17-2017-cm762249,Benchmarks finished mostly in the red on Thursday after declines in healthcare and energy stocks outpaced gains in financials sectors Healthcare stocks declined yesterday following President Trump s move to slash the overall budget for medical research and increase regulatory fees
BIIB,BIIB:UW,BBG000C18861,AveXis Inc Stock Is Spiking Again Today -- Here's Why,2017-03-17 15:44:00 +0000,https://www.fool.com/investing/2017/03/17/avexis-inc-stock-is-spiking-again-today-heres-why.aspx,AveXis Inc Stock Is Spiking Again Today -- Here's Why
BIIB,BIIB:UW,BBG000C18861,Get Ready For A Slew of Data As Weekend Nears,2017-03-17 14:29:52 +0000,http://finance.yahoo.com/news/ready-slew-data-weekend-nears-142952478.html,Get Ready For A Slew of Data As Weekend Nears
BIIB,BIIB:UW,BBG000C18861,AveXis Reports Positive Data for SMA Gene Therapy,2017-03-17 14:25:00 +0000,http://www.investopedia.com/news/avexis-sma-gene-drug-reports-positive-data-avxs/?partner=YahooSA,AveXis Reports Positive Data for SMA Gene Therapy
BIIB,BIIB:UW,BBG000C18861,Why Did the Healthcare Sector Fall on March 16?,2017-03-17 11:39:21 +0000,http://marketrealist.com/2017/03/health-care-sector-decline-march-16/?utm_source=yahoo&utm_medium=feed,Why Did the Healthcare Sector Fall on March 16?
BIIB,BIIB:UW,BBG000C18861,"Market Close Report: NASDAQ Composite index closes at 5,900.76 up .71 points",2017-03-16 20:48:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FLMrib__v-g/market-close-report-nasdaq-composite-index-closes-at-590076-up-71-points-cm761911,Thursday s session closes with the NASDAQ Composite Index at 5 900 76 The total shares traded for the NASDAQ was over 1 85 billion Thursday s session closes with the NASDAQ Composite Index at 5 900 76 The total shares traded for the NASDAQ was over 1 85 billion Advancers stocks led declining
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Wall St slips with healthcare stocks, Nasdaq flat",2017-03-16 20:24:45 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-slips-202445387.html,"US STOCKS-Wall St slips with healthcare stocks, Nasdaq flat"
BIIB,BIIB:UW,BBG000C18861,The Biggest Loser: Biogen Tumbles 4.7%,2017-03-16 20:24:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/16/the-biggest-loser-biogen-tumbles-4-7/?mod=yahoobarrons&ru=yahoo,The Biggest Loser: Biogen Tumbles 4.7%
BIIB,BIIB:UW,BBG000C18861,"Thursday Sector Laggards: Healthcare, Utilities",2017-03-16 20:05:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mylO90T1BO8/thursday-sector-laggards-healthcare-utilities-cm761869,Looking at the sectors faring worst as of midday Thursday shares of Healthcare companies are underperforming other sectors showing a 1 2 loss Within that group Biogen Inc Symbol BIIB and Illumina Inc Symbol ILMN are two of the day s laggards showing a loss of 4 8 and 4
BIIB,BIIB:UW,BBG000C18861,"Biogen Dives As Takeover Buzz Fades, Drugs Hit Snags",2017-03-16 20:05:48 +0000,http://www.investors.com/news/technology/top-biotech-slumps-on-low-ma-interest-as-generics-horn-in-on-key-drug/?src=A00220A,"Biogen Dives As Takeover Buzz Fades, Drugs Hit Snags"
BIIB,BIIB:UW,BBG000C18861,"Stock market pares post-Fed bounce as health care, utilities slump",2017-03-16 19:12:27 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=453C1BCA-0A28-11E7-8AF9-BD2AEA951EA6&siteid=yhoof2,"Stock market pares post-Fed bounce as health care, utilities slump"
BIIB,BIIB:UW,BBG000C18861,Biogen Inc (BIIB): Profit From the BIIB Stock Bears,2017-03-16 19:07:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zOZiOhal7JE/biogen-inc-biib-profit-from-the-biib-stock-bears-cm761877,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB stock much like the rest of the biotech and healthcare industry has had a tumultuous few months First Hillary Clinton used biotechs as political scapegoats and now President Donald Trump
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Thursday Option Activity: MPC, BIIB, HUM",2017-03-16 19:06:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ec88N0xibgM/noteworthy-thursday-option-activity-mpc-biib-hum-cm761842,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Marathon Petroleum Corp Symbol MPC where a total volume of 35 867 contracts has been traded thus far today a contract volume which is representative of approximately 3
BIIB,BIIB:UW,BBG000C18861,"Thursday's ETF Movers: ITB, BBH",2017-03-16 19:06:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hUmCUK_6MfM/thursdays-etf-movers-itb-bbh-cm761838,In trading on Thursday the iShares U S Home Construction ETF ITB is outperforming other ETFs up about 2 1 on the day Components of that ETF showing particular strength include shares of Hovnanian Enterprises HOV up about 7 1 and shares of Meritage Homes MTH up about 5 3
BIIB,BIIB:UW,BBG000C18861,"Biogen, LendingClub, IBM, and More: Here’s What Analysts Had to Say About These Five Stocks",2017-03-16 18:32:15 +0000,http://www.insidermonkey.com/blog/biogen-lendingclub-ibm-and-more-heres-what-analysts-had-to-say-about-these-five-stocks-566913/,"Biogen, LendingClub, IBM, and More: Here’s What Analysts Had to Say About These Five Stocks"
BIIB,BIIB:UW,BBG000C18861,Mid-Day Market Update: U.S. Stocks Turn Negative; GoPro Shares Spike Higher,2017-03-16 17:35:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7LWryMBBDSI/mid-day-market-update-us-stocks-turn-negative-gopro-shares-spike-higher-cm761818,Midway through trading Thursday the Dow traded down 0 20 percent to 20 907 94 while the NASDAQ declined 0 18 percent to 5 889 52 The S amp P also fell dropping 0 29 percent to 2 378 39 Leading and Lagging Sectors Telecommunications services shares climbed 0 58 percent in
BIIB,BIIB:UW,BBG000C18861,BIIB Crosses Below Key Moving Average Level,2017-03-16 17:06:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lZ_1BHqO8y4/biib-crosses-below-key-moving-average-level-cm761756,In trading on Thursday shares of Biogen Inc Symbol BIIB crossed below their 200 day moving average of 288 14 changing hands as low as 277 32 per share Biogen Inc shares are currently trading off about 5 1 on the day The chart below shows the one year performance of BIIB shares versus
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Wall St edges down as healthcare stocks hit by budget plan,2017-03-16 16:58:56 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-edges-165856957.html,US STOCKS-Wall St edges down as healthcare stocks hit by budget plan
BIIB,BIIB:UW,BBG000C18861,"Biogen stock drops 5.5% after downgrades at Morgan Stanley, Leerink",2017-03-16 16:08:11 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=E9F257C5-BD30-4B27-8178-6201099A0350&siteid=yhoof2,"Biogen stock drops 5.5% after downgrades at Morgan Stanley, Leerink"
BIIB,BIIB:UW,BBG000C18861,"S&P 500 Movers: BIIB, ORCL",2017-03-16 16:08:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nsa332Si2sw/sp-500-movers-biib-orcl-cm761681,In early trading on Thursday shares of Oracle ORCL topped the list of the day s best performing components of the S amp P 500 index trading up 8 4 Year to date Oracle registers a 21 4 gain And the worst performing S amp P 500 component thus far on the day is Biogen
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: BIIB, QVCA",2017-03-16 16:07:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/851RTLzGmTE/nasdaq-100-movers-biib-qvca-cm761679,In early trading on Thursday shares of Liberty Interactive Corp QVCA topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 6 Year to date Liberty Interactive Corp registers a 1 9 gain And the worst performing Nasdaq 100 component thus far
BIIB,BIIB:UW,BBG000C18861,"Noteworthy ETF Outflows: IBB, BIIB, REGN, INCY",2017-03-16 16:06:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sOzP9EyINyQ/noteworthy-etf-outflows-ibb-biib-regn-incy-cm761661,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Nasdaq Biotechnology ETF Symbol IBB where we have detected an approximate 45 1 million dollar outflow that s a 0 5 decrease week over week
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Wall St slightly lower as healthcare stocks weigh,2017-03-16 15:32:03 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-slightly-153203038.html,US STOCKS-Wall St slightly lower as healthcare stocks weigh
BIIB,BIIB:UW,BBG000C18861,Biogen: Double Trouble?,2017-03-16 15:25:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/16/biogen-double-trouble/?mod=yahoobarrons&ru=yahoo,Biogen: Double Trouble?
BIIB,BIIB:UW,BBG000C18861,Biogen's Catalysts May Be Waning; Leerink Downgrades To Market Perform,2017-03-16 14:41:02 +0000,http://finance.yahoo.com/news/biogens-catalysts-may-waning-leerink-144102378.html,Biogen's Catalysts May Be Waning; Leerink Downgrades To Market Perform
BIIB,BIIB:UW,BBG000C18861,Biogen shares drop after Morgan Stanley downgrade; rest of biotech also dragged lower,2017-03-16 14:06:28 +0000,http://www.cnbc.com/id/104345971?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104345971,Biogen shares drop after Morgan Stanley downgrade; rest of biotech also dragged lower
BIIB,BIIB:UW,BBG000C18861,"Morgan Stanley Takes A Breather On Biogen, Downgrades Stock",2017-03-16 13:32:02 +0000,http://finance.yahoo.com/news/morgan-stanley-takes-breather-biogen-133202383.html,"Morgan Stanley Takes A Breather On Biogen, Downgrades Stock"
BIIB,BIIB:UW,BBG000C18861,"Analysts' Actions -- Liberty Global, RPM International, TJX, Biogen and More",2017-03-16 13:15:00 +0000,http://finance.yahoo.com/news/analysts-actions-liberty-global-rpm-131500914.html,"Analysts' Actions -- Liberty Global, RPM International, TJX, Biogen and More"
BIIB,BIIB:UW,BBG000C18861,"Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development",2017-03-16 11:00:00 +0000,http://finance.yahoo.com/news/biogen-appoints-anirvan-ghosh-senior-110000747.html,"[Business Wire] - Biogen today announced the appointment of Anirvan Ghosh, Ph.D., as senior vice president, Research and Early Development . Dr. Ghosh will lead Biogen’s RED organization in the discovery and development of drug candidates from idea through proof of concept."
BIIB,BIIB:UW,BBG000C18861,Biogen downgraded by Morgan Stanley and Leerink Partners,2017-03-16 10:48:22 +0000,http://finance.yahoo.com/q/ud?s=BIIB,Biogen downgraded by Morgan Stanley and Leerink Partners
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. (BIIB) Is Losing Ground Following Downgrade,2017-03-16 09:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jC-gbw0jsOk/biogen-inc-biib-is-losing-ground-following-downgrade-20170316-00670,Biogen Inc. (BIIB) Is Losing Ground Following Downgrade
BIIB,BIIB:UW,BBG000C18861,"Biogen Spinoff Downgraded On Mounting Roche, Shire Rivalry",2017-03-13 20:39:05 +0000,http://www.investors.com/news/technology/biogen-spinoff-downgraded-on-mounting-roche-shire-rivalry-stock-dips/?src=A00220A,"Biogen Spinoff Downgraded On Mounting Roche, Shire Rivalry"
BIIB,BIIB:UW,BBG000C18861,Biotech stocks are turning bullish—here's how to profit,2017-03-13 18:08:34 +0000,http://finance.yahoo.com/news/biotech-stocks-are-turning-bullish-heres-how-to-profit-190834183.html,Biotech stocks are turning bullish—here's how to profit
BIIB,BIIB:UW,BBG000C18861,Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears,2017-03-13 16:51:00 +0000,https://www.thestreet.com/story/14040641/1/neurotrope-shares-soar-as-alzheimer-s-drug-trial-lottery-ticket-call-nears.html?puc=yahoo&cm_ven=YAHOO,Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears
BIIB,BIIB:UW,BBG000C18861,"Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise",2017-03-13 16:10:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/boqI3w0tzrY/acordas-four-ampyra-patents-upheld-by-ptab-shares-rise-cm760019,Acorda Therapeutics Inc s ACOR shares gained almost 7 after the U S Patent and Trademark Office USPTO Patent Trials and Appeal Board PTAB upheld four patents of its key growth driver Ampyra Acorda holds five Orange Book listed patents for Ampyra that run until 2027 The
BIIB,BIIB:UW,BBG000C18861,"Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise",2017-03-13 13:40:01 +0000,http://finance.yahoo.com/news/acordas-four-ampyra-patents-upheld-134001478.html,"Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise"
BIIB,BIIB:UW,BBG000C18861,"Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2017",2017-03-13 13:20:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ReeyHp4WskA/gilead-sciences-inc-gild-ex-dividend-date-scheduled-for-march-14-2017-cm759840,Gilead Sciences Inc GILD will begin trading ex dividend on March 14 2017 A cash dividend payment of 0 52 per share is scheduled to be paid on March 30 2017 Shareholders who purchased GILD prior to the ex dividend date are eligible for the cash dividend payment This represents an 10
BIIB,BIIB:UW,BBG000C18861,AbbVie Stock Upgraded: What You Need to Know,2017-03-11 00:17:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UR2egSnJxIo/abbvie-stock-upgraded-what-you-need-to-know-cm759527,Every day Wall Street analysts upgrade some stocks downgrade others and initiate coverage on a few more But do these analysts even know what they re talking about Today we re taking one high profile Wall Street pick and putting it under the microscope
BIIB,BIIB:UW,BBG000C18861,AbbVie Stock Upgraded: What You Need to Know,2017-03-10 18:12:33 +0000,http://www.fool.com/investing/2017/03/10/abbvie-stock-upgraded-what-you-need-to-know.aspx,AbbVie Stock Upgraded: What You Need to Know
BIIB,BIIB:UW,BBG000C18861,Biogen Spinoff Takes Flight With Focus On Hemophilia Drugs,2017-03-10 15:13:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cP0HQw4Jkwo/biogen-spinoff-takes-flight-with-focus-on-hemophilia-drugs-cm759185,Bioverativ BIVV is not your standard biotech startup For one the drug developer is profitable It also holds a wad of cash with no debt And the maker of treatments for blood disorders is looking 160 at the prospect of 1 billion in sales this year Not bad for a
BIIB,BIIB:UW,BBG000C18861,Biogen Spinoff Takes Flight With Focus On Hemophilia Drugs,2017-03-10 13:00:33 +0000,http://www.investors.com/research/the-new-america/biogen-spinoff-takes-flight-with-focus-on-drugs-for-hemophilia/?src=A00220A,Biogen Spinoff Takes Flight With Focus On Hemophilia Drugs
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharmaceuticals Rallied 12% in February,2017-03-09 23:14:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fX9j-7eUk4o/why-ionis-pharmaceuticals-rallied-12-in-february-cm758894,What happened After reporting better than expected results in the fourth quarter and providing investors with an update on its R amp D progress 160 shares in Ionis Pharmaceuticals NASDAQ IONS increased more than 12 last month 160 according to S amp P Global
BIIB,BIIB:UW,BBG000C18861,3 Biotech Stocks to Buy Now…and 1 to Dump ASAP,2017-03-09 17:38:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/09/3-biotech-stocks-to-buy-now-and-1-to-dump-asap/?mod=yahoobarrons&ru=yahoo,3 Biotech Stocks to Buy Now…and 1 to Dump ASAP
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. :BIIB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 8, 2017",2017-03-08 17:10:12 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-biib-us-earnings-analysis-q4-2016-by-the-numbers-march-8-2017/,"Biogen, Inc. :BIIB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 8, 2017"
BIIB,BIIB:UW,BBG000C18861,Pharma says high prices fund drug development. This study says otherwise,2017-03-08 16:08:50 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=547D1EB2-040C-11E7-B423-D9A672D73401&siteid=yhoof2,Pharma says high prices fund drug development. This study says otherwise
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal",2017-03-08 15:17:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XBWuHu8s6qM/biotech-stock-roundup-trump-tweet-hits-biotech-stocks-concert-gains-on-vertex-deal-cm757792,Once again a tweet kept the biotech industry on edge with President Donald Trump declaring that he is working on a new system where there will be competition in the Drug Industry and pricing for the American people will come way down The tweet triggered a 1 6 decline in the
BIIB,BIIB:UW,BBG000C18861,​Biogen loses another top executive as tech guru departs,2017-03-08 14:40:11 +0000,http://www.bizjournals.com/boston/news/2017/03/08/biogen-loses-another-top-executive-as-tech-guru.html?ana=yahoo,​Biogen loses another top executive as tech guru departs
BIIB,BIIB:UW,BBG000C18861,5 Things Biogen's CEO Just Said That You Don't Want to Miss,2017-03-07 23:14:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pa4DV7hwBJ0/5-things-biogens-ceo-just-said-that-you-dont-want-to-miss-cm757608,Despite headwinds for its multiple sclerosis MS franchise Biogen NASDAQ BIIB has been on a roll lately The biotech won U S regulatory approval for spinal muscular atrophy SMA drug Spinraza in December It also spun off its hemophilia business into a new company
BIIB,BIIB:UW,BBG000C18861,Biogen Tech EVP Andi Karaboutis Leaves Company,2017-03-07 21:40:59 +0000,http://blogs.wsj.com/cio/2017/03/07/biogen-tech-evp-andi-karaboutis-leaves-company/?mod=yahoo_hs,Biogen Tech EVP Andi Karaboutis Leaves Company
BIIB,BIIB:UW,BBG000C18861,5 Things Biogen's CEO Just Said That You Don't Want to Miss,2017-03-07 21:22:00 +0000,http://www.fool.com/investing/2017/03/07/5-things-biogens-ceo-just-said-that-you-dont-want.aspx,5 Things Biogen's CEO Just Said That You Don't Want to Miss
BIIB,BIIB:UW,BBG000C18861,"Notable ETF Inflow Detected - IYH, GILD, AGN, BIIB",2017-03-07 18:13:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tqBCjGfqaII/notable-etf-inflow-detected-iyh-gild-agn-biib-cm757346,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares U S Healthcare ETF Symbol IYH where we have detected an approximate 71 2 million dollar inflow that s a 3 9 increase week over week in
BIIB,BIIB:UW,BBG000C18861,Repros (RPRX) Q4 Earnings: What's in Store for the Stock?,2017-03-07 17:15:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cDlpJrfqGJ8/repros-rprx-q4-earnings-whats-in-store-for-the-stock-cm757305,Repros Therapeutics Inc RPRX is expected to report fourth quarter 2016 results this month Let s see how things are shaping up for this quarter Repros Therapeutics share price decreased 8 3 year to date while the Zacks classified Medical Biomed Genetics industry gained 10
BIIB,BIIB:UW,BBG000C18861,Is This the Right Time to Invest in Biotech Stocks?,2017-03-07 14:16:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XB4ddS57gBw/is-this-the-right-time-to-invest-in-biotech-stocks-cm757033,The biotech industry was once a Wall Street favorite chalking up impressive gains until 2015 when the drug pricing issue started weighing on the sector However a look at the industry s year to date YTD price performance indicates that the sector is showing signs of recovery But will the
BIIB,BIIB:UW,BBG000C18861,"Jeff Auxier Invests in Gilead, Wells Fargo, Apple",2017-03-06 19:35:20 +0000,http://finance.yahoo.com/news/jeff-auxier-invests-gilead-wells-193520954.html,"Jeff Auxier Invests in Gilead, Wells Fargo, Apple"
BIIB,BIIB:UW,BBG000C18861,Weekly CEO Buys Highlights,2017-03-06 18:18:14 +0000,http://finance.yahoo.com/news/weekly-ceo-buys-highlights-181814634.html,Weekly CEO Buys Highlights
BIIB,BIIB:UW,BBG000C18861,BioDelivery (BDSI): What's in Store this Earnings Season?,2017-03-06 16:17:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fR0k5t-5pr8/biodelivery-bdsi-whats-in-store-this-earnings-season-cm756577,BioDelivery Sciences International Inc BDSI is expected to report fourth quarter 2016 results on Mar 17 before the opening bell Last quarter the company s loss was wider than expected Year to date BioDelivery s shares have outperformed the Zacks classified Medical Biomed
BIIB,BIIB:UW,BBG000C18861,Inovio (INO): What's in the Cards this Earnings Season?,2017-03-06 16:16:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OPBwHIeYKBs/inovio-ino-whats-in-the-cards-this-earnings-season-cm756569,Inovio Pharmaceuticals Inc INO is expected to report fourth quarter 2016 results this month The company incurred wider than expected loss in the last quarter In the last one year Inovio s shares have underperformed the Zacks classified Medical Biomed Genetics industry Specifically
BIIB,BIIB:UW,BBG000C18861,4 Things Alkermes Wants Investors to Know,2017-03-06 16:16:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AmsJZ_R72R0/4-things-alkermes-wants-investors-to-know-cm756593,In reporting results for the final quarter of 2016 the management of mid cap biotech Alkermes plc NASDAQ ALKS made its case that 2017 will bring plenty of good news to investors With accelerating sales and several drugs in the pipeline approaching commercial status Alkermes
BIIB,BIIB:UW,BBG000C18861,Inovio (INO): What's in the Cards this Earnings Season?,2017-03-06 14:28:02 +0000,http://finance.yahoo.com/news/inovio-ino-whats-cards-earnings-142802531.html,Inovio (INO): What's in the Cards this Earnings Season?
BIIB,BIIB:UW,BBG000C18861,4 Things Alkermes Wants Investors to Know,2017-03-06 14:21:00 +0000,http://www.fool.com/investing/2017/03/06/4-things-alkermes-wants-investors-to-know.aspx,4 Things Alkermes Wants Investors to Know
BIIB,BIIB:UW,BBG000C18861,Biogen To Present At Cowen & Co. Conference; Webcast At 3:20 PM ET,2017-03-06 14:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w3Op6z8JCTo/biogen-to-present-at-cowen--co-conference-webcast-at-320-pm-et-20170306-01048,Biogen To Present At Cowen & Co. Conference; Webcast At 3:20 PM ET
BIIB,BIIB:UW,BBG000C18861,Israel's BrainStorm names Biogen senior executive Kern as COO,2017-03-06 07:16:56 +0000,http://finance.yahoo.com/news/israels-brainstorm-names-biogen-senior-071656220.html,"[Reuters] - Israel's BrainStorm Cell Therapeutics, which is developing an adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), on Monday named Ralph Kern as chief operating officer. Kern, who has also been named chief medical officer, joins BrainStorm from Biogen, where he was senior vice president and head of worldwide medical."
BIIB,BIIB:UW,BBG000C18861,Icahn's (Potential) Move Into Biotech,2017-03-05 00:25:01 +0000,http://finance.yahoo.com/news/icahns-potential-move-biotech-002501246.html,Icahn's (Potential) Move Into Biotech
BIIB,BIIB:UW,BBG000C18861,New Features: Individual Portfolio Tracker and Value Screens Tracker,2017-03-04 18:12:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jgztGRoQRDo/new-features-individual-portfolio-tracker-and-value-screens-tracker-cm756319,As discussed in a previous article GuruFocus launched a new user friendly home page in February The page contains two useful features Individual Portfolio Tracker and the Value Screens Tracker The former allows you to view snapshots of each of your portfolios and view alerts If
BIIB,BIIB:UW,BBG000C18861,Why Celgene's Shares Rallied Higher in February,2017-03-02 22:13:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LnZAZJvqy-U/why-celgenes-shares-rallied-higher-in-february-cm755653,What happened After reporting fourth quarter financials in late January and announcing positive phase 3 trial results for its promising multiple sclerosis drug in February shares in Celgene Corp NASDAQ CELG 160 climbed more than 5 last month according to S amp P
BIIB,BIIB:UW,BBG000C18861,Drug Companies Block Shareholder Votes on Price Transparency Proposals,2017-03-02 05:37:30 +0000,https://www.wsj.com/articles/drug-companies-block-shareholder-votes-on-price-transparency-proposals-1488406027?ru=yahoo?mod=yahoo_itp,Drug Companies Block Shareholder Votes on Price Transparency Proposals
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money,2017-03-01 22:13:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hKIxpY9yD84/ionis-pharmaceuticals-inc-turns-a-profit-with-other-drugmakers-money-cm755063,Ionis Pharmaceuticals NASDAQ IONS reported fourth quarter earnings on Tuesday The biotech has two drugs on the market but given Kynamro s low sales and the fact that spinal muscular atrophy drug Spinraza only launched in late December most of the revenue came from partners who
BIIB,BIIB:UW,BBG000C18861,[$$] Drug Companies Block Shareholders' Voting on Price Transparency,2017-03-01 22:07:10 +0000,https://www.wsj.com/articles/drug-companies-block-shareholder-votes-on-price-transparency-proposals-1488406027?mod=yahoo_hs,[$$] Drug Companies Block Shareholders' Voting on Price Transparency
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money,2017-03-01 20:56:00 +0000,http://www.fool.com/investing/2017/03/01/ionis-pharmaceuticals-inc-turns-a-profit-with-othe.aspx,Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money
BIIB,BIIB:UW,BBG000C18861,Investors have stopped believing Trump’s drug price threats,2017-03-01 18:24:04 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=523C5BAE-FD22-11E6-AA05-2D5F757E4B72&siteid=yhoof2,Investors have stopped believing Trump’s drug price threats
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: AT&T, Visa, Biogen, Tesla and PG&E",2017-03-01 17:15:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BFexvKs4OI8/the-zacks-analyst-blog-highlights-att-visa-biogen-tesla-and-pge-cm754915,For Immediate Release Chicago IL March 01 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BIIB,BIIB:UW,BBG000C18861,Regeneron Could See a Modest Rise in Net Profit Margins in 2017,2017-03-01 15:37:18 +0000,http://marketrealist.com/2017/02/regeneron-expected-witness-modest-rise-net-profit-margins-2017/?utm_source=yahoo&utm_medium=feed,Regeneron Could See a Modest Rise in Net Profit Margins in 2017
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: AT&T, Visa, Biogen, Tesla and PG&E",2017-03-01 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-t-143002903.html,"The Zacks Analyst Blog Highlights: AT&T, Visa, Biogen, Tesla and PG&E"
BIIB,BIIB:UW,BBG000C18861,"[$$] Gormley's Take: With Biotech Talent In Demand, CEO Takes Helm at Two Companies",2017-03-01 12:30:05 +0000,https://www.wsj.com/articles/gormleys-take-ceo-runs-two-startups-at-once-1488371402?mod=yahoo_hs,"[$$] Gormley's Take: With Biotech Talent In Demand, CEO Takes Helm at Two Companies"
BIIB,BIIB:UW,BBG000C18861,Biogen to Present at the Cowen & Company 37th Annual Health Care Conference,2017-02-28 21:01:00 +0000,http://finance.yahoo.com/news/biogen-present-cowen-company-37th-210100392.html,"[Business Wire] - Biogen Inc. announced today that it will present at the Cowen & Company 37th Annual Health Care Conference. The webcast will be live on Monday, March 6, 2017 at 3:20 p.m."
BIIB,BIIB:UW,BBG000C18861,Get in Biogen Inc (BIIB) Stock Before It Breaks Out,2017-02-28 19:50:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HutAHy2XZuQ/get-in-biogen-inc-biib-stock-before-it-breaks-out-cm754440,InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB has had its down moments in 2015 Then in 2016 the whole industry took a beating from then Presidential Nominee Clinton Now President Trump has the baton and continues to promise that
BIIB,BIIB:UW,BBG000C18861,"​At rare disease panel, ex-FDA new drug head preaches evidence over empathy",2017-02-28 19:10:08 +0000,http://www.bizjournals.com/boston/news/2017/02/28/at-rare-disease-panel-ex-fda-new-drug-head.html?ana=yahoo,"​At rare disease panel, ex-FDA new drug head preaches evidence over empathy"
BIIB,BIIB:UW,BBG000C18861,Roche Attempts New Trial for Alzheimer's,2017-02-28 17:12:00 +0000,http://www.investopedia.com/news/roche-attempts-new-trial-alzheimers-rhhby/?partner=YahooSA,Roche Attempts New Trial for Alzheimer's
BIIB,BIIB:UW,BBG000C18861,Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View,2017-02-28 16:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_KYVEAe9-6Y/perrigo-to-sell-tysabri-royalties-issues-tepid-2017-view-cm754244,Perrigo Company Plc PRGO recently reported preliminary numbers for 2016 and issued a lackluster guidance for 2017 The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug Tysabri in order to monetize the asset The company
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for February 28, 2017",2017-02-28 16:40:04 +0000,http://finance.yahoo.com/news/top-research-reports-february-28-164004573.html,"Top Research Reports for February 28, 2017"
BIIB,BIIB:UW,BBG000C18861,"Accera's Alzheimer's trial fails, in yet another setback for disease",2017-02-28 13:30:00 +0000,http://finance.yahoo.com/news/acceras-alzheimers-trial-fails-yet-133000260.html,"[Reuters] - Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting disease. Accera's AC-1204 failed to induce a statistically significant improvement in symptoms versus a placebo in patients with a mild-to-moderate form of the disease, the company said. The announcement comes weeks after Merck & Co Inc said it would halt a late-stage trial of its Alzheimer's drug, verubecestat, after determining that it had no chance of working."
BIIB,BIIB:UW,BBG000C18861,Understanding Alexion’s Profit Margin Trend in 2017,2017-02-28 12:37:55 +0000,http://marketrealist.com/2017/02/alexion-pharmaceuticals-expected-witness-rise-profit-margins-2017/?utm_source=yahoo&utm_medium=feed,Understanding Alexion’s Profit Margin Trend in 2017
BIIB,BIIB:UW,BBG000C18861,"After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B",2017-02-28 02:22:00 +0000,https://www.thestreet.com/story/14017968/1/after-starboard-agitation-perrigo-sells-ms-drug-royalties-for-up-to-2-85b.html?puc=yahoo&cm_ven=YAHOO,"After Starboard Agitation, Perrigo Sells MS Drug Royalties for Up to $2.85B"
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Gilead Sciences Inc.,2017-02-27 18:21:18 +0000,http://www.fool.com/investing/2017/02/27/better-buy-biogen-inc-vs-gilead-sciences.aspx,Better Buy: Biogen Inc. vs. Gilead Sciences Inc.
BIIB,BIIB:UW,BBG000C18861,"QUAL, KMB, PEG, BIIB: ETF Inflow Alert",2017-02-27 17:49:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b0A_Fm53K_c/qual-kmb-peg-biib-etf-inflow-alert-cm753664,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Edge MSCI USA Quality Factor ETF Symbol QUAL where we have detected an approximate 117 3 million dollar inflow that s a 3 4 increase week over week
BIIB,BIIB:UW,BBG000C18861,Perrigo To Divest Its Rights To Royalty Stream From Tysabri To Royalty Pharma,2017-02-27 16:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OyEh_6ex678/perrigo-to-divest-its-rights-to-royalty-stream-from-tysabri-to-royalty-pharma-20170227-01522,Perrigo To Divest Its Rights To Royalty Stream From Tysabri To Royalty Pharma
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Gilead Sciences Inc.,2017-02-27 14:52:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RA6okPf6x1s/better-buy-biogen-inc-vs-gilead-sciences-inc-cm753424,Biogen NASDAQ BIIB and Gilead Sciences NASDAQ GILD don t compete against each other at least not yet Both biotechs are interested in the oncology and autoimmune disease therapeutic areas so there s always a chance they could become rivals The two stocks do
BIIB,BIIB:UW,BBG000C18861,"Biogen alums team up to launch Waltham biotech, with backing from Henri Termeer",2017-02-27 12:15:08 +0000,http://www.bizjournals.com/boston/news/2017/02/27/biogen-alums-team-up-to-launch-waltham-biotech.html?ana=yahoo,"Biogen alums team up to launch Waltham biotech, with backing from Henri Termeer"
BIIB,BIIB:UW,BBG000C18861,Ring the Register With These Upcoming Spinoffs,2017-02-24 12:35:00 +0000,https://www.thestreet.com/story/14001112/1/ring-the-register-with-these-upcoming-spinoffs.html?puc=yahoo&cm_ven=YAHOO,Ring the Register With These Upcoming Spinoffs
BIIB,BIIB:UW,BBG000C18861,Teva Is Expected to See a Fall in Its Profit Margins in 2017,2017-02-23 22:06:29 +0000,http://marketrealist.com/2017/02/teva-pharmaceutical-expected-witness-drop-profit-margins-2017/?utm_source=yahoo&utm_medium=feed,Teva Is Expected to See a Fall in Its Profit Margins in 2017
BIIB,BIIB:UW,BBG000C18861,"Andreas Halvorsen Buys Maker of First-in-Class Cancer Treatments, Calithera Biosciences",2017-02-23 18:49:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E8Pl3fl32Tg/andreas-halvorsen-buys-maker-of-first-in-class-cancer-treatments-calithera-biosciences-cm752251,Andreas Halvorsen Trades Portfolio CALA INCY KITE TSRO BIIB Andreas Halvorsen Premium Members This article first appeared on GuruFocus This article first appeared
BIIB,BIIB:UW,BBG000C18861,Here's Why Celgene's Latest Drug Is So Exciting,2017-02-23 14:52:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xwj1XiTO7bc/heres-why-celgenes-latest-drug-is-so-exciting-cm751796,Celgene NASDAQ CELG recently reported that its multiple sclerosis drug ozanimod successfully met its endpoints in reducing multiple sclerosis MS relapses and assuming a second trial pans out similarly that s got the biotech targeting a filing for FDA approval by the end of
BIIB,BIIB:UW,BBG000C18861,Here's Why Celgene's Latest Drug Is So Exciting,2017-02-23 13:02:10 +0000,http://www.fool.com/investing/2017/02/23/heres-why-celgenes-latest-drug-is-so-exciting.aspx,Here's Why Celgene's Latest Drug Is So Exciting
BIIB,BIIB:UW,BBG000C18861,Did Biogen Inc. Shoot Itself in the Foot?,2017-02-22 14:15:19 +0000,http://www.fool.com/investing/2017/02/21/did-biogen-inc-shoot-itself-in-the-foot.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Did Biogen Inc. Shoot Itself in the Foot?
BIIB,BIIB:UW,BBG000C18861,Biogen To Present At RBC Capital Markets Conference ; Webcast At 3:05 PM ET,2017-02-22 14:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TAG9MJOpdPc/biogen-to-present-at-rbc-capital-markets-conference--webcast-at-305-pm-et-20170222-01191,Biogen To Present At RBC Capital Markets Conference ; Webcast At 3:05 PM ET
BIIB,BIIB:UW,BBG000C18861,Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?,2017-02-22 01:06:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OLMZz2LbYGI/ionis-ions-q4-earnings-whats-in-the-cards-for-the-stock-cm750955,Ionis Pharmaceuticals Inc IONS is scheduled to report fourth quarter 2016 results on Feb 28 Last quarter the company recorded a negative earnings surprise of 14 29 Let s see how things are shaping up for this announcement Ionis share price decreased 1 9 year to date compared with
BIIB,BIIB:UW,BBG000C18861,​Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A,2017-02-21 20:40:11 +0000,http://www.bizjournals.com/boston/news/2017/02/21/top-pharma-lobbyist-casts-biogen-as-the-anti.html?ana=yahoo,​Top pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A
BIIB,BIIB:UW,BBG000C18861,Did Biogen Inc. Shoot Itself in the Foot?,2017-02-21 15:54:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rb-dRBNnWFA/did-biogen-inc-shoot-itself-in-the-foot-cm750471,How would you feel about shelling out 750 000 for a year of treatment for a life threatening disease Well you re not alone Spinraza the second drug to earn FDA approval from Ionis Pharmaceuticals NASDAQ IONS is a potential life saver but the enormous list price set by
BIIB,BIIB:UW,BBG000C18861,Celgene MS Drug Reports Positive Phase 3 Data,2017-02-20 15:30:00 +0000,http://www.investopedia.com/news/celgene-ms-drug-reports-positive-phase-3-data-celg/?partner=YahooSA,Celgene MS Drug Reports Positive Phase 3 Data
BIIB,BIIB:UW,BBG000C18861,3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter,2017-02-20 14:54:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mBuvdy6qDvo/3-top-drug-stocks-that-can-be-purchased-on-the-cheap-this-winter-cm750193,Drug stocks have been a volatile group since the beginning of 2016 with many selling off and still more than a year later struggling to recover what they lost Meanwhile the broad based S amp P 500 has moved substantially higher It s not hard to understand why investors view
BIIB,BIIB:UW,BBG000C18861,3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter,2017-02-20 13:24:10 +0000,http://www.fool.com/investing/2017/02/20/3-top-drug-stocks-that-can-be-purchased-on-the-che.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter
BIIB,BIIB:UW,BBG000C18861,This Keeps Driving Sanofi’s Growth,2017-02-20 12:37:20 +0000,http://marketrealist.com/2017/02/this-keeps-driving-sanofis-growth/?utm_source=yahoo&utm_medium=feed,This Keeps Driving Sanofi’s Growth
BIIB,BIIB:UW,BBG000C18861,Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment,2017-02-20 12:36:42 +0000,http://finance.yahoo.com/news/nordic-nanovector-sees-interest-non-123642264.html,Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment
BIIB,BIIB:UW,BBG000C18861,Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?,2017-02-19 17:51:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eRsxZf19eeg/could-celgene-have-another-billion-dollar-blockbuster-on-its-hands-cm750114,A new and highly anticipated study by Celgene Corp NASDAQ CELG shows that its promising multiple sclerosis drug could soon reshape the 19 billion multiple sclerosis market On Friday management reported that ozanimod met its primary endpoint for reducing MS relapses better
BIIB,BIIB:UW,BBG000C18861,Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?,2017-02-19 16:41:05 +0000,http://www.fool.com/investing/2017/02/19/could-celgene-have-another-billion-dollar-blockbus.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?
BIIB,BIIB:UW,BBG000C18861,"​Shkreli defends drug prices, spars with protesters at heated UMass Boston event",2017-02-17 02:40:12 +0000,http://www.bizjournals.com/boston/news/2017/02/16/shkreli-defends-drug-prices-spars-with-protesters.html?ana=yahoo,"​Shkreli defends drug prices, spars with protesters at heated UMass Boston event"
BIIB,BIIB:UW,BBG000C18861,Tesaro sees a $5B market opportunity for its cancer drug,2017-02-17 02:37:28 +0000,http://www.bizjournals.com/boston/news/2017/02/16/a-5b-drug-for-a-massachusetts-biotech-tesaro.html?ana=yahoo,Tesaro sees a $5B market opportunity for its cancer drug
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharmaceuticals (IONS) Looks Worth the Risk,2017-02-16 16:28:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MYHsze6laNg/why-ionis-pharmaceuticals-ions-looks-worth-the-risk-cm749018,"The biotech sector is always popular with traders and investors who have a healthy appetite for risk, as the rewards of success in the rapidly developing industry are so huge. Said risk, on the other hand, has always been high, with only a fairly small percentage of therapies with potential actually achieving any"
BIIB,BIIB:UW,BBG000C18861,Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback,2017-02-16 14:27:02 +0000,http://finance.yahoo.com/news/alzheimers-market-suffers-yet-another-142702582.html,Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
BIIB,BIIB:UW,BBG000C18861,Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?,2017-02-16 00:34:18 +0000,http://www.fool.com/investing/2017/02/15/another-potential-alzheimers-disease-treatment-bit.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?
BIIB,BIIB:UW,BBG000C18861,Another Potential Alzheimer's Disease Treatment Bites the Dust: What's Next?,2017-02-15 23:54:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AP8zTqmzHqk/another-potential-alzheimers-disease-treatment-bites-the-dust-whats-next-cm748650,And another one bites the dust Merck NYSE MRK announced on Tuesday that it was halting a phase 2 3 clinical study of 160 verubecestat in treating Alzheimer s disease This news marked the second major clinical failure in recent months by a big drugmaker for a disease that
BIIB,BIIB:UW,BBG000C18861,Biogen to Present at the 2017 RBC Capital Markets Global Healthcare Conference,2017-02-15 22:29:00 +0000,http://finance.yahoo.com/news/biogen-present-2017-rbc-capital-222900547.html,"[Business Wire] - Biogen Inc. announced today that it will present at the 2017 RBC Capital Markets Global Healthcare Conference. The webcast will be live on Wednesday, February 22, 2017 at 3:05 p.m."
BIIB,BIIB:UW,BBG000C18861,"Merck's Alzheimer's Drug Fails; Are Biogen, Roche, AstraZeneca Next?",2017-02-15 21:18:06 +0000,http://www.investors.com/news/technology/mercks-alzheimers-drug-fails-are-biogen-roche-astrazeneca-next/,"Merck's Alzheimer's Drug Fails; Are Biogen, Roche, AstraZeneca Next?"
BIIB,BIIB:UW,BBG000C18861,Merck Halts Late-Stage Alzheimer’s Drug Trial,2017-02-15 15:46:00 +0000,http://www.investopedia.com/news/merck-halts-latestage-alzheimers-trial-mrk/?partner=YahooSA,Merck Halts Late-Stage Alzheimer’s Drug Trial
BIIB,BIIB:UW,BBG000C18861,Bioverativ's hemophilia hopes,2017-02-15 12:18:00 +0000,http://finance.yahoo.com/video/bioveratives-hemophilia-hopes-121800492.html,Bioverativ's hemophilia hopes
BIIB,BIIB:UW,BBG000C18861,Biogen To Present At Leerink Partners Conference; Webcast At 1:00 PM ET,2017-02-15 12:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A9fgpp_1lMQ/biogen-to-present-at-leerink-partners-conference-webcast-at-100-pm-et-20170215-01016,Biogen To Present At Leerink Partners Conference; Webcast At 1:00 PM ET
BIIB,BIIB:UW,BBG000C18861,Another Alzheimer's Drug Study Fails. This Time It's Merck's.,2017-02-15 12:00:00 +0000,http://www.forbes.com/sites/matthewherper/2017/02/15/another-alzheimers-drug-study-fails-is-there-hope/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Another Alzheimer's Drug Study Fails. This Time It's Merck's.
BIIB,BIIB:UW,BBG000C18861,"PRIMECAP Management Buys AstraZeneca PLC, Alkermes PLC, Whirlpool, Sells Union Pacific, ...",2017-02-14 16:17:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G7izrmIteCs/primecap-management-buys-astrazeneca-plc-alkermes-plc-whirlpool-sells-union-pacific-cm747673,PRIMECAP Management New Purchases LGF B LGF A GD CBS SIG MXL TPX DHX A SKX SPLK Added Positions AZN ALKS WHR LLY BMRN NVS KLAC IMAX AAL DAL Reduced Positions AMGN SCHW NVDA MSFT MDT UNP TXN MMC POT XOM Sold Out CPHD
BIIB,BIIB:UW,BBG000C18861,Key Presenters At Leerink's Healthcare Conference,2017-02-13 20:52:10 +0000,http://finance.yahoo.com/news/key-presenters-leerinks-healthcare-conference-205210539.html,Key Presenters At Leerink's Healthcare Conference
BIIB,BIIB:UW,BBG000C18861,Regeneron: It's All Riding On Dupixent,2017-02-13 19:25:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/13/regeneron-its-all-riding-on-dupixent/?mod=yahoobarrons&ru=yahoo,Regeneron: It's All Riding On Dupixent
BIIB,BIIB:UW,BBG000C18861,"BIB, BIIB, REGN, ILMN: Large Outflows Detected at ETF",2017-02-13 17:18:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5OFsfESPEl4/bib-biib-regn-ilmn-large-outflows-detected-at-etf-cm747097,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the ProShares Ultra Nasdaq Biotechnology Symbol BIB where we have detected an approximate 16 0 million dollar outflow that s a 3 8 decrease week over week
BIIB,BIIB:UW,BBG000C18861,Biogen’s Spinraza Faces Insurance Coverage Hurdles,2017-02-13 14:00:00 +0000,http://www.investopedia.com/news/biogens-spinraza-hits-insurance-hurdles-biib/?partner=YahooSA,Biogen’s Spinraza Faces Insurance Coverage Hurdles
BIIB,BIIB:UW,BBG000C18861,A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease,2017-02-12 12:43:11 +0000,http://www.fool.com/investing/2017/02/11/a-potential-20-billion-indication-2-must-have-biot.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease
BIIB,BIIB:UW,BBG000C18861,A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer's Disease,2017-02-11 14:17:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2rxVclc7Gv0/a-potential-20-billion-indication-2-must-have-biotechs-taking-on-alzheimers-disease-cm746666,Alzheimer s disease is a terrible illness which affects an estimated 5 4 million Americans today Alzheimer s is also the 6 th leading cause of death nationally Unfortunately there are currently only two types of FDA approved drugs memantine and cholinesterase inhibitors
BIIB,BIIB:UW,BBG000C18861,Is Biogen a Risky Stock?,2017-02-10 21:14:18 +0000,http://www.fool.com/investing/2017/02/10/is-biogen-a-risky-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Biogen a Risky Stock?
BIIB,BIIB:UW,BBG000C18861,Is Biogen a Risky Stock?,2017-02-10 16:20:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DnPiXoHJ-BU/is-biogen-a-risky-stock-cm746269,Following the spinoff of two of its fastest growing drugs Biogen Inc NASDAQ BIIB is more focused on neurological disease than it s been in years However the company could face a stiff new challenger in multiple sclerosis soon and the best drug in its research pipeline is
BIIB,BIIB:UW,BBG000C18861,Major Biotechs Scare Off Loads of Short Sellers,2017-02-10 14:55:35 +0000,http://finance.yahoo.com/news/major-biotechs-scare-off-loads-145535906.html,Major Biotechs Scare Off Loads of Short Sellers
BIIB,BIIB:UW,BBG000C18861,"Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for February 13, 2017",2017-02-10 14:18:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xUJEzu6DdDs/amgen-inc-amgn-ex-dividend-date-scheduled-for-february-13-2017-cm746085,Amgen Inc AMGN will begin trading ex dividend on February 13 2017 A cash dividend payment of 1 15 per share is scheduled to be paid on March 08 2017 Shareholders who purchased AMGN prior to the ex dividend date are eligible for the cash dividend payment This represents an 15
BIIB,BIIB:UW,BBG000C18861,Biotech ETFs Powered by Q4 Earnings,2017-02-10 13:38:01 +0000,http://finance.yahoo.com/news/biotech-etfs-powered-q4-earnings-133801922.html,Biotech ETFs Powered by Q4 Earnings
BIIB,BIIB:UW,BBG000C18861,Humana to limit coverage of pricy Biogen drug,2017-02-09 14:05:07 +0000,http://www.bizjournals.com/boston/news/2017/02/09/humana-to-limit-coverage-of-pricy-biogen-drug.html?ana=yahoo,Humana to limit coverage of pricy Biogen drug
BIIB,BIIB:UW,BBG000C18861,Forward Pharma Gets $1.25 Bln On Settlement And License Deal With Biogen,2017-02-09 08:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pxNXS-pRR8w/forward-pharma-gets-125-bln-on-settlement-and-license-deal-with-biogen-20170209-00822,Forward Pharma Gets $1.25 Bln On Settlement And License Deal With Biogen
BIIB,BIIB:UW,BBG000C18861,"What's Behind Bioverativ's Spin-Out, and Should You Buy?",2017-02-08 22:31:10 +0000,http://www.fool.com/investing/2017/02/08/whats-behind-bioverativs-spin-out-and-should-you-b.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"What's Behind Bioverativ's Spin-Out, and Should You Buy?"
BIIB,BIIB:UW,BBG000C18861,How Biogen Inc (BIIB) Stock Could Gain Another 25%,2017-02-08 22:17:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/clHrZpv1T_I/how-biogen-inc-biib-stock-could-gain-another-25-cm745210,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Biotech specialist Biogen Inc 160 NASDAQ BIIB didn t excite Wall Street with breathtaking fourth quarter earnings results recently but analysts remain bullish about
BIIB,BIIB:UW,BBG000C18861,BIOGEN INC. Financials,2017-02-08 18:04:08 +0000,http://finance.yahoo.com/q/is?s=biib,BIOGEN INC. Financials
BIIB,BIIB:UW,BBG000C18861,"What's Behind Bioverativ's Spin-Out, and Should You Buy?",2017-02-08 16:21:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9uFx_2z12sM/whats-behind-bioverativs-spin-out-and-should-you-buy-cm744835,Biogen Inc NASDAQ BIIB recently completed spinning off its fast growing hemophilia drugs into a new company Bioverativ NASDAQ BIVV The spinoff creates one of the most interesting players in a 10 billion market for hemophilia drugs but the market is very competitive
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib",2017-02-08 14:21:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KxZmCwylC0o/biotech-stock-roundup-amgen-gilead-report-4q-results-ariad-seeks-eu-nod-for-brigatinib-cm744687,Major biotech stocks like Amgen AMGN and Gilead GILD reported fourth quarter results while both topped estimates revenue outlook fell short of expectations Recap of the Week s Most Important Stories Amgen Delivers Strong Quarter but Sales Guidance Falls Short Amgen s
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib",2017-02-08 11:45:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-amgen-gilead-114511982.html,"Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib"
BIIB,BIIB:UW,BBG000C18861,Biogen's Slow Rebound Prompts A Vetr Downgrade,2017-02-07 21:53:08 +0000,http://finance.yahoo.com/news/biogens-slow-rebound-prompts-vetr-215308887.html,Biogen's Slow Rebound Prompts A Vetr Downgrade
BIIB,BIIB:UW,BBG000C18861,"Caterpillar, Biogen, CSX, Big-Box Stores In Analyst Crosshairs",2017-02-07 21:20:51 +0000,http://www.investors.com/news/caterpillar-biogen-csx-big-box-stores-in-analyst-crosshairs/,"Caterpillar, Biogen, CSX, Big-Box Stores In Analyst Crosshairs"
BIIB,BIIB:UW,BBG000C18861,Biogen to Present at the Leerink Partners 6th Annual Global Healthcare Conference,2017-02-07 21:01:00 +0000,http://finance.yahoo.com/news/biogen-present-leerink-partners-6th-210100026.html,"[Business Wire] - Biogen Inc. announced today that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. The webcast will be live on Wednesday, February 15, 2017 at 1:00 p.m."
BIIB,BIIB:UW,BBG000C18861,"In an Ironic Twist, Generics Take Aim at Teva Pharmaceutical",2017-02-07 15:19:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kOpN-ZWPHb4/in-an-ironic-twist-generics-take-aim-at-teva-pharmaceutical-cm744098,Teva Pharmaceutical s NYSE TEVA top selling drug is the long standing multiple sclerosis therapy Copaxone The drug racks up billions of dollars in annual sales for the generic drug powerhouse but that could change because Teva Pharmaceutical s generic rivals are
BIIB,BIIB:UW,BBG000C18861,"In an Ironic Twist, Generics Take Aim at Teva Pharmaceutical",2017-02-07 13:30:15 +0000,http://www.fool.com/investing/2017/02/07/in-an-ironic-twist-generics-take-aim-at-teva-pharm.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"In an Ironic Twist, Generics Take Aim at Teva Pharmaceutical"
BIIB,BIIB:UW,BBG000C18861,3 Healthcare Tickers That Will Return Profits in 3 Months,2017-02-06 23:18:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_drU689GeBU/3-healthcare-tickers-that-will-return-profits-in-3-months-cm743922,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips 2016 was a tough year for healthcare stocks Drug companies were political footballs most notably from then presidential candidate Hillary Clinton Donald Trump s election was supposed to bring relief to
BIIB,BIIB:UW,BBG000C18861,Chardan Analyst Suggests An AveXis-Ionis Pair Trade,2017-02-06 15:41:43 +0000,http://finance.yahoo.com/news/chardan-analyst-suggests-avexis-ionis-154143342.html,Chardan Analyst Suggests An AveXis-Ionis Pair Trade
BIIB,BIIB:UW,BBG000C18861,"Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More",2017-02-06 13:45:01 +0000,http://finance.yahoo.com/news/drug-stocks-reporting-earnings-feb-134501581.html,"Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More"
BIIB,BIIB:UW,BBG000C18861,Why Biogen Inc (BIIB) Stock Is a Solid Long-Term Bet,2017-02-03 20:59:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1jkEyYT_19s/why-biogen-inc-biib-stock-is-a-solid-long-term-bet-cm743150,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Over the last five years the shares of Biogen Inc 160 NASDAQ BIIB have traded at an average price to earnings ratio of almost 28 Today BIIB stock s 160 multiple is 11 on a forward basis
BIIB,BIIB:UW,BBG000C18861,"Biogen Faces Federal Probes for Drug Prices, Rebates",2017-02-03 20:55:00 +0000,http://www.investopedia.com/news/feds-probe-biogen-over-drug-prices-rebates-biib/?partner=YahooSA,"Biogen Faces Federal Probes for Drug Prices, Rebates"
BIIB,BIIB:UW,BBG000C18861,"It’s a Scratch, Not a Ding for Biogen Inc (BIIB) Stock",2017-02-03 20:33:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RTvDqTll4uk/its-a-scratch-not-a-ding-for-biogen-inc-biib-stock-cm743119,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Did Biogen Inc NASDAQ BIIB give you a surprise headache Thursday If it did relax it was only a scratch at worse courtesy of a distribution from Biogen stock and one that could pay big dividends
BIIB,BIIB:UW,BBG000C18861,Why Forward Pharma A/S Stock Surged 107% in January,2017-02-03 18:45:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uabp9MFUk7Q/why-forward-pharma-as-stock-surged-107-in-january-cm742992,Image source Getty Images What happened Shares of Forward 160 Pharma A S NASDAQ FWP 160 jumped 106 7 in January according to data from S amp P Global Market Intelligence The Danish biopharmaceutical company is developing a proprietary formulation of the
BIIB,BIIB:UW,BBG000C18861,Why Forward Pharma A/S Stock Surged 107% in January,2017-02-03 16:03:08 +0000,http://www.fool.com/investing/2017/02/03/why-forward-pharma-as-stock-surged-107-in-january.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Forward Pharma A/S Stock Surged 107% in January
BIIB,BIIB:UW,BBG000C18861,Hunting down the year’s 5 hottest M&A targets,2017-02-03 10:55:41 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=AC815BC6-E4BF-11E6-8855-08962D199CE8&siteid=yhoof2,Hunting down the year’s 5 hottest M&A targets
BIIB,BIIB:UW,BBG000C18861,"Biogen Reveals Federal Investigation Into Pricing, Rebate Payments",2017-02-02 22:55:00 +0000,https://www.thestreet.com/story/13977435/1/biogen-reveals-federal-investigation-into-pricing-rebate-payments.html?puc=yahoo&cm_ven=YAHOO,"Biogen Reveals Federal Investigation Into Pricing, Rebate Payments"
BIIB,BIIB:UW,BBG000C18861,Biogen: What Now?,2017-02-02 22:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/02/biogen-what-now/?mod=yahoobarrons&ru=yahoo,Biogen: What Now?
BIIB,BIIB:UW,BBG000C18861,Biogen subpoenaed by federal government over MS drug prices,2017-02-02 22:09:17 +0000,http://www.bizjournals.com/boston/news/2017/02/02/biogen-subpoenaed-by-federal-government-over-ms.html?ana=yahoo,Biogen subpoenaed by federal government over MS drug prices
BIIB,BIIB:UW,BBG000C18861,"Biogen Trails Merck, Lilly In Alzheimer's; Hemophilia Spinoff Begins Trading",2017-02-02 21:51:25 +0000,http://www.investors.com/news/technology/biogen-trails-merck-lilly-in-alzheimers-hemophilia-spin-off-begins-trading/,"Biogen Trails Merck, Lilly In Alzheimer's; Hemophilia Spinoff Begins Trading"
BIIB,BIIB:UW,BBG000C18861,[$$] Bioverativ: New Spinoff and Attractive Target,2017-02-02 20:54:00 +0000,http://www.barrons.com/articles/bioverativ-new-spinoff-and-attractive-target-1486068843?mod=yahoobarrons&ru=yahoo,[$$] Bioverativ: New Spinoff and Attractive Target
BIIB,BIIB:UW,BBG000C18861,5 Drugmakers Battle Over the $10 Billion Hemophilia Market,2017-02-02 17:34:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D2bi5k3OM9I/5-drugmakers-battle-over-the-10-billion-hemophilia-market-cm742334,Biogen 160 spun off of its long lasting hemophilia drugs as a new company today but that company Bioverativ NASDAQ BIVV 160 may struggle to deliver breakneck growth this year Why Because Shire Plc NASDAQ SHPG Bayer NASDAQOTH BAYRY CSL
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: BIIB, TSCO",2017-02-02 17:34:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/857Nhpe1nco/nasdaq-100-movers-biib-tsco-cm742329,In early trading on Thursday shares of Tractor Supply topped the list of the day s best performing components of the Nasdaq 100 index trading up 4 3 Year to date Tractor Supply has lost about 0 4 of its value And the worst performing Nasdaq 100 component thus far on the day is
BIIB,BIIB:UW,BBG000C18861,"QUAL, KMB, PEG, BIIB: ETF Outflow Alert",2017-02-02 17:33:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ROZnjnH_lu8/qual-kmb-peg-biib-etf-outflow-alert-cm742293,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Edge MSCI USA Quality Factor ETF Symbol QUAL where we have detected an approximate 34 9 million dollar outflow that s a 1 0 decrease week over
BIIB,BIIB:UW,BBG000C18861,"ETFs with exposure to Biogen, Inc. : February 2, 2017",2017-02-02 17:30:04 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-biogen-inc-february-2-2017/,"ETFs with exposure to Biogen, Inc. : February 2, 2017"
BIIB,BIIB:UW,BBG000C18861,Biogen Cancels Autoimmune Drug Deal With Tanabe,2017-02-02 16:13:00 +0000,http://www.investopedia.com/news/biogen-cancels-multiple-sclerosis-drug-deal-biib/?partner=YahooSA,Biogen Cancels Autoimmune Drug Deal With Tanabe
BIIB,BIIB:UW,BBG000C18861,5 Drugmakers Battle Over the $10 Billion Hemophilia Market,2017-02-02 15:40:06 +0000,http://www.fool.com/investing/2017/02/02/5-drugmakers-battle-over-the-10-billion-hemophilia.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Drugmakers Battle Over the $10 Billion Hemophilia Market
BIIB,BIIB:UW,BBG000C18861,Implied RYH Analyst Target Price: $172,2017-02-02 15:32:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yhrrTPar9r0/implied-ryh-analyst-target-price-172-cm742111,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
BIIB,BIIB:UW,BBG000C18861,What Could Make Biogen Crash?,2017-02-02 14:35:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qua6mrkFBeQ/what-could-make-biogen-crash-cm742007,Although Biogen Inc NASDAQ BIIB is one of the globe s biggest biotechs and it has the balance sheet to prove it it could face a big threat soon from an unexpected competitor Celgene Corp NASDAQ CELG Celgene is best known for its cancer drugs but it s in the
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data",2017-02-02 13:34:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iTZggseE-VE/biotech-stock-roundup-celgene-biogen-abbv-post-q4-results-catabasis-falls-on-dmd-data-cm741986,Major biotech stocks like Celgene CELG Biogen BIIB and AbbVie ABBV reported fourth quarter results last week Meanwhile Catabasis CATB shares plunged on data from an ongoing study on its lead pipeline candidate Recap of the Week s Most Important Stories A Look at
BIIB,BIIB:UW,BBG000C18861,What Could Make Biogen Crash?,2017-02-02 13:02:11 +0000,http://www.fool.com/investing/2017/02/02/what-could-make-biogen-crash.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,What Could Make Biogen Crash?
BIIB,BIIB:UW,BBG000C18861,"BIOGEN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition",2017-02-02 12:47:33 +0000,http://biz.yahoo.com/e/170202/biib8-k.html,"BIOGEN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition"
BIIB,BIIB:UW,BBG000C18861,Understanding Celgene’s Operational Performance Projections for 2017,2017-02-02 12:35:48 +0000,http://marketrealist.com/2017/01/celgene-projects-solid-operational-performance-2017/?utm_source=yahoo&utm_medium=feed,Understanding Celgene’s Operational Performance Projections for 2017
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data",2017-02-02 11:27:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-celgene-biogen-112711812.html,"Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data"
BIIB,BIIB:UW,BBG000C18861,Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN,2017-02-01 13:52:01 +0000,http://finance.yahoo.com/news/drug-stocks-report-q4-earnings-135201611.html,Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN
BIIB,BIIB:UW,BBG000C18861,Biogen's hemophilia business spin-off will trade on its own starting Thursday,2017-02-01 12:38:33 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=E6B58A1F-DD55-42BF-BA75-018A74F22329&siteid=yhoof2,Biogen's hemophilia business spin-off will trade on its own starting Thursday
BIIB,BIIB:UW,BBG000C18861,"Biogen Completes Separation of Global Hemophilia Business, Bioverativ",2017-02-01 12:30:00 +0000,http://uk.finance.yahoo.com/news/biogen-completes-separation-global-hemophilia-123000033.html,"Biogen Completes Separation of Global Hemophilia Business, Bioverativ"
BIIB,BIIB:UW,BBG000C18861,Biogen’s hemophilia spinoff launches this week. Here’s what you need to know.,2017-01-31 16:15:06 +0000,http://www.bizjournals.com/boston/news/2017/01/29/biogen-s-hemophilia-spinoff-launches-this-week.html?ana=yahoo,Biogen’s hemophilia spinoff launches this week. Here’s what you need to know.
BIIB,BIIB:UW,BBG000C18861,Spinraza: First Approved Therapy for Spinal Muscular Atrophy in the US,2017-01-31 15:37:30 +0000,http://marketrealist.com/2017/01/biogens-spinraza-became-first-therapy-approved-spinal-muscular-atrophy-u-s/?utm_source=yahoo&utm_medium=feed,Spinraza: First Approved Therapy for Spinal Muscular Atrophy in the US
BIIB,BIIB:UW,BBG000C18861,"Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence",2017-01-31 14:45:00 +0000,https://www.thestreet.com/story/13970376/1/unlike-silicon-valley-biopharma-s-top-execs-react-to-trump-migration-ban-with-cowed-silence.html?puc=yahoo&cm_ven=YAHOO,"Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence"
BIIB,BIIB:UW,BBG000C18861,Biosimilar Segment May Drive Biogen’s Revenue Growth,2017-01-31 14:08:12 +0000,http://marketrealist.com/2017/01/biosimilar-segment-may-drive-biogens-revenue-growth-future-years/?utm_source=yahoo&utm_medium=feed,Biosimilar Segment May Drive Biogen’s Revenue Growth
BIIB,BIIB:UW,BBG000C18861,Tysabri Witnessed Robust Growth in the Number of Patients in 2016,2017-01-31 12:39:19 +0000,http://marketrealist.com/2017/01/tysabri-managed-witness-robust-growth-patients-2016/?utm_source=yahoo&utm_medium=feed,Tysabri Witnessed Robust Growth in the Number of Patients in 2016
BIIB,BIIB:UW,BBG000C18861,Biogen Continues Its Dominance in the Multiple Sclerosis Segment,2017-01-30 22:06:12 +0000,http://marketrealist.com/2017/01/biogen-continues-dominant-player-multiple-sclerosis-segment/?utm_source=yahoo&utm_medium=feed,Biogen Continues Its Dominance in the Multiple Sclerosis Segment
BIIB,BIIB:UW,BBG000C18861,Biogen Reported Modest Revenue Growth in 4Q16,2017-01-30 20:28:18 +0000,http://marketrealist.com/2017/01/biogen-reported-modest-revenue-growth-4q16/?utm_source=yahoo&utm_medium=feed,Biogen Reported Modest Revenue Growth in 4Q16
BIIB,BIIB:UW,BBG000C18861,Celgene’s Financial Performance in 2016: Strong Growth in Volumes,2017-01-30 19:36:03 +0000,http://marketrealist.com/2017/01/strong-growth-volumes-driven-celgenes-financial-performance-2016/?utm_source=yahoo&utm_medium=feed,Celgene’s Financial Performance in 2016: Strong Growth in Volumes
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean",2017-01-30 16:35:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5yQfSTzhE3g/the-zacks-analyst-blog-highlights-att-biogen-qualcomm-facebook-and-royal-caribbean-cm740164,For Immediate Release Chicago IL January 30 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. :BIIB-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017",2017-01-30 14:43:38 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-biib-us-earnings-analysis-2016-by-the-numbers-january-30-2017/,"Biogen, Inc. :BIIB-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017"
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean",2017-01-30 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-t-143002934.html,"The Zacks Analyst Blog Highlights: AT&T, Biogen, Qualcomm, Facebook and Royal Caribbean"
BIIB,BIIB:UW,BBG000C18861,Biogen Inc Makes Up for Lackluster Revenue Growth,2017-01-27 20:31:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8o8GYbMJ2-s/biogen-inc-makes-up-for-lackluster-revenue-growth-cm739551,Biogen s NASDAQ BIIB fourth quarter revenue 160 left something to be desired but the biotech made up for the lackluster growth with a curtailing of expenses resulting in a solid 12 increase in adjusted earnings per share Image source Getty Images
BIIB,BIIB:UW,BBG000C18861,Biogen Inc Makes Up for Lackluster Revenue Growth,2017-01-27 19:28:57 +0000,http://www.fool.com/investing/2017/01/27/biogen-inc-makes-up-for-lackluster-revenue-growth.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biogen Inc Makes Up for Lackluster Revenue Growth
BIIB,BIIB:UW,BBG000C18861,"Q4 Scorecard and Analyst Reports for AT&T, Biogen & Qualcomm",2017-01-27 18:22:06 +0000,http://finance.yahoo.com/news/q4-scorecard-analyst-reports-t-182206912.html,"Q4 Scorecard and Analyst Reports for AT&T, Biogen & Qualcomm"
BIIB,BIIB:UW,BBG000C18861,Biogen 4Q Net $2.99 a Share Vs $3.77 Last Year,2017-01-27 15:45:00 +0000,http://www.investopedia.com/news/biogen-4q-net-299-share-beats-street-biib/?partner=YahooSA,Biogen 4Q Net $2.99 a Share Vs $3.77 Last Year
BIIB,BIIB:UW,BBG000C18861,"Biogen Sidesteps Q4, 2016 Sales Misses On Strong Ex-Hemophilia Guide",2017-01-26 21:47:02 +0000,http://www.investors.com/news/technology/biogen-sidesteps-q4-2016-sales-misses-on-strong-ex-hemophilia-guide/,"Biogen Sidesteps Q4, 2016 Sales Misses On Strong Ex-Hemophilia Guide"
BIIB,BIIB:UW,BBG000C18861,"Notable Thursday Option Activity: PYPL, BIIB, MJN",2017-01-26 20:31:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RXS_wr5zQaQ/notable-thursday-option-activity-pypl-biib-mjn-cm738914,Among the underlying components of the S amp P 500 index we saw noteworthy options trading volume today in PayPal Holdings Inc Symbol PYPL where a total of 35 945 contracts have traded so far representing approximately 3 6 million underlying shares That amounts to about 66 9 of PYPL
BIIB,BIIB:UW,BBG000C18861,Edited Transcript of BIIB earnings conference call or presentation 26-Jan-17 1:00pm GMT,2017-01-26 19:50:40 +0000,http://finance.yahoo.com/news/edited-transcript-biib-earnings-conference-195040078.html,Edited Transcript of BIIB earnings conference call or presentation 26-Jan-17 1:00pm GMT
BIIB,BIIB:UW,BBG000C18861,Biotech ETFs: Is It Time To Buy?,2017-01-26 18:21:00 +0000,http://blogs.barrons.com/focusonfunds/2017/01/26/biotech-etfs-is-it-time-to-buy/?mod=yahoobarrons&ru=yahoo,Biotech ETFs: Is It Time To Buy?
BIIB,BIIB:UW,BBG000C18861,Biogen Rallies Despite Mixed Revenue Guidance,2017-01-26 17:50:00 +0000,https://www.thestreet.com/story/13967452/1/biogen-2017-revenue-guidance-looks-ok-with-spinout-adjustment.html?puc=yahoo&cm_ven=YAHOO,Biogen Rallies Despite Mixed Revenue Guidance
BIIB,BIIB:UW,BBG000C18861,How to Trade Biogen Inc (BIIB) Stock After Its Q4 Beat,2017-01-26 17:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zwfVhc1xRXE/how-to-trade-biogen-inc-biib-stock-after-its-q4-beat-cm738848,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB stepped into the earnings confessional this morning and the 22 year over year decline in earnings were less inspiring than analysts were hoping for Yes adjusted earnings
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb",2017-01-26 16:35:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rvepgBebphE/the-zacks-analyst-blog-highlights-johnson-johnson-biogen-celgene-and-bristol-myers-squibb-cm738687,For Immediate Release Chicago IL January 26 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft,2017-01-26 16:35:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uWJ5xAj4aK8/biogen-biib-q4-earnings-top-estimates-17-sales-view-soft-cm738677,Biogen Inc BIIB a well known name in the multiple sclerosis MS market reported mixed fourth quarter 2016 results with the company surpassing earnings expectations while missing the same for sales Moreover the company s 2017 sales guidance fell short of expectations In the past one
BIIB,BIIB:UW,BBG000C18861,"Biogen earnings lift shares, but concerns about multiple sclerosis drug sales persist",2017-01-26 15:15:06 +0000,http://www.bizjournals.com/boston/news/2017/01/26/biogen-earnings-lift-shares-but-concerns-about.html?ana=yahoo,"Biogen earnings lift shares, but concerns about multiple sclerosis drug sales persist"
BIIB,BIIB:UW,BBG000C18861,Why Biogen is Flying,2017-01-26 14:50:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/01/26/why-biogen-is-flying/?mod=yahoobarrons&ru=yahoo,Why Biogen is Flying
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Beats on Q4 Earnings; Misses Sales,2017-01-26 14:33:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QZQXJqPmXqo/biogen-biib-beats-on-q4-earnings-misses-sales-cm738644,Cambridge MA based Biogen Inc BIIB one of the world s leading biotechnology companies focuses on therapeutic areas including neurology immunology and hemophilia The company is best known for its multiple sclerosis MS franchise comprising treatments like Avonex Tysabri Tecfidera
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft,2017-01-26 14:32:02 +0000,http://finance.yahoo.com/news/biogen-biib-q4-earnings-top-143202613.html,Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb",2017-01-26 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-johnson-143002915.html,"The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb"
BIIB,BIIB:UW,BBG000C18861,"3 Top Biotech Stocks You Can Still Buy With the Dow at 20,000",2017-01-26 13:33:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xNt5nIWD3i0/3-top-biotech-stocks-you-can-still-buy-with-the-dow-at-20000-cm738478,The Dow Jones Industrial Index is crossing over the 20 000 mark and while that s only a number it may have you wondering if there are any stocks that you can still buy No one knows where the stock market will go in the short term but long term investors might want to buy 160
BIIB,BIIB:UW,BBG000C18861,Biogen MS Drug Tecfidera Gets Liver Injury Warning,2017-01-26 13:05:00 +0000,http://www.investopedia.com/news/biogens-ms-drug-gets-liver-injury-warning-biib/?partner=YahooSA,Biogen MS Drug Tecfidera Gets Liver Injury Warning
BIIB,BIIB:UW,BBG000C18861,"Early movers: CMCSA, F, LUV, CAT, PHM, BIIB & more",2017-01-26 13:03:23 +0000,http://www.cnbc.com/id/104242087?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104242087,"Early movers: CMCSA, F, LUV, CAT, PHM, BIIB & more"
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Beats on Q4 Earnings; Misses Sales,2017-01-26 13:00:01 +0000,http://finance.yahoo.com/news/biogen-biib-beats-q4-earnings-130001593.html,Biogen (BIIB) Beats on Q4 Earnings; Misses Sales
BIIB,BIIB:UW,BBG000C18861,Q4 2016 Biogen Inc Earnings Release - Before Market Open,2017-01-26 12:07:07 +0000,http://biz.yahoo.com/research/earncal/20170126.html?t=biib,Q4 2016 Biogen Inc Earnings Release - Before Market Open
BIIB,BIIB:UW,BBG000C18861,"3 Top Biotech Stocks You Can Still Buy With the Dow at 20,000",2017-01-26 12:01:06 +0000,http://www.fool.com/investing/2017/01/26/3-top-biotech-stocks-you-can-still-buy-with-the-do.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Top Biotech Stocks You Can Still Buy With the Dow at 20,000"
BIIB,BIIB:UW,BBG000C18861,"[$$] Biogen Profit Skids, Revenue Grows Less Than Expected",2017-01-26 12:00:18 +0000,http://www.wsj.com/articles/biogen-profit-skids-revenue-grows-less-than-expected-1485432011?mod=yahoo_hs,"[$$] Biogen Profit Skids, Revenue Grows Less Than Expected"
BIIB,BIIB:UW,BBG000C18861,Biogen tops 4Q profit forecasts,2017-01-26 11:45:47 +0000,http://sg.finance.yahoo.com/news/biogen-tops-4q-profit-forecasts-114145724.html,Biogen tops 4Q profit forecasts
BIIB,BIIB:UW,BBG000C18861,Biogen profit drops 22 pct due to Tecfidera-related costs,2017-01-26 11:41:05 +0000,http://finance.yahoo.com/news/biogen-profit-drops-22-pct-114105524.html,Biogen profit drops 22 pct due to Tecfidera-related costs
BIIB,BIIB:UW,BBG000C18861,Biogen Profit Beats Estimates as New CEO Takes the Helm,2017-01-26 11:37:37 +0000,http://www.bloomberg.com/news/articles/2017-01-26/biogen-beats-estimates-as-new-ceo-vounatsos-takes-the-helm?cmpid=yhoo.headline,Biogen Profit Beats Estimates as New CEO Takes the Helm
BIIB,BIIB:UW,BBG000C18861,"BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition",2017-01-26 11:35:42 +0000,http://biz.yahoo.com/e/170126/biib8-k.html,"BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition"
BIIB,BIIB:UW,BBG000C18861,"6:34 am Biogen beats by $0.08, misses on revs; guides FY17 EPS in-line, revs below consensus",2017-01-26 11:34:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#biib,"6:34 am Biogen beats by $0.08, misses on revs; guides FY17 EPS in-line, revs below consensus"
BIIB,BIIB:UW,BBG000C18861,Biogen Reports 2016 Revenues of $11.4 Billion,2017-01-26 11:30:00 +0000,http://finance.yahoo.com/news/biogen-reports-2016-revenues-11-113000515.html,"[Business Wire] - Biogen Inc. today reported full year and fourth quarter 2016 financial results, including:"
BIIB,BIIB:UW,BBG000C18861,"Earnings Reaction History: Biogen Idec, 50.0% Follow-Through Indicator, 4.5% Sensitive",2017-01-26 11:11:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZcdkTqtgkMU/earnings-reaction-history-biogen-idec-500-follow-through-indicator-45-sensitive-cm738436,Expected Earnings Release 01 26 2017 PremarketExpected Earnings Release 01 26 2017 Premarket Avg Extended Hours Dollar Volume 72 989 351Avg Extended Hours Dollar Volume 72 989 351 Biogen Idec BIIB is due to issue its quarterly earnings report in the upcoming extended hours
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. (BIIB) Is Climbing On Better Than Expected Q4 Earnings,2017-01-26 09:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kmy6OygGqLE/biogen-inc-biib-is-climbing-on-better-than-expected-q4-earnings-20170126-00893,Biogen Inc. (BIIB) Is Climbing On Better Than Expected Q4 Earnings
BIIB,BIIB:UW,BBG000C18861,Wall Street Setting Higher Goals,2017-01-26 08:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q5LS5l_QaNM/wall-street-setting-higher-goals-20170126-00595,Wall Street Setting Higher Goals
BIIB,BIIB:UW,BBG000C18861,Biogen Q4 16 Earnings Conference Call At 8:00 AM ET,2017-01-26 07:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Wyta43WXk-s/biogen-q4-16-earnings-conference-call-at-800-am-et-20170126-00402,Biogen Q4 16 Earnings Conference Call At 8:00 AM ET
BIIB,BIIB:UW,BBG000C18861,"Biogen Sees FY17 Earnings In-line With Estimates, Revenues Below View",2017-01-26 06:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EFBHYrQ-1ew/biogen-sees-fy17-earnings-inline-with-estimates-revenues-below-view-20170126-00326,"Biogen Sees FY17 Earnings In-line With Estimates, Revenues Below View"
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Reports 9% Gain In Q4 Profit,2017-01-26 06:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K2cUuBXWSl4/biogen-inc-reports-9-gain-in-q4-profit-20170126-00299,Biogen Inc. Reports 9% Gain In Q4 Profit
BIIB,BIIB:UW,BBG000C18861,"Pre-Market Earnings Report for January 26, 2017 :  CMCSA, CELG, BMY, DOW, BIIB, CAT, F, RTN, NOC, PX, AEP, LUV",2017-01-25 21:20:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8eFr0qivFZo/pre-market-earnings-report-for-january-26-2017-cmcsa-celg-bmy-dow-biib-cat-f-rtn-noc-px-aep-luv-cm738325,The following companies are expected to report earnings prior to market open on 01 26 2017 Visit our Earnings Calendar for a full list of expected earnings releases Comcast Corporation CMCSA is reporting for the quarter ending December 31 2016 The cable
BIIB,BIIB:UW,BBG000C18861,5 Stocks to Watch Before the Market Opens Tomorrow,2017-01-25 20:47:34 +0000,http://finance.yahoo.com/tumblr/blog-5-stocks-to-watch-before-the-market-opens-tomorrow-204745719.html,5 Stocks to Watch Before the Market Opens Tomorrow
BIIB,BIIB:UW,BBG000C18861,What to look for when Biogen reports earnings on Thursday,2017-01-25 19:30:08 +0000,http://www.bizjournals.com/boston/news/2017/01/25/what-to-look-for-when-biogen-reports-earnings-on.html?ana=yahoo,What to look for when Biogen reports earnings on Thursday
BIIB,BIIB:UW,BBG000C18861,Possible liver injury added to label of Biogen MS drug,2017-01-25 19:29:50 +0000,http://finance.yahoo.com/news/possible-liver-injury-added-label-192950402.html,"[Reuters] - The prescribing label for Biogen Inc's big-selling oral multiple sclerosis drug Tecfidera has been updated to include a warning of potential liver injury that could require hospitalization, the company said on Wednesday. The new liver injury information can be found in a warning section under prescribing information on the drug's website tecfidera.com."
BIIB,BIIB:UW,BBG000C18861,Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA,2017-01-25 17:35:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mPc_hHbnnzs/perrigos-prgo-generic-version-of-topicort-okayed-by-fda-cm738113,Perrigo Company plc PRGO recently announced that the FDA has approved its first to file AB rated generic version of Taro Pharmaceuticals USA Inc s TARO Topicort spray 0 25 desoximetasone topical spray 0 25 indicated for the treatment of plaque psoriasis in patients of 18 years or
BIIB,BIIB:UW,BBG000C18861,Bristol-Myers Squibb May Report Strong Revenue Performance for 2017,2017-01-25 16:51:15 +0000,http://marketrealist.com/2017/01/bristol-myers-squibb-may-report-strong-revenue-performance-2017/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb May Report Strong Revenue Performance for 2017
BIIB,BIIB:UW,BBG000C18861,"Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY",2017-01-25 16:37:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iKm14iqHKm8/drug-stock-earnings-to-watch-on-jan-26-biib-celg-bmy-cm738039,Investors around the world are seeing a ray of hope as the fourth quarter earnings season kicked off on an encouraging note Both earnings and sales growth in Q4 are tracking above other recent periods and on track to reach the highest level in the last eight quarters With Q4
BIIB,BIIB:UW,BBG000C18861,What to Expect From Major Health Care Stocks Reporting This Week,2017-01-25 16:25:15 +0000,http://finance.yahoo.com/news/expect-major-health-care-stocks-162515341.html,What to Expect From Major Health Care Stocks Reporting This Week
BIIB,BIIB:UW,BBG000C18861,Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA,2017-01-25 15:26:03 +0000,http://finance.yahoo.com/news/perrigos-prgo-generic-version-topicort-152603949.html,Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA
BIIB,BIIB:UW,BBG000C18861,"Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY",2017-01-25 14:08:02 +0000,http://finance.yahoo.com/news/drug-stock-earnings-watch-jan-140802252.html,"Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY"
BIIB,BIIB:UW,BBG000C18861,Earnings Preview: What To Expect From Biogen On Thursday,2017-01-25 11:59:00 +0000,http://www.forbes.com/sites/adamsarhan/2017/01/25/earnings-preview-what-to-expect-from-biogen-on-thursday/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Earnings Preview: What To Expect From Biogen On Thursday
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Gilead Sciences Inc.,2017-01-25 00:31:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/47lDOB1amdQ/better-buy-biogen-inc-vs-gilead-sciences-inc-cm737720,Investors who bought Biogen NASDAQ BIIB shares five years ago and held on to them would have received a return of more than 130 Those who bought and held Gilead Sciences NASDAQ GILD stock for the period would have nearly tripled their initial investment But it s Biogen
BIIB,BIIB:UW,BBG000C18861,LogMeIn and Bioverativ Set to Join the S&P MidCap 400; Others to Join S&P SmallCap 600,2017-01-24 23:10:00 +0000,http://finance.yahoo.com/news/logmein-bioverativ-set-join-p-231000802.html,"[PR Newswire] - NEW YORK, Jan. 24, 2017 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices: S&P SmallCap 600 constituent LogMeIn Inc. (NASD: LOGM) ..."
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Gilead Sciences Inc.,2017-01-24 22:42:16 +0000,http://www.fool.com/investing/2017/01/24/better-buy-biogen-inc-vs-gilead-sciences.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Biogen Inc. vs. Gilead Sciences Inc.
BIIB,BIIB:UW,BBG000C18861,Biogen Inc (BIIB) Stock Enters Uncharted Waters,2017-01-24 20:31:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lAcVpFyXV1c/biogen-inc-biib-stock-enters-uncharted-waters-cm737564,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB reminds me of a company making big computers in 1977 Source Biogen via YouTube The industry is about to be transformed completely but most people are focused only
BIIB,BIIB:UW,BBG000C18861,Top Biosimilar Drug Companies,2017-01-24 13:47:00 +0000,http://www.investopedia.com/news/top-biosimilar-drug-companies-nvs-amgn/?partner=YahooSA,Top Biosimilar Drug Companies
BIIB,BIIB:UW,BBG000C18861,[video]5 Reasons Celgene Should Buy Biogen,2017-01-23 18:30:00 +0000,https://www.thestreet.com/story/13962383/1/5-reasons-celgene-should-buy-biogen.html?puc=yahoo&cm_ven=YAHOO,[video]5 Reasons Celgene Should Buy Biogen
BIIB,BIIB:UW,BBG000C18861,Celgene Estimates Robust Revenue in 2017,2017-01-23 17:40:38 +0000,http://marketrealist.com/2017/01/celgene-estimates-robust-revenue-performance-2017/?utm_source=yahoo&utm_medium=feed,Celgene Estimates Robust Revenue in 2017
BIIB,BIIB:UW,BBG000C18861,5 Reasons Celgene Should Buy Biogen,2017-01-23 16:18:00 +0000,http://realmoney.thestreet.com/articles/01/23/2017/5-reasons-celgene-should-buy-biogen?puc=yahoo&cm_ven=YAHOO,5 Reasons Celgene Should Buy Biogen
BIIB,BIIB:UW,BBG000C18861,5 Drugs That Are Way Cheaper in Canada,2017-01-21 20:37:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LAI1U5myHdo/5-drugs-that-are-way-cheaper-in-canada-cm736393,A lot of the discussion related to curbing runaway drug prices in the United States has focused on the importation of drugs from neighboring Canada But are drugs really less expensive there Often the answer is yes For instance here are five common medicines that are much cheaper to
BIIB,BIIB:UW,BBG000C18861,5 Drugs That Are Way Cheaper in Canada,2017-01-21 19:02:06 +0000,http://www.fool.com/investing/2017/01/21/5-drugs-that-are-way-cheaper-in-canada.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Drugs That Are Way Cheaper in Canada
BIIB,BIIB:UW,BBG000C18861,7 Stocks for 2017,2017-01-20 23:23:44 +0000,http://finance.yahoo.com/news/7-stocks-2017-232225443.html,7 Stocks for 2017
BIIB,BIIB:UW,BBG000C18861,Nektar Therapeutics: An Undervalued Biopharmaceuticals Company With Plenty In The Pipeline,2017-01-20 16:38:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AedYyFhCAB4/nektar-therapeutics-an-undervalued-biopharmaceuticals-company-with-plenty-in-the-pipeline-cm736083,By Robert Lowy ByRobert Lowy Nektar Therapeutics Company Analysis and Recommendation Nektar Therapeutics Company Analysis and RecommendationNektar Therapeutics Company Analysis and Recommendation Date 01 17 2017 Date 01 17 201701 17 2017 Ticker
BIIB,BIIB:UW,BBG000C18861,"Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump",2017-01-19 21:34:50 +0000,http://www.investors.com/research/ibd-industry-themes/merck-biogen-lilly-top-2016-drug-approvals-despite-fda-slump/,"Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump"
BIIB,BIIB:UW,BBG000C18861,"Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst",2017-01-19 19:27:07 +0000,http://www.investors.com/news/technology/gilead-merck-alexion-2017-views-hazy-biogen-likely-to-surge-analyst/,"Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst"
BIIB,BIIB:UW,BBG000C18861,"Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump",2017-01-19 18:06:50 +0000,http://www.investors.com/news/technology/merck-biogen-lilly-top-2016-drug-approvals-despite-fda-slump/,"Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump"
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Thursday Option Activity: NANO, BIIB, SWKS",2017-01-19 17:53:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n_Ct6iX_l5Q/noteworthy-thursday-option-activity-nano-biib-swks-cm735527,Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Nanometrics Inc Symbol NANO where a total of 902 contracts have traded so far representing approximately 90 200 underlying shares That amounts to about 47 7 of NANO s
BIIB,BIIB:UW,BBG000C18861,Biogen and Siemens Healthineers Ink MS MRI Deal,2017-01-19 16:45:00 +0000,http://www.investopedia.com/news/biogen-siemens-launch-ms-mri-venture-biib-siegy/?partner=YahooSA,Biogen and Siemens Healthineers Ink MS MRI Deal
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?,2017-01-19 15:41:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-IICdyRleIM/biogen-biib-q4-earnings-whats-in-store-for-the-stock-cm735329,Biogen Inc BIIB a well known name in the multiple sclerosis MS market will be reporting fourth quarter 2016 and full year earnings on Jan 26 before the market opens Last quarter the company delivered a positive earnings surprise of 4 01 Biogen s shares rose 5 3 in the past one
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?,2017-01-19 13:40:01 +0000,http://finance.yahoo.com/news/biogen-biib-q4-earnings-whats-134001308.html,Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?
BIIB,BIIB:UW,BBG000C18861,"Gilead 2017 Outlook Hamstrung On Hep C, But RBC Bullish On Amgen, Biogen",2017-01-18 21:33:27 +0000,http://www.investors.com/news/technology/gilead-2017-outlook-hamstrung-on-hep-c-but-rbc-bullish-on-amgen-biogen/,"Gilead 2017 Outlook Hamstrung On Hep C, But RBC Bullish On Amgen, Biogen"
BIIB,BIIB:UW,BBG000C18861,Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug,2017-01-18 19:37:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0rec-CZjFHM/alcobra-stock-down-on-poor-late-stage-data-on-adhd-drug-cm734979,Shares of Alcobra Ltd ADHD declined 50 7 after the company reported disappointing top line results from a phase III study MEASURE on experimental candidate metadoxine extended release MDX for the treatment of ADHD in adult patients Alcobra s share price has grossly
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. -- Moody's: Biogen's settlement with Forward Pharma is credit negative,2017-01-18 17:46:02 +0000,http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_360817&WT.mc_id=AM~WWFob29fRmluYW5jZTQyX1NCX1JhdGluZyBOZXdzX0FsbF9Fbmc=~20170118_PR_360817,Biogen Inc. -- Moody's: Biogen's settlement with Forward Pharma is credit negative
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway",2017-01-18 16:41:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7hpqY5f35Xg/the-zacks-analyst-blog-highlights-microsoft-biogen-home-depot-bristol-myers-and-berkshire-hathaway-cm734815,For Immediate Release Chicago IL January 18 2017 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the
BIIB,BIIB:UW,BBG000C18861,Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit,2017-01-18 14:41:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-o79eyo_TrI/biogen-to-pay-125b-to-forward-pharma-in-tecfidera-lawsuit-cm734764,Biogen Inc BIIB recently entered into a settlement and license agreement with Danish biotech Forward Pharma A S FWP with respect to an ongoing patent dispute for Biogen s best selling multiple sclerosis MS drug Tecfidera While Forward Pharma s shares surged 48 on Tuesday Biogen s
BIIB,BIIB:UW,BBG000C18861,Why Forward Pharma A/S Stock Gained 48.2% on Tuesday,2017-01-18 14:38:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eMvtTNZQfo0/why-forward-pharma-as-stock-gained-482-on-tuesday-cm734606,Image source Getty Images What happened Shares of the 160 Danish drugmaker Forward Pharma A S NASDAQ FWP gained 48 2 yesterday as the result of a settlement and licensing deal with Biogen NASDAQ BIIB involving an ongoing patent dispute over the multiple sclerosis
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway",2017-01-18 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-microsoft-143002903.html,"The Zacks Analyst Blog Highlights: Microsoft, Biogen, Home Depot, Bristol-Myers and Berkshire Hathaway"
BIIB,BIIB:UW,BBG000C18861,Biogen to Pay $1.25B to Forward Pharma in Patient Suit,2017-01-18 13:40:00 +0000,http://www.investopedia.com/news/biogen-pay-125b-settle-patent-lawsuit-biib/?partner=YahooSA,Biogen to Pay $1.25B to Forward Pharma in Patient Suit
BIIB,BIIB:UW,BBG000C18861,Why Forward Pharma A/S Stock Gained 48.2% on Tuesday,2017-01-18 13:29:47 +0000,http://www.fool.com/investing/2017/01/18/why-forward-pharma-as-gained-482-on-tuesday.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Forward Pharma A/S Stock Gained 48.2% on Tuesday
BIIB,BIIB:UW,BBG000C18861,Blog Coverage Benitec Biopharma Secures Orphan Drug Designation for its Product Treating Patients with Oculopharyngeal Muscular Dystrophy,2017-01-18 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-benitec-biopharma-secures-131500864.html,"[Accesswire] - Upcoming AWS Coverage on Biogen LONDON, UK / ACCESSWIRE / January 18, 2017 / Active Wall St. blog coverage looks at the headline from Benitec Biopharma Ltd (NASDAQ: BNTC ) as the Company announced on January ..."
BIIB,BIIB:UW,BBG000C18861,Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit,2017-01-18 13:02:01 +0000,http://finance.yahoo.com/news/biogen-pay-1-25b-forward-130201042.html,Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen’s Pricey Anxiety Cure Worth Every Penny,2017-01-18 05:17:57 +0000,http://www.wsj.com/articles/biogens-pricey-anxiety-cure-worth-every-penny-1484672693?ru=yahoo?mod=yahoo_itp,[$$] Biogen’s Pricey Anxiety Cure Worth Every Penny
BIIB,BIIB:UW,BBG000C18861,Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017,2017-01-18 00:37:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g1OYcEmX86w/biogens-multiple-sclerosis-franchise-to-drive-growth-in-2017-cm734525,We issued an updated research report on Biogen Inc BIIB on Jan 16 The leading biotechnological company holds a strong position in the multiple sclerosis MS market with a wide range of products including Avonex Tysabri Tecfidera and Plegridy Biogen s share price has gained 4 2 in
BIIB,BIIB:UW,BBG000C18861,Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?,2017-01-18 00:37:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/to6IsInq1BY/merrimack-mack-goes-uphill-is-a-turnaround-likely-cm734520,Shares of Merrimack Pharmaceuticals Inc MACK have increased 47 9 in the last twelve months The plunge in the share price was much steeper than the 11 3 decline witnessed by the Zacks classified Medical Biomed Genetics market It has been a roller coaster for the shareholders
BIIB,BIIB:UW,BBG000C18861,"Why Clayton Williams Energy, Forward Pharma, and Luxottica Jumped Today",2017-01-17 23:37:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fZuFvECfP3o/why-clayton-williams-energy-forward-pharma-and-luxottica-jumped-today-cm734506,Tuesday was a poor day for the stock market as major market benchmarks were down between 0 3 and 0 6 on the day Investors appear to view Friday s inauguration of Donald Trump as president as a potential endpoint to the stock market rally of the past couple of months and
BIIB,BIIB:UW,BBG000C18861,"Why Clayton Williams Energy, Forward Pharma, and Luxottica Jumped Today",2017-01-17 22:23:00 +0000,http://www.fool.com/investing/2017/01/17/why-clayton-williams-energy-forward-pharma-and-lux.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Clayton Williams Energy, Forward Pharma, and Luxottica Jumped Today"
BIIB,BIIB:UW,BBG000C18861,Biogen Resolves Multiple Sclerosis Drug Dispute,2017-01-17 22:09:00 +0000,http://www.thestreet.com/video/13956630/biogen-resolves-multiple-sclerosis-drug-dispute.html?puc=yahoov&cm_ven=YAHOOV,Biogen Resolves Multiple Sclerosis Drug Dispute
BIIB,BIIB:UW,BBG000C18861,Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017,2017-01-17 22:08:10 +0000,http://finance.yahoo.com/news/biogens-multiple-sclerosis-franchise-drive-220810472.html,Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017
BIIB,BIIB:UW,BBG000C18861,Close Update: Wall Street Braces For &quot;Sell-The-Fact&quot; Reaction After Inauguration,2017-01-17 21:56:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AGS1ukA5Im4/close-update-wall-street-braces-for-sell-the-fact-reaction-after-inauguration-cm734465,U S investors continued to cash in on the Trump rally leaving the Dow Jones Industrial Average lower for a third straight day on heavy losses in financial and industrial stocks U S investors continued to cash in on the Trump rally leaving the Dow Jones Industrial Average lower for a
BIIB,BIIB:UW,BBG000C18861,Biogen Pays Forward Pharma $1.25 Billion To Settle Tecfidera Suit,2017-01-17 21:14:49 +0000,http://www.investors.com/news/technology/biogen-pays-forward-pharma-1-25-billion-to-settle-tecfidera-suit/,Biogen Pays Forward Pharma $1.25 Billion To Settle Tecfidera Suit
BIIB,BIIB:UW,BBG000C18861,"Biogen Fourth Quarter and Year End 2016 Financial Results Webcast Adjusted to 8:00 am on January 26, 2017",2017-01-17 21:01:00 +0000,http://finance.yahoo.com/news/biogen-fourth-quarter-end-2016-210100854.html,[Business Wire] - Please note: the start time of the webcast has moved to 8:00 am ET.
BIIB,BIIB:UW,BBG000C18861,Mid-Day Market Update: Clayton Williams Energy Surges On Acquisition News; Christopher & Banks Shares Slide,2017-01-17 18:47:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v-jMGE0xX0c/mid-day-market-update-clayton-williams-energy-surges-on-acquisition-news-christopher-banks-shares-slide-cm734389,Midway through trading Tuesday the Dow traded down 0 27 percent to 19 831 39 while the NASDAQ declined 0 54 percent to 5 543 93 The S amp P also fell dropping 0 29 percent to 2 268 01 Leading and Lagging Sectors Non cyclical consumer goods amp services shares gained around 1
BIIB,BIIB:UW,BBG000C18861,"Midday Update: Stocks Pressured By Trump's Dollar Warning, Earnings and Inauguration Sell-0ff",2017-01-17 18:16:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DcQrYXn7qmc/midday-update-stocks-pressured-by-trumps-dollar-warning-earnings-and-inauguration-sell-0ff-cm734365,Weighed down by comments from President elect Donald Trump expressing concerns about a strengthening dollar and rising pharmaceutical prices the benchmark averages were trading with modest losses on Tuesday with financial and healthcare stocks taking the brunt of today s losses Weighed down
BIIB,BIIB:UW,BBG000C18861,"Agree To Buy Biogen At $180, Earn 5.3% Using Options",2017-01-17 17:39:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2PRQ7-js3oY/agree-to-buy-biogen-at-180-earn-53-using-options-cm734308,Investors eyeing a purchase of Biogen Inc Symbol BIIB shares but tentative about paying the going market price of 285 79 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the January 2019 put
BIIB,BIIB:UW,BBG000C18861,"Why Netflix, Inc. (NFLX) Stock Could Pop After Q4 Earnings",2017-01-17 17:38:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S_feH3SBDwc/why-netflix-inc-nflx-stock-could-pop-after-q4-earnings-cm734277,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Internet movie streaming giant Netflix Inc NASDAQ NFLX will report fourth quarter 2016 earnings results after the closing bell Wednesday And given the the history of NFLX stock which tends
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen's Pricey Anxiety Cure Worth Every Penny,2017-01-17 17:04:56 +0000,http://www.wsj.com/articles/biogens-pricey-anxiety-cure-worth-every-penny-1484672693?mod=yahoo_hs,[$$] Biogen's Pricey Anxiety Cure Worth Every Penny
BIIB,BIIB:UW,BBG000C18861,Forward Pharma Shares Jump on Biogen License Agreement,2017-01-17 17:00:00 +0000,https://www.thestreet.com/story/13956211/1/forward-pharma-shares-jump-on-biogen-license-agreement.html?puc=yahoo&cm_ven=YAHOO,Forward Pharma Shares Jump on Biogen License Agreement
BIIB,BIIB:UW,BBG000C18861,"3 Stocks to Watch on Tuesday: Chipotle Mexican Grill, Inc. (CMG), Noble Energy, Inc. (NBL) and Wells Fargo & Co (WFC)",2017-01-17 16:38:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qrF6CQSirxE/3-stocks-to-watch-on-tuesday-chipotle-mexican-grill-inc-cmg-noble-energy-inc-nbl-and-wells-fargo-co-wfc-cm734306,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips U S markets will get back up to speed today after a long holiday weekend But the shortened week will still be an interesting week as earnings season will kick into high gear before it s
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for Microsoft, Biogen & Home Depot",2017-01-17 16:36:04 +0000,http://finance.yahoo.com/news/top-research-reports-microsoft-biogen-163604664.html,"Top Research Reports for Microsoft, Biogen & Home Depot"
BIIB,BIIB:UW,BBG000C18861,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates,2017-01-17 16:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9BHelqEtYCs/mid-morning-market-update-markets-open-lower-morgan-stanley-tops-q4-estimates-cm734250,Following the market opening Tuesday the Dow traded down 0 33 percent to 19 820 99 while the NASDAQ declined 0 56 percent to 5 543 14 The S amp P also fell dropping 0 33 percent to 2 267 06 Leading and Lagging Sectors Utilities shares gained around 0 85 percent in trading
BIIB,BIIB:UW,BBG000C18861,Tuesday’s Top Biopharma Movers,2017-01-17 16:05:41 +0000,http://finance.yahoo.com/news/tuesday-top-biopharma-movers-160541880.html,Tuesday’s Top Biopharma Movers
BIIB,BIIB:UW,BBG000C18861,Biogen’s $1.25 billion agreement with Forward Pharma is a very expensive insurance policy on its most valuable drug,2017-01-17 15:46:29 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=AB6E6658-DCC1-11E6-A24A-91C583C99698&siteid=yhoof2,Biogen’s $1.25 billion agreement with Forward Pharma is a very expensive insurance policy on its most valuable drug
BIIB,BIIB:UW,BBG000C18861,"Biogen Inc (BIIB) Will Win a Battle, But Could Lose the War",2017-01-17 15:36:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7SmbskNbYT0/biogen-inc-biib-will-win-a-battle-but-could-lose-the-war-cm734112,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips New Biogen Inc NASDAQ BIIB CEO Michel Vounatsos must not have been paying much attention to American media or politics over the past year and a half That or he has
BIIB,BIIB:UW,BBG000C18861,Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis,2017-01-17 15:30:00 +0000,http://uk.finance.yahoo.com/news/siemens-healthineers-biogen-announce-agreement-153000252.html,Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis
BIIB,BIIB:UW,BBG000C18861,Biogen to pay $1.25B settlement in multiple sclerosis drug case,2017-01-17 15:05:07 +0000,http://www.bizjournals.com/boston/news/2017/01/17/biogen-to-pay-1-25b-settlement-in-tecfidera.html?ana=yahoo,Biogen to pay $1.25B settlement in multiple sclerosis drug case
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen Reaches Settlement and License Agreement for MS Drug,2017-01-17 14:45:50 +0000,http://www.wsj.com/articles/biogen-reaches-settlement-and-license-agreement-for-ms-drug-1484664347?mod=yahoo_hs,[$$] Biogen Reaches Settlement and License Agreement for MS Drug
BIIB,BIIB:UW,BBG000C18861,Forward Pharma stock skyrockets 53% on $1.25 bln cash licensing agreement with Biogen,2017-01-17 12:52:47 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=6993A7E5-657D-4499-AE4E-C1A9ED718195&siteid=yhoof2,Forward Pharma stock skyrockets 53% on $1.25 bln cash licensing agreement with Biogen
BIIB,BIIB:UW,BBG000C18861,"BIOGEN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex",2017-01-17 12:39:39 +0000,http://biz.yahoo.com/e/170117/biib8-k.html,"BIOGEN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex"
BIIB,BIIB:UW,BBG000C18861,Biogen and Forward Pharma Agree to Enter into Settlement and License Agreement,2017-01-17 12:30:00 +0000,http://finance.yahoo.com/news/biogen-forward-pharma-agree-enter-123000405.html,"[Business Wire] - Biogen Inc. today announced that it has agreed to enter into a settlement and license agreement with Forward Pharma, subject to the approval of Forward Pharma’s shareholders and other customary conditions."
BIIB,BIIB:UW,BBG000C18861,New and Returning Bio-Tech Stock Picks for 2017,2017-01-17 09:49:00 +0000,http://www.investopedia.com/news/new-and-returning-biotech-stock-picks-2017-gild-incy/?partner=YahooSA,New and Returning Bio-Tech Stock Picks for 2017
BIIB,BIIB:UW,BBG000C18861,Biogen To Pay $1.25 Bln For Forward Pharma Intellectual Property - Quick Facts,2017-01-17 07:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/luSZ1UvGGRM/biogen-to-pay-125-bln-for-forward-pharma-intellectual-property--quick-facts-20170117-00437,Biogen To Pay $1.25 Bln For Forward Pharma Intellectual Property - Quick Facts
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal",2017-01-16 16:38:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dCSEWzbJpnQ/the-zacks-analyst-blog-highlights-alibaba-costco-walgreens-boots-biogen-and-paypal-cm733910,For Immediate Release Chicago IL January 16 2017 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the
BIIB,BIIB:UW,BBG000C18861,Biogen Says Spinraza Drug Did Well In Phase 3 Trial,2017-01-16 14:45:00 +0000,http://www.investopedia.com/news/biogens-spinraza-did-well-phase-3-biib-ions/?partner=YahooSA,Biogen Says Spinraza Drug Did Well In Phase 3 Trial
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Presents Positive Phase III Data on Spinraza,2017-01-16 14:39:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2gxAH3CYbxs/biogen-biib-presents-positive-phase-iii-data-on-spinraza-cm733815,Biogen Inc BIIB presented positive data from the phase III ENDEAR study evaluating Spinraza nusinersen for the treatment of spinal muscular atrophy SMA Data from the study demonstrated a statistically significant reduction in the risk of death or permanent ventilation in infants
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal",2017-01-16 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-alibaba-143002029.html,"The Zacks Analyst Blog Highlights: Alibaba, Costco, Walgreens Boots, Biogen and PayPal"
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Presents Positive Phase III Data on Spinraza,2017-01-16 12:41:12 +0000,http://finance.yahoo.com/news/biogen-biib-presents-positive-phase-124112129.html,Biogen (BIIB) Presents Positive Phase III Data on Spinraza
BIIB,BIIB:UW,BBG000C18861,Is Biogen's Stock Ready to Heat Up After a Forgettable 2016?,2017-01-13 23:39:44 +0000,http://www.fool.com/investing/2017/01/13/is-biogens-stock-ready-to-heat-up-after-a-forgetta.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Biogen's Stock Ready to Heat Up After a Forgettable 2016?
BIIB,BIIB:UW,BBG000C18861,"Market Close Report: Historical high reached as NASDAQ Composite Index closes at 5,574.12.",2017-01-13 21:48:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5qHJ7qNQ0FY/market-close-report-historical-high-reached-as-nasdaq-composite-index-closes-at-557412-cm733533,Friday s session closes with the NASDAQ Composite Index reaching a historical high The index closed at 5 574 12 up 26 63 for the day The index first reached the 5000 mark on 01 11 2017 The total shares traded for the NASDAQ was over 1 8 billion Friday s session closes with the NASDAQ
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for Alibaba, Costco & Walgreens",2017-01-13 21:37:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wfdiiSy-8sM/top-research-reports-for-alibaba-costco-walgreens-cm733520,Friday January 13 2017 Today s Research Daily features new research reports on 16 major stocks including Alibaba BABA Costco COST and Walgreens Boots WBA Alibaba have outperformed the broader market as well as the peer e commerce space over the last one year it is up more
BIIB,BIIB:UW,BBG000C18861,"Biogen's latest drug may be costly, but new data suggests it saves lives",2017-01-13 19:20:08 +0000,http://www.bizjournals.com/boston/news/2017/01/13/biogens-latest-drug-may-be-costly-but-new-data.html?ana=yahoo,"Biogen's latest drug may be costly, but new data suggests it saves lives"
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for Alibaba, Costco & Walgreens",2017-01-13 18:32:06 +0000,http://finance.yahoo.com/news/top-research-reports-alibaba-costco-183206039.html,"Top Research Reports for Alibaba, Costco & Walgreens"
BIIB,BIIB:UW,BBG000C18861,Is Biogen's Stock Ready to Heat Up After a Forgettable 2016?,2017-01-13 17:39:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sIzZtjnkiuw/is-biogens-stock-ready-to-heat-up-after-a-forgettable-2016-cm733364,Image source Getty Images What happened According to data from S amp P Global Market Intelligence Biogen s NASDAQ BIIB shares lost 7 in 2016 The underlying reason for this dip is the biotech s inability to shake off the political turmoil surrounding specialty
BIIB,BIIB:UW,BBG000C18861,Biogen Spinoff Bioverativ In Good Shape for Launch,2017-01-13 15:16:00 +0000,http://www.investopedia.com/news/biogen-spinoff-bioverativ-set-takeoff-biib/?partner=YahooSA,Biogen Spinoff Bioverativ In Good Shape for Launch
BIIB,BIIB:UW,BBG000C18861,Ionis Has High Hopes for Heart Drug Volanesorsen,2017-01-13 14:55:00 +0000,http://www.investopedia.com/news/ionis-sets-sights-volanesorsen-heart-drug-ions/?partner=YahooSA,Ionis Has High Hopes for Heart Drug Volanesorsen
BIIB,BIIB:UW,BBG000C18861,"Bioverativ Makes Splash in Trading Debut, Gaining 18% on Day One",2017-01-13 13:31:00 +0000,https://www.thestreet.com/story/13953217/1/bioverativ-makes-splash-in-trading-debut-gaining-18-on-day-one.html?puc=yahoo&cm_ven=YAHOO,"Bioverativ Makes Splash in Trading Debut, Gaining 18% on Day One"
BIIB,BIIB:UW,BBG000C18861,New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy,2017-01-13 12:30:00 +0000,http://uk.finance.yahoo.com/news/data-show-spinraza-nusinersen-significantly-123000661.html,New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
BIIB,BIIB:UW,BBG000C18861,Biogen Presents New Data From Phase 3 ENDEAR Study Of SPINRAZA,2017-01-13 07:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ezScfZuJxXI/biogen-presents-new-data-from-phase-3-endear-study-of-spinraza-20170113-00142,Biogen Presents New Data From Phase 3 ENDEAR Study Of SPINRAZA
BIIB,BIIB:UW,BBG000C18861,​Trump’s HHS nominee has promised to divest from these Mass. companies,2017-01-12 22:10:08 +0000,http://www.bizjournals.com/boston/news/2017/01/12/trump-s-hhs-nominee-has-promised-to-divest-from.html?ana=yahoo,​Trump’s HHS nominee has promised to divest from these Mass. companies
BIIB,BIIB:UW,BBG000C18861,Energous Corp Shines Brightly as the Next Fortune-Building Company (WATT),2017-01-12 16:01:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lI6DOiBivEM/energous-corp-shines-brightly-as-the-next-fortune-building-company-watt-cm732815,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The student threw his hands up in frustration Professor he said I just don t get it He slumped in his chair totally defeated I understood the feeling I had spent more than
BIIB,BIIB:UW,BBG000C18861,Biotech Short Sellers Run for Cover,2017-01-12 14:35:19 +0000,http://finance.yahoo.com/news/biotech-short-sellers-run-cover-143519393.html,Biotech Short Sellers Run for Cover
BIIB,BIIB:UW,BBG000C18861,Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again,2017-01-12 13:59:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zeRYgq2tqVE/deja-vu-for-drug-stocks-as-trump-slams-drug-pricing-again-cm732558,It was déjà vu for the healthcare sector with pharma and biotech stocks once again being hit by President elect Donald Trump s comments regarding drug pricing Although drug stocks had rallied following Trump s surprise win in November reflecting relief that the price controls that Hillary
BIIB,BIIB:UW,BBG000C18861,Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock,2017-01-12 13:00:00 +0000,http://finance.yahoo.com/news/biogen-spin-off-bioverativ-commences-130000372.html,"[Business Wire] - Biogen today announced that it has been advised by NASDAQ that the common stock for Bioverativ, the spinoff of its global hemophilia business, begins trading today, Thursday, January 12, 2017, on a ""when-issued"" basis under the symbol ""BIVVV"" on the NASDAQ Global Select Market."
BIIB,BIIB:UW,BBG000C18861,"Choppy Day As Trump Targets Pharma, Lockheed; Netflix, Amazon Up",2017-01-11 23:38:29 +0000,http://finance.yahoo.com/video/choppy-day-trump-targets-pharma-233829891.html,"Choppy Day As Trump Targets Pharma, Lockheed; Netflix, Amazon Up"
BIIB,BIIB:UW,BBG000C18861,"Notable Wednesday Option Activity: BIIB, MRK, AMGN",2017-01-11 20:57:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LZ4vCH65tAI/notable-wednesday-option-activity-biib-mrk-amgn-cm732407,Looking at options trading activity among components of the S amp P 500 index there is noteworthy activity today in Biogen Inc Symbol BIIB where a total volume of 8 770 contracts has been traded thus far today a contract volume which is representative of approximately 877 000
BIIB,BIIB:UW,BBG000C18861,Trump's Comments Slam Drug Stocks,2017-01-11 18:59:35 +0000,http://blogs.wsj.com/moneybeat/2017/01/11/trump-slams-drug-stocks-at-press-conference/?mod=yahoo_hs,Trump's Comments Slam Drug Stocks
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short",2017-01-11 15:59:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p5QQEtaGVTI/biotech-stock-roundup-ariad-to-be-acquired-for-52b-vertex-outlook-falls-short-cm732170,The big news in the biotech sector this week is the acquisition agreement under which Japanese firm Takeda will be acquiring cancer focused ARIAD ARIA for a whopping 5 2 billion Several other licensing deals and agreements were announced this week as well Recap of the Week s Most
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : January 11, 2017",2017-01-11 15:27:56 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-value-analysis-nasdaqbiib-january-11-2017/,"Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : January 11, 2017"
BIIB,BIIB:UW,BBG000C18861,The 1 Biotech Stock I Want to Own in 2017,2017-01-11 14:57:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lbvtJSx9Jks/the-1-biotech-stock-i-want-to-own-in-2017-cm732099,For most biotechs about to turn the profitability corner launching the first ever treatment for the most common genetic cause of infant mortality might be their biggest headline of the year But the launch of Spinraza is just the beginning of a year packed with catalysts for
BIIB,BIIB:UW,BBG000C18861,Biogen Inc (BIIB) Stock Should Move Higher in 2017,2017-01-11 14:57:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y0VU6JBAAYo/biogen-inc-biib-stock-should-move-higher-in-2017-cm732091,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The rising cost of prescription drugs or price gouging as some would say was the prevailing theme within the biotech sector in 2016 sending Biogen Inc NASDAQ BIIB and BIIB stock lower by
BIIB,BIIB:UW,BBG000C18861,Todd Hagopian's Top Biotech Takeover Targets For 2017,2017-01-10 17:59:00 +0000,http://www.forbes.com/sites/kenkam/2017/01/10/todd-hagopians-top-biotech-takeover-targets-for-2017/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Todd Hagopian's Top Biotech Takeover Targets For 2017
BIIB,BIIB:UW,BBG000C18861,"Stock Market News for January 10, 2017",2017-01-10 17:52:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A1kLfWq71wQ/stock-market-news-for-january-10-2017-cm731728,Benchmarks mostly ended in the red on Monday led by declines in energy shares Rise in oil prices dragged energy shares down Oil prices took a beating on concerns that rise in Iraqi exports and US output could adversely affect the impact of a deal among major oil producers to curtail
BIIB,BIIB:UW,BBG000C18861,3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock,2017-01-10 16:54:31 +0000,http://www.fool.com/investing/2017/01/10/3-big-reasons-and-6-smaller-ones-to-buy-ionis-phar.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock
BIIB,BIIB:UW,BBG000C18861,3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock,2017-01-10 16:54:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FEyk7s7HQNU/3-big-reasons-and-8-smaller-ones-to-buy-ionis-pharmaceuticals-stock-cm731674,If you were looking for a reason to buy Ionis Pharmaceuticals NASDAQ IONS stock the biotech s CEO gave several in his presentation at the J P Morgan Healthcare Conference on Monday Here are three big reasons to buy Ionis shares in 2017 and eight smaller
BIIB,BIIB:UW,BBG000C18861,"Biogen CEO Vounatsos on Drug Pipeline, Pricing",2017-01-10 16:01:27 +0000,http://finance.yahoo.com/video/biogen-ceo-vounatsos-drug-pipeline-160127518.html,"Biogen CEO Vounatsos on Drug Pipeline, Pricing"
BIIB,BIIB:UW,BBG000C18861,Top Stocks to Buy Now That the 21st Century Cures Act Has Passed,2017-01-10 14:39:05 +0000,http://www.fool.com/investing/2017/01/09/top-stocks-to-buy-now-that-the-21st-century-cures.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Top Stocks to Buy Now That the 21st Century Cures Act Has Passed
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : January 10, 2017",2017-01-10 12:26:02 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-biib-us-january-10-2017/,"Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : January 10, 2017"
BIIB,BIIB:UW,BBG000C18861,This Could Very Well Be the Greatest Drug Advancement in a Decade,2017-01-09 19:50:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5e5_lqVKef0/this-could-very-well-be-the-greatest-drug-advancement-in-a-decade-cm731243,There have been a lot of exciting advances in medicine over the past 10 years Drugs that help cancer patients live longer have become available as have therapies that functionally cure hepatitis C However one area of research that hasn t advanced is the development of new weapons in
BIIB,BIIB:UW,BBG000C18861,This Could Very Well Be the Greatest Drug Advancement in a Decade,2017-01-09 18:01:07 +0000,http://www.fool.com/investing/2017/01/09/this-could-very-well-be-the-greatest-drug-advancem.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,This Could Very Well Be the Greatest Drug Advancement in a Decade
BIIB,BIIB:UW,BBG000C18861,Top Stocks to Buy Now That the 21st Century Cures Act Has Passed,2017-01-09 15:52:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kMQaWvon3ZM/top-stocks-to-buy-now-that-the-21st-century-cures-act-has-passed-cm731004,Now that Washington has signed off on the 21st Century Cures Act deregulation streamlining and billions of additional research dollars could cause healthcare stocks to pop Do you own the stocks most likely to benefit In this clip from The Motley Fool s Industry
BIIB,BIIB:UW,BBG000C18861,3 Takeover Candidates in the Drug Space,2017-01-08 19:00:00 +0000,http://realmoney.thestreet.com/articles/01/08/2017/3-takeover-candidates-drug-space?puc=yahoo&cm_ven=YAHOO,3 Takeover Candidates in the Drug Space
BIIB,BIIB:UW,BBG000C18861,"Biogen's New CEO: Lots of Questions, Few Answers",2017-01-07 00:25:00 +0000,http://www.fool.com/investing/2017/01/06/biogens-new-ceo-lots-of-questions-few-answers.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Biogen's New CEO: Lots of Questions, Few Answers"
BIIB,BIIB:UW,BBG000C18861,Biotech icon George Scangos returns to Bay Area with big startup,2017-01-07 00:21:48 +0000,http://www.bizjournals.com/sanfrancisco/news/2017/01/06/george-scangos-vir-gates-arch-biogen-biib.html?ana=yahoo,Biotech icon George Scangos returns to Bay Area with big startup
BIIB,BIIB:UW,BBG000C18861,"Biogen's New CEO: Lots of Questions, Few Answers",2017-01-06 21:49:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W2gX_0zs6wo/biogens-new-ceo-lots-of-questions-few-answers-cm730580,Biogen NASDAQ BIIB named Michel 160 Vounatsos as CEO on Dec 19 2016 Just a few weeks later Vounatsos had his first moment to shine at the Goldman Sachs Healthcare CEOs Unscripted event held on Jan 5 2017 Biogen s new CEO was asked plenty of questions but by my count
BIIB,BIIB:UW,BBG000C18861,Biotech Investing: 3 Bold Predictions for 2017,2017-01-06 15:55:41 +0000,http://www.fool.com/investing/2017/01/06/biotech-investing-3-bold-predictions-for-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech Investing: 3 Bold Predictions for 2017
BIIB,BIIB:UW,BBG000C18861,Biogen Licenses Amunix's XTEN Technology for Factor IX Drug,2017-01-06 15:42:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YvXiAd85Cv8/biogen-licenses-amunixs-xten-technology-for-factor-ix-drug-cm730322,Biogen Inc BIIB exercised its option to enter into an exclusive global license agreement with California based private biotechnology company Amunix Operating Inc to incorporate the latter s proprietary XTEN half life extension technology in developing a recombinant Factor IX
BIIB,BIIB:UW,BBG000C18861,Biotech Investing: 3 Bold Predictions for 2017,2017-01-06 14:40:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75sL-Uy4MWA/biotech-investing-3-bold-predictions-for-2017-cm730229,Making bold predictions actually isn t too hard to do Having them come true is another story altogether Nevertheless a new year is now upon us and I can t resist the urge to make a few bold predictions about the world of biotech investing in 2017 A handful of biotechs showed up in
BIIB,BIIB:UW,BBG000C18861,Biogen Licenses Amunix's XTEN Technology for Factor IX Drug,2017-01-06 13:32:01 +0000,http://finance.yahoo.com/news/biogen-licenses-amunixs-xten-technology-133201190.html,Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
BIIB,BIIB:UW,BBG000C18861,​New Biogen CEO explains hefty price tag for newest drug,2017-01-06 12:05:06 +0000,http://www.bizjournals.com/boston/news/2017/01/06/new-biogen-ceo-explains-hefty-price-tag-for.html?ana=yahoo,​New Biogen CEO explains hefty price tag for newest drug
BIIB,BIIB:UW,BBG000C18861,Biogen Investor Day At 10:00 AM ET,2017-01-06 06:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WaNPX94OFmw/biogen-investor-day-at-1000-am-et-20170106-00081,Biogen Investor Day At 10:00 AM ET
BIIB,BIIB:UW,BBG000C18861,5 Slides Every Ionis Pharmaceuticals Inc Investor Needs to See,2017-01-05 23:37:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IkXBWX9U0Ec/5-slides-every-ionis-pharmaceuticals-inc-investor-needs-to-see-cm730148,Ionis Pharmaceuticals NASDAQ IONS gave investors an update on its pipeline today with a slide deck that contained a whopping 65 entries The whole presentation is worth a listen but here are the five slides investors absolutely must see 1 Now that s what I call a
BIIB,BIIB:UW,BBG000C18861,5 Slides Every Ionis Pharmaceuticals Inc Investor Needs to See,2017-01-05 21:55:23 +0000,http://www.fool.com/investing/2017/01/05/5-slides-every-ionis-pharmaceuticals-inc-investor.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Slides Every Ionis Pharmaceuticals Inc Investor Needs to See
BIIB,BIIB:UW,BBG000C18861,Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference,2017-01-05 19:40:11 +0000,http://www.bizjournals.com/boston/news/2017/01/05/heres-what-to-expect-from-mass-biotechs-at-this.html?ana=yahoo,Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference
BIIB,BIIB:UW,BBG000C18861,Drug Price Debate May Lead to Smaller Price Hikes,2017-01-05 17:43:00 +0000,http://www.investopedia.com/news/drug-makers-may-cap-price-hikes-2017-agn/?partner=YahooSA,Drug Price Debate May Lead to Smaller Price Hikes
BIIB,BIIB:UW,BBG000C18861,"Noteworthy ETF Outflows: IYH, CELG, BIIB, AET",2017-01-05 17:37:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/icxUke8jXv8/noteworthy-etf-outflows-iyh-celg-biib-aet-cm729874,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares U S Healthcare ETF Symbol IYH where we have detected an approximate 73 5 million dollar outflow that s a 4 0 decrease week over week from 12 600
BIIB,BIIB:UW,BBG000C18861,"Biogen exercises option to enter into exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN(R) half-life extension technology",2017-01-05 17:30:00 +0000,http://finance.yahoo.com/news/biogen-exercises-option-enter-exclusive-173000336.html,"[Marketwired] - Amunix Operating Inc. announced today that Biogen has exercised its option to enter into an exclusive, worldwide license agreement to develop and commercialize a novel, recombinant Factor IX product candidate ..."
BIIB,BIIB:UW,BBG000C18861,Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile Vomiting,2017-01-05 16:04:00 +0000,https://www.thestreet.com/story/13943872/1/warning-sell-side-analyst-call-on-failed-ionis-biogen-drug-causes-projectile-vomiting.html?puc=yahoo&cm_ven=YAHOO,Warning: Sell-Side Analyst Call on Failed Ionis-Biogen Drug Causes Projectile Vomiting
BIIB,BIIB:UW,BBG000C18861,Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data,2017-01-05 14:41:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pw4sLEZ9kOU/ionis-ions-stock-up-on-positive-type-ii-diabetes-drug-data-cm729791,Shares of Ionis Pharmaceuticals Inc IONS were up 4 2 after the company announced encouraging data from a phase II study on IONIS GCGR for the treatment type II diabetes Ionis share price movement in 2016 shows that the company has outperformed the Zacks classified Medical
BIIB,BIIB:UW,BBG000C18861,Is Biogen Playing With Fire?,2017-01-05 11:54:57 +0000,http://www.fool.com/investing/2017/01/04/spinrazas-price-is-333-higher-than-expected-is-bio.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Biogen Playing With Fire?
BIIB,BIIB:UW,BBG000C18861,Is Biogen Playing With Fire?,2017-01-04 23:37:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GPYsFl7vs94/is-biogen-playing-with-fire-cm729582,Yesterday Biogen NASDAQ BIIB and its partner Ionis Pharmaceuticals NASDAQ IONS announced that their newly approved spinal muscular atrophy SMA drug Spinraza will sport an 160 initial WAC price of 125 000 per vial That translates into an annual cost of 750 000 for
BIIB,BIIB:UW,BBG000C18861,Buy health care despite Obamacare battle?,2017-01-04 22:19:00 +0000,http://finance.yahoo.com/video/buy-health-care-despite-obamacare-221900214.html,Buy health care despite Obamacare battle?
BIIB,BIIB:UW,BBG000C18861,Did Biogen Just Throw in the Towel to Celgene?,2017-01-04 16:55:26 +0000,http://www.fool.com/investing/2017/01/04/did-biogen-just-throw-in-the-towel-to-celgene.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Did Biogen Just Throw in the Towel to Celgene?
BIIB,BIIB:UW,BBG000C18861,"Biogen, Ionis Under Fire for Pricey Drug Spinraza",2017-01-04 15:57:00 +0000,http://www.investopedia.com/news/biogen-ionis-under-fire-spinraza-biib-ions/?partner=YahooSA,"Biogen, Ionis Under Fire for Pricey Drug Spinraza"
BIIB,BIIB:UW,BBG000C18861,Did Biogen Just Throw in the Towel to Celgene?,2017-01-04 14:39:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eUaAJovuKYw/did-biogen-just-throw-in-the-towel-to-celgene-cm729112,Image source kb3training com Specialty medicines are only used by 1 2 of the U S population but they re downright costly In fact in 2015 specialty drugs represented 37 of nationwide drug spend and this figure is expected to reach 50 by 2018 With inflammatory conditions
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation",2017-01-04 13:38:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1Nr2bJB8Qk8/biotech-stock-roundup-inotek-plunges-on-pipeline-setback-kite-files-ind-for-study-initiation-cm729122,It was a relatively slow week for the biotech sector though companies like Inotek ITEK and OPKO OPK made it to the headlines due to pipeline setbacks Recap of the Week s Most Important Stories Inotek Shares Hit by Disappointing Data Inotek s shares plunged 71 3 on news that
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation",2017-01-04 12:21:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-inotek-plunges-122112679.html,"Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation"
BIIB,BIIB:UW,BBG000C18861,My Worst Predictions for Biotech in 2016,2017-01-04 00:37:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LkRSCAzdKpU/my-worst-predictions-for-biotech-in-2016-cm729008,It s never fun to admit you re wrong but anyone who has been involved in the markets for years knows that much like in baseball failure is more common than success Last year my 5 Biotech Predictions for 2016 was filled with failure including a doozy of a prediction that
BIIB,BIIB:UW,BBG000C18861,My Worst Predictions for Biotech in 2016,2017-01-03 22:41:09 +0000,http://www.fool.com/investing/2017/01/03/my-worst-predictions-for-biotech-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,My Worst Predictions for Biotech in 2016
BIIB,BIIB:UW,BBG000C18861,"New year, new drug prices",2017-01-03 19:42:00 +0000,http://finance.yahoo.com/video/drug-prices-194200228.html,"New year, new drug prices"
BIIB,BIIB:UW,BBG000C18861,"Biogen boosts price of top MS drugs, analyst says",2017-01-03 18:30:08 +0000,http://www.bizjournals.com/boston/news/2017/01/03/biogen-boosts-price-of-top-drugs-analyst-says.html?ana=yahoo,"Biogen boosts price of top MS drugs, analyst says"
BIIB,BIIB:UW,BBG000C18861,17 Thoughts on Biotech Stocks to Kick Off 2017,2017-01-03 11:35:00 +0000,https://www.thestreet.com/story/13939672/1/17-thoughts-on-biotech-stocks-to-kick-off-2017.html?puc=yahoo&cm_ven=YAHOO,17 Thoughts on Biotech Stocks to Kick Off 2017
BIIB,BIIB:UW,BBG000C18861,Biotech Stocks: What to Watch in 2017,2017-01-02 16:54:17 +0000,http://www.fool.com/investing/2017/01/01/biotech-stocks-what-to-watch-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biotech Stocks: What to Watch in 2017
BIIB,BIIB:UW,BBG000C18861,Gilead Sciences’ Valuation Compared to Its Peers,2016-12-30 21:16:51 +0000,http://marketrealist.com/2016/12/gilead-sciences-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,Gilead Sciences’ Valuation Compared to Its Peers
BIIB,BIIB:UW,BBG000C18861,Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains?,2016-12-30 17:45:24 +0000,http://www.investors.com/news/technology/which-top-5-biotech-performers-are-slated-for-triple-digit-gains/,Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains?
BIIB,BIIB:UW,BBG000C18861,AbbVie's Humira and Imbruvica Drive Performance in 2016,2016-12-30 15:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lFdGUIrPtiM/abbvies-humira-and-imbruvica-drive-performance-in-2016-cm727887,North Chicago IL based AbbVie Inc ABBV came into existence on Jan 1 2013 after Abbott Laboratories ABT divested its pharmaceutical division AbbVie has a presence in the rheumatoid arthritis cancer psoriasis Crohn s disease HIV hepatitis C virus HCV testosterone thyroid
BIIB,BIIB:UW,BBG000C18861,"Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says",2016-12-30 11:59:21 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=374D584A-CDF5-11E6-BC29-4D3093487538&siteid=yhoof2,"Extremely expensive Biogen rare disease drug could invite tweet by President-elect Trump, analyst says"
BIIB,BIIB:UW,BBG000C18861,"Investors Siphon Biogen, Ionis Gains After Spinal Disease Drug's OK",2016-12-29 21:09:16 +0000,http://www.investors.com/news/technology/investors-siphon-biogen-ionis-profits-after-spinal-disease-drug-ok/,"Investors Siphon Biogen, Ionis Gains After Spinal Disease Drug's OK"
BIIB,BIIB:UW,BBG000C18861,"Texas Instruments A Buy; Biogen, 21st Century Fox PTs Hiked",2016-12-29 21:07:32 +0000,http://www.investors.com/news/biogen-pt-hiked-texas-instruments-a-buy-senior-housing-upgraded/,"[at Investor's Business Daily] - Texas Instruments was initiated with a buy rating, and Biogen's price target was hiked."
BIIB,BIIB:UW,BBG000C18861,Red flag over Biogen's very expensive drug,2016-12-29 18:23:00 +0000,http://finance.yahoo.com/video/red-flag-over-biogens-very-182300564.html,Red flag over Biogen's very expensive drug
BIIB,BIIB:UW,BBG000C18861,​Analyst hikes sales estimates for Biogen’s spinal-disease drug,2016-12-29 15:10:02 +0000,http://www.bizjournals.com/boston/news/2016/12/28/analyst-hikes-sales-estimates-for-biogen-s-spinal.html?ana=yahoo,​Analyst hikes sales estimates for Biogen’s spinal-disease drug
BIIB,BIIB:UW,BBG000C18861,Biogen: Starting the New Year Off With a Bang?,2016-12-29 15:03:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/29/biogen-starting-the-new-year-off-with-a-bang/?mod=yahoobarrons&ru=yahoo,Biogen: Starting the New Year Off With a Bang?
BIIB,BIIB:UW,BBG000C18861,Will Spinraza Supercharge Biogen's Top Line Next Year?,2016-12-28 23:57:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L35GNbl_nYw/will-spinraza-supercharge-biogens-top-line-next-year-cm727201,Last Friday Christmas came early for Biogen NASDAQ BIIB and Ionis Pharmaceuticals NASDAQ IONS 160 with the FDA approval of their spinal muscular atrophy SMA drug Spinraza nusinersen SMA is an inherited neurological disorder that results in progressive muscle
BIIB,BIIB:UW,BBG000C18861,"Why Twilio, Northern Dynasty Minerals, and Ionis Pharmaceuticals Slumped Today",2016-12-28 23:57:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P42_cIKu92A/why-twilio-northern-dynasty-minerals-and-ionis-pharmaceuticals-slumped-today-cm727194,The stock market performed poorly on Wednesday coasting into the end of what has been a strong year for most major market benchmarks Popular stock market indexes were down as much as 1 on the day and the Dow Jones Industrials fell by triple digits getting further away from
BIIB,BIIB:UW,BBG000C18861,"Why Twilio, Northern Dynasty Minerals, and Ionis Pharmaceuticals Slumped Today",2016-12-28 22:39:00 +0000,http://www.fool.com/investing/2016/12/28/why-twilio-northern-dynasty-minerals-and-ionis-pha.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news,"Why Twilio, Northern Dynasty Minerals, and Ionis Pharmaceuticals Slumped Today"
BIIB,BIIB:UW,BBG000C18861,Will Spinraza Supercharge Biogen's Top Line Next Year?,2016-12-28 22:22:31 +0000,http://www.fool.com/investing/2016/12/28/will-spinraza-supercharge-biogens-top-line-next-ye.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Will Spinraza Supercharge Biogen's Top Line Next Year?
BIIB,BIIB:UW,BBG000C18861,Biogen Could Suffer Near Term as the Chart Picture Erodes,2016-12-28 18:43:00 +0000,http://realmoney.thestreet.com/articles/12/28/2016/biogen-could-suffer-near-term-chart-picture-erodes?puc=yahoo&cm_ven=YAHOO,Biogen Could Suffer Near Term as the Chart Picture Erodes
BIIB,BIIB:UW,BBG000C18861,iShares Edge MSCI USA Quality Factor ETF Experiences Big Outflow,2016-12-28 17:00:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FpmD-3PQfUw/ishares-edge-msci-usa-quality-factor-etf-experiences-big-outflow-cm726968,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Edge MSCI USA Quality Factor ETF Symbol QUAL where we have detected an approximate 59 3 million dollar outflow that s a 1 7 decrease week over
BIIB,BIIB:UW,BBG000C18861,Biotech Short Interest Sinks,2016-12-28 15:10:48 +0000,http://finance.yahoo.com/news/biotech-short-interest-sinks-151048968.html,Biotech Short Interest Sinks
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold",2016-12-28 15:02:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5Jkz0UVgKkE/biotech-stock-roundup-fda-nod-for-biogenionis-drug-seattle-genetics-hit-by-clinical-hold-cm726791,Biogen BIIB and Ionis IONS got an early Christmas gift with the FDA approving their spinal muscular atrophy SMA treatment Spinraza three months within the filing of the regulatory application Meanwhile Seattle Genetics SGEN has been hit by clinical holds on several early stage
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold",2016-12-28 12:32:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-fda-nod-123212945.html,"Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold"
BIIB,BIIB:UW,BBG000C18861,The 3 Biggest Risks for Pfizer in 2017,2016-12-28 12:23:22 +0000,http://www.fool.com/investing/2016/12/27/3-biggest-risks-for-pfizer-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The 3 Biggest Risks for Pfizer in 2017
BIIB,BIIB:UW,BBG000C18861,Biotech plays for the new year,2016-12-28 11:52:00 +0000,http://finance.yahoo.com/video/biotech-plays-115200673.html,Biotech plays for the new year
BIIB,BIIB:UW,BBG000C18861,"Biogen, Ionis Get FDA Approval For SMA Drug",2016-12-28 08:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eucfeC5bOOA/biogen-ionis-get-fda-approval-for-sma-drug-20161228-00112,"Biogen, Ionis Get FDA Approval For SMA Drug"
BIIB,BIIB:UW,BBG000C18861,[$$] Surprise Drug Approval Is Holiday Gift for Biogen,2016-12-28 04:43:11 +0000,http://www.wsj.com/articles/surprise-drug-approval-is-holiday-gift-for-biogen-1482856447?ru=yahoo?mod=yahoo_itp,[$$] Surprise Drug Approval Is Holiday Gift for Biogen
BIIB,BIIB:UW,BBG000C18861,3 Biggest Risks for AbbVie in 2017,2016-12-27 21:57:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eQh4Vq8ESko/3-biggest-risks-for-abbvie-in-2017-cm726661,On paper 2016 should have been a pretty good year for AbbVie NYSE ABBV Revenue climbed nearly 15 year over year in the first three quarters Earnings jumped 26 during this period from the prior year And yet AbbVie s stock price hasn t gone up much What s more the new
BIIB,BIIB:UW,BBG000C18861,"Health Care Sector Update for 12/27/2016: IONS,BIIB,CAPN,ENGX",2016-12-27 21:17:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t1us-I_fg5g/health-care-sector-update-for-12272016-ionsbiibcapnengx-cm726668,Top Health Care StocksTop Health Care Stocks JNJ 0 19 JNJ 0 19 PFE 0 28 PFE 0 28 MRK 0 55 MRK 0 55 ABT 0 49 ABT 0 49 AMGN 0 78 AMGN 0 78 Health care stocks were moderately higher today with the NYSE Health Care Index climbing about 0 2 while shares of health care companies in
BIIB,BIIB:UW,BBG000C18861,3 Biggest Risks for AbbVie in 2017,2016-12-27 20:53:23 +0000,http://www.fool.com/investing/2016/12/27/3-biggest-risks-for-abbvie-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biggest Risks for AbbVie in 2017
BIIB,BIIB:UW,BBG000C18861,Time for biotech to boom ... or bust?,2016-12-27 19:45:00 +0000,http://finance.yahoo.com/video/time-biotech-boom-bust-194500895.html,Time for biotech to boom ... or bust?
BIIB,BIIB:UW,BBG000C18861,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,2016-12-27 19:32:56 +0000,http://finance.yahoo.com/news/expect-availability-biogens-newly-approved-193256344.html,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week
BIIB,BIIB:UW,BBG000C18861,Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval,2016-12-27 17:07:00 +0000,http://www.thestreet.com/video/13937472/biogen-s-spinal-muscular-atrophy-drug-wins-fda-approval.html?puc=yahoov&cm_ven=YAHOOV,Biogen's Spinal Muscular Atrophy Drug Wins FDA Approval
BIIB,BIIB:UW,BBG000C18861,[$$] Surprise Drug Approval Is Holiday Gift for Biogen,2016-12-27 16:34:13 +0000,http://www.wsj.com/articles/surprise-drug-approval-is-holiday-gift-for-biogen-1482856447?mod=yahoo_hs,[$$] Surprise Drug Approval Is Holiday Gift for Biogen
BIIB,BIIB:UW,BBG000C18861,Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy,2016-12-27 16:01:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Unm7Z1fEhoE/ionisbiogen-spinraza-approved-for-spinal-muscular-atrophy-cm726392,Ionis Pharmaceuticals Inc IONS and Biogen Inc BIIB announced that the FDA has approved Spinraza nusinersen an antisense drug for the treatment of spinal muscular atrophy SMA While Ionis shares were up 8 1 during Tuesday s pre market trading session shares of Biogen
BIIB,BIIB:UW,BBG000C18861,"Spinraza Wins 'Best Case Approval'; Leerink Raises Targets On Biogen, Ionis",2016-12-27 15:56:34 +0000,http://finance.yahoo.com/news/spinraza-wins-best-case-approval-155634896.html,"Spinraza Wins 'Best Case Approval'; Leerink Raises Targets On Biogen, Ionis"
BIIB,BIIB:UW,BBG000C18861,Why Ionis Approval Could Lift Biogen 25%,2016-12-27 15:42:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/27/why-ionis-approval-could-lift-biogen-25/?mod=yahoobarrons&ru=yahoo,Why Ionis Approval Could Lift Biogen 25%
BIIB,BIIB:UW,BBG000C18861,[$$] Ionis and Biogen's Spinraza Drug Wins FDA Approval,2016-12-27 15:18:17 +0000,http://www.wsj.com/articles/ioniss-spinraza-drug-for-spinal-muscular-atrophy-wins-fda-approval-1482537148?mod=yahoo_hs,[$$] Ionis and Biogen's Spinraza Drug Wins FDA Approval
BIIB,BIIB:UW,BBG000C18861,"Health Care Sector Update for 12/27/2016: SGEN, IONS, JNJ, PFE, ABT, MRK, AMGN",2016-12-27 15:17:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FONYCDmnwe0/health-care-sector-update-for-12272016-sgen-ions-jnj-pfe-abt-mrk-amgn-cm726382,Top Health care stocks Top Health care stocks JNJ 0 6 JNJ 0 6 PFE 0 5 PFE 0 5 ABT 0 5 ABT 0 5 MRK 0 3 MRK 0 3 AMGN 1 AMGN 1 Health care shares were higher as Tuesday s regular session commencedHealth care shares were higher as Tuesday s regular session commenced In
BIIB,BIIB:UW,BBG000C18861,Biogen Scores FDA Approval for First Spinal Muscular Atrophy Drug,2016-12-27 15:10:00 +0000,https://www.thestreet.com/story/13937257/1/biogen-scores-fda-approval-for-first-spinal-muscular-atrophy-drug.html?puc=yahoo&cm_ven=YAHOO,Biogen Scores FDA Approval for First Spinal Muscular Atrophy Drug
BIIB,BIIB:UW,BBG000C18861,"Top Analysts Upgrades and Downgrades: Biogen, FedEx, Lions Gate, Rexnord, Ionis Pharmaceutical and More",2016-12-27 15:05:43 +0000,http://247wallst.com/investing/2016/12/27/top-analysts-upgrades-and-downgrades-biogen-fedex-lions-gate-rexnord-ionis-pharmaceutical-and-more/,"Top Analysts Upgrades and Downgrades: Biogen, FedEx, Lions Gate, Rexnord, Ionis Pharmaceutical and More"
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Dow nears 20,000, Nasdaq hits record as tech stocks gain",2016-12-27 15:02:33 +0000,http://finance.yahoo.com/news/us-stocks-dow-nears-20-150233345.html,"US STOCKS-Dow nears 20,000, Nasdaq hits record as tech stocks gain"
BIIB,BIIB:UW,BBG000C18861,Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy,2016-12-27 14:13:02 +0000,http://finance.yahoo.com/news/ionis-biogen-spinraza-approved-spinal-141302386.html,Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy
BIIB,BIIB:UW,BBG000C18861,The 3 Biggest Risks for Pfizer in 2017,2016-12-27 13:57:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BfG7UnLCm8k/the-3-biggest-risks-for-pfizer-in-2017-cm726141,Pfizer NYSE PFE appears to be on track to end 2016 with its stock price at roughly the same level as it began the year Could the new year present better opportunities for the big pharma Yes but challenges remain Here are three of Pfizer s biggest risks in
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Wall St set to open flat after Christmas,2016-12-27 13:56:29 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-set-135629216.html,US STOCKS-Wall St set to open flat after Christmas
BIIB,BIIB:UW,BBG000C18861,"Early movers: BIIB, IONS, FRED, TSLA, SNE, DIS & more",2016-12-27 12:45:26 +0000,http://www.cnbc.com/id/104188025?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104188025,"Early movers: BIIB, IONS, FRED, TSLA, SNE, DIS & more"
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Futures slightly higher after Christmas holiday,2016-12-27 12:36:34 +0000,http://finance.yahoo.com/news/us-stocks-futures-slightly-higher-123634318.html,US STOCKS-Futures slightly higher after Christmas holiday
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. (BIIB) Is Climbing After FDA Approves Spinraza,2016-12-27 09:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pbr_Lvhdutc/biogen-inc-biib-is-climbing-after-fda-approves-spinraza-20161227-00204,Biogen Inc. (BIIB) Is Climbing After FDA Approves Spinraza
BIIB,BIIB:UW,BBG000C18861,Biogen: FDA Approved A New Treatment For Spinal Muscular Atrophy,2016-12-27 08:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1khulfPVNT4/biogen-fda-approved-a-new-treatment-for-spinal-muscular-atrophy-20161227-00140,Biogen: FDA Approved A New Treatment For Spinal Muscular Atrophy
BIIB,BIIB:UW,BBG000C18861,Coming soon to the Nasdaq: Biogen's hemophilia spinoff,2016-12-27 03:55:06 +0000,http://www.bizjournals.com/boston/news/2016/12/26/coming-soon-to-the-nasdaq-biogens-hemophilia.html?ana=yahoo,Coming soon to the Nasdaq: Biogen's hemophilia spinoff
BIIB,BIIB:UW,BBG000C18861,"5 Trade Ideas for Tuesday: Ashland, Biogen, Crown Castle, Monster and Norfolk Southern",2016-12-26 18:30:38 +0000,http://finance.yahoo.com/tumblr/blog-5-trade-ideas-for-tuesday-ashland-biogen-crown-183049381.html,"5 Trade Ideas for Tuesday: Ashland, Biogen, Crown Castle, Monster and Norfolk Southern"
BIIB,BIIB:UW,BBG000C18861,The FDA's Christmas Breakthrough,2016-12-24 01:16:00 +0000,http://www.forbes.com/sites/matthewherper/2016/12/23/the-fdas-christmas-breakthrough/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,The FDA's Christmas Breakthrough
BIIB,BIIB:UW,BBG000C18861,"IONS Scripts History, PTLA Gets FDA Date, Strongbridge Slumps, NEOT On Watch",2016-12-23 22:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S7zA7XycUqc/ions-scripts-history-ptla-gets-fda-date-strongbridge-slumps-neot-on-watch-20161223-00490,"IONS Scripts History, PTLA Gets FDA Date, Strongbridge Slumps, NEOT On Watch"
BIIB,BIIB:UW,BBG000C18861,"U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy",2016-12-23 22:38:09 +0000,http://www.publicnow.com/view/64833CACF7ECE8511F2EBA25D116922D60B16A14,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) SPINRAZA™ (nusinersen) under Priority Review for the treatment of spinal muscular atrophy ..."
BIIB,BIIB:UW,BBG000C18861,FDA approves Biogen drug for lead genetic cause of infant death,2016-12-23 21:53:08 +0000,http://finance.yahoo.com/news/fda-approves-biogen-drug-lead-215308203.html,"[Reuters] - The U.S. Food and Drug Administration on Friday said it has approved Biogen Inc's drug to treat spinal muscular atrophy, the leading genetic cause of death in infants. The drug, nusinersen, which was discovered by Ionis Pharmaceuticals and licensed to Biogen, will be sold under the brand name Spinraza. It is the first FDA-approved medicine for spinal muscular atrophy, a devastating disease that affects about one in 10,000 live births."
BIIB,BIIB:UW,BBG000C18861,FDA Approves Ionis's Spinraza Drug for Spinal Muscular Atrophy,2016-12-23 19:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7OxOa8cQiOE/fda-approves-ioniss-spinraza-drug-for-spinal-muscular-atrophy-20161223-00480,FDA Approves Ionis's Spinraza Drug for Spinal Muscular Atrophy
BIIB,BIIB:UW,BBG000C18861,"Celgene, Evotec Target Unmet Demand in Neurodegenerative Segment",2016-12-23 14:06:22 +0000,http://marketrealist.com/2016/12/celgene-evotec-target-unmet-demand-neurodegenerative-segment/?utm_source=yahoo&utm_medium=feed,"Celgene, Evotec Target Unmet Demand in Neurodegenerative Segment"
BIIB,BIIB:UW,BBG000C18861,Health Care Companies Showing Good Defensive Potential,2016-12-22 23:14:04 +0000,http://finance.yahoo.com/news/health-care-companies-showing-good-231404984.html,Health Care Companies Showing Good Defensive Potential
BIIB,BIIB:UW,BBG000C18861,Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement,2016-12-22 21:48:14 +0000,http://www.publicnow.com/view/2E48C23F31396447762BBD35A5CCA0E51CD37927,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the Registration Statement on Form 10 filed by ..."
BIIB,BIIB:UW,BBG000C18861,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016,2016-12-22 16:20:00 +0000,https://www.thestreet.com/story/13935497/1/what-adam-feuerstein-got-right-and-wrong-about-biotech-stock-in-2016.html?puc=yahoo&cm_ven=YAHOO,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
BIIB,BIIB:UW,BBG000C18861,"DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline - December 23, 2016",2016-12-22 15:15:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-151500308.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 22, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,2016's Worst Clinical Failures,2016-12-22 14:36:19 +0000,http://www.fool.com/investing/2016/12/21/2016s-worst-clinical-failures.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2016's Worst Clinical Failures
BIIB,BIIB:UW,BBG000C18861,RBC Likes Large Cap Biotech Leaders for 2017,2016-12-22 13:25:48 +0000,http://247wallst.com/healthcare-business/2016/12/22/rbc-likes-large-cap-biotech-leaders-for-2017/,RBC Likes Large Cap Biotech Leaders for 2017
BIIB,BIIB:UW,BBG000C18861,"Biogen Announces that Bioverativ will Host an Investor Day on January 6, 2017",2016-12-22 13:02:06 +0000,http://www.publicnow.com/view/025E16E04B229526F6CFFE72A85302C9B5C915E3,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that Bioverativ, the planned spin-off of Biogen's hemophilia business, will host an Investor Day on January 6, 2017. The webcast ..."
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-12-22 01:00:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-010000909.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 21, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,Christmas Came Early for These Biotech Stocks,2016-12-21 22:57:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kEGir9Jg4IQ/christmas-came-early-for-these-biotech-stocks-cm724840,The week before Christmas is typically a slow time of the year for news releases a staple of biotech valuation changes But Clovis Oncology NASDAQ CLVS Akebia Therapeutics NASDAQ AKBA Merus NASDAQ MRUS and Ionis Pharmaceuticals NASDAQ IONS all had news
BIIB,BIIB:UW,BBG000C18861,Biogen and Spin-off Bioverativ will Present at the Goldman Sachs Healthcare CEOs Unscripted Conference,2016-12-21 22:12:08 +0000,http://www.publicnow.com/view/A99F9F5E8C5C1EAFEA71B9E2AE4C69FDFCDA01A7,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Goldman Sachs Healthcare CEOs Unscripted Conference. The webcast will be live on Thursday, January ..."
BIIB,BIIB:UW,BBG000C18861,"Biogen Likely To Trim EPS View On Hemophilia Spinoff, Floundering MS Unit",2016-12-21 21:17:45 +0000,http://www.investors.com/news/technology/biogen-likely-to-trim-eps-view-on-hemophilia-spinoff-floundering-ms-unit/,"Biogen Likely To Trim EPS View On Hemophilia Spinoff, Floundering MS Unit"
BIIB,BIIB:UW,BBG000C18861,Biotech Giant Biogen To Spin-Off Bioverativ,2016-12-21 18:33:00 +0000,http://www.forbes.com/sites/joecornell/2016/12/21/biotech-giant-biogen-to-spin-off-bioverativ/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Biotech Giant Biogen To Spin-Off Bioverativ
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline - December 23, 2016",2016-12-21 17:54:00 +0000,http://finance.yahoo.com/news/investor-alert-bronstein-gewirtz-grossman-175400717.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 21, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug",2016-12-21 17:02:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c_VJiHA4VFo/biotech-stock-roundup-conatus-soars-on-novartis-deal-early-fda-nod-for-clovis-drug-cm724634,Conatus CNAT is ending the year on a high note with the company signing a lucrative deal with Swiss pharma giant Novartis Investors applauded the deal sending the company s shares soaring 141 3 Meanwhile Gilead GILD was hit by a jury decision awarding 2 54 billion to Merck in a
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Board Okays Hemophilia Business Spin-off,2016-12-21 16:01:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wRNn011mcvw/biogen-biib-board-okays-hemophilia-business-spin-off-cm724519,Biogen Inc BIIB announced that its board of directors has approved the spin off of its hemophilia business into a new company Bioverativ Inc A look at Biogen year to date share price movement shows that the company has underperformed the Zacks classified Large Cap Pharmaceutical
BIIB,BIIB:UW,BBG000C18861,2016's Worst Clinical Failures,2016-12-21 15:59:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1Y3zSc1N59g/2016s-worst-clinical-failures-cm724489,It s been a depressing year for drugmakers and clinical trial failures made 2016 particularly upsetting Neurology has always been a difficult field but this one was unusually nerve wracking for Eli LIlly amp Co NYSE LLY and Biogen NASDAQ BIIB In their own
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug",2016-12-21 14:25:02 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-conatus-soars-142502788.html,"Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug"
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Board Okays Hemophilia Business Spin-off,2016-12-21 13:41:01 +0000,http://finance.yahoo.com/news/biogen-biib-board-okays-hemophilia-134101064.html,Biogen (BIIB) Board Okays Hemophilia Business Spin-off
BIIB,BIIB:UW,BBG000C18861,"Biogen to Report Fourth Quarter and Year End 2016 Financial Results on January 26, 2017",2016-12-21 13:12:10 +0000,http://www.publicnow.com/view/B1C77F3BC57110971F4817E57FE6C23F728A7AF0,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report fourth quarter 2016 financial results on Thursday, January 26, 2016, before the financial markets open. ... This ..."
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen Faces No Easy Opportunities,2016-12-21 05:35:43 +0000,http://www.wsj.com/articles/biogen-faces-no-easy-opportunities-1482254868?ru=yahoo?mod=yahoo_itp,[$$] Biogen Faces No Easy Opportunities
BIIB,BIIB:UW,BBG000C18861,Investors see Biogen CEO choice as friendly to potential takeover,2016-12-20 22:50:58 +0000,http://finance.yahoo.com/news/investors-see-biogen-ceo-choice-225058542.html,Investors see Biogen CEO choice as friendly to potential takeover
BIIB,BIIB:UW,BBG000C18861,3 Reasons Biogen Inc. Stock Is Set to Soar in 2017,2016-12-20 22:36:26 +0000,http://www.fool.com/investing/2016/12/20/3-reasons-biogen-inc-stock-is-set-to-soar-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Reasons Biogen Inc. Stock Is Set to Soar in 2017
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen Declares Special Dividend to Complete Hemophilia Spinoff,2016-12-20 22:01:42 +0000,http://www.wsj.com/articles/biogen-declares-special-dividend-to-complete-hemophilia-spinoff-1482269719?mod=yahoo_hs,[$$] Biogen Declares Special Dividend to Complete Hemophilia Spinoff
BIIB,BIIB:UW,BBG000C18861,3 Reasons Biogen Inc. Stock Is Set to Soar in 2017,2016-12-20 21:57:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8slgPY6_Fy4/3-reasons-biogen-inc-stock-is-set-to-soar-in-2017-cm724261,It s looking like 2016 will turn out to be disappointing for Biogen NASDAQ BIIB shareholders Part of the stock s lackluster performance stemmed from a midstage clinical setback for experimental multiple sclerosis drug opicinumab The broader slowdown for biotech stocks was
BIIB,BIIB:UW,BBG000C18861,Biogen Approves Spin-out of Hemophilia Business,2016-12-20 21:56:00 +0000,https://www.thestreet.com/story/13933325/1/biogen-announces-intent-to-spin-out-hemophilia-business.html?puc=yahoo&cm_ven=YAHOO,Biogen Approves Spin-out of Hemophilia Business
BIIB,BIIB:UW,BBG000C18861,Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock,2016-12-20 21:52:06 +0000,http://www.publicnow.com/view/DF520D4758B56393E1CBCCDDD61C4F6D7DEBB1DA,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today announced that its board of directors has approved the planned spin-off of its hemophilia business, which will be known as Bioverativ ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Names Michel Vounatsos as New CEO,2016-12-20 21:25:03 +0000,http://www.investopedia.com/stock-analysis/122016/biogen-names-michel-vounatsos-new-ceo-biib.aspx?partner=YahooSA,Biogen Names Michel Vounatsos as New CEO
BIIB,BIIB:UW,BBG000C18861,Biogen Takeout Still Possible After Internal Promotion For CEO: RBC,2016-12-20 21:20:21 +0000,http://www.investors.com/news/technology/biogen-takeout-still-possible-after-internal-promotion-for-ceo-rbc/,Biogen Takeout Still Possible After Internal Promotion For CEO: RBC
BIIB,BIIB:UW,BBG000C18861,Why Healthcare and Trade Stocks Tempered Moat Index Upside,2016-12-20 20:05:29 +0000,http://marketrealist.com/2016/12/healthcare-trade-focused-companies-restrict-upside-us-moat-index/?utm_source=yahoo&utm_medium=feed,Why Healthcare and Trade Stocks Tempered Moat Index Upside
BIIB,BIIB:UW,BBG000C18861,Biotech Stocks: There Go the Generalists,2016-12-20 18:28:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/20/biotech-stocks-there-go-the-generalists/?mod=yahoobarrons&ru=yahoo,Biotech Stocks: There Go the Generalists
BIIB,BIIB:UW,BBG000C18861,Reasons To Own Regeneron In 2017; CS Sees 30% Upside,2016-12-20 17:59:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/20/reasons-to-own-regeneron-in-2017-cs-sees-30-upside/?mod=yahoobarrons&ru=yahoo,Reasons To Own Regeneron In 2017; CS Sees 30% Upside
BIIB,BIIB:UW,BBG000C18861,"Biogen Shares Rebound as New CEO Outlines Growth, M&A Prospects Linger",2016-12-20 17:43:00 +0000,https://www.thestreet.com/story/13932610/1/biogen-shares-up-early-after-new-ceo-indicates-company-could-eye-m-amp-a.html?puc=yahoo&cm_ven=YAHOO,"Biogen Shares Rebound as New CEO Outlines Growth, M&A Prospects Linger"
BIIB,BIIB:UW,BBG000C18861,"Celgene Added To CS Focus List; ""The Best House In The Biotech Neighborhood""",2016-12-20 17:36:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/20/celgene-added-to-cs-focus-list-the-best-house-in-the-biotech-neighborhood/?mod=yahoobarrons&ru=yahoo,"Celgene Added To CS Focus List; ""The Best House In The Biotech Neighborhood"""
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen Faces No Easy Opportunities,2016-12-20 17:27:51 +0000,http://www.wsj.com/articles/biogen-faces-no-easy-opportunities-1482254868?mod=yahoo_hs,[$$] Biogen Faces No Easy Opportunities
BIIB,BIIB:UW,BBG000C18861,Why Biogen's new CEO stands to gain from an acquisition,2016-12-20 17:15:06 +0000,http://www.bizjournals.com/boston/news/2016/12/20/why-biogens-new-ceo-stands-to-gain-from-an.html?ana=yahoo,Why Biogen's new CEO stands to gain from an acquisition
BIIB,BIIB:UW,BBG000C18861,Biogen Declares Special Dividend to Complete Hemophilia Spinoff -- Update,2016-12-20 17:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nA7RijU5xl4/biogen-declares-special-dividend-to-complete-hemophilia-spinoff--update-20161220-00921,Biogen Declares Special Dividend to Complete Hemophilia Spinoff -- Update
BIIB,BIIB:UW,BBG000C18861,Biogen Declares Special Dividend to Complete Hemophilia Spinoff,2016-12-20 17:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_f_rDeJnj44/biogen-declares-special-dividend-to-complete-hemophilia-spinoff-20161220-00891,Biogen Declares Special Dividend to Complete Hemophilia Spinoff
BIIB,BIIB:UW,BBG000C18861,"3 Stocks to Watch on Tuesday: Biogen Inc (BIIB), Conatus Pharmaceuticals Inc (CNAT) and General Motors Company (GM)",2016-12-20 16:57:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eVnZl9VfkUY/3-stocks-to-watch-on-tuesday-biogen-inc-biib-conatus-pharmaceuticals-inc-cnat-and-general-motors-company-gm-cm723962,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips It was a positive start to the week for U S equities as telecoms gained 1 1 while REITs surged 1 The 160 Dow Jones Industrial Average gained 0 2 the 160 S amp P 500 rose 0
BIIB,BIIB:UW,BBG000C18861,What Does Biogen's New CEO Mean For The Buyout Argument?,2016-12-20 15:58:46 +0000,http://finance.yahoo.com/news/does-biogens-ceo-mean-buyout-155846255.html,What Does Biogen's New CEO Mean For The Buyout Argument?
BIIB,BIIB:UW,BBG000C18861,"Wait, Biogen's Heading Higher?",2016-12-20 15:58:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/20/wait-biogens-heading-higher/?mod=yahoobarrons&ru=yahoo,"Wait, Biogen's Heading Higher?"
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-12-20 15:36:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-153600206.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 20, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,"BIIB UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016",2016-12-20 14:59:31 +0000,http://finance.yahoo.com/news/biib-upcoming-deadline-law-offices-145931867.html,"[GlobeNewswire] - NEW YORK, Dec. 20, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen ..."
BIIB,BIIB:UW,BBG000C18861,Biogen to Present at the 35th Annual J.P. Morgan Healthcare Conference,2016-12-20 14:00:00 +0000,http://finance.yahoo.com/news/biogen-present-35th-annual-j-140000125.html,"[Business Wire] - Biogen Inc. announced today that it will present at the 35th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 9, 2017 at 4:30 p.m."
BIIB,BIIB:UW,BBG000C18861,"Biogen Names Commercial Officer as New CEO, Shares Fall",2016-12-20 13:59:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/low-NExMo6M/biogen-names-commercial-officer-as-new-ceo-shares-fall-cm723820,Biogen Inc BIIB has appointed its present chief commercial officer CCO Michel Vounatsos as the new chief executive officer CEO effective Jan 6 2017 Vounatsos who also holds the position of executive vice president at Biogen will replace George A Scangos In July Scangos
BIIB,BIIB:UW,BBG000C18861,"Biogen Names Commercial Officer as New CEO, Shares Fall",2016-12-20 12:26:12 +0000,http://finance.yahoo.com/news/biogen-names-commercial-officer-ceo-122612434.html,"Biogen Names Commercial Officer as New CEO, Shares Fall"
BIIB,BIIB:UW,BBG000C18861,Hot Stocks to Watch in the U.S. and Canada,2016-12-20 09:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ezm574S4OYw/hot-stocks-to-watch-in-the-us-and-canada-20161220-00501,Hot Stocks to Watch in the U.S. and Canada
BIIB,BIIB:UW,BBG000C18861,Biogen names chief commercial officer as new CEO,2016-12-20 00:16:12 +0000,http://www.bizjournals.com/boston/news/2016/12/19/biogen-to-name-chief-commercial-officer-as-new-ceo.html?ana=yahoo,Biogen names chief commercial officer as new CEO
BIIB,BIIB:UW,BBG000C18861,Biogen names top executive Vounatsos as CEO,2016-12-19 22:37:11 +0000,http://finance.yahoo.com/news/biogen-names-top-executive-vounatsos-213527828.html,Biogen names top executive Vounatsos as CEO
BIIB,BIIB:UW,BBG000C18861,"After-hours buzz: BIIB, DIS & more",2016-12-19 22:28:33 +0000,http://www.cnbc.com/id/104176428?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104176428,"After-hours buzz: BIIB, DIS & more"
BIIB,BIIB:UW,BBG000C18861,"Biogen Looks Within for Next CEO, Raising Concerns Top Outside Talent Passed on Job",2016-12-19 22:25:00 +0000,https://www.thestreet.com/story/13931919/1/biogen-looks-within-for-next-ceo-raising-concerns-top-outside-talent-passed-on-job.html?puc=yahoo&cm_ven=YAHOO,"Biogen Looks Within for Next CEO, Raising Concerns Top Outside Talent Passed on Job"
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen Names New CEO,2016-12-19 22:22:09 +0000,http://www.wsj.com/articles/biogen-names-michel-vounatsos-as-next-ceo-1482184649?mod=yahoo_hs,[$$] Biogen Names New CEO
BIIB,BIIB:UW,BBG000C18861,"BIOGEN INC. Files SEC form 8-K, Change in Directors or Principal Officers",2016-12-19 22:20:57 +0000,http://biz.yahoo.com/e/161219/biib8-k.html,"BIOGEN INC. Files SEC form 8-K, Change in Directors or Principal Officers"
BIIB,BIIB:UW,BBG000C18861,"Biogen Names Insider New CEO After Five-Month Search, Stock Falls",2016-12-19 22:04:16 +0000,http://www.investors.com/news/technology/biogen-names-insider-new-ceo-after-five-month-search-stock-falls/,"Biogen Names Insider New CEO After Five-Month Search, Stock Falls"
BIIB,BIIB:UW,BBG000C18861,Biogen Names Michel Vounatsos Chief Executive Officer,2016-12-19 21:31:28 +0000,http://www.publicnow.com/view/F2F0E17F5475068876F21EF15E6A3BEBBA592A62,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced that its Board of Directors has appointed Michel Vounatsos as Chief Executive Officer and member of the Board of Directors, effective ..."
BIIB,BIIB:UW,BBG000C18861,Biogen shares slip following announcement of new CEO,2016-12-19 21:30:49 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=E4D9E618-3845-492F-B485-3469C379B3F7&siteid=yhoof2,Biogen shares slip following announcement of new CEO
BIIB,BIIB:UW,BBG000C18861,Biogen Names Chief Commercial Officer Michel Vounatsos As New CEO,2016-12-19 21:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l8_y3e8CYWk/biogen-names-chief-commercial-officer-michel-vounatsos-as-new-ceo-20161219-01007,Biogen Names Chief Commercial Officer Michel Vounatsos As New CEO
BIIB,BIIB:UW,BBG000C18861,Biogen picks Michel Vounatsos for its next CEO,2016-12-19 21:05:00 +0000,http://finance.yahoo.com/video/biogen-picks-michel-vounatsos-next-210500399.html,Biogen picks Michel Vounatsos for its next CEO
BIIB,BIIB:UW,BBG000C18861,Biogen Names New CEO -- Update,2016-12-19 17:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jvW-lV2mRNk/biogen-names-new-ceo--update-20161219-00952,Biogen Names New CEO -- Update
BIIB,BIIB:UW,BBG000C18861,Biogen Names Michel Vounatsos as Next CEO,2016-12-19 17:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z-mhAXCbO6M/biogen-names-michel-vounatsos-as-next-ceo-20161219-00928,Biogen Names Michel Vounatsos as Next CEO
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-12-19 17:07:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-170700796.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 19, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Biogen Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline",2016-12-19 17:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-faruqi-faruqi-llp-170000622.html,"[PR Newswire] - NEW YORK, Dec. 19, 2016 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Biogen Inc. (""Biogen"" or the ""Company"") (BIIB) of the December 23, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. The lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of all those who purchased Biogen stock or options between July 23, 2014 and July 23, 2015 (the ""Class Period""). The case, Electrical Workers Pension Fund, Local 103, IBEW v. Kingsley et al, No. 1:16-cv-12101 was filed on October 20, 2016."
BIIB,BIIB:UW,BBG000C18861,Stocks Close Modestly Higher But Off Best Levels - U.S. Commentary,2016-12-19 16:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eyw5-E0jF0I/stocks-close-modestly-higher-but-off-best-levels--us-commentary-20161219-00862,Stocks Close Modestly Higher But Off Best Levels - U.S. Commentary
BIIB,BIIB:UW,BBG000C18861,"DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline - December 23, 2016",2016-12-19 15:10:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-151000258.html,"[GlobeNewswire] - NEW YORK, Dec. 19, 2016-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. and certain of its officers. The class ..."
BIIB,BIIB:UW,BBG000C18861,3 Low-Volatility Biotech Stocks to Buy,2016-12-18 19:56:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/czbWM7lu0JY/3-low-volatility-biotech-stocks-to-buy-cm723007,Are you hesitant to buy biotech stocks because of their volatility If so it s understandable Many biotech stocks are very volatile with frequent big swings up and down However there are some biotechs that have relatively low volatility If you re wary of biotechs here s why
BIIB,BIIB:UW,BBG000C18861,3 Low-Volatility Biotech Stocks to Buy,2016-12-18 18:36:39 +0000,http://www.fool.com/investing/2016/12/18/3-biotech-stocks-to-buy-if-youre-wary-of-biotechs.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Low-Volatility Biotech Stocks to Buy
BIIB,BIIB:UW,BBG000C18861,"OEF, WBA, TWX, BIIB: ETF Outflow Alert",2016-12-16 17:57:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E3_AdqMRxAE/oef-wba-twx-biib-etf-outflow-alert-cm722612,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares S amp P 100 ETF Symbol OEF where we have detected an approximate 55 4 million dollar outflow that s a 1 2 decrease week over week from 46 000 000
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-12-16 17:49:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-174900053.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 16, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: ..."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-12-16 17:46:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-174600940.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 16, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016 – BIIB",2016-12-16 16:03:03 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-160303244.html,"[GlobeNewswire] - NEW YORK, Dec. 16, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc. between July 23, 2014 ..."
BIIB,BIIB:UW,BBG000C18861,"DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline - December 23, 2016",2016-12-16 15:13:00 +0000,http://finance.yahoo.com/news/deadline-alert-bronstein-gewirtz-grossman-151300372.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 16, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,"Top Analysts Upgrades and Downgrades: Apple, Biogen, FedEx, GE, Las Vegas Sands and More",2016-12-16 13:55:59 +0000,http://247wallst.com/investing/2016/12/16/top-analysts-upgrades-and-downgrades-apple-biogen-fedex-ge-las-vegas-sands-and-more/,"Top Analysts Upgrades and Downgrades: Apple, Biogen, FedEx, GE, Las Vegas Sands and More"
BIIB,BIIB:UW,BBG000C18861,3 Top Biotech Stocks to Buy on Sale,2016-12-14 22:57:50 +0000,http://www.fool.com/investing/2016/12/13/3-top-biotech-stocks-to-buy-on-sale.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Biotech Stocks to Buy on Sale
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & ChemicalThe Zacks Analyst Blog Highlights: Barclays, Netflix, NIKE, Biogen and China Petroleum & Chemical",2016-12-14 16:59:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vcKcBGRSCOM/the-zacks-analyst-blog-highlights-barclays-netflix-nike-biogen-and-china-petroleum-chemicalthe-zacks-analyst-blog-highlights-barclays-netflix-nike-biogen-and-china-petroleum-chemical-cm721400,For Immediate Release Chicago IL December 14 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-12-14 16:36:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-163600539.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 14, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: ..."
BIIB,BIIB:UW,BBG000C18861,"Investor Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline - December 23, 2016",2016-12-14 15:12:00 +0000,http://finance.yahoo.com/news/investor-alert-bronstein-gewirtz-grossman-151200703.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 14, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Ophthotech Slumps on Fovista Results, Achaogen Skyrockets on Data",2016-12-14 13:59:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z3h1L1Yneak/biotech-stock-roundup-ophthotech-slumps-on-fovista-results-achaogen-skyrockets-on-data-cm721141,This week several companies presented data on pipeline candidates as well as approved products While companies like Achaogen AKAO soared on positive data others like Horizon HZNP and Ophthotech OPHT were hit by study results Meanwhile Alexion s ALXN shares were impacted by the
BIIB,BIIB:UW,BBG000C18861,Is Biogen Idec Inc. (BIIB) a Good Stock to Buy?,2016-12-14 07:27:47 +0000,http://www.insidermonkey.com/blog/is-biogen-idec-inc-biib-a-good-stock-to-buy-508270/,Is Biogen Idec Inc. (BIIB) a Good Stock to Buy?
BIIB,BIIB:UW,BBG000C18861,Biogen to cut more than 200 jobs as part of Mass. manufacturing exit,2016-12-14 01:37:58 +0000,http://www.bizjournals.com/boston/news/2016/12/13/biogen-to-cut-more-than-200-jobs-as-part-of-mass.html?ana=yahoo,Biogen to cut more than 200 jobs as part of Mass. manufacturing exit
BIIB,BIIB:UW,BBG000C18861,3 Top Biotech Stocks to Buy on Sale,2016-12-13 23:56:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M1hg9s2kwpg/3-top-biotech-stocks-to-buy-on-sale-cm721014,Despite the turmoil caused by the U S presidential election this year biotech stocks still sport some of the richest valuations in the market Even so there are a handful of compelling bargains within this highly coveted space that are worth checking out right now The biotech
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for Barclays, Netflix and Nike",2016-12-13 18:57:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5afkHXT2IzI/top-research-reports-for-barclays-netflix-and-nike-cm720920,Tuesday December 13 2016 Today s Research Daily features new research reports on 16 major stocks including Barclays BCS Netflix NFLX and NIKE NKE Barclays shares significantly outperformed the Zacks categorized Foreign Bank sector over the past three months surging 28 2
BIIB,BIIB:UW,BBG000C18861,Trade Valeant Pharmaceuticals Intl Inc (VRX) Stock for Free Profits,2016-12-13 16:57:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JIPzdVytWQA/trade-valeant-pharmaceuticals-intl-inc-vrx-stock-for-free-profits-cm720711,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Valeant Pharmaceuticals Intl Inc NYSE VRX finished down 5 on Monday which caught my attention The last trade I wrote on VRX stock was an easy win using the December contract and I think it s
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for Barclays, Netflix and Nike",2016-12-13 16:04:04 +0000,http://finance.yahoo.com/news/top-research-reports-barclays-netflix-160404411.html,"Top Research Reports for Barclays, Netflix and Nike"
BIIB,BIIB:UW,BBG000C18861,Sellers Are Dominating the Price Action in Biogen,2016-12-13 14:09:00 +0000,http://realmoney.thestreet.com/articles/12/13/2016/sellers-are-dominating-price-action-biogen?puc=yahoo&cm_ven=YAHOO,Sellers Are Dominating the Price Action in Biogen
BIIB,BIIB:UW,BBG000C18861,The 3 Most Profit-Friendly Biotech Stocks,2016-12-12 22:56:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dn-hgcu2isQ/the-3-most-profit-friendly-biotech-stocks-cm720399,Developing game changing medicine isn t easy and it s certainly not cheap It can cost hundreds of millions of dollars to create new drugs and with a clinical trial failure rate of 90 the risks to biotech companies are enormous Yet the reward can be even bigger when drugmakers get
BIIB,BIIB:UW,BBG000C18861,The 3 Most Profit-Friendly Biotech Stocks,2016-12-12 21:21:06 +0000,http://www.fool.com/investing/2016/12/12/the-3-most-profit-friendly-biotech-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The 3 Most Profit-Friendly Biotech Stocks
BIIB,BIIB:UW,BBG000C18861,Help Wanted: Large-Cap Biotech CEOs Capable of Soothing Raw Nerves of Health Care Investors in 2017,2016-12-12 18:54:00 +0000,https://www.thestreet.com/story/13922604/1/help-wanted-large-cap-biotech-ceos-capable-of-soothing-raw-nerves-of-healthcare-investors-in-2017.html?puc=yahoo&cm_ven=YAHOO,Help Wanted: Large-Cap Biotech CEOs Capable of Soothing Raw Nerves of Health Care Investors in 2017
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-12-12 16:14:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-161400323.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 12, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,Lilly/AstraZeneca Expand Alzheimer Disease Collaboration,2016-12-12 16:00:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ot5Bf4-IUi4/lillyastrazeneca-expand-alzheimer-disease-collaboration-cm719999,Eli Lilly and Company LLY and AstraZeneca plc AZN expanded their existing collaboration to develop the second treatment for Alzheimer s disease MEDI1814 Incidentally failure of Lilly s high profile investigational Alzheimer disease candidate solanezumab hurt the company s share price
BIIB,BIIB:UW,BBG000C18861,Biogen Presents Positive Early Data from Alzheimer's Study,2016-12-12 16:00:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OsmoRopeX1A/biogen-presents-positive-early-data-from-alzheimers-study-cm719988,Last week Biogen Inc BIIB presented positive data from a phase I study PRIME on its anti amyloid treatments in development aducanumab at the Clinical Trials on Alzheimer s Disease CTAD meeting in San Diego Biogen s share price has slipped 10 5 in the past one month underperforming
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016",2016-12-12 14:52:00 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-145200332.html,"[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:"
BIIB,BIIB:UW,BBG000C18861,Biogen Presents Positive Early Data from Alzheimer's Study,2016-12-12 14:21:02 +0000,http://finance.yahoo.com/news/biogen-presents-positive-early-data-142102177.html,Biogen Presents Positive Early Data from Alzheimer's Study
BIIB,BIIB:UW,BBG000C18861,Biotech Short Interest Remains Mixed,2016-12-12 14:10:59 +0000,http://finance.yahoo.com/news/biotech-short-interest-remains-mixed-141059205.html,Biotech Short Interest Remains Mixed
BIIB,BIIB:UW,BBG000C18861,"BIOGEN INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits",2016-12-12 11:01:45 +0000,http://biz.yahoo.com/e/161212/biib8-k.html,"BIOGEN INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits"
BIIB,BIIB:UW,BBG000C18861,Better Buy: Amgen Inc. vs. Biogen,2016-12-12 05:34:49 +0000,http://www.fool.com/investing/2016/12/11/better-buy-amgen-inc-vs-biogen.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Amgen Inc. vs. Biogen
BIIB,BIIB:UW,BBG000C18861,"Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016",2016-12-12 05:12:00 +0000,http://finance.yahoo.com/news/investor-alert-bronstein-gewirtz-grossman-051200062.html,"[Accesswire] - NEW YORK / ACCESSWIRE / December 12, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,Better Buy: Amgen Inc. vs. Biogen,2016-12-11 13:56:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K-Fjuz18xKA/better-buy-amgen-inc-vs-biogen-cm719810,Two of the biggest biotechs in the world haven t exactly had a great 2016 Shares of Amgen NASDAQ AMGN and Biogen NASDAQ BIIB are both down year to date Which of these two stocks is the better pick for investors headed into the new year Here s how Amgen and Biogen
BIIB,BIIB:UW,BBG000C18861,Is Biogen's Aducanumab a Game-Changing Alzheimer's Drug?,2016-12-10 13:56:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIS1ZhkEVZo/is-biogens-aducanumab-a-game-changing-alzheimers-drug-cm719708,Biogen NASDAQ BIIB is spending big money on an Alzheimer s disease moonshot it hopes can transform how doctors treat this devastating disease This week data from a trial evaluating Biogen s aducanumab suggest that may be money well spent Could aducanumab usher in a
BIIB,BIIB:UW,BBG000C18861,Is Biogen's Aducanumab a Game-Changing Alzheimer's Drug?,2016-12-10 12:41:06 +0000,http://www.fool.com/investing/general/2016/12/10/is-biogens-aducanumab-a-game-changing-alzheimers-d.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Biogen's Aducanumab a Game-Changing Alzheimer's Drug?
BIIB,BIIB:UW,BBG000C18861,Biogen Underplays Promising Alzheimer's Data On Seizure Worries,2016-12-09 22:29:57 +0000,http://www.investors.com/news/technology/biogen-underplays-promising-alzheimers-data-on-seizure-worries/,Biogen Underplays Promising Alzheimer's Data On Seizure Worries
BIIB,BIIB:UW,BBG000C18861,Biotech ETFs: A Short-Lived Boon From Biogen,2016-12-09 21:14:00 +0000,http://blogs.barrons.com/focusonfunds/2016/12/09/biotech-etfs-a-short-lived-boon-from-biogen/?mod=yahoobarrons&ru=yahoo,Biotech ETFs: A Short-Lived Boon From Biogen
BIIB,BIIB:UW,BBG000C18861,[$$] Biotech Bargain: Biogen On Sale After Good News,2016-12-09 20:29:00 +0000,http://www.barrons.com/articles/biotech-bargain-biogen-on-sale-after-good-news-1481315370?mod=yahoobarrons&ru=yahoo,[$$] Biotech Bargain: Biogen On Sale After Good News
BIIB,BIIB:UW,BBG000C18861,Why the latest Alzheimer’s data is (mostly) great news for Biogen,2016-12-09 19:55:06 +0000,http://www.bizjournals.com/boston/news/2016/12/09/why-the-latest-alzheimer-s-data-is-mostly-great.html?ana=yahoo,Why the latest Alzheimer’s data is (mostly) great news for Biogen
BIIB,BIIB:UW,BBG000C18861,Postive results in study of Alzheimer's,2016-12-09 19:37:00 +0000,http://finance.yahoo.com/video/postive-results-study-alzheimers-193700902.html,Postive results in study of Alzheimer's
BIIB,BIIB:UW,BBG000C18861,"When Will The Dow Hit 20,000? Apple Retakes Key Level, Broadcom Pops",2016-12-09 18:55:45 +0000,http://finance.yahoo.com/video/dow-hit-20-000-apple-185545128.html,"When Will The Dow Hit 20,000? Apple Retakes Key Level, Broadcom Pops"
BIIB,BIIB:UW,BBG000C18861,Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study,2016-12-09 18:51:00 +0000,http://www.thestreet.com/video/13920991/biogen-shares-up-following-eli-lilly-s-failed-alzheimer-s-study.html?puc=yahoov&cm_ven=YAHOOV,Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen buoyed by hopes for Alzheimer's drug,2016-12-09 18:24:38 +0000,"http://www.ft.com/cms/s/b4504c5e-be36-11e6-8b45-b8b81dd5d080,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[at Financial Times] - Biogen bucked the recent sell-off in biotechnology stocks to climb by as much as 6 per cent on Friday amid fresh optimism over the company's experimental Alzheimer's drug. The stock rose by the most in ...
BIIB,BIIB:UW,BBG000C18861,"Stock Market News for December 09, 2016",2016-12-09 17:58:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0VQEkg8IiPs/stock-market-news-for-december-09-2016-cm719409,Markets finished at record highs again on Thursday following ECB s announcement about trimming bond buying volume and the continuing Trump induced rally Meanwhile decline in initial claims also added to the optimism Moreover strong gains in financials and rebound in healthcare sector
BIIB,BIIB:UW,BBG000C18861,Does New Alzheimer's Data Make Biogen Stock a Buy Now?,2016-12-09 17:56:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nHX7Nq2hLMY/does-new-alzheimers-data-make-biogen-stock-a-buy-now-cm719366,A trial snapshot from Biogen NASDAQ BIIB is giving the 160 Alzheimer s disease community a reason to cheer just weeks after a similar candidate from Eli Lilly failed miserably and gave investors a reason to be concerned about similarities between the two programs Let s
BIIB,BIIB:UW,BBG000C18861,"Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’",2016-12-09 17:55:27 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=FDE25AB0-BE13-11E6-A55C-7986D69D84E4&siteid=yhoof2,"Biogen gains on new Eli Lilly Alzheimer’s data, as beta-amyloid hypothesis ‘lives to see another day’"
BIIB,BIIB:UW,BBG000C18861,"Stocks Up Again; Apple Strengthens, Reclaims 50-Day Line",2016-12-09 17:04:07 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-up-again-apple-strengthens-reclaims-50-day-line/,"Stocks Up Again; Apple Strengthens, Reclaims 50-Day Line"
BIIB,BIIB:UW,BBG000C18861,"S&P 500 Movers: GRMN, BIIB",2016-12-09 16:59:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a9Ldw4cpi6M/sp-500-movers-grmn-biib-cm719334,In early trading on Friday shares of Biogen BIIB topped the list of the day s best performing components of the S amp P 500 index trading up 5 1 Year to date Biogen has lost about 0 7 of its value And the worst performing S amp P 500 component thus far on the day is Garmin
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: LRCX, BIIB",2016-12-09 16:59:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9vGgIQkBlNM/nasdaq-100-movers-lrcx-biib-cm719330,In early trading on Friday shares of Biogen BIIB topped the list of the day s best performing components of the Nasdaq 100 index trading up 5 5 Year to date Biogen has lost about 0 3 of its value And the worst performing Nasdaq 100 component thus far on the day is Lam
BIIB,BIIB:UW,BBG000C18861,Does New Alzheimer's Data Make Biogen Stock a Buy Now?,2016-12-09 16:50:11 +0000,http://www.fool.com/investing/2016/12/09/does-new-alzheimers-data-make-biogen-stock-a-buy-n.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Does New Alzheimer's Data Make Biogen Stock a Buy Now?
BIIB,BIIB:UW,BBG000C18861,"Stocks Up, Biogen Rebounds; Why Apple Is Flexing Strength Again",2016-12-09 16:30:49 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-up-biogen-rebounds-why-apple-is-flexing-strength-again/,"Stocks Up, Biogen Rebounds; Why Apple Is Flexing Strength Again"
BIIB,BIIB:UW,BBG000C18861,Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results,2016-12-09 15:39:00 +0000,https://www.thestreet.com/story/13920670/1/attention-shifts-to-biogen-s-alzheimer-s-drug-in-wake-of-lilly-results.html?puc=yahoo&cm_ven=YAHOO,Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results
BIIB,BIIB:UW,BBG000C18861,Should You Buy Drug Stocks on Their Post-Election Drop?,2016-12-09 15:19:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMGviIAT390/should-you-buy-drug-stocks-on-their-post-election-drop-cm719282,"We have seen a strong rally in stocks since the U.S Presidential election, based on the assumption that, as a businessperson, the President elect will usher in a business-friendly era. The general feeling seems to be that some of the things said on the campaign trail, things like restricting trade, deporting millions"
BIIB,BIIB:UW,BBG000C18861,Biogen Alzheimer's Drug Shows Promise in Study,2016-12-09 15:19:00 +0000,http://www.investopedia.com/news/biogen-spikes-positive-alzheimers-data-biib/?partner=YahooSA,Biogen Alzheimer's Drug Shows Promise in Study
BIIB,BIIB:UW,BBG000C18861,Health Care Sector Update for 12/09/2016: BIIB,2016-12-09 14:56:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QAN-vD8PX6Q/health-care-sector-update-for-12092016-biib-cm719181,Top Health care stocks Top Health care stocks JNJ flatJNJ flat PFE 0 3 PFE 0 3 ABT flatABT flat MRK flatMRK flat AMGN 0 7 AMGN 0 7 Health care shares were mainly unchanged in pre market trade on Friday Health care shares were mainly unchanged in pre market trade on Friday
BIIB,BIIB:UW,BBG000C18861,"Cramer's Stop Trading: BIIB, AAPL",2016-12-09 14:54:00 +0000,http://finance.yahoo.com/video/cramers-stop-trading-biib-aapl-145400849.html,"Cramer's Stop Trading: BIIB, AAPL"
BIIB,BIIB:UW,BBG000C18861,"Eli Lilly Continues Alzheimer's Push After Flop, Biogen Extends Rise",2016-12-09 14:39:25 +0000,http://www.investors.com/news/technology/biogen-alzheimers-drug-shows-more-promise-lilly-data-tonight/,"Eli Lilly Continues Alzheimer's Push After Flop, Biogen Extends Rise"
BIIB,BIIB:UW,BBG000C18861,"Pre-Market Most Active for Dec 9, 2016 :  SWC, MGM, BAC, TLK, LVS, MPEL, WYNN, VOD, VALE, SQQQ, BIIB, TVIX",2016-12-09 13:56:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uev5zRBgX74/pre-market-most-active-for-dec-9-2016-swc-mgm-bac-tlk-lvs-mpel-wynn-vod-vale-sqqq-biib-tvix-cm719128,The NASDAQ 100 Pre Market Indicator is up 12 6 to 4 871 79 The total Pre Market volume is currently 9 179 030 shares traded The following are the most active stocks for the pre market session Stillwater Mining Company SWC is 2 92 at 17 60 with 965 523 shares
BIIB,BIIB:UW,BBG000C18861,"Top Analyst Upgrades and Downgrades: Alliance Data, Autodesk, Biogen, Broadcom, Delta Air Lines, Finisar and More",2016-12-09 13:55:21 +0000,http://247wallst.com/investing/2016/12/09/top-analyst-upgrades-and-downgrades-alliance-data-autodesk-biogen-broadcom-delta-air-lines-finisar-and-more/,"Top Analyst Upgrades and Downgrades: Alliance Data, Autodesk, Biogen, Broadcom, Delta Air Lines, Finisar and More"
BIIB,BIIB:UW,BBG000C18861,"Astra, Lilly stick with Alzheimer's approach despite setback",2016-12-09 13:22:17 +0000,http://uk.finance.yahoo.com/news/astra-lilly-stick-alzheimers-approach-132217527.html,"Astra, Lilly stick with Alzheimer's approach despite setback"
BIIB,BIIB:UW,BBG000C18861,Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA™ (Daclizumab Beta) for Multiple Sclerosis,2016-12-09 13:00:00 +0000,http://finance.yahoo.com/news/biogen-abbvie-receive-health-canada-130000602.html,[CNW Group] - Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA™ (Daclizumab Beta) for Multiple Sclerosis
BIIB,BIIB:UW,BBG000C18861,"Early movers: LVS, MGM, WYNN, RH, AFL, MTN & more",2016-12-09 12:55:42 +0000,http://www.cnbc.com/id/104157149?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104157149,"Early movers: LVS, MGM, WYNN, RH, AFL, MTN & more"
BIIB,BIIB:UW,BBG000C18861,Biogen stock gains on leaked Alzheimer's drug data,2016-12-09 10:51:54 +0000,http://www.bizjournals.com/boston/news/2016/12/08/biogen-stock-gains-on-leaked-alzheimers-drug-data.html?ana=yahoo,Biogen stock gains on leaked Alzheimer's drug data
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. (BIIB) Is Up Sharply On Study Results For Alzheimer's Drug,2016-12-09 09:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R6s_VN4k2lI/biogen-inc-biib-is-up-sharply-on-study-results-for-alzheimers-drug-20161209-00314,Biogen Inc. (BIIB) Is Up Sharply On Study Results For Alzheimer's Drug
BIIB,BIIB:UW,BBG000C18861,Biogen And AbbVie Receive Health Canada Approval Of Once-Monthly ZINBRYTA,2016-12-09 08:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GmfuPaiqrtw/biogen-and-abbvie-receive-health-canada-approval-of-oncemonthly-zinbryta-20161209-00207,Biogen And AbbVie Receive Health Canada Approval Of Once-Monthly ZINBRYTA
BIIB,BIIB:UW,BBG000C18861,Biogen And AbbVie Receive Health Canada Approval Of Once-Monthly ZINBRYTA,2016-12-09 08:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ld81tjEKFg8/biogen-and-abbvie-receive-health-canada-approval-of-oncemonthly-zinbryta-20161209-00208,Biogen And AbbVie Receive Health Canada Approval Of Once-Monthly ZINBRYTA
BIIB,BIIB:UW,BBG000C18861,Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting,2016-12-08 23:16:00 +0000,http://uk.finance.yahoo.com/news/biogen-presents-data-phase-1b-231600535.html,Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
BIIB,BIIB:UW,BBG000C18861,The 3 Best Biotech Stocks for 2017,2016-12-08 22:57:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w92Ey8DhjdY/the-3-best-biotech-stocks-for-2017-cm718946,Trying to pick the best biotech stocks for 2017 defined as those with the best returns is a bit of a crapshoot The biotech stocks that ultimately produce the best returns are likely to be the ones that investors had little confidence in You can certainly find winners among
BIIB,BIIB:UW,BBG000C18861,Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key,2016-12-08 22:24:38 +0000,http://www.investors.com/news/technology/biotechs-round-trip-trump-inspired-rally-fda-appointment-key/,Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key
BIIB,BIIB:UW,BBG000C18861,Further promising data seen with Biogen Alzheimer's drug -study,2016-12-08 22:20:04 +0000,http://finance.yahoo.com/news/further-promising-data-seen-biogen-222004418.html,Further promising data seen with Biogen Alzheimer's drug -study
BIIB,BIIB:UW,BBG000C18861,Further promising data seen with Biogen Alzheimer's drug-study,2016-12-08 21:41:46 +0000,http://finance.yahoo.com/news/further-promising-data-seen-biogen-214146914.html,Further promising data seen with Biogen Alzheimer's drug-study
BIIB,BIIB:UW,BBG000C18861,Biogen shares rise 1.6% on leaked Alzheimer's drug data,2016-12-08 21:06:55 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=8221E44B-27F8-4B71-A596-754C94B8D690&siteid=yhoof2,Biogen shares rise 1.6% on leaked Alzheimer's drug data
BIIB,BIIB:UW,BBG000C18861,Biogen Shares Spike on Leaked Alzheimer's Drug Data,2016-12-08 20:47:00 +0000,https://www.thestreet.com/story/13919848/1/biogen-shares-spike-higher-on-leaked-alzheimer-s-drug-data.html?puc=yahoo&cm_ven=YAHOO,Biogen Shares Spike on Leaked Alzheimer's Drug Data
BIIB,BIIB:UW,BBG000C18861,Biogen Inc (BIIB) Stock Trade Showcases the ‘Art of the Steal’,2016-12-08 17:59:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vMp7VC2va6I/biogen-inc-biib-stock-trade-showcases-the-art-of-the-steal-cm718768,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips It has been nearly a month and for Biogen Inc NASDAQ BIIB and the biotech sector it has been a period of Trump amp Dump Now it s time to take advantage of value
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-12-08 17:11:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-171100461.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 8, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: ..."
BIIB,BIIB:UW,BBG000C18861,"Stock Market News for December 08, 2016",2016-12-08 16:57:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uIHL9Elek24/stock-market-news-for-december-08-2016-cm718651,The Trump induced rally continued to boost major benchmarks to finish at all time record highs on Wednesday offsetting the decline in healthcare stocks Though Trump s comment about putting a brake on drug prices led the healthcare sector to end with losses substantial broad based gains later
BIIB,BIIB:UW,BBG000C18861,Can Biogen solve the Alzheimer’s drug riddle? We could find out within days,2016-12-08 15:15:08 +0000,http://www.bizjournals.com/boston/news/2016/12/07/can-biogen-solve-the-alzheimer-s-drug-riddle-we.html?ana=yahoo,Can Biogen solve the Alzheimer’s drug riddle? We could find out within days
BIIB,BIIB:UW,BBG000C18861,"Investor Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016",2016-12-08 15:10:00 +0000,http://finance.yahoo.com/news/investor-alert-bronstein-gewirtz-grossman-151000702.html,"[Accesswire] - NEW YORK / ACCESSWIRE / December 8, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,[$$] US biotech shares tumble as Trump warns on soaring drug prices,2016-12-07 23:27:58 +0000,"http://www.ft.com/cms/s/108b814c-bc97-11e6-8b45-b8b81dd5d080,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[at Financial Times] - US biotechnology shares faced the sharpest sell-off in more than a month after comments from Donald Trump brought the spectre of tougher drug-price regulation back to the fore. Mr Trump's win in last month's ...
BIIB,BIIB:UW,BBG000C18861,Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point,2016-12-07 19:45:34 +0000,http://www.investors.com/market-trend/stock-market-today/trump-vow-on-drug-prices-hammers-drug-stocks-but-sp-500-nyse-up/,Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point
BIIB,BIIB:UW,BBG000C18861,Biogen Breaks Below 200-Day Moving Average - Notable for BIIB,2016-12-07 17:58:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WwJ2jExqu88/biogen-breaks-below-200-day-moving-average-notable-for-biib-cm718118,In trading on Wednesday shares of Biogen Inc Symbol BIIB crossed below their 200 day moving average of 281 48 changing hands as low as 281 09 per share Biogen Inc shares are currently trading off about 3 on the day The chart below shows the one year performance of BIIB shares versus
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-12-07 17:51:00 +0000,http://finance.yahoo.com/news/important-investor-alert-khang-khang-175100832.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 7, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,3 Top Healthcare Stocks,2016-12-07 16:19:03 +0000,http://www.fool.com/investing/2016/12/06/3-top-healthcare-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Healthcare Stocks
BIIB,BIIB:UW,BBG000C18861,"BIIB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016",2016-12-07 15:48:00 +0000,http://finance.yahoo.com/news/biib-shareholder-alert-law-offices-154800534.html,[Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc.
BIIB,BIIB:UW,BBG000C18861,Drug Stocks Tumble After Trump Vows to Pressure Prices,2016-12-07 15:36:58 +0000,http://blogs.wsj.com/moneybeat/2016/12/07/drug-stocks-tumble-after-trump-vows-to-pressure-drug-prices/?mod=yahoo_hs,Drug Stocks Tumble After Trump Vows to Pressure Prices
BIIB,BIIB:UW,BBG000C18861,How Can Value Screener Record Trends Explain Market Valuations?,2016-12-06 23:55:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qNeid0Ak-To/how-can-value-screener-record-trends-explain-market-valuations-cm717745,As we approach the end of 6 we can review the value screener record trends to further understand global market valuations and the predictability of companies Each value screener lists stocks meeting specific criteria Some value screeners list companies trading at deep discounts while
BIIB,BIIB:UW,BBG000C18861,Can Biogen Beat the Broader Markets in 2017?,2016-12-06 22:56:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/og-swQayzz0/can-biogen-beat-the-broader-markets-in-2017-cm717703,Large cap biotech Biogen NASDAQ BIIB is somewhat of an oddball in that it s currently experiencing a rapid deceleration in revenue growth yet Wall Street analysts are suggesting that its shares could still rise by a healthy 13 7 over the next year Analysts seem unfazed by
BIIB,BIIB:UW,BBG000C18861,Can Biogen Beat the Broader Markets in 2017?,2016-12-06 21:34:03 +0000,http://www.fool.com/investing/2016/12/06/can-biogen-beat-the-broader-markets-in-2017.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Can Biogen Beat the Broader Markets in 2017?
BIIB,BIIB:UW,BBG000C18861,3 Top Healthcare Stocks,2016-12-06 21:27:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PzkFGUyg87I/3-top-healthcare-stocks-cm717617,The populations in U S and developed nations around the globe are getting older and their healthcare costs are getting bigger Whether you re looking for dazzling growth or stability Celgene NASDAQ CELG Ionis Pharmacuticals NASDAQ IONS and Johnson amp
BIIB,BIIB:UW,BBG000C18861,Stock Exchange: Model Picks Teach Us To Manage Risk,2016-12-06 21:25:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xxUTh9FtZG0/stock-exchange-model-picks-teach-us-to-manage-risk-cm717556,By Jeff Miller ByJeff Miller Individual investors are intensely focused on the concept of risk And why shouldn t they be Finding an appropriate level of downside risk is paramount However too few give equal weight to the potential upside risk in their decisions Permabears
BIIB,BIIB:UW,BBG000C18861,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,2016-12-05 20:55:28 +0000,http://finance.yahoo.com/news/pressure-biosciences-ceo-biological-samples-205528437.html,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-12-05 16:57:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-165700023.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / December 5, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: ..."
BIIB,BIIB:UW,BBG000C18861,"Paul Tudor Jones Betting On Emerging Markets, Pepsi, Facebook, More",2016-12-05 15:09:16 +0000,http://www.insidermonkey.com/blog/paul-tudor-jones-betting-on-emerging-markets-pepsi-facebook-more-489783/,"Paul Tudor Jones Betting On Emerging Markets, Pepsi, Facebook, More"
BIIB,BIIB:UW,BBG000C18861,"Shareholder Alert - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016",2016-12-05 15:09:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150900303.html,"[Accesswire] - NEW YORK / ACCESSWIRE / December 5, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,5 Healthcare Stocks Billionaires Love The Most,2016-12-04 23:05:39 +0000,http://www.insidermonkey.com/blog/5-healthcare-stocks-billionaires-love-the-most-494391/,5 Healthcare Stocks Billionaires Love The Most
BIIB,BIIB:UW,BBG000C18861,4 Factors That Catapulted Ionis Pharmaceuticals Inc. 68% Higher in November,2016-12-04 18:24:07 +0000,http://www.fool.com/investing/2016/12/04/4-factors-that-catapulted-ionis-pharmaceuticals-in.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Factors That Catapulted Ionis Pharmaceuticals Inc. 68% Higher in November
BIIB,BIIB:UW,BBG000C18861,Why Eli Lilly Shares Lost 8% in November,2016-12-03 13:04:03 +0000,http://www.fool.com/investing/2016/12/03/why-eli-lilly-shares-lost-8-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Eli Lilly Shares Lost 8% in November
BIIB,BIIB:UW,BBG000C18861,Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting,2016-12-03 12:00:00 +0000,http://uk.finance.yahoo.com/news/data-reinforcing-long-term-safety-120000051.html,Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting
BIIB,BIIB:UW,BBG000C18861,"Biogen Spinoff Gets Gene Therapy Drugs (BIIB, SGMO)",2016-12-02 17:35:00 +0000,http://www.investopedia.com/news/biogens-gene-therapy-pipeline-bolstered-biib/?partner=YahooSA,"Biogen Spinoff Gets Gene Therapy Drugs (BIIB, SGMO)"
BIIB,BIIB:UW,BBG000C18861,Biogen MS Drug Sued for Patent Infringement (BIIB),2016-12-02 17:10:00 +0000,http://www.investopedia.com/news/biogens-ms-drug-faces-patent-challenge-biib/?partner=YahooSA,Biogen MS Drug Sued for Patent Infringement (BIIB)
BIIB,BIIB:UW,BBG000C18861,3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline,2016-12-02 13:03:04 +0000,http://www.fool.com/investing/2016/12/01/3-things-you-need-to-know-about-ionis-pharmaceutic.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline
BIIB,BIIB:UW,BBG000C18861,"Biogen may have edge in high-stakes Tecfidera patent battle, analyst says",2016-12-02 11:10:09 +0000,http://www.bizjournals.com/boston/news/2016/12/02/biogen-may-have-edge-in-high-stakes-tecfidera.html?ana=yahoo,"Biogen may have edge in high-stakes Tecfidera patent battle, analyst says"
BIIB,BIIB:UW,BBG000C18861,[$$] Patent Feud Is Underappreciated Risk at Biogen,2016-12-02 05:25:37 +0000,http://www.wsj.com/articles/patent-feud-is-underappreciated-risk-at-biogen-1480604461?ru=yahoo?mod=yahoo_itp,[$$] Patent Feud Is Underappreciated Risk at Biogen
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-12-01 17:43:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-174300838.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / December 1, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?,2016-12-01 17:21:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uv1EuhYbzQ8/gw-pharmaceuticals-gwph-what-awaits-in-q4-earnings-cm716383,GW Pharmaceuticals plc GWPH is scheduled to report fourth quarter fiscal 2016 results on Dec 5 before the opening bell The company has an impressive track record so far In fact in the four trailing quarters GW Pharma has surpassed estimates every time with an average positive surprise
BIIB,BIIB:UW,BBG000C18861,[$$] Patent Feud Is Underappreciated Risk at Biogen,2016-12-01 17:07:35 +0000,http://www.wsj.com/articles/patent-feud-is-underappreciated-risk-at-biogen-1480604461?mod=yahoo_hs,[$$] Patent Feud Is Underappreciated Risk at Biogen
BIIB,BIIB:UW,BBG000C18861,"ETFs with exposure to Biogen, Inc. : December 1, 2016",2016-12-01 15:50:10 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-biogen-inc-december-1-2016/,"ETFs with exposure to Biogen, Inc. : December 1, 2016"
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline December 23, 2016",2016-12-01 15:08:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150800531.html,"[Accesswire] - NEW YORK / ACCESSWIRE / December 1, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline,2016-12-01 14:17:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TeigZk1o1zc/3-things-you-need-to-know-about-ionis-pharmaceuticals-pipeline-cm716200,Few biotechs have as robust of a pipeline as Ionis Pharmaceuticals NASDAQ IONS The company has certainly experienced ups and downs in 2016 with its pipeline candidates but Ionis is ending the year on a good note Wade Walke vice president of corporate communications
BIIB,BIIB:UW,BBG000C18861,"Biogen, Forward Square Off In Multiple Sclerosis Patent Battle",2016-11-30 21:22:38 +0000,http://www.investors.com/news/technology/biogen-forward-square-off-in-multiple-sclerosis-patent-battle/,"Biogen, Forward Square Off In Multiple Sclerosis Patent Battle"
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-11-30 18:51:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-185100626.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 30, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: ..."
BIIB,BIIB:UW,BBG000C18861,"BIIB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016",2016-11-30 16:02:00 +0000,http://finance.yahoo.com/news/biib-investor-alert-law-offices-160200544.html,"[PR Newswire] - NEW YORK, Nov. 30, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who ..."
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Amgen,2016-11-30 15:55:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jCXMfrSJcZ4/better-buy-biogen-inc-vs-amgen-cm715653,If you re looking for top stocks to gain exposure to the high growth biotech space Biogen Inc NASDAQ BIIB and Amgen NASDAQ AMGN are both solid picks Let s consider which stock is the hands down better buy right now Image source Getty Images Biogen
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Actelion Soars on Acquisition Talks, Another Clinical Hold for Juno",2016-11-30 14:58:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/atDqxlHRKLw/biotech-stock-roundup-actelion-soars-on-acquisition-talks-another-clinical-hold-for-juno-cm715582,Switzerland based Actelion ALIOF confirmed that it is in preliminary talks with Johnson amp Johnson which is looking to acquire the company that is focused on the discovery development and commercialization of drugs for diseases with significant unmet medical needs Meanwhile Juno JUNO
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Amgen,2016-11-30 14:33:48 +0000,http://www.fool.com/investing/2016/11/30/better-buy-biogen-inc-vs-amgen.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Biogen Inc. vs. Amgen
BIIB,BIIB:UW,BBG000C18861,"After Lilly Bombs, Could Alzheimer's Become Healthcare's Trumpshot?",2016-11-30 13:35:00 +0000,http://www.forbes.com/sites/stephenbrozak/2016/11/30/after-lilly-bombs-could-alzheimers-become-healthcares-trumpshot/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"After Lilly Bombs, Could Alzheimer's Become Healthcare's Trumpshot?"
BIIB,BIIB:UW,BBG000C18861,Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield,2016-11-30 13:34:00 +0000,https://www.thestreet.com/story/13908604/1/biotech-stock-mailbag-looking-for-an-investable-idea-in-alzheimer-s-mine-field.html?puc=yahoo&cm_ven=YAHOO,Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : November 30, 2016",2016-11-30 12:38:05 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-biib-us-november-30-2016/,"Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : November 30, 2016"
BIIB,BIIB:UW,BBG000C18861,"Charles Payne on Biotech: Biogen Inc (BIIB), Intercept Pharmaceuticals Inc (ICPT)",2016-11-29 19:54:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s9RvKo38FPI/charles-payne-on-biotech-biogen-inc-biib-intercept-pharmaceuticals-inc-icpt-cm715299,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips I ve been talking a lot recently about where I see opportunity after the election and looking ahead to a Donald Trump administration Today I want to talk about the potential within the biotechnology
BIIB,BIIB:UW,BBG000C18861,"Visualizing Financial Trends With Interactive Charts, Other Topics",2016-11-29 17:04:23 +0000,http://finance.yahoo.com/news/visualizing-financial-trends-interactive-charts-170423626.html,"Visualizing Financial Trends With Interactive Charts, Other Topics"
BIIB,BIIB:UW,BBG000C18861,Biogen loses $4 billion in market cap on Eli Lilly Alzheimer's news,2016-11-29 16:50:08 +0000,http://www.bizjournals.com/boston/news/2016/11/23/biogen-loses-4-billion-in-market-cap-on-eli-lilly.html?ana=yahoo,Biogen loses $4 billion in market cap on Eli Lilly Alzheimer's news
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-11-28 20:42:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-khang-khang-204200704.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / November 28, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen Unfazed by Lilly Disappointment,2016-11-28 19:24:00 +0000,http://www.barrons.com/articles/biogen-unfazed-by-lilly-disappointment-1480361095?mod=yahoobarrons&ru=yahoo,[$$] Biogen Unfazed by Lilly Disappointment
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline - December 23, 2016",2016-11-28 15:07:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150700293.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 28, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails,2016-11-28 14:45:31 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=5651B1BE-B315-11E6-9EED-D4A5BAE29302&siteid=yhoof2,Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails
BIIB,BIIB:UW,BBG000C18861,Short Sellers Grow More Aggressive on Major Biotechs,2016-11-28 12:35:16 +0000,http://finance.yahoo.com/news/short-sellers-grow-more-aggressive-123516310.html,Short Sellers Grow More Aggressive on Major Biotechs
BIIB,BIIB:UW,BBG000C18861,"EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-11-25 21:58:00 +0000,http://finance.yahoo.com/news/equity-alert-lundin-law-pc-215800078.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 25, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: ..."
BIIB,BIIB:UW,BBG000C18861,Gurus Invest in Undervalued Biotech Stocks,2016-11-25 18:14:55 +0000,http://finance.yahoo.com/news/gurus-invest-undervalued-biotech-stocks-181455873.html,Gurus Invest in Undervalued Biotech Stocks
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016",2016-11-25 15:30:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-153000550.html,"[Business Wire] - The following statement is being issued by Levi & Korsinsky, LLP:"
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline - December 23, 2016",2016-11-25 15:06:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150600786.html,"[Accesswire] - NEW YORK / ACCESSWIRE / November 25, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?,2016-11-25 14:07:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d3o-q7ihY2I/will-lillys-solanezumab-setback-weigh-on-other-alzheimers-stocks-cm713781,Eli Lilly and Company s LLY shares tumbled 10 5 following the release of highly awaited data on its experimental Alzheimer s disease AD treatment solanezumab from a late stage study The candidate was being investigated to see whether it can slow the progression of memory problems
BIIB,BIIB:UW,BBG000C18861,What Eli Lilly’s hard fall in Alzheimer’s treatment race means for its competitors,2016-11-25 12:09:33 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=CB425EBE-B17C-11E6-909D-6A360671FDAB&siteid=yhoof2,What Eli Lilly’s hard fall in Alzheimer’s treatment race means for its competitors
BIIB,BIIB:UW,BBG000C18861,Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?,2016-11-25 12:00:12 +0000,http://finance.yahoo.com/news/lillys-solanezumab-setback-weigh-other-120012409.html,Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
BIIB,BIIB:UW,BBG000C18861,[$$] Failure of Another Alzheimer’s Drug Forces a Reassessment,2016-11-25 05:16:08 +0000,http://www.wsj.com/articles/eli-lillys-setback-highlights-challenges-of-alzheimers-treatment-1479932924?ru=yahoo?mod=yahoo_itp,[$$] Failure of Another Alzheimer’s Drug Forces a Reassessment
BIIB,BIIB:UW,BBG000C18861,"Pre-Market Most Active for Nov 23, 2016 :  LLY, NVO, TGT, MT, BAC, DE, JUNO, BIIB, ERIC, QQQ, XIV, TVIX",2016-11-24 13:54:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wJ8IhHvVFj8/pre-market-most-active-for-nov-23-2016-lly-nvo-tgt-mt-bac-de-juno-biib-eric-qqq-xiv-tvix-cm713634,The NASDAQ 100 Pre Market Indicator is down 17 96 to 4 855 88 The total Pre Market volume is currently 27 535 190 shares traded The following are the most active stocks for the pre market session Eli Lilly and Company LLY is 11 69 at 64 30 with 6 253 901
BIIB,BIIB:UW,BBG000C18861,"Lilly's Alzheimer Drug Fails Phase III Study, Stock Down",2016-11-24 13:06:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SV-ZlB57ots/lillys-alzheimer-drug-fails-phase-iii-study-stock-down-cm713614,Lilly s Eli Lilly and Company LLY announced that its key pipeline candidate solanezumab failed to meet the primary endpoint in a phase III study EXPEDITION3 in patients with mild Alzheimer s dementia The drugmaker s shares declined almost 11 on Wednesday following the disappointing
BIIB,BIIB:UW,BBG000C18861,Is Lilly's Alzheimer's Fail Good for Biogen? (BIIB),2016-11-24 12:39:00 +0000,http://www.investopedia.com/news/does-lillys-alzheimers-fail-hurt-biogen-biib/?partner=YahooSA,Is Lilly's Alzheimer's Fail Good for Biogen? (BIIB)
BIIB,BIIB:UW,BBG000C18861,"Biogen Inc (BIIB) Stock Tumbles In Sympathy To Eli Lilly And Co (LLY), C’mon Man!",2016-11-24 00:07:48 +0000,http://www.insidermonkey.com/blog/biogen-inc-biib-stock-tumbles-in-sympathy-to-eli-lilly-and-co-lly-cmon-man-490463/,"Biogen Inc (BIIB) Stock Tumbles In Sympathy To Eli Lilly And Co (LLY), C’mon Man!"
BIIB,BIIB:UW,BBG000C18861,"3 Potentially Huge Catalysts for Ionis Pharmaceuticals, Inc. in 2017",2016-11-23 23:04:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V40d4B-x-g0/3-potentially-huge-catalysts-for-ionis-pharmaceuticals-inc-in-2017-cm713564,To say that 2016 has been an up and down year for Ionis Pharmaceuticals Inc NASDAQ IONS is an understatement In the first half of the year shares of the biotech plunged more than 60 Since July though Ionis stock has rebounded by over 75 Next year could be critical for
BIIB,BIIB:UW,BBG000C18861,Eli Lilly's Alzheimer's Drug Is a Bust,2016-11-23 23:04:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dkCfU_EgK5c/eli-lillys-alzheimers-drug-is-a-bust-cm713558,In a highly disappointing yet not all too surprising news release earlier today Eli Lilly amp Company NYSE LLY 160 says that its late stage drug solanezumab failed to improve cognition in patients diagnosed with mild to moderate Alzheimer s disease The failure marks the
BIIB,BIIB:UW,BBG000C18861,Drug bust hits healthcare stocks,2016-11-23 22:16:00 +0000,http://finance.yahoo.com/video/drug-bust-hits-healthcare-stocks-221600920.html,Drug bust hits healthcare stocks
BIIB,BIIB:UW,BBG000C18861,Eli Lilly's Alzheimer's Drug Is a Bust,2016-11-23 22:01:09 +0000,http://www.fool.com/investing/general/2016/11/23/eli-lillys-alzheimers-drug-is-a-bust.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Eli Lilly's Alzheimer's Drug Is a Bust
BIIB,BIIB:UW,BBG000C18861,"Market Close Report: NASDAQ Composite index closes at 5,380.68 down -5.67 points",2016-11-23 21:49:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Teh7U4JYR1A/market-close-report-nasdaq-composite-index-closes-at-538068-down-567-points-cm713552,Wednesday s session closes with the NASDAQ Composite Index at 5 380 68 The total shares traded for the NASDAQ was over 1 69 billion Wednesday s session closes with the NASDAQ Composite Index at 5 380 68 The total shares traded for the NASDAQ was over 1 69 billion Advancers stocks led
BIIB,BIIB:UW,BBG000C18861,"3 Potentially Huge Catalysts for Ionis Pharmaceuticals, Inc. in 2017",2016-11-23 21:29:16 +0000,http://www.fool.com/investing/2016/11/23/3-potentially-huge-catalysts-for-ionis-pharmaceuti.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Potentially Huge Catalysts for Ionis Pharmaceuticals, Inc. in 2017"
BIIB,BIIB:UW,BBG000C18861,[$$] Failure of Another Alzheimer's Drug Forces a Reassessment,2016-11-23 21:27:57 +0000,http://www.wsj.com/articles/eli-lillys-setback-highlights-challenges-of-alzheimers-treatment-1479932924?mod=yahoo_hs,[$$] Failure of Another Alzheimer's Drug Forces a Reassessment
BIIB,BIIB:UW,BBG000C18861,Lilly's drug for Alzheimer's fails big trial; shares drop,2016-11-23 21:25:38 +0000,http://sg.finance.yahoo.com/news/lillys-drug-alzheimers-fails-big-190703746.html,Lilly's drug for Alzheimer's fails big trial; shares drop
BIIB,BIIB:UW,BBG000C18861,"Eli Lilly Topples As Alzheimer's Darling Sola Fails; Biogen, Merck Down",2016-11-23 21:07:29 +0000,http://www.investors.com/news/technology/eli-lilly-biogen-merck-topple-after-alzheimers-darling-sola-fails/,"Eli Lilly Topples As Alzheimer's Darling Sola Fails; Biogen, Merck Down"
BIIB,BIIB:UW,BBG000C18861,"Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks",2016-11-23 20:35:01 +0000,http://sg.finance.yahoo.com/news/alzheimers-setback-prompts-rethink-lilly-203501852.html,"Alzheimer's setback prompts rethink of Lilly, Biogen stock outlooks"
BIIB,BIIB:UW,BBG000C18861,3 Biotechs That Don't Pay Dividends -- but Could,2016-11-23 20:14:40 +0000,http://www.fool.com/investing/2016/11/22/3-biotechs-that-dont-pay-dividends-but-could.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs That Don't Pay Dividends -- but Could
BIIB,BIIB:UW,BBG000C18861,Eli Lilly and Co (LLY) Drug Failure Doesn’t Answer the Bigger Question,2016-11-23 20:05:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KUePqSjdx6k/eli-lilly-and-co-lly-drug-failure-doesnt-answer-the-bigger-question-cm713492,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips A tough break for Eli Lilly and Co NYSE LLY shareholders today reports of another failed drug trial have sent LLY shares 12 lower as of this writing The current price near 67 is a two year
BIIB,BIIB:UW,BBG000C18861,Why Biogen Shareholders Lost $3 Billion Today,2016-11-23 20:05:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qd7rXDyH1s0/why-biogen-shareholders-lost-3-billion-today-cm713483,Image source Getty Images What happened Shares of Biogen NASDAQ BIIB were down more than 4 in early afternoon trading on Wednesday in response to Eli Lilly NYSE LLY reporting disappointing news about a late stage clinical trial involving an
BIIB,BIIB:UW,BBG000C18861,Why Biogen Shareholders Lost $3 Billion Today,2016-11-23 18:29:59 +0000,http://www.fool.com/investing/2016/11/23/why-biogen-shareholders-lost-3-billion-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Biogen Shareholders Lost $3 Billion Today
BIIB,BIIB:UW,BBG000C18861,"Analyst on LLY: In general, I believe Biogen drug is bett...",2016-11-23 18:05:00 +0000,http://finance.yahoo.com/video/analyst-lly-general-believe-biogen-180500934.html,"Analyst on LLY: In general, I believe Biogen drug is bett..."
BIIB,BIIB:UW,BBG000C18861,Trades gone 'fowl': Big losers in large cap S&P,2016-11-23 17:51:00 +0000,http://finance.yahoo.com/video/trades-gone-fowl-big-losers-175100755.html,Trades gone 'fowl': Big losers in large cap S&P
BIIB,BIIB:UW,BBG000C18861,"Eli Lilly Alzheimer's Drug Fails Key Trial; Lilly, Biogen Dive",2016-11-23 17:26:58 +0000,http://www.investors.com/news/technology/eli-lilly-alzheimers-drug-fails-key-trial-stock-dives/,"Eli Lilly Alzheimer's Drug Fails Key Trial; Lilly, Biogen Dive"
BIIB,BIIB:UW,BBG000C18861,Eli Lilly & Juno Therapeutics plummet after failed drug t...,2016-11-23 17:21:00 +0000,http://finance.yahoo.com/video/eli-lilly-juno-therapeutics-plummet-172100581.html,Eli Lilly & Juno Therapeutics plummet after failed drug t...
BIIB,BIIB:UW,BBG000C18861,Instant Analysis: Eli Lilly Drops Pre-holiday Alzheimer's Bomb,2016-11-23 17:06:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NYzPiFu277I/instant-analysis-eli-lilly-drops-pre-holiday-alzheimers-bomb-cm713302,What happened This morning Eli Lilly NYSE LLY dropped a data bomb that s going to spoil the Alzheimer s community s Thanksgiving appetite Long awaited results from a late stage study showed patients with mild Alzheimer s Disease related dementia didn t experience a
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: BIIB, EA",2016-11-23 17:04:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uwX-tce9vRc/nasdaq-100-movers-biib-ea-cm713311,In early trading on Wednesday shares of Electronic Arts topped the list of the day s best performing components of the Nasdaq 100 index trading up 1 9 Year to date Electronic Arts registers a 15 3 gain And the worst performing Nasdaq 100 component thus far on the day is Biogen
BIIB,BIIB:UW,BBG000C18861,Biotechs Weigh On Nasdaq; Veeva Up On Earnings; 10-Yr Yield Soars Again,2016-11-23 17:02:55 +0000,http://www.investors.com/market-trend/stock-market-today/biotechs-weigh-on-nasdaq-veeva-up-on-earnings-10-yr-yield-soars-again/,Biotechs Weigh On Nasdaq; Veeva Up On Earnings; 10-Yr Yield Soars Again
BIIB,BIIB:UW,BBG000C18861,5 Biotech Stocks George Soros Is Buying,2016-11-23 15:29:28 +0000,http://www.fool.com/investing/2016/11/22/5-biotech-stocks-george-soros-is-buying.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Biotech Stocks George Soros Is Buying
BIIB,BIIB:UW,BBG000C18861,"Stocks Open Lower; Deere Soars, Eli Lilly Crumbles",2016-11-23 14:45:30 +0000,http://www.investors.com/market-trend/stock-market-today/stock-futures-quiet-tightly-mixed-deere-soars-eli-lilly-crumbles/,"Stocks Open Lower; Deere Soars, Eli Lilly Crumbles"
BIIB,BIIB:UW,BBG000C18861,"Shares of Eli Lilly Are Down 12% After Trial Miss (LLY, BIIB)",2016-11-23 14:15:00 +0000,http://www.investopedia.com/news/eli-lillys-drug-solanezumab-failed-key-alzheimers-disease-trial-lly-biib/?partner=YahooSA,"Shares of Eli Lilly Are Down 12% After Trial Miss (LLY, BIIB)"
BIIB,BIIB:UW,BBG000C18861,"Pre-Market Most Active for Nov 23, 2016 :  LLY, DE, RDY, NVO, BIIB, ERIC, MT, SNY, JUNO, QQQ, XIV, TVIX",2016-11-23 13:53:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kID8OF6hPdw/pre-market-most-active-for-nov-23-2016-lly-de-rdy-nvo-biib-eric-mt-sny-juno-qqq-xiv-tvix-cm713147,The NASDAQ 100 Pre Market Indicator is down 12 65 to 4 861 19 The total Pre Market volume is currently 9 642 054 shares traded The following are the most active stocks for the pre market session Eli Lilly and Company LLY is 10 22 at 65 77 with 3 698 726
BIIB,BIIB:UW,BBG000C18861,"Trending Stocks: First Solar, Inc. (FSLR), Eli Lilly and Co (LLY), and More",2016-11-23 13:41:11 +0000,http://www.insidermonkey.com/blog/trending-stocks-first-solar-inc-fslr-eli-lilly-and-co-lly-and-more-489934/,"Trending Stocks: First Solar, Inc. (FSLR), Eli Lilly and Co (LLY), and More"
BIIB,BIIB:UW,BBG000C18861,Eli Lilly's Alzheimer's Drug Fails Key Clinical Trial,2016-11-23 13:07:00 +0000,https://www.thestreet.com/story/13903616/1/eli-lilly-s-alzheimer-s-drug-fails-key-clinical-trial.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly's Alzheimer's Drug Fails Key Clinical Trial
BIIB,BIIB:UW,BBG000C18861,Are Biogen and Gilead Sciences in Denial?,2016-11-23 12:30:50 +0000,http://www.fool.com/investing/2016/11/22/are-biogen-and-gilead-sciences-in-denial.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Are Biogen and Gilead Sciences in Denial?
BIIB,BIIB:UW,BBG000C18861,Lilly Alzheimer's drug fails to slow memory loss in big study,2016-11-23 11:58:38 +0000,http://finance.yahoo.com/news/lilly-alzheimers-drug-fails-slow-115838073.html,Lilly Alzheimer's drug fails to slow memory loss in big study
BIIB,BIIB:UW,BBG000C18861,Eli Lilly Alzheimer's Drug Fails Trial; Shares Plunge,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yEDUkOEyy10/eli-lilly-alzheimers-drug-fails-trial-shares-plunge-20161123-00715,Eli Lilly Alzheimer's Drug Fails Trial; Shares Plunge
BIIB,BIIB:UW,BBG000C18861,Eli Lilly Alzheimer's Drug Fails Trial,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oR0x61LPaHI/eli-lilly-alzheimers-drug-fails-trial-20161123-00309,Eli Lilly Alzheimer's Drug Fails Trial
BIIB,BIIB:UW,BBG000C18861,Eli Lilly Alzheimer''s Drug Fails Trial; Shares Plunge,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h3Nid7pkXD0/eli-lilly-alzheimers-drug-fails-trial-shares-plunge-20161123-00393,Eli Lilly Alzheimer''s Drug Fails Trial; Shares Plunge
BIIB,BIIB:UW,BBG000C18861,Eli Lilly''s Late-Stage Alzheimer''s Trial Fails to Achieve Goal,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_7DK5LyNrts/eli-lillys-latestage-alzheimers-trial-fails-to-achieve-goal-20161123-00222,Eli Lilly''s Late-Stage Alzheimer''s Trial Fails to Achieve Goal
BIIB,BIIB:UW,BBG000C18861,Eli Lilly's Late-Stage Alzheimer's Trial Fails to Achieve Goal,2016-11-23 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/84WUktpAKNM/eli-lillys-latestage-alzheimers-trial-fails-to-achieve-goal-20161123-00221,Eli Lilly's Late-Stage Alzheimer's Trial Fails to Achieve Goal
BIIB,BIIB:UW,BBG000C18861,Stocks Calm After Dow Record,2016-11-23 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LFi9bKKKhFE/stocks-calm-after-dow-record-20161123-00203,Stocks Calm After Dow Record
BIIB,BIIB:UW,BBG000C18861,U.S. Stocks Hit Fresh High,2016-11-23 03:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GfVjUxMRdDU/us-stocks-hit-fresh-high-20161123-00708,U.S. Stocks Hit Fresh High
BIIB,BIIB:UW,BBG000C18861,5 Biotech Stocks George Soros Is Buying,2016-11-22 23:19:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ttlUPyNBqXQ/5-biotech-stocks-george-soros-is-buying-cm713020,George Soros namesake fund known as Soros Fund Management has continued to show interest in the beaten down biotech space this year even as most of its hedge fund peers have run for cover due to the political headwinds emanating from the U S presidential election
BIIB,BIIB:UW,BBG000C18861,3 Biotechs That Don't Pay Dividends -- but Could,2016-11-22 21:19:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/82jlcx1t41w/3-biotechs-that-dont-pay-dividends-but-could-cm712939,Biotech stocks aren t generally known for their dividends There are a few exceptions but as a rule most biotechs either don t have the ability to reward shareholders with dividends or they need the cash to fuel additional growth However some biotechs could easily pay dividends if
BIIB,BIIB:UW,BBG000C18861,"Lilly Poised For Big December On Alzheimer's Data, Diabetes Ruling",2016-11-22 21:01:57 +0000,http://www.investors.com/news/technology/lilly-poised-for-holly-december-on-alzheimers-data-diabetes-ruling/,"Lilly Poised For Big December On Alzheimer's Data, Diabetes Ruling"
BIIB,BIIB:UW,BBG000C18861,Acorda Stops Post-Stroke Development Program on Ampyra,2016-11-22 16:22:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TqqoBWusnoI/acorda-stops-post-stroke-development-program-on-ampyra-cm712688,Acorda Therapeutics Inc ACOR has decided to discontinue development of Ampyra dalfampridine for an expanded indication of post stroke walking difficulties PSWD The company s shares fell 4 2 on the news The decision was based on an interim analysis of a clinical study
BIIB,BIIB:UW,BBG000C18861,Are Biogen and Gilead Sciences in Denial?,2016-11-22 15:19:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SrXUS_aZpsU/are-biogen-and-gilead-sciences-in-denial-cm712548,Biogen NASDAQ BIIB and Gilead Sciences NASDAQ GILD 160 have both entered the phase of their life cycle where it becomes popular to essentially buy revenue by cutting deals for so called bolt on acquisitions Oddly enough though these top biotechs have largely shied away
BIIB,BIIB:UW,BBG000C18861,Acorda Stops Post-Stroke Development Program on Ampyra,2016-11-22 13:53:01 +0000,http://finance.yahoo.com/news/acorda-stops-post-stroke-development-135301400.html,Acorda Stops Post-Stroke Development Program on Ampyra
BIIB,BIIB:UW,BBG000C18861,Cramer: Trump Rally is a FANG + FANG Affair,2016-11-22 00:01:00 +0000,http://realmoney.thestreet.com/articles/11/21/2016/cramer-trump-rally-fang-fang-affair?puc=yahoo&cm_ven=YAHOO,Cramer: Trump Rally is a FANG + FANG Affair
BIIB,BIIB:UW,BBG000C18861,3 Irrefutable Reasons to Sell Johnson & Johnson Stock,2016-11-21 23:18:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NMG5S6a9sGM/3-irrefutable-reasons-to-sell-johnson-johnson-stock-cm712362,Johnson amp Johnson NYSE JNJ has arguably been one of the best stocks to own for years The company claims multiple successful brands from Aveeno to Zytiga But as much as I like J amp J investors might want to consider selling the stock Here are three irrefutable reasons
BIIB,BIIB:UW,BBG000C18861,Copaxone May Face Competitive Pressures in the Future,2016-11-21 22:04:14 +0000,http://marketrealist.com/2016/11/copaxone-franchise-may-face-competitive-pressures-future-years/?utm_source=yahoo&utm_medium=feed,Copaxone May Face Competitive Pressures in the Future
BIIB,BIIB:UW,BBG000C18861,3 Irrefutable Reasons to Sell Johnson & Johnson Stock,2016-11-21 21:33:27 +0000,http://www.fool.com/investing/2016/11/21/3-irrefutable-reasons-to-sell-johnson-johnson-stoc.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Irrefutable Reasons to Sell Johnson & Johnson Stock
BIIB,BIIB:UW,BBG000C18861,"Amgen, Biogen, Celgene Eye M&A In Trump's 'Pro-Biotech' World",2016-11-21 21:07:25 +0000,http://www.investors.com/news/technology/amgen-biogen-celgene-eye-ma-in-trumps-pro-biotech-world/,"Amgen, Biogen, Celgene Eye M&A In Trump's 'Pro-Biotech' World"
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-11-21 18:03:00 +0000,http://finance.yahoo.com/news/investor-alert-khang-khang-llp-180300461.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / November 21, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,"Billionaire John Paulson’s Most Bullish Q3 Moves: Biogen (BIIB), eBay Inc. (EBAY) & More",2016-11-21 15:46:14 +0000,http://www.insidermonkey.com/blog/billionaire-john-paulsons-most-bullish-q3-moves-biogen-biib-ebay-inc-ebay-more-488668/,"Billionaire John Paulson’s Most Bullish Q3 Moves: Biogen (BIIB), eBay Inc. (EBAY) & More"
BIIB,BIIB:UW,BBG000C18861,"BIIB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016",2016-11-21 15:28:00 +0000,http://finance.yahoo.com/news/biib-shareholder-alert-law-offices-152800462.html,[Business Wire] - The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc.
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016",2016-11-21 15:05:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150500051.html,"[Accesswire] - NEW YORK / ACCESSWIRE / November 21, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,$13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Market,2016-11-21 14:53:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MeNQveCzpFM/13-billion-opportunity-5-companies-that-could-dominate-the-alzheimers-disease-market-cm711826,Alzheimer s disease affects over 5 million Americans It s the sixth highest cause of death in the U S There s such an intense demand for effective treatments that 160 research and consulting firm GlobalData projects the market for Alzheimer s disease drugs could top 13 billion by
BIIB,BIIB:UW,BBG000C18861,$13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Market,2016-11-21 13:46:45 +0000,http://www.fool.com/investing/2016/11/21/13-billion-opportunity-5-companies-that-could-domi.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,$13 Billion Opportunity: 5 Companies That Could Dominate the Alzheimer's Disease Market
BIIB,BIIB:UW,BBG000C18861,3 Beaten-Down Biotech Stocks to Buy for Huge Gains,2016-11-18 21:50:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0juU5e11Db4/3-beaten-down-biotech-stocks-to-buy-for-huge-gains-cm710891,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips In addition to financial stocks the healthcare sector and biotech stocks breathed a collective sigh of relief following the election of Donald Trump as President It is widely believed that a secular trend
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-11-18 18:02:00 +0000,http://finance.yahoo.com/news/shareholder-alert-lundin-law-pc-180200224.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 18, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (NASDAQ: ..."
BIIB,BIIB:UW,BBG000C18861,How's Life For The Other Half Of The Big Cap 20?,2016-11-18 17:55:34 +0000,http://www.investors.com/stock-lists/ibd-big-cap-20/hows-life-for-the-other-half-of-the-big-cap-20/,How's Life For The Other Half Of The Big Cap 20?
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline - December 23, 2016",2016-11-18 15:04:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150400733.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 18, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know,2016-11-18 12:48:00 +0000,https://www.thestreet.com/story/13899121/1/lilly-s-alzheimer-s-drug-study-results-are-coming-here-s-what-investors-need-to-know.html?puc=yahoo&cm_ven=YAHOO,Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know
BIIB,BIIB:UW,BBG000C18861,U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early Alzheimer's Disease,2016-11-18 02:39:00 +0000,http://au.finance.yahoo.com/news/u-fda-grants-fast-track-023900974.html,"[ACN Newswire] - TOKYO, Nov 18, 2016 - (JCN Newswire) - Eisai Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609 which was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc. E2609 is currently being investigated in Phase III clinical studies for early Alzheimer's disease. Fast Track is a process designed to facilitate the development and review of drugs to treat serious conditions and tackle key unmet medical needs by allowing for frequent interactions with the FDA."
BIIB,BIIB:UW,BBG000C18861,Stock Trading Ideas for 11/17/16,2016-11-17 21:46:26 +0000,http://finance.yahoo.com/tumblr/blog-stock-trading-ideas-for-111716-214633236.html,Stock Trading Ideas for 11/17/16
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties",2016-11-17 16:51:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2F-WHKrnN3o/the-zacks-analyst-blog-highlights-biogen-honda-intel-csx-and-general-growth-properties-cm710614,For Immediate Release Chicago IL November 17 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BIIB,BIIB:UW,BBG000C18861,Performance of Novartis’s Innovative Medicines Segment in 3Q16,2016-11-17 15:04:35 +0000,http://marketrealist.com/2016/11/performance-of-novartiss-innovative-medicines-segment-in-3q16/?utm_source=yahoo&utm_medium=feed,Performance of Novartis’s Innovative Medicines Segment in 3Q16
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties",2016-11-17 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-biogen-143002887.html,"The Zacks Analyst Blog Highlights: Biogen, Honda, Intel, CSX and General Growth Properties"
BIIB,BIIB:UW,BBG000C18861,"Top Research Reports for Intel, Honda & Biogen",2016-11-16 16:51:04 +0000,http://finance.yahoo.com/news/top-research-reports-intel-honda-165104741.html,"Top Research Reports for Intel, Honda & Biogen"
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-11-16 16:28:00 +0000,http://finance.yahoo.com/news/shareholder-alert-khang-khang-llp-162800212.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / November 16, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (Nasdaq: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,"BIIB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016",2016-11-16 14:27:17 +0000,http://finance.yahoo.com/news/biib-investor-alert-law-offices-142717485.html,"[GlobeNewswire] - NEW YORK, Nov. 16, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen ..."
BIIB,BIIB:UW,BBG000C18861,"Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'",2016-11-15 21:28:18 +0000,http://www.investors.com/news/technology/amgen-biogen-eli-lilly-poised-to-rocket-on-the-most-important-event/,"Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'"
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-11-15 15:53:00 +0000,http://finance.yahoo.com/news/investor-alert-lundin-law-pc-155300456.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 15, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (Nasdaq: ..."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline - December 23, 2016",2016-11-15 15:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-151000324.html,"[GlobeNewswire] - NEW YORK, Nov. 15, 2016-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. and certain of its officers. The class ..."
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Celgene Corporation,2016-11-15 13:28:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IhaX6gHLg9s/better-buy-biogen-inc-vs-celgene-corporation-cm709146,This year might have started off poorly for biotech stocks but things have certainly changed after the surprising election results Two of the biggest biotechs around Biogen NASDAQ BIIB and Celgene NASDAQ CELG are now enjoying nice runs Which of these two stocks is
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Celgene Corporation,2016-11-15 12:40:15 +0000,http://www.fool.com/investing/2016/11/15/better-buy-biogen-inc-vs-celgene-corporation.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Biogen Inc. vs. Celgene Corporation
BIIB,BIIB:UW,BBG000C18861,Biogen Announces Additional Members of Management Team of Hemophilia Spin-off Company Bioverativ,2016-11-15 12:38:17 +0000,http://www.publicnow.com/view/10D9A1D944BF7C33E9A0BBF2918F9DA925BE0CA7,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced the addition of two members to the executive management team of Bioverativ Inc., Biogen's planned spin-off company focused on the ..."
BIIB,BIIB:UW,BBG000C18861,"George Soros buys stakes in Alphabet, Netflix, dumps Disney, General Motors",2016-11-15 10:51:35 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=F0FB8970-E779-41BA-B113-4B24DDB65791&siteid=yhoof2,"George Soros buys stakes in Alphabet, Netflix, dumps Disney, General Motors"
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharmaceuticals Soared 11.7% Higher Today,2016-11-14 21:16:13 +0000,http://www.fool.com/investing/2016/11/14/why-ionis-pharmaceuticals-soared-117-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Ionis Pharmaceuticals Soared 11.7% Higher Today
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-11-14 18:47:00 +0000,http://finance.yahoo.com/news/important-equity-alert-khang-khang-184700769.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / November 14, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (Nasdaq: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,How To Invest During The Trump Presidency,2016-11-14 15:06:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mJKGj5qKm5o/how-to-invest-during-the-trump-presidency-cm708605,"It is reasonable to assume that once the 2016 election results were known, U.S. electorate divided into three groups. One quarter or so probably felt delirious, if for no other reason than Donald Trump’s victory mean that Hillary Clinton was defeated, regardless of the apparent character of the man that actually won."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline: December 23, 2016",2016-11-14 15:03:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150300701.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 14, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Inc Back in the Black (for Now),2016-11-12 21:17:51 +0000,http://www.fool.com/investing/2016/11/11/ionis-pharmaceuticals-inc-back-in-the-black-for-no.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Ionis Pharmaceuticals Inc Back in the Black (for Now)
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Inc Back in the Black (for Now),2016-11-11 22:28:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fUqj3sxSNoQ/ionis-pharmaceuticals-inc-back-in-the-black-for-now-cm708133,Image source Getty Images Ionis Pharmaceuticals NASDAQ IONS reported third quarter earnings on Wednesday but investors are rightfully focused on the pending approval of Spinraza for spinal muscular atrophy SMA and its progressing pipeline Ionis Pharmaceuticals
BIIB,BIIB:UW,BBG000C18861,3 Biotech Stocks You MUST Buy for Donald Trump’s Presidency,2016-11-11 20:29:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XGKLDkkun44/3-biotech-stocks-you-must-buy-for-donald-trumps-presidency-cm707294,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The biotech industry has been dealt a Trump card Wednesday Now it s your turn to vote and go long in a much more hospitable environment in these three large cap biotech stocks Source Pixelbay
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-11-11 17:28:00 +0000,http://finance.yahoo.com/news/important-equity-alert-lundin-law-172800830.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 11, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (Nasdaq: ..."
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016 – BIIB",2016-11-11 15:52:27 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-155227471.html,"[GlobeNewswire] - NEW YORK, Nov. 11, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc. between July 23, 2014 ..."
BIIB,BIIB:UW,BBG000C18861,"Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for November 14, 2016",2016-11-11 14:14:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fm5nrTO2b2s/amgen-inc-amgn-ex-dividend-date-scheduled-for-november-14-2016-cm707640,Amgen Inc AMGN will begin trading ex dividend on November 14 2016 A cash dividend payment of 1 per share is scheduled to be paid on December 08 2016 Shareholders who purchased AMGN prior to the ex dividend date are eligible for the cash dividend payment This marks the 4th quarter
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : November 11, 2016",2016-11-11 12:18:28 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-breached-its-50-day-moving-average-in-a-bullish-manner-biib-us-november-11-2016/,"Biogen, Inc. breached its 50 day moving average in a Bullish Manner : BIIB-US : November 11, 2016"
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-11-10 19:18:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-khang-khang-191800031.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / November 10, 2016 / Khang & Khang LLP (the ""Firm"") announces the filing of a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,3 Reasons Trump Victory Brings New Day for Biotech,2016-11-10 17:30:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/10/3-reasons-its-a-new-day-for-biotech/?mod=yahoobarrons&ru=yahoo,3 Reasons Trump Victory Brings New Day for Biotech
BIIB,BIIB:UW,BBG000C18861,3 Reasons to Sell Biogen,2016-11-10 17:03:30 +0000,http://www.fool.com/investing/2016/11/10/3-reasons-to-sell-biogen.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Reasons to Sell Biogen
BIIB,BIIB:UW,BBG000C18861,"Biotechs to Buy After Trump Victory (CELG, BIIB)",2016-11-10 16:16:00 +0000,http://www.investopedia.com/stock-analysis/cotd/111016/biotechs-buy-after-trump-victory-celg-biib-celg-biib-sgeb.aspx?partner=YahooSA,"Biotechs to Buy After Trump Victory (CELG, BIIB)"
BIIB,BIIB:UW,BBG000C18861,"XLV, JNJ, GILD, BIIB: ETF Inflow Alert",2016-11-10 16:12:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0MSerLHip2U/xlv-jnj-gild-biib-etf-inflow-alert-cm707114,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Health Care Select Sector SPDR Fund Symbol XLV where we have detected an approximate 427 7 million dollar inflow that s a 3 6 increase week over week
BIIB,BIIB:UW,BBG000C18861,"Perrigo (PRGO) Beats on Q3 Earnings, Revenues; View Intact",2016-11-10 15:56:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l6bH2BK5fMg/perrigo-prgo-beats-on-q3-earnings-revenues-view-intact-cm707078,Perrigo Company plc s PRGO third quarter 2016 earnings of 1 65 per share beat the Zacks Consensus Estimate of 1 59 Reported earnings however declined 6 from the year ago figure The company s shares are up around 4 in pre market trading FindTheCompany
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline: December 23, 2016",2016-11-10 15:04:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150400817.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 10, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,Peek Into Drug Stocks' Q3 Earnings on Nov 11: XBIT & REPH,2016-11-10 13:55:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jtFY2BiQwkc/peek-into-drug-stocks-q3-earnings-on-nov-11-xbit-reph-cm706952,The Q3 earnings season has almost come to an end with 445 S amp P 500 members as of Nov 9 accounting for 89 of the index s total market capitalization having reported results according to the latest Earnings Preview While total earnings for these index members were up 4 0 from
BIIB,BIIB:UW,BBG000C18861,Short Sellers Grow More Selective on Major Biotechs,2016-11-10 12:20:09 +0000,http://finance.yahoo.com/news/short-sellers-grow-more-selective-122009544.html,Short Sellers Grow More Selective on Major Biotechs
BIIB,BIIB:UW,BBG000C18861,"Biotech, Drug Stocks Fly On Clinton Loss, But 'Trump Uncertainty'",2016-11-09 21:33:40 +0000,http://www.investors.com/research/ibd-industry-themes/biotechs-drugs-fly-on-clinton-defeat-but-trump-uncertainty-lingers/,"Biotech, Drug Stocks Fly On Clinton Loss, But 'Trump Uncertainty'"
BIIB,BIIB:UW,BBG000C18861,Stocks Surge After Trump Victory,2016-11-09 21:25:00 +0000,https://www.thestreet.com/story/13887085/1/stocks-surge-after-trump-victory.html?puc=yahoo&cm_ven=YAHOO,Stocks Surge After Trump Victory
BIIB,BIIB:UW,BBG000C18861,Stocks Maintain Solid Gains After Donald Trump Wins the White House,2016-11-09 20:16:00 +0000,https://www.thestreet.com/story/13886780/1/stocks-post-solid-gains-as-wall-street-weighs-trump-as-president.html?puc=yahoo&cm_ven=YAHOO,Stocks Maintain Solid Gains After Donald Trump Wins the White House
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharma Is Rocketing 25% Higher Today,2016-11-09 19:54:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zOFxn1JjypE/why-ionis-pharma-is-rocketing-25-higher-today-cm706663,Image source Getty Images What happened After updating investors on its third quarter performance this morning and in the wake of the U S presidential election shares in Ionis Pharmaceuticals NASDAQ IONS are soaring 25 higher at 1 30 p m EST So
BIIB,BIIB:UW,BBG000C18861,What Do Analysts Say about Regeneron after 3Q16 Earnings?,2016-11-09 19:04:05 +0000,http://marketrealist.com/2016/11/what-do-analysts-say-about-regeneron-after-3q16-earnings/?utm_source=yahoo&utm_medium=feed,What Do Analysts Say about Regeneron after 3Q16 Earnings?
BIIB,BIIB:UW,BBG000C18861,How a Donald Trump Presidency Could Affect Biotech Stocks,2016-11-09 18:54:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ch66dk87DsQ/how-a-donald-trump-presidency-could-affect-biotech-stocks-cm706631,Image source 160 Flickr user Jamelle Bouie Hillary Clinton has not been a friend to biotechnology stocks on the campaign trail and as as result investors have sold off biotech stocks in anticipation of her winning the Presidency Now that Donald Trump has successfully upset
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharma Is Rocketing 25% Higher Today,2016-11-09 18:47:23 +0000,http://www.fool.com/investing/2016/11/09/why-ionis-pharma-is-rocketing-25-higher-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Ionis Pharma Is Rocketing 25% Higher Today
BIIB,BIIB:UW,BBG000C18861,Biotech: Is Today's Trump Rally Just the Beginning?,2016-11-09 18:18:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/09/biotech-is-todays-trump-rally-just-the-beginning/?mod=yahoobarrons&ru=yahoo,Biotech: Is Today's Trump Rally Just the Beginning?
BIIB,BIIB:UW,BBG000C18861,How a Donald Trump Presidency Could Affect Biotech Stocks,2016-11-09 17:21:07 +0000,http://www.fool.com/investing/2016/11/09/how-a-donald-trump-presidency-could-affect-biotech.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How a Donald Trump Presidency Could Affect Biotech Stocks
BIIB,BIIB:UW,BBG000C18861,Stocks Turn Positive After Trump's Surprising Election Win,2016-11-09 16:27:00 +0000,https://www.thestreet.com/story/13886429/1/stocks-rise-as-wall-street-weighs-a-trump-presidency.html?puc=yahoo&cm_ven=YAHOO,Stocks Turn Positive After Trump's Surprising Election Win
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Rises Despite Missing Earnings,2016-11-09 16:20:32 +0000,http://finance.yahoo.com/news/ionis-pharmaceuticals-rises-despite-missing-162032472.html,Ionis Pharmaceuticals Rises Despite Missing Earnings
BIIB,BIIB:UW,BBG000C18861,Why Biogen Inc. Stock Lost 10.5% of Its Value In October,2016-11-09 14:55:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hIhUIWJYsiQ/why-biogen-inc-stock-lost-105-of-its-value-in-october-cm706278,Image source Getty Images What happened Ahead of third quarter earnings on Oct 26 Biogen Inc s NASDAQ BIIB shares declined 10 5 in October 160 according to S amp P Global Market Intelligence So what Investors steadily steered away from the large cap
BIIB,BIIB:UW,BBG000C18861,Why Biogen Inc. Stock Lost 10.5% of Its Value In October,2016-11-09 13:04:10 +0000,http://www.fool.com/investing/2016/11/09/why-biogen-inc-stock-lost-105-of-its-value-in-octo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Biogen Inc. Stock Lost 10.5% of Its Value In October
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Ionis Soars on Spinraza Data, Regeneron's Q3 Results Mixed",2016-11-09 11:38:11 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-ionis-soars-113811687.html,"Biotech Stock Roundup: Ionis Soars on Spinraza Data, Regeneron's Q3 Results Mixed"
BIIB,BIIB:UW,BBG000C18861,Drug & Biotech Stocks Leap After Hillary Clinton''s Election Defeat,2016-11-09 09:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uFQavD9grdA/drug--biotech-stocks-leap-after-hillary-clintons-election-defeat-20161109-00724,Drug & Biotech Stocks Leap After Hillary Clinton''s Election Defeat
BIIB,BIIB:UW,BBG000C18861,"Biotech Gainers On Tuesday: Amicus Therapeutics, Inc. (FOLD) And Ionis Pharmaceuticals Inc (IONS)",2016-11-08 21:51:30 +0000,http://www.insidermonkey.com/blog/biotech-gainers-on-tuesday-amicus-therapeutics-inc-fold-and-ionis-pharmaceuticals-inc-ions-485902/,"Biotech Gainers On Tuesday: Amicus Therapeutics, Inc. (FOLD) And Ionis Pharmaceuticals Inc (IONS)"
BIIB,BIIB:UW,BBG000C18861,Biogen's Growth Is Far Weaker Than You May Think,2016-11-08 21:39:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vUfNSpTN7LA/biogens-growth-is-far-weaker-than-you-may-think-cm705856,Image source Getty Images Over the past year Biogen s NASDAQ BIIB stock has essentially traded sideways due to the increasingly competitive landscape facing its flagship multiple sclerosis treatment franchise which includes key drugs like Tecfidera and Avonex The biotech s
BIIB,BIIB:UW,BBG000C18861,"Company News for November 08, 2016",2016-11-08 21:33:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fDQE0Z4itdU/company-news-for-november-08-2016-cm705842,160 160 160 Shares of Berkshire Hathaway Inc BRK B gained 2 8 after the company posted third quarter earnings per share of 1 97 that beat the Zacks Consensus Estimate of 1 88 160 160 160 Shares of LendingClub Corp LC surged 15 2 after the company reported
BIIB,BIIB:UW,BBG000C18861,"Can Small-Cap Biotech Take On Gilead, Celgene, Biogen In Alzheimer's?",2016-11-08 21:24:30 +0000,http://www.investors.com/news/technology/can-this-small-cap-biotech-take-on-gilead-celgene-biogen-in-alzheimers/,"Can Small-Cap Biotech Take On Gilead, Celgene, Biogen In Alzheimer's?"
BIIB,BIIB:UW,BBG000C18861,Biotechs Climb For Third Straight Day; Which Leaders Are Buyable?,2016-11-08 21:03:18 +0000,http://www.investors.com/news/technology/biotechs-climb-for-third-straight-day-which-leaders-are-buyable/,Biotechs Climb For Third Straight Day; Which Leaders Are Buyable?
BIIB,BIIB:UW,BBG000C18861,"Biogen, Ionis Gain on Spinraza News (BIIB, IONS)",2016-11-08 20:36:00 +0000,http://www.investopedia.com/news/biogen-ionis-rise-sma-drug-news-biib-ions/?partner=YahooSA,"Biogen, Ionis Gain on Spinraza News (BIIB, IONS)"
BIIB,BIIB:UW,BBG000C18861,Biotech ETFs Slumping on Q3 Results,2016-11-08 20:26:08 +0000,http://finance.yahoo.com/news/biotech-etfs-slumping-q3-results-202608322.html,Biotech ETFs Slumping on Q3 Results
BIIB,BIIB:UW,BBG000C18861,"Drug Stock Earnings to Watch on Nov 9: MYL, IONS & More",2016-11-08 18:15:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iAhLrDR2TQ8/drug-stock-earnings-to-watch-on-nov-9-myl-ions-more-cm705436,It s nearing the closing bell of the third quarter 2016 earnings season with approximately 423 S amp P 500 members representing 84 6 of the index s total market capitalization having reported quarterly results as of Nov 4 An impressive 72 8 of these companies managed to record an
BIIB,BIIB:UW,BBG000C18861,"Spinal Muscular Atrophy in Focus as Biogen, IONS Shoot Up on Data",2016-11-08 18:10:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XXkp3S_f-Ew/spinal-muscular-atrophy-in-focus-as-biogen-ions-shoot-up-on-data-cm705417,Yesterday Biogen Inc BIIB and partner Ionis Pharmaceuticals Inc IONS saw their shares soar on positive interim data from a late stage study on Spinraza their investigational treatment for spinal muscular atrophy SMA The companies said that Spinraza met the primary endpoint in the
BIIB,BIIB:UW,BBG000C18861,See Which Of The Latest 13F Filers Holds Biogen,2016-11-08 18:01:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ilsm_DtJkKo/see-which-of-the-latest-13f-filers-holds-biogen-cm705537,At Holdings Channel we have reviewed the latest batch of the 20 most recent 13F filings for the 09 30 2016 reporting period and noticed that Biogen Inc Symbol BIIB was held by 8 of these funds When hedge fund managers appear to be thinking alike we find it is a good idea to take a
BIIB,BIIB:UW,BBG000C18861,Biogen's Growth Is Far Weaker Than You May Think,2016-11-08 17:37:35 +0000,http://www.fool.com/investing/2016/11/08/biogens-growth-is-far-weaker-than-you-may-think.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biogen's Growth Is Far Weaker Than You May Think
BIIB,BIIB:UW,BBG000C18861,Analyst ups revenue estimates for Biogen's infant disease drug,2016-11-08 16:21:43 +0000,http://www.bizjournals.com/boston/news/2016/11/07/analyst-ups-revenue-estimates-for-biogens-infant.html?ana=yahoo,Analyst ups revenue estimates for Biogen's infant disease drug
BIIB,BIIB:UW,BBG000C18861,"Company News for November 08, 2016",2016-11-08 15:10:03 +0000,http://finance.yahoo.com/news/company-news-november-08-2016-151003248.html,"Company News for November 08, 2016"
BIIB,BIIB:UW,BBG000C18861,"Spinal Muscular Atrophy in Focus as Biogen, IONS Shoot Up on Data",2016-11-08 13:19:01 +0000,http://finance.yahoo.com/news/spinal-muscular-atrophy-focus-biogen-131901364.html,"Spinal Muscular Atrophy in Focus as Biogen, IONS Shoot Up on Data"
BIIB,BIIB:UW,BBG000C18861,"MDCO Tastes Bitter, PRTO Awaits Phase 3 Data In Dec., It''s Time To Cherish IONS",2016-11-08 05:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M0DGzlGr9Js/mdco-tastes-bitter-prto-awaits-phase-3-data-in-dec-its-time-to-cherish-ions-20161108-00167,"MDCO Tastes Bitter, PRTO Awaits Phase 3 Data In Dec., It''s Time To Cherish IONS"
BIIB,BIIB:UW,BBG000C18861,"Zacks Industry Outlook Highlights: Bristol-Myers, Biogen, Merck, Celgene and ARIAD Pharmaceuticals",2016-11-08 00:56:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G2GYMALdCpQ/zacks-industry-outlook-highlights-bristol-myers-biogen-merck-celgene-and-ariad-pharmaceuticals-cm705007,For Immediate Release Chicago IL November 07 2016 Today Zacks Equity Research discusses the Pharmaceuticals Part 2 including Bristol Myers NYSE BMY Free Report Biogen NASDAQ BIIB Free Report Merck amp Co Inc NYSE MRK Free Report
BIIB,BIIB:UW,BBG000C18861,Close Update: Stocks Soar As FBI Clears Potential Path For Clinton on Election Day,2016-11-07 22:12:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pPjUWcxEOns/close-update-stocks-soar-as-fbi-clears-potential-path-for-clinton-on-election-day-cm705271,Risk averse investors breathed a sigh of relief and poured back into equity assets when the FBI said late Sunday that there was no evidence of wrongdoing in an another batch of emails unearthed from Democratic presidential candidate Hillary Clinton With Clinton viewed as the presidential
BIIB,BIIB:UW,BBG000C18861,Biogen Sees Positive Drug Study Results,2016-11-07 20:02:00 +0000,http://www.thestreet.com/video/13883528/biogen-sees-positive-drug-study-results.html?puc=yahoov&cm_ven=YAHOOV,Biogen Sees Positive Drug Study Results
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharmaceuticals Inc. Skyrocketed Higher Today,2016-11-07 19:55:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SBgogkwbMpM/why-ionis-pharmaceuticals-inc-skyrocketed-higher-today-cm705204,Image source Getty Images What happened Ionis Pharmaceuticals NASDAQ IONS is up 20 8 at noon EST after announcing with its partner Biogen NASDAQ BIIB that their spinal muscular atrophy SMA drug nusinersen which now goes by the branded name Spinraza
BIIB,BIIB:UW,BBG000C18861,Mid-Day Market Update: Dow Gains Over 300 Points; Concordia International Shares Drop Following Disappointing Earnings,2016-11-07 18:37:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TIqIt4YF3BQ/mid-day-market-update-dow-gains-over-300-points-concordia-international-shares-drop-following-disappointing-earnings-cm705166,Midway through trading Monday the Dow traded up 1 92 percent to 18 231 49 while the NASDAQ climbed 2 38 percent to 5 166 42 The S amp P also rose gaining 2 09 percent to 2 128 68 Leading and Lagging Sectors On Monday technology shares gained by 2 34 percent Meanwhile top
BIIB,BIIB:UW,BBG000C18861,Biotech ETFs Boosted By Biogen,2016-11-07 18:22:00 +0000,http://blogs.barrons.com/focusonfunds/2016/11/07/biotech-etfs-boosted-by-biogen/?mod=yahoobarrons&ru=yahoo,Biotech ETFs Boosted By Biogen
BIIB,BIIB:UW,BBG000C18861,Midday Update: Wall Street's Appetite For Risk Returns After Clinton Cleared by FBI,2016-11-07 18:15:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oihdHScMtko/midday-update-wall-streets-appetite-for-risk-returns-after-clinton-cleared-by-fbi-cm705114,The major benchmark indices were significantly higher with Monday s meteoric gains attributed to the Federal Bureau of Investigation s decision to close its probe into Democratic candidate Hillary Clinton s misuse of a private email server during her term as Secretary of State The major
BIIB,BIIB:UW,BBG000C18861,"Biogen (BIIB) Upgraded to 'Buy' at Piper, Analysts Weigh In",2016-11-07 17:52:00 +0000,https://www.thestreet.com/story/13883741/1/biogen-biib-upgraded-to-buy-at-piper-analysts-weigh-in.html?puc=yahoo&cm_ven=YAHOO,"Biogen (BIIB) Upgraded to 'Buy' at Piper, Analysts Weigh In"
BIIB,BIIB:UW,BBG000C18861,Why Ionis Pharmaceuticals Inc. Skyrocketed Higher Today,2016-11-07 17:50:12 +0000,http://www.fool.com/investing/2016/11/07/why-ionis-pharmaceuticals-inc-skyrocketed-higher-t.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Ionis Pharmaceuticals Inc. Skyrocketed Higher Today
BIIB,BIIB:UW,BBG000C18861,"Ionis, Biogen muscle drug succeeds in second key study",2016-11-07 17:27:44 +0000,http://finance.yahoo.com/news/ionis-biogen-second-study-testing-151803503.html,"Ionis, Biogen muscle drug succeeds in second key study"
BIIB,BIIB:UW,BBG000C18861,3 Mid-Cap Stocks to Buy in November,2016-11-07 17:21:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q90EeCi8ysI/3-mid-cap-stocks-to-buy-in-november-cm705024,Image source Getty Images With winter approaching how about warming up your portfolio with some quality mid cap stocks that could earn you good returns in the long haul Mid cap stocks are typically well established companies with a market capitalization between 2 billion and
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: LVNTA, BIIB",2016-11-07 17:12:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iufIMiTe5BU/nasdaq-100-movers-lvnta-biib-cm704962,In early trading on Monday shares of Biogen BIIB topped the list of the day s best performing components of the Nasdaq 100 index trading up 5 9 Year to date Biogen has lost about 4 3 of its value And the worst performing Nasdaq 100 component thus far on the day is Liberty
BIIB,BIIB:UW,BBG000C18861,Biogen: The Early Bird…,2016-11-07 17:10:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/07/biogen-the-early-bird/?mod=yahoobarrons&ru=yahoo,Biogen: The Early Bird…
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-11-07 16:57:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-lundin-law-165700546.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 7, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (Nasdaq: ..."
BIIB,BIIB:UW,BBG000C18861,"Biogen, Ionis Rocket On $1 Billion-Plus Drug Opportunity Post-Trial",2016-11-07 16:52:32 +0000,http://www.investors.com/news/technology/biogen-ionis-rocket-on-1-billion-plus-sma-opportunity-post-trial/,"Biogen, Ionis Rocket On $1 Billion-Plus Drug Opportunity Post-Trial"
BIIB,BIIB:UW,BBG000C18861,"Twitter, Ionis, Biogen, and More: Here’s Why These Five Stocks Are Making Headlines",2016-11-07 16:44:53 +0000,http://www.insidermonkey.com/blog/twitter-ionis-biogen-and-more-heres-why-these-five-stocks-are-making-headlines-485230/,"Twitter, Ionis, Biogen, and More: Here’s Why These Five Stocks Are Making Headlines"
BIIB,BIIB:UW,BBG000C18861,"Shares of Biogen, Ionis Gain on Positive Spinraza Trial",2016-11-07 16:44:00 +0000,https://www.thestreet.com/story/13882922/1/shares-of-biogen-ionis-gain-on-positive-spinraza-trial.html?puc=yahoo&cm_ven=YAHOO,"Shares of Biogen, Ionis Gain on Positive Spinraza Trial"
BIIB,BIIB:UW,BBG000C18861,Mid-Morning Market Update: Markets Open Higher; LendingClub Posts Narrower-Than-Expected Loss,2016-11-07 16:37:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/StIgf_9Rgwc/mid-morning-market-update-markets-open-higher-lendingclub-posts-narrower-than-expected-loss-cm705027,Following the market opening Monday the Dow traded up 1 46 percent to 18 148 79 while the NASDAQ climbed 1 67 percent to 5 130 51 The S amp P also rose gaining 1 54 percent to 2 117 27 Leading and Lagging Sectors Monday morning financial shares gained by 1 87 percent
BIIB,BIIB:UW,BBG000C18861,"Gilead Sciences: No M&A, No Pipeline?",2016-11-07 15:50:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/11/07/gilead-sciences-no-ma-no-pipeline/?mod=yahoobarrons&ru=yahoo,"Gilead Sciences: No M&A, No Pipeline?"
BIIB,BIIB:UW,BBG000C18861,"[$$] Biogen, Ionis Shares Up After Positive Study Results",2016-11-07 15:45:09 +0000,http://www.wsj.com/articles/biogen-ionis-shares-rise-after-positive-study-results-1478533503?mod=yahoo_hs,"[$$] Biogen, Ionis Shares Up After Positive Study Results"
BIIB,BIIB:UW,BBG000C18861,Stocks Rush Ahead In Bold Bid To End Losing Streak,2016-11-07 15:24:03 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-rush-ahead-in-bold-bid-to-end-losing-streak/,Stocks Rush Ahead In Bold Bid To End Losing Streak
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Biogen Inc. (BIIB) and Lead Plaintiff Deadline: December 23, 2016",2016-11-07 15:04:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-150400346.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 7, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016 - BIIB",2016-11-07 14:52:00 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-145200608.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 7, 2016 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc. ..."
BIIB,BIIB:UW,BBG000C18861,Hang On for Biogen,2016-11-07 14:25:00 +0000,https://www.thestreet.com/story/13882412/1/hang-on-for-biogen.html?puc=yahoo&cm_ven=YAHOO,Hang On for Biogen
BIIB,BIIB:UW,BBG000C18861,Why These 2 Biopharma Companies Are Running,2016-11-07 14:05:54 +0000,http://247wallst.com/healthcare-business/2016/11/07/why-these-2-biopharma-companies-are-running/,Why These 2 Biopharma Companies Are Running
BIIB,BIIB:UW,BBG000C18861,"Biogen Is A Frustrating Case, And Piper Jaffray Hopes It Doesn't Regret Upgrade",2016-11-07 13:58:41 +0000,http://finance.yahoo.com/news/biogen-frustrating-case-piper-jaffray-135841136.html,"Biogen Is A Frustrating Case, And Piper Jaffray Hopes It Doesn't Regret Upgrade"
BIIB,BIIB:UW,BBG000C18861,"Biogen, Ionis shares rally on positive trial of treatment for spinal muscular atrophy",2016-11-07 13:44:12 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=02E291DE-59A8-4A90-8760-30846AA011FA&siteid=yhoof2,"Biogen, Ionis shares rally on positive trial of treatment for spinal muscular atrophy"
BIIB,BIIB:UW,BBG000C18861,Ionis and Biogen's muscular disorder treatment meets main goal,2016-11-07 13:04:45 +0000,http://finance.yahoo.com/news/ionis-biogens-muscular-disorder-treatment-130445570.html,Ionis and Biogen's muscular disorder treatment meets main goal
BIIB,BIIB:UW,BBG000C18861,Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy,2016-11-07 12:34:04 +0000,http://www.publicnow.com/view/70695D2DC46B90825293F4126E56A7026C52FC41,"[at noodls] - CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) announced that SPINRAZA (nusinersen), an investigational treatment for spinal muscular ..."
BIIB,BIIB:UW,BBG000C18861,"Biogen, Ionis Shares Up After Positive Study Results",2016-11-07 11:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z2P1Fxj_178/biogen-ionis-shares-up-after-positive-study-results-20161107-00915,"Biogen, Ionis Shares Up After Positive Study Results"
BIIB,BIIB:UW,BBG000C18861,"Biogen, Ionis Shares Rise After Positive Study Results",2016-11-07 11:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qcdXmhkOtY8/biogen-ionis-shares-rise-after-positive-study-results-20161107-00891,"Biogen, Ionis Shares Rise After Positive Study Results"
BIIB,BIIB:UW,BBG000C18861,Biogen To Present At Credit Suisse Healthcare Conference; Webcast At 11:00 AM ET,2016-11-07 10:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TGbylhJx7zI/biogen-to-present-at-credit-suisse-healthcare-conference-webcast-at-1100-am-et-20161107-00824,Biogen To Present At Credit Suisse Healthcare Conference; Webcast At 11:00 AM ET
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals (IONS) & Biogen  (BIIB) Are Up On Phase 3 Study Results,2016-11-07 09:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L3hAOXzGafc/ionis-pharmaceuticals-ions--biogen--biib-are-up-on-phase-3-study-results-20161107-00786,Ionis Pharmaceuticals (IONS) & Biogen  (BIIB) Are Up On Phase 3 Study Results
BIIB,BIIB:UW,BBG000C18861,Biogen & Ionis: SPINRAZA Meets Primary Endpoint In Phase 3 Study - Quick Facts,2016-11-07 07:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YIwcvs1sxAc/biogen--ionis-spinraza-meets-primary-endpoint-in-phase-3-study--quick-facts-20161107-00422,Biogen & Ionis: SPINRAZA Meets Primary Endpoint In Phase 3 Study - Quick Facts
BIIB,BIIB:UW,BBG000C18861,Tracking ETF Losers Can Be Valuable To Your Investment Strategy,2016-11-04 20:46:11 +0000,http://www.investors.com/etfs-and-funds/etfs/tracking-etf-losers-can-be-valuable-to-your-investment-strategy/,Tracking ETF Losers Can Be Valuable To Your Investment Strategy
BIIB,BIIB:UW,BBG000C18861,Fundamentals Remain Strong in the Pharma Sector,2016-11-04 19:10:07 +0000,http://finance.yahoo.com/news/fundamentals-remain-strong-pharma-sector-191007373.html,Fundamentals Remain Strong in the Pharma Sector
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-11-04 15:53:00 +0000,http://finance.yahoo.com/news/important-investor-alert-khang-khang-155300816.html,"[Accesswire] - IRVINE, CA / ACCESSWIRE / November 4, 2016 / Khang & Khang LLP (the ""Firm"") announces a class action lawsuit against Biogen Inc. (""Biogen"" or the ""Company"") (Nasdaq: BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016",2016-11-04 14:05:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-140500414.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 4, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Helped Healthcare Funds Like This One Dominate The Third Quarter,2016-11-04 06:43:43 +0000,http://www.insidermonkey.com/blog/biogen-biib-helped-healthcare-funds-like-this-one-dominate-the-third-quarter-484895/,Biogen (BIIB) Helped Healthcare Funds Like This One Dominate The Third Quarter
BIIB,BIIB:UW,BBG000C18861,BIIB Crosses Below Key Moving Average Level,2016-11-03 18:09:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KDt7ZGO1uV8/biib-crosses-below-key-moving-average-level-cm703484,In trading on Thursday shares of Biogen Inc Symbol BIIB crossed below their 200 day moving average of 276 66 changing hands as low as 275 56 per share Biogen Inc shares are currently trading down about 0 1 on the day The chart below shows the one year performance of BIIB shares
BIIB,BIIB:UW,BBG000C18861,How Did Novo’s Biopharmaceuticals Segment Perform in 3Q16?,2016-11-03 15:04:13 +0000,http://marketrealist.com/2016/11/how-did-novos-biopharmaceuticals-segment-perform-in-3q16/?utm_source=yahoo&utm_medium=feed,How Did Novo’s Biopharmaceuticals Segment Perform in 3Q16?
BIIB,BIIB:UW,BBG000C18861,3 Top Biotech Stocks to Buy in November,2016-11-02 21:08:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wdQ-hSCMES0/3-top-biotech-stocks-to-buy-in-november-cm702818,Image source Getty Images Like Rodney Dangerfield the biotech sector isn t getting a lot of respect these days The iShares Nasdaq Biotech ETF NASDAQ IBB a popular exchange traded fund that owns a wide range of biotech stocks is down 24 year to date which badly trails
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-11-02 20:40:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-204000098.html,"[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / November 2, 2016 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,3 Top Biotech Stocks to Buy in November,2016-11-02 19:47:14 +0000,http://www.fool.com/investing/2016/11/02/3-top-biotech-stocks-to-buy-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Biotech Stocks to Buy in November
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline - December 23, 2016",2016-11-02 19:00:00 +0000,http://finance.yahoo.com/news/investor-alert-bronstein-gewirtz-grossman-190000890.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 2, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,2 Bullish Biotech Trades to Take Your Mind off the Election (BIIB CELG),2016-11-02 17:08:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mmYJol4ltYc/2-bullish-biotech-trades-to-take-your-mind-off-the-election-biib-celg-cm702607,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips If the market is always right it may finally be time for a different sort of bullish pairs trade in Biogen Inc NASDAQ BIIB and Celgene Corporation NASDAQ
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-11-02 15:26:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-khang-khang-152600363.html,"[Business Wire] - Khang & Khang LLP announces a class action lawsuit against Biogen Inc. . Investors who purchased or otherwise acquired shares between July 23, 2014 and July 23, 2015 inclusive , are encouraged to contact the Firm prior to the December 23, 2016 lead plaintiff motion deadline."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016",2016-11-02 14:02:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-140200205.html,"[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 2, 2016 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" or the ""Company"") ..."
BIIB,BIIB:UW,BBG000C18861,Moat Investing: Staying Ahead of the Competition,2016-11-01 13:55:14 +0000,http://marketrealist.com/2016/11/moat-investing-staying-ahead-competition/?utm_source=yahoo&utm_medium=feed,Moat Investing: Staying Ahead of the Competition
BIIB,BIIB:UW,BBG000C18861,"IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm",2016-10-31 15:44:00 +0000,http://finance.yahoo.com/news/important-shareholder-alert-lundin-law-154400453.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces a class action lawsuit has been filed against Biogen Inc. concerning possible violations of federal securities laws between July 23, 2014 and July 23, 2015 inclusive ."
BIIB,BIIB:UW,BBG000C18861,What Do Analysts Recommend for Biogen after Its 3Q16 Earnings?,2016-10-31 15:04:43 +0000,http://marketrealist.com/2016/10/analyst-recommendations-biogen-release-3q16-earnings/?utm_source=yahoo&utm_medium=feed,What Do Analysts Recommend for Biogen after Its 3Q16 Earnings?
BIIB,BIIB:UW,BBG000C18861,"INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016 - BIIB",2016-10-31 14:36:21 +0000,http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-143621465.html,"[Marketwired] - October 31, 2016 - The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc. between July 23, 2014 and ..."
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016",2016-10-31 14:10:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-141000468.html,"[GlobeNewswire] - NEW YORK, Oct. 31, 2016-- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. and certain of its officers. The class ..."
BIIB,BIIB:UW,BBG000C18861,Biosimilar Business May Become Key for Biogen in Future Years,2016-10-31 14:04:53 +0000,http://marketrealist.com/2016/10/biosimilar-business-may-become-key-growth-driver-biogen-future-years/?utm_source=yahoo&utm_medium=feed,Biosimilar Business May Become Key for Biogen in Future Years
BIIB,BIIB:UW,BBG000C18861,"Noteworthy ETF Outflows: QUAL, PEG, COST, BIIB",2016-10-31 13:15:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sGVSuFpSjhQ/noteworthy-etf-outflows-qual-peg-cost-biib-cm700253,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Edge MSCI USA Quality Factor ETF Symbol QUAL where we have detected an approximate 23 1 million dollar outflow that s a 0 7 decrease week over
BIIB,BIIB:UW,BBG000C18861,Injectable Therapies Still a Major Part of Biogen’s MS Franchise,2016-10-31 12:05:26 +0000,http://marketrealist.com/2016/10/injectable-therapies-continue-major-part-biogens-multiple-sclerosis-franchise-3q16/?utm_source=yahoo&utm_medium=feed,Injectable Therapies Still a Major Part of Biogen’s MS Franchise
BIIB,BIIB:UW,BBG000C18861,"BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal",2016-10-30 23:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p8uOjKiX6VQ/biib-to-face-fda-its-a-thumb-down-for-regn-stj-meets-trial-goal-20161030-00093,"BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal"
BIIB,BIIB:UW,BBG000C18861,"BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal",2016-10-30 23:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SwT3Zmfq57M/biib-to-face-fda-its-a-thumb-down-for-regn-stj-meets-trial-goal-20161030-00078,"BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal"
BIIB,BIIB:UW,BBG000C18861,Here's Why Biogen Should Buy Ionis Pharmaceuticals,2016-10-29 21:37:47 +0000,http://www.fool.com/investing/2016/10/28/heres-why-biogen-should-buy-ionis-pharmaceuticals.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's Why Biogen Should Buy Ionis Pharmaceuticals
BIIB,BIIB:UW,BBG000C18861,Biogen Quietly Abandons a Key Next-Gen Multiple Sclerosis Drug,2016-10-29 13:38:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CTI7Vic5EMk/biogen-quietly-abandons-a-key-next-gen-multiple-sclerosis-drug-cm700675,Biogen Inc NASDAQ BIIB 160 controls over 30 of market share in the 19 billion and growing multiple sclerosis drug market but a recent decision to abandon development of MT 1303 calls into question whether or not Biogen can maintain its dominance in the indication over
BIIB,BIIB:UW,BBG000C18861,Biogen Quietly Abandons a Key Next-Gen Multiple Sclerosis Drug,2016-10-29 10:41:08 +0000,http://www.fool.com/investing/2016/10/29/biogen-quietly-abandons-a-key-next-gen-multiple-sc.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biogen Quietly Abandons a Key Next-Gen Multiple Sclerosis Drug
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm",2016-10-29 01:23:00 +0000,http://finance.yahoo.com/news/shareholder-alert-goldberg-law-pc-012300370.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Biogen Inc. . Investors who purchased or otherwise acquired Biogen shares between July 23, 2014 and July 23, 2015 inclusive are encouraged to contact the firm in advance of the December 23, 2016 lead plaintiff motion deadline."
BIIB,BIIB:UW,BBG000C18861,Here's Why Biogen Should Buy Ionis Pharmaceuticals,2016-10-28 22:32:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HIbpcisBAFk/heres-why-biogen-should-buy-ionis-pharmaceuticals-cm700584,Despite the uncertainly created by the forthcoming retirement of Biogen s NASDAQ BIIB longtime CEO George Scangos the biotech is reportedly continuing to hunt for deals that would diversify its clinical and product portfolios The things is it may not have to
BIIB,BIIB:UW,BBG000C18861,Tysabri Continues to Witness Strong Growth in 3Q16,2016-10-28 22:04:13 +0000,http://marketrealist.com/2016/10/tysabri-continues-witness-strong-growth-3q16/?utm_source=yahoo&utm_medium=feed,Tysabri Continues to Witness Strong Growth in 3Q16
BIIB,BIIB:UW,BBG000C18861,Tecfidera Continued to Lead in the Oral Multiple Sclerosis Market,2016-10-28 21:04:16 +0000,http://marketrealist.com/2016/10/tecfidera-continues-leader-oral-multiple-sclerosis-market-3q16/?utm_source=yahoo&utm_medium=feed,Tecfidera Continued to Lead in the Oral Multiple Sclerosis Market
BIIB,BIIB:UW,BBG000C18861,Make Valeant Pharmaceuticals Intl Inc (VRX) Stock Pay YOU,2016-10-28 20:34:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3W2XeqIiy1k/make-valeant-pharmaceuticals-intl-inc-vrx-stock-pay-you-cm700527,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Valeant Pharmaceuticals Intl Inc NYSE VRX has been nothing short of a casino trade for most traders Luckily we ve used the options markets to sell risk and that
BIIB,BIIB:UW,BBG000C18861,"ETF’s with exposure to Biogen, Inc. : October 28, 2016",2016-10-28 18:50:48 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-biogen-inc-october-28-2016/,"ETF’s with exposure to Biogen, Inc. : October 28, 2016"
BIIB,BIIB:UW,BBG000C18861,Biogen Reported a Positive Financial Performance in 3Q16,2016-10-28 18:41:04 +0000,http://marketrealist.com/2016/10/biogen-reports-strong-financial-performance-3q16/?utm_source=yahoo&utm_medium=feed,Biogen Reported a Positive Financial Performance in 3Q16
BIIB,BIIB:UW,BBG000C18861,First Eagle Fund of America 3rd Quarter Commentary,2016-10-28 17:17:21 +0000,http://finance.yahoo.com/news/first-eagle-fund-america-3rd-171721390.html,First Eagle Fund of America 3rd Quarter Commentary
BIIB,BIIB:UW,BBG000C18861,"Lifshitz & Miller Law Firm Announces Investigation of Advaxis, Inc., Banc of California, Inc., Biogen Inc., Franklin Resources, Inc., Juniper Pharmaceuticals, Inc., Opus Bank, Taro Pharmaceutical Industries Ltd., and Tyson Foods, Inc.",2016-10-28 17:15:00 +0000,http://finance.yahoo.com/news/lifshitz-miller-law-firm-announces-171500113.html,"[PR Newswire] - NEW YORK, Oct. 28, 2016 /PRNewswire/ -- Advaxis, Inc. (ADXS) Lifshitz & Miller announces investigation on behalf of ADXS investors. The investigation concerns whether over 1.5 million stock options were ..."
BIIB,BIIB:UW,BBG000C18861,5 Reasons Ionis Pharmaceuticals Is a Top Stock to Buy Now,2016-10-28 16:23:00 +0000,http://www.fool.com/investing/2016/10/28/5-reasons-ionis-pharmaceuticals-is-a-top-stock-to.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Reasons Ionis Pharmaceuticals Is a Top Stock to Buy Now
BIIB,BIIB:UW,BBG000C18861,5 Reasons Ionis Pharmaceuticals Is a Top Stock to Buy Now,2016-10-28 15:34:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ah7TiUe4coI/5-reasons-ionis-pharmaceuticals-is-a-top-stock-to-buy-now-cm700203,Image source Getty Images Given a huge pipeline of drugs in various stages of development it isn t easy to pin a number on Ionis Pharmaceuticals Inc NASDAQ IONS Any way you slice it though the sum of this drugmaker s parts seems much larger than its 3 1 billion
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Biogen, Merck, Eli Lilly, AbbVie and ImmunoGen",2016-10-28 14:34:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JYmxfv0718g/the-zacks-analyst-blog-highlights-biogen-merck-eli-lilly-abbvie-and-immunogen-cm700193,For Immediate Release Chicago IL October 28 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
BIIB,BIIB:UW,BBG000C18861,"Acorda (ACOR) Reports Wider Q3 Loss, Revenues Down Y/Y",2016-10-28 13:43:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q7IIsXF_F7A/acorda-acor-reports-wider-q3-loss-revenues-down-yy-cm700121,Acorda Therapeutics Inc ACOR reported a loss of 28 cents per share in the third quarter of 2016 including the impact of stock based compensation expense and other non recurring items which was wider than the Zacks Consensus Estimate of a loss of 26 cents However including the impact
BIIB,BIIB:UW,BBG000C18861,Biogen’s Regulatory Applications for Nusinersen as a Treatment for Spinal Muscular Atrophy Accepted by FDA and EMA,2016-10-28 11:58:04 +0000,http://www.publicnow.com/view/3A7BF47DC650054DC11DEEA96A154728F07CE20E,"[at noodls] - Nusinersen Granted Priority Review by FDA EMA Plans to Follow Accelerated Assessment Timeline CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 28, 2016-- Biogen (NASDAQ: BIIB) today announced that its New Drug ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Says FDA Accepts Its NDA For Nusinersen,2016-10-28 07:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-sayC0LX2Pk/biogen-says-fda-accepts-its-nda-for-nusinersen-20161028-00273,Biogen Says FDA Accepts Its NDA For Nusinersen
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Working With What It's Got as It Looks to Diversify,2016-10-27 21:44:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QnZy39zbfpo/biogen-inc-working-with-what-its-got-as-it-looks-to-diversify-cm699820,Image source Getty Images Given the dampening U S market for multiple sclerosis drugs Biogen s NASDAQ BIIB bread and butter the biotech s third quarter earnings release on Wednesday was about as good as investors could have hoped for Biogen results The raw
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Working With What It's Got as It Looks to Diversify,2016-10-27 20:17:41 +0000,http://www.fool.com/investing/2016/10/27/biogen-inc-working-with-what-its-got-as-it-looks-t.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biogen Inc. Working With What It's Got as It Looks to Diversify
BIIB,BIIB:UW,BBG000C18861,Biogen to Present at the 25th Annual Credit Suisse Healthcare Conference,2016-10-27 20:01:00 +0000,http://finance.yahoo.com/news/biogen-present-25th-annual-credit-200100278.html,"[Business Wire] - Biogen Inc. announced today that it will present at the 25th Annual Credit Suisse Healthcare Conference. The webcast will be live on Monday, November 7, 2016 at 9:00a.m."
BIIB,BIIB:UW,BBG000C18861,IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses to Contact the Firm,2016-10-27 16:27:00 +0000,http://finance.yahoo.com/news/important-investor-alert-khang-khang-162700155.html,"[Business Wire] - Khang & Khang LLP announces a class action lawsuit against Biogen Inc. . Investors who purchased or otherwise acquired shares between July 23, 2014 and July 23, 2015 inclusive , are encouraged to contact the Firm prior to the December 23, 2016 lead plaintiff motion deadline."
BIIB,BIIB:UW,BBG000C18861,Bioverativ Could Be Why Investors Should Buy Biogen,2016-10-27 15:44:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Imwpyib_O94/bioverativ-could-be-why-investors-should-buy-biogen-cm699376,Image source Getty Images Biogen NASDAQ BIIB is planning to spin off its hemophilia drug business to investors early in 2017 and given that third quarter earnings show demand for Eloctate and Alprolix are at record highs the potential to get shares in this new
BIIB,BIIB:UW,BBG000C18861,The Good (Celgene) and Bad (Biogen) Ways to Deliver Drug Revenue Growth,2016-10-27 15:23:00 +0000,https://www.thestreet.com/story/13870174/1/the-good-celgene-and-bad-biogen-ways-to-deliver-drug-revenue-growth.html?puc=yahoo&cm_ven=YAHOO,The Good (Celgene) and Bad (Biogen) Ways to Deliver Drug Revenue Growth
BIIB,BIIB:UW,BBG000C18861,"Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars",2016-10-27 14:45:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NNj5s05PCvY/key-takeaways-from-biogens-q3-call-tecfidera-pipeline-biosimilars-cm699225,Biotech company Biogen Inc BIIB known for its strong position in the multiple sclerosis MS market reported third quarter 2016 results before the market opened yesterday with both earnings and revenues surpassing expectations Read more Biogen Beats on Q3 Earnings Tecfidera Propels
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016",2016-10-27 14:15:00 +0000,http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-141500777.html,"[PR Newswire] - NEW YORK, Oct. 27, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Biogen Inc. (""Biogen"" ..."
BIIB,BIIB:UW,BBG000C18861,Bioverativ Could Be Why Investors Should Buy Biogen,2016-10-27 13:48:49 +0000,http://www.fool.com/investing/2016/10/27/one-big-reason-why-investors-should-buy-biogen.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Bioverativ Could Be Why Investors Should Buy Biogen
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. :BIIB-US: Earnings Analysis: Q3, 2016 By the Numbers : October 27, 2016",2016-10-27 13:01:19 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-biib-us-earnings-analysis-q3-2016-by-the-numbers-october-27-2016/,"Biogen, Inc. :BIIB-US: Earnings Analysis: Q3, 2016 By the Numbers : October 27, 2016"
BIIB,BIIB:UW,BBG000C18861,"Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars",2016-10-27 12:57:12 +0000,http://finance.yahoo.com/news/key-takeaways-biogens-q3-call-125712428.html,"Key Takeaways from Biogen's Q3 Call: Tecfidera, Pipeline, Biosimilars"
BIIB,BIIB:UW,BBG000C18861,Peek Into Drug Stocks' Earnings on Oct 28: ABBV & IMGN,2016-10-27 12:43:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9v6PELMb3YI/peek-into-drug-stocks-earnings-on-oct-28-abbv-imgn-cm699144,The third quarter earnings season is seeing possibly the best growth pace since the first quarter of 2015 As of Oct 26 198 S amp P 500 members as of Oct 26 accounting for 48 9 of the index s total market capitalization have reported results according to the Earnings Trends report
BIIB,BIIB:UW,BBG000C18861,5 Stocks to Watch After the Market Closes Today,2016-10-27 12:30:09 +0000,http://finance.yahoo.com/tumblr/blog-5-stocks-to-watch-after-the-market-closes-today-123012474.html,5 Stocks to Watch After the Market Closes Today
BIIB,BIIB:UW,BBG000C18861,[$$] Overheard: Cheering On a Rival,2016-10-27 04:24:10 +0000,http://www.wsj.com/articles/overheard-cheering-on-a-rival-1477526084?ru=yahoo?mod=yahoo_itp,"[at The Wall Street Journal] - Companies don’t usually root for their competitors, but Biogen is pulling for Eli Lilly. The latter’s pending data for its experimental Alzheimer’s disease treatment will be an important read-through for ..."
BIIB,BIIB:UW,BBG000C18861,Edited Transcript of BIIB earnings conference call or presentation 26-Oct-16 12:30pm GMT,2016-10-26 23:11:11 +0000,http://finance.yahoo.com/news/edited-transcript-biib-earnings-conference-231111852.html,Edited Transcript of BIIB earnings conference call or presentation 26-Oct-16 12:30pm GMT
BIIB,BIIB:UW,BBG000C18861,IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses to Contact the Firm,2016-10-26 22:47:00 +0000,http://finance.yahoo.com/news/important-investor-alert-lundin-law-224700555.html,"[Business Wire] - Lundin Law PC, a shareholder rights firm, announces a class action lawsuit has been filed against Biogen Inc. concerning possible violations of federal securities laws between July 23, 2014 and July 23, 2015 inclusive ."
BIIB,BIIB:UW,BBG000C18861,Novartis' Is Challenging Biogen on Biogen's Own Turf,2016-10-26 21:02:07 +0000,http://www.fool.com/investing/2016/10/26/novartis-is-challenging-biogen-on-biogens-own-turf.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Novartis' Is Challenging Biogen on Biogen's Own Turf
BIIB,BIIB:UW,BBG000C18861,Biogen Q3 Tops; Alzheimer's Data Vs. Eli Lilly Positive,2016-10-26 20:10:08 +0000,http://www.investors.com/news/technology/biogen-q3-tops-by-50-million-alzheimers-data-vs-eli-lilly-positive/,Biogen Q3 Tops; Alzheimer's Data Vs. Eli Lilly Positive
BIIB,BIIB:UW,BBG000C18861,"BIIB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016",2016-10-26 20:07:53 +0000,http://finance.yahoo.com/news/biib-shareholder-alert-law-offices-200753638.html,"[GlobeNewswire] - NEW YORK, Oct. 26, 2016-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Inc (BIIB) Stock Rises on Better-Than-Expected Quarter,2016-10-26 19:49:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hwEmr8iCRvQ/biogen-inc-biib-stock-rises-on-better-than-expected-quarter-cm698873,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Biogen Inc NASDAQ BIIB saw its stock increase on Wednesday 160 following the release of its earnings report for the third quarter of 2016 Biogen
BIIB,BIIB:UW,BBG000C18861,Biogen is Still in Limbo,2016-10-26 18:38:45 +0000,http://www.bloomberg.com/gadfly/articles/2016-10-26/biogen-earnings-still-in-limbo?cmpid=yhoo.headline,Biogen is Still in Limbo
BIIB,BIIB:UW,BBG000C18861,INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses to Contact the Firm,2016-10-26 18:31:00 +0000,http://finance.yahoo.com/news/investor-alert-goldberg-law-pc-183100216.html,"[Business Wire] - Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Biogen Inc. . Investors who purchased or otherwise acquired Biogen shares between July 23, 2014 and July 23, 2015 inclusive are encouraged to contact the firm in advance of the December 23, 2016 lead plaintiff motion deadline."
BIIB,BIIB:UW,BBG000C18861,"Biogen: Solid Enough to Keep Focus on Alzheimer's, M&A",2016-10-26 18:07:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/26/biogen-solid-enough-to-keep-focus-on-alzheimers-ma/?mod=yahoobarrons&ru=yahoo,"Biogen: Solid Enough to Keep Focus on Alzheimer's, M&A"
BIIB,BIIB:UW,BBG000C18861,Midday Update: Stocks Trim Losses on Supply-Related Bounce in Oil,2016-10-26 17:29:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iQgdzJPbeVM/midday-update-stocks-trim-losses-on-supply-related-bounce-in-oil-cm698770,Fueled by a rebound in oil futures the Dow Jones Industrial Average has erased its early losses and was now trading in the plus column The S amp P 500 and Nasdaq Composite however were still trading slightly lower with the Nasdaq pressured by shares of Apple AAPL Fueled by a rebound in
BIIB,BIIB:UW,BBG000C18861,Biogen Posts 3Q Net of $1B on $3B Revenue (BIIB),2016-10-26 17:07:00 +0000,http://www.investopedia.com/news/biogen-3q-earnings-beat-street-estimates-biib/?partner=YahooSA,Biogen Posts 3Q Net of $1B on $3B Revenue (BIIB)
BIIB,BIIB:UW,BBG000C18861,Eaton Vance Worldwide Health Sciences Fund 3rd Quarter Commentary,2016-10-26 17:06:45 +0000,http://finance.yahoo.com/news/eaton-vance-worldwide-health-sciences-165736042.html,Eaton Vance Worldwide Health Sciences Fund 3rd Quarter Commentary
BIIB,BIIB:UW,BBG000C18861,"Biogen: Heads Is a Win, Tails Is Complicated",2016-10-26 15:55:54 +0000,http://blogs.wsj.com/moneybeat/2016/10/26/biogen-heads-is-a-win-tails-is-complicated/?mod=yahoo_hs,"Biogen: Heads Is a Win, Tails Is Complicated"
BIIB,BIIB:UW,BBG000C18861,"Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta",2016-10-26 15:54:00 +0000,https://www.thestreet.com/story/13868013/1/pardon-me-but-i-have-a-few-things-to-say-vertex-biogen-ariad-sarepta.html?puc=yahoo&cm_ven=YAHOO,"Pardon Me, but I Have a Few Things to Say... Vertex, Biogen, Ariad, Sarepta"
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Clinical Holds Hit Inovio & Aduro, Vertex Q3 Results Miss Estimates",2016-10-26 15:53:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XPVh1FUgdLQ/biotech-stock-roundup-clinical-holds-hit-inovio-aduro-vertex-q3-results-miss-estimates-cm698538,Vertex VRTX reported results earlier this week though the company missed estimates Vertex s pipeline update regarding its next generation correctors brought some relief Meanwhile a couple of companies Inovio INO and Aduro ADRO were hit by clinical holds placed by the FDA on
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: AAPL, AKAM",2016-10-26 15:50:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/12NcTudPDQU/nasdaq-100-movers-aapl-akam-cm698503,In early trading on Wednesday shares of Akamai Technologies AKAM topped the list of the day s best performing components of the Nasdaq 100 index trading up 14 3 Year to date Akamai Technologies registers a 28 3 gain And the worst performing Nasdaq 100 component thus far on the
BIIB,BIIB:UW,BBG000C18861,"Biogen profit tops expectations; focus on CEO search, new drugs",2016-10-26 14:47:10 +0000,http://finance.yahoo.com/news/biogen-quarterly-profit-beats-ms-113026418.html,"Biogen profit tops expectations; focus on CEO search, new drugs"
BIIB,BIIB:UW,BBG000C18861,Biogen Rises on Solid Earnings Beat,2016-10-26 14:05:45 +0000,http://finance.yahoo.com/news/biogen-rises-solid-earnings-beat-140545004.html,Biogen Rises on Solid Earnings Beat
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Beats on Q3 Earnings and Sales,2016-10-26 13:51:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w4S-qd_2_o0/biogen-biib-beats-on-q3-earnings-and-sales-cm698468,Cambridge MA based Biogen Inc BIIB one of the world s leading biotechnology companies focuses on therapeutic areas including neurology immunology and hemophilia The company is best known for its multiple sclerosis MS franchise comprising treatments like Avonex Tysabri Tecfidera
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Beats on Q3 Earnings; Tecfidera Propels Sales,2016-10-26 13:50:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xzFi4fguv9k/biogen-biib-beats-on-q3-earnings-tecfidera-propels-sales-cm698456,Biotech company Biogen Inc s BIIB shares were up more than 2 in pre market trading with the company surpassing earnings as well as sales expectations The company reported third quarter 2016 earnings per share of 5 19 beating the Zacks Consensus Estimate of 4 99 by 4 and 16
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Beats on Q3 Earnings; Tecfidera Propels Sales,2016-10-26 12:54:12 +0000,http://finance.yahoo.com/news/biogen-biib-beats-q3-earnings-125412854.html,Biogen (BIIB) Beats on Q3 Earnings; Tecfidera Propels Sales
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Wall St set to open lower as Apple drags,2016-10-26 12:50:36 +0000,http://finance.yahoo.com/news/us-stocks-wall-st-set-125036810.html,US STOCKS-Wall St set to open lower as Apple drags
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Beats on Q3 Earnings and Sales,2016-10-26 12:40:12 +0000,http://finance.yahoo.com/news/biogen-biib-beats-q3-earnings-124012521.html,Biogen (BIIB) Beats on Q3 Earnings and Sales
BIIB,BIIB:UW,BBG000C18861,"Biogen (BIIB) Stock Rises, Q3 Results Beat Expectations",2016-10-26 12:03:00 +0000,https://www.thestreet.com/story/13867307/1/biogen-biib-stock-rises-q3-results-beat-expectations.html?puc=yahoo&cm_ven=YAHOO,"Biogen (BIIB) Stock Rises, Q3 Results Beat Expectations"
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Biogen Inc. To Contact The Firm Before Lead Plaintiff Deadline",2016-10-26 12:00:00 +0000,http://finance.yahoo.com/news/shareholder-alert-faruqi-faruqi-llp-120000423.html,"[GlobeNewswire] - NEW YORK, Oct. 26, 2016-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Biogen Inc. of the December 23, 2016 deadline to seek the role of lead plaintiff in a federal ..."
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen Profit Easily Tops Views,2016-10-26 11:55:15 +0000,http://www.wsj.com/articles/biogen-profit-easily-tops-views-1477482908?mod=yahoo_hs,[$$] Biogen Profit Easily Tops Views
BIIB,BIIB:UW,BBG000C18861,Biogen stock lifts as much as 3% as MS drugs propel third-quarter beat,2016-10-26 11:21:23 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=BD0B1269-C56E-458F-9556-3DF6E85BC9FE&siteid=yhoof2,Biogen stock lifts as much as 3% as MS drugs propel third-quarter beat
BIIB,BIIB:UW,BBG000C18861,Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion,2016-10-26 11:15:11 +0000,http://www.publicnow.com/view/6C516BD52671FA318301B3BCAC16360FEBA42445,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2016 financial results, including: Total revenues of $3.0 billion, a 6% increase versus the same quarter in the ..."
BIIB,BIIB:UW,BBG000C18861,Short Sellers Can’t Make Up Their Minds on Major Biotechs,2016-10-26 11:15:00 +0000,http://247wallst.com/healthcare-business/2016/10/26/short-sellers-cant-make-up-their-minds-on-major-biotechs/,Short Sellers Can’t Make Up Their Minds on Major Biotechs
BIIB,BIIB:UW,BBG000C18861,Biogen tops Street 3Q forecasts,2016-10-26 11:10:59 +0000,http://sg.finance.yahoo.com/news/biogen-tops-street-3q-forecasts-111059814.html,Biogen tops Street 3Q forecasts
BIIB,BIIB:UW,BBG000C18861,"BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition",2016-10-26 11:10:00 +0000,http://biz.yahoo.com/e/161026/biib8-k.html,"BIOGEN INC. Files SEC form 8-K, Results of Operations and Financial Condition"
BIIB,BIIB:UW,BBG000C18861,Q3 2016 Biogen Inc Earnings Release - Before Market Open,2016-10-26 11:07:02 +0000,http://biz.yahoo.com/research/earncal/20161026.html?t=biib,Q3 2016 Biogen Inc Earnings Release - Before Market Open
BIIB,BIIB:UW,BBG000C18861,Drugmaker Biogen quarterly profit rises 7 pct,2016-10-26 11:06:58 +0000,http://finance.yahoo.com/news/drugmaker-biogen-quarterly-profit-rises-110658003.html,Drugmaker Biogen quarterly profit rises 7 pct
BIIB,BIIB:UW,BBG000C18861,Biogen Profit Easily Tops Views,2016-10-26 08:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3lgLAOqFQtQ/biogen-profit-easily-tops-views-20161026-00429,Biogen Profit Easily Tops Views
BIIB,BIIB:UW,BBG000C18861,Biogen Q3 16 Earnings Conference Call At 8:30 AM ET,2016-10-26 07:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U3pgsuY-epA/biogen-q3-16-earnings-conference-call-at-830-am-et-20161026-00302,Biogen Q3 16 Earnings Conference Call At 8:30 AM ET
BIIB,BIIB:UW,BBG000C18861,Biogen Inc. Q3 Profit Rises 10%,2016-10-26 07:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QskOwA34NNc/biogen-inc-q3-profit-rises-10-20161026-00231,Biogen Inc. Q3 Profit Rises 10%
BIIB,BIIB:UW,BBG000C18861,"Pre-Market Earnings Report for October 26, 2016 :  KO, CMCSA, BA, MDLZ, BIIB, SPG, GD, NOC, BSX, STT, WM, NSC",2016-10-25 20:14:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EP1_Df3-2XE/pre-market-earnings-report-for-october-26-2016-ko-cmcsa-ba-mdlz-biib-spg-gd-noc-bsx-stt-wm-nsc-cm698179,The following companies are expected to report earnings prior to market open on 10 26 2016 Visit our Earnings Calendar for a full list of expected earnings releases Coca Cola Company KO is reporting for the quarter ending September 30 2016 The
BIIB,BIIB:UW,BBG000C18861,5 Stocks to Watch Before the Market Opens Tomorrow,2016-10-25 20:00:40 +0000,http://finance.yahoo.com/tumblr/blog-5-stocks-to-watch-before-the-market-opens-tomorrow-200044473.html,5 Stocks to Watch Before the Market Opens Tomorrow
BIIB,BIIB:UW,BBG000C18861,"Here's the big news we're likely to hear when Vertex, Biogen report Q3 this week",2016-10-25 15:26:52 +0000,http://www.bizjournals.com/boston/news/2016/10/23/heres-the-big-news-were-likely-to-hear-when-vertex.html?ana=yahoo,"Here's the big news we're likely to hear when Vertex, Biogen report Q3 this week"
BIIB,BIIB:UW,BBG000C18861,"Drug Stock Earnings to Watch on Oct 26: BIIB, MDCO & More",2016-10-25 13:26:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2lwFmTsnxU0/drug-stock-earnings-to-watch-on-oct-26-biib-mdco-more-cm697724,With Q3 earnings picking up pace approximately 116 S amp P 500 members representing 23 2 of the index s total market capitalization have already reported quarterly results as of Oct 21 An impressive 80 2 of these companies managed to post an earnings beat while 62 9
BIIB,BIIB:UW,BBG000C18861,"Drug Stock Earnings to Watch on Oct 26: BIIB, MDCO & More",2016-10-25 12:27:12 +0000,http://finance.yahoo.com/news/drug-stock-earnings-watch-oct-122712297.html,"Drug Stock Earnings to Watch on Oct 26: BIIB, MDCO & More"
BIIB,BIIB:UW,BBG000C18861,Labaton Sucharow LLP Files Class Action Lawsuit on Behalf of Biogen Inc. Investors,2016-10-24 22:04:21 +0000,http://finance.yahoo.com/news/labaton-sucharow-llp-files-class-220421689.html,"[GlobeNewswire] - NEW YORK, Oct. 24, 2016-- Labaton Sucharow LLP announces that on October 20, 2016, it filed a securities class action lawsuit on behalf of its client Electrical Workers Pension Fund, Local 103, International ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug: RBC,2016-10-24 20:15:02 +0000,http://www.investors.com/news/technology/biogen-could-add-1-billion-in-2017-on-muscular-dystrophy-drug-rbc/,Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug: RBC
BIIB,BIIB:UW,BBG000C18861,What to Look for When Biogen (BIIB) Reports Q3 Results,2016-10-24 18:51:00 +0000,https://www.thestreet.com/story/13864355/1/what-to-look-for-when-biogen-biib-reports-q3-results.html?puc=yahoo&cm_ven=YAHOO,What to Look for When Biogen (BIIB) Reports Q3 Results
BIIB,BIIB:UW,BBG000C18861,Top Health Care Earnings Coming Next Week,2016-10-23 14:35:30 +0000,http://247wallst.com/healthcare-business/2016/10/23/top-health-care-earnings-coming-next-week/,Top Health Care Earnings Coming Next Week
BIIB,BIIB:UW,BBG000C18861,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit – BIIB",2016-10-21 16:13:28 +0000,http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-161328116.html,"[GlobeNewswire] - NEW YORK, Oct. 21, 2016-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc. between July 23, 2014 ..."
BIIB,BIIB:UW,BBG000C18861,Best And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry,2016-10-21 14:00:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oYmB58AyONI/best-and-worst-biotech-etfs-of-2016-tell-a-tale-about-this-industry-cm696324,An election year has added to the pressures that hit biotechnology stocks hard but a look under the hood of two sibling biotech ETFs is revealing 160 It shows the more speculative companies in 160 this extremely heterogeneous industry caused 160 much of the hurt
BIIB,BIIB:UW,BBG000C18861,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?,2016-10-20 16:28:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZpbkDdnx5VQ/can-biogen-biib-keep-the-earnings-streak-alive-in-q3-cm696043,Biogen Inc BIIB a well known name in the multiple sclerosis MS market will be reporting third quarter 2016 earnings on Oct 26 before market open Last quarter the company delivered a positive earnings surprise of 11 09 Biogen s performance has been pretty impressive with
BIIB,BIIB:UW,BBG000C18861,7 Drug Stocks to Consider as Biosimilars Pick Up Pace,2016-10-20 14:29:02 +0000,http://finance.yahoo.com/news/7-drug-stocks-consider-biosimilars-142902130.html,7 Drug Stocks to Consider as Biosimilars Pick Up Pace
BIIB,BIIB:UW,BBG000C18861,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?,2016-10-20 14:21:02 +0000,http://finance.yahoo.com/news/biogen-biib-keep-earnings-streak-142102268.html,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?
BIIB,BIIB:UW,BBG000C18861,Biotech Stocks: Do Earnings Even Matter Anymore?,2016-10-20 13:58:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/20/biotech-stocks-do-earnings-even-matter-anymore/?mod=yahoobarrons&ru=yahoo,Biotech Stocks: Do Earnings Even Matter Anymore?
BIIB,BIIB:UW,BBG000C18861,Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains,2016-10-20 13:55:36 +0000,http://247wallst.com/healthcare-business/2016/10/20/mega-cap-biotechs-cheapest-in-years-4-to-buy-for-2017-gains/,Mega-Cap Biotechs Cheapest in Years: 4 to Buy for 2017 Gains
BIIB,BIIB:UW,BBG000C18861,What Biogen Is Doing that Put It in Good Favor with Analysts,2016-10-20 12:05:37 +0000,http://marketrealist.com/2016/10/analyst-recommendations-biogen-peers-2016-2/?utm_source=yahoo&utm_medium=feed,What Biogen Is Doing that Put It in Good Favor with Analysts
BIIB,BIIB:UW,BBG000C18861,3 Stocks That Will Be Bought Out Before Twitter,2016-10-19 20:47:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-YV7SJFQfl8/3-stocks-that-will-be-bought-out-before-twitter-cm695590,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Last week 160 Twitter Inc NYSE TWTR was on the tip of everyone s tongue as investors speculated about whether 160 s alesforce com inc NYSE CRM would acquire the social media
BIIB,BIIB:UW,BBG000C18861,Biogen’s Multiple Sclerosis Drug Driving Its Growth This Year,2016-10-19 20:04:12 +0000,http://marketrealist.com/2016/10/tecfidera-expected-key-growth-driver-biogen-3q16/?utm_source=yahoo&utm_medium=feed,Biogen’s Multiple Sclerosis Drug Driving Its Growth This Year
BIIB,BIIB:UW,BBG000C18861,4 Strategic Areas Expected to Boost Biogen’s Growth in 2016,2016-10-19 19:04:12 +0000,http://marketrealist.com/2016/10/four-key-strategic-areas-expected-boost-biogens-growth-2016/?utm_source=yahoo&utm_medium=feed,4 Strategic Areas Expected to Boost Biogen’s Growth in 2016
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: ARIAD Down on Drug Pricing Tweet, Regeneron Study on Clinical Hold",2016-10-19 16:51:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6egD9qN3o2A/biotech-stock-roundup-ariad-down-on-drug-pricing-tweet-regeneron-study-on-clinical-hold-cm695455,Once again a single tweet on drug pricing resulted in weakness in the biotech sector with ARIAD ARIA losing ground on a tweet regarding the company s price hikes for cancer drug Iclusig Meanwhile Regeneron REGN suffered a pipeline setback with the FDA putting a clinical hold on one of
BIIB,BIIB:UW,BBG000C18861,iShares Edge MSCI USA Quality Factor ETF Experiences Big Outflow,2016-10-19 16:48:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WtufVR-lNmw/ishares-edge-msci-usa-quality-factor-etf-experiences-big-outflow-cm695421,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Edge MSCI USA Quality Factor ETF Symbol QUAL where we have detected an approximate 39 9 million dollar outflow that s a 1 3 decrease week over
BIIB,BIIB:UW,BBG000C18861,Biogen Expected to Report Modest Revenue Growth in 3Q16,2016-10-19 16:39:45 +0000,http://marketrealist.com/2016/10/biogen-expected-report-modest-revenue-growth-3q16/?utm_source=yahoo&utm_medium=feed,Biogen Expected to Report Modest Revenue Growth in 3Q16
BIIB,BIIB:UW,BBG000C18861,"Better Buy: Biogen Inc. vs. Gilead Sciences, Inc.",2016-10-19 12:37:56 +0000,http://www.fool.com/investing/2016/10/18/better-buy-biogen-inc-vs-gilead-sciences-inc.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Biogen Inc. vs. Gilead Sciences, Inc."
BIIB,BIIB:UW,BBG000C18861,How Did Markets React to the Fed’s September 2016 Minutes?,2016-10-18 19:28:08 +0000,http://marketrealist.com/2016/10/markets-react-feds-september-2016-meeting-minutes/?utm_source=yahoo&utm_medium=feed,How Did Markets React to the Fed’s September 2016 Minutes?
BIIB,BIIB:UW,BBG000C18861,"Better Buy: Biogen Inc. vs. Gilead Sciences, Inc.",2016-10-18 17:47:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4VlnLh2gMAY/better-buy-biogen-inc-vs-gilead-sciences-inc-cm694887,Image source Getty Images Two of the biggest biotechs around have also been two of the best long term investments If you had bought shares of Biogen NASDAQ BIIB five years ago and held on to the stock your initial amount would have nearly tripled If you d taken the
BIIB,BIIB:UW,BBG000C18861,"Commit To Buy Biogen At $180, Earn 5% Using Options",2016-10-18 16:47:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WQkC0W_UGOo/commit-to-buy-biogen-at-180-earn-5-using-options-cm694811,Investors eyeing a purchase of Biogen Inc Symbol BIIB shares but tentative about paying the going market price of 294 96 share might benefit from considering selling puts among the alternative strategies at their disposal One interesting put contract in particular is the January 2019 put
BIIB,BIIB:UW,BBG000C18861,Alzheimer's Remains a Top Priority for Big Pharma,2016-10-18 11:37:36 +0000,http://www.fool.com/investing/2016/10/17/alzheimers-remains-a-top-priority-for-big-pharma.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Alzheimer's Remains a Top Priority for Big Pharma
BIIB,BIIB:UW,BBG000C18861,Alzheimer's Remains a Top Priority for Big Pharma,2016-10-17 21:47:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpPqR__TpuM/alzheimers-remains-a-top-priority-for-big-pharma-cm694462,Alzheimer s disease AD has been a graveyard for experimental medications A recent study for instance reported that a whopping 99 6 of experimental AD drugs 160 failed to improve patient outcomes over the course of 2002 to 2012 Despite this sky high failure rate
BIIB,BIIB:UW,BBG000C18861,"Celgene Pitted Against Gilead, Biogen In Crohn's Drug Battle",2016-10-17 20:03:12 +0000,http://www.investors.com/news/technology/celgene-pitted-against-gilead-biogen-in-crohns-drug-battle/,"Celgene Pitted Against Gilead, Biogen In Crohn's Drug Battle"
BIIB,BIIB:UW,BBG000C18861,BioMarin Issues Encouraging Update on Hemophilia A Drug,2016-10-14 16:42:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7SPyB2f8C8Y/biomarin-issues-encouraging-update-on-hemophilia-a-drug-cm693510,BioMarin Pharmaceutical Inc BMRN announced that the UK Medicines and Healthcare Products Regulatory Agency MHRA has approved the resumption of enrollment in the open label phase I II study on its pipeline candidate BMN 270 which is an experimental gene therapy being evaluated for
BIIB,BIIB:UW,BBG000C18861,How Valeant Is Trying to Improve Its Profit Margins,2016-10-14 15:04:41 +0000,http://marketrealist.com/2016/10/valeant-pharmaceutical-focuses-improving-profit-margins-2016/?utm_source=yahoo&utm_medium=feed,How Valeant Is Trying to Improve Its Profit Margins
BIIB,BIIB:UW,BBG000C18861,Is AveXis a Major Threat to Ionis Pharmaceuticals?,2016-10-14 13:43:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bnW__aKfJbI/is-avexis-a-major-threat-to-ionis-pharmaceuticals-cm693302,Image source AveXis Inc Shares of 160 Ionis Pharmaceuticals Inc NASDAQ IONS 160 have lost about 12 1 of their value since AveXis Inc NASDAQ AVXS shared early evidence that its gene therapy benefited infants with spinal muscular atrophy SMA One of the
BIIB,BIIB:UW,BBG000C18861,Is AveXis a Major Threat to Ionis Pharmaceuticals?,2016-10-14 11:44:19 +0000,http://www.fool.com/investing/2016/10/14/is-avexis-a-major-threat-to-ionis-pharmaceuticals.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is AveXis a Major Threat to Ionis Pharmaceuticals?
BIIB,BIIB:UW,BBG000C18861,"Why This Top Columbia Fund Loads Up On Facebook, Other Stock Leaders",2016-10-13 23:40:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oekysv614fw/why-this-top-columbia-fund-loads-up-on-facebook-other-stock-leaders-cm693194,You ve heard the old Wall Street saw countless times A rising tide lifts all boats So what s a mutual fund helmsman to do when it s hard to tell if the tide is rising at all That s the challenge facing John Wilson Peter Deininger and Tchintcia Barros managers of 3 3 billion
BIIB,BIIB:UW,BBG000C18861,"Why This Top Columbia Fund Loads Up On Facebook, Other Stock Leaders",2016-10-13 22:28:16 +0000,http://www.investors.com/etfs-and-funds/mutual-funds/why-this-top-columbia-fund-loads-up-on-these-stock-leaders/,"Why This Top Columbia Fund Loads Up On Facebook, Other Stock Leaders"
BIIB,BIIB:UW,BBG000C18861,"Does a Clinton Victory Scare the Biotech Sector? (AMGN, ILMN)",2016-10-13 21:02:00 +0000,http://www.investopedia.com/news/biotech-drop-may-fear-democratic-win-amgn-ilmn/?partner=YahooSA,"Does a Clinton Victory Scare the Biotech Sector? (AMGN, ILMN)"
BIIB,BIIB:UW,BBG000C18861,Biogen Stabilizes Near Major Support,2016-10-13 18:25:00 +0000,https://www.thestreet.com/story/13852803/1/biogen-stabilizes-near-major-support.html?puc=yahoo&cm_ven=YAHOO,Biogen Stabilizes Near Major Support
BIIB,BIIB:UW,BBG000C18861,"Stock Market News for October 12, 2016",2016-10-12 16:43:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/90vuM7odOIk/stock-market-news-for-october-12-2016-cm692454,Disappointing start to the third quarter earnings season weighed on benchmarks on Tuesday Alcoa unofficially kicked off the earnings season with its earnings and revenues falling short of expectations while a retreat in oil prices also hurt sentiments Increase in production levels by
BIIB,BIIB:UW,BBG000C18861,Trading the biotech sell-off,2016-10-12 16:15:00 +0000,http://finance.yahoo.com/video/trading-biotech-sell-off-161500602.html,Trading the biotech sell-off
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO",2016-10-12 14:21:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xRxdEZs_O1o/biotech-stock-roundup-alnylam-slumps-on-revusiran-update-tesaro-impresses-at-esmo-cm692293,Alnylam ALNY focused on developing novel therapeutics based on RNA interference RNAi saw its shares slump on its decision to discontinue the development of a late stage pipeline candidate Meanwhile several biotech companies were present at the congress of the European Society for
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO",2016-10-12 12:39:12 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-alnylam-slumps-123912498.html,"Biotech Stock Roundup: Alnylam Slumps on Revusiran Update, TESARO Impresses at ESMO"
BIIB,BIIB:UW,BBG000C18861,3 Biotechs Most Likely to Be Acquired,2016-10-12 11:28:03 +0000,http://www.fool.com/investing/2016/10/11/3-biotechs-most-likely-to-be-acquired.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Biotechs Most Likely to Be Acquired
BIIB,BIIB:UW,BBG000C18861,Short Sellers Have Mixed Views on Major Biotechs,2016-10-12 11:10:47 +0000,http://247wallst.com/healthcare-business/2016/10/12/short-sellers-have-mixed-views-on-major-biotechs/,Short Sellers Have Mixed Views on Major Biotechs
BIIB,BIIB:UW,BBG000C18861,3 Top Biotech Stocks to Buy Right Now,2016-10-11 20:21:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VXk2-HnZmAY/3-top-biotech-stocks-to-buy-right-now-cm691445,IMAGE SOURCE GETTY IMAGES Looking for great biotech stocks to buy You have plenty of options Biotech stocks in general have performed great over the past few years and are bouncing back from a slump that began in the second half of 2015 The good news is that you can make
BIIB,BIIB:UW,BBG000C18861,Biogen Gets Competition for SMA Therapy (BIIB),2016-10-11 19:40:00 +0000,http://www.investopedia.com/news/biogen-gets-competition-sma-therapy-biib/?partner=YahooSA,Biogen Gets Competition for SMA Therapy (BIIB)
BIIB,BIIB:UW,BBG000C18861,3 Biotechs Most Likely to Be Acquired,2016-10-11 18:19:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tEgLZ4W6cao/3-biotechs-most-likely-to-be-acquired-cm691966,Image source Getty Images Mergers and acquisitions are a way of life in the biotech world Several big buyouts have taken place this year and it s only a matter of time before the industry is abuzz over the next one But which biotech stocks are most likely to be
BIIB,BIIB:UW,BBG000C18861,3 Top Biotech Stocks to Buy Right Now,2016-10-11 12:21:31 +0000,http://www.fool.com/investing/2016/10/11/3-top-biotech-stocks-to-buy-right-now.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Top Biotech Stocks to Buy Right Now
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen vs. Celgene,2016-10-10 15:29:44 +0000,http://www.fool.com/investing/2016/10/10/better-buy-biogen-vs-celgene.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Biogen vs. Celgene
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen vs. Celgene,2016-10-10 14:21:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X1rK2Bhiq_Q/better-buy-biogen-vs-celgene-cm690962,Image source Flickr Fresh off a strong Q2 earnings beat and riding high on takeout rumors the past 3 months have been good to Biogen NASDAQ BIIB investors with shares up 27 since July The same however cannot be said for Celgene NASDAQ CELG up a measly 3
BIIB,BIIB:UW,BBG000C18861,New Data Presented at World Muscle Society Congress Support Potential Benefit of Investigational Treatment Nusinersen in Spinal Muscular Atrophy,2016-10-08 14:00:00 +0000,http://finance.yahoo.com/news/data-presented-world-muscle-society-140000816.html,"[Business Wire] - New data from the clinical program for nusinersen, an investigational treatment for spinal muscular atrophy , were presented by Biogen and Ionis Pharmaceuticals in the late-breaking session at the 2016 World Muscle Society Congress in Granada, Spain."
BIIB,BIIB:UW,BBG000C18861,"Noteworthy Friday Option Activity: NLNK, SRPT, BIIB",2016-10-07 20:43:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z23XTZFhmqE/noteworthy-friday-option-activity-nlnk-srpt-biib-cm690520,Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in NewLink Genetics Corp Symbol NLNK where a total volume of 2 144 contracts has been traded thus far today a contract volume which is representative of approximately 214
BIIB,BIIB:UW,BBG000C18861,"The Key Reason Ionis Pharmaceuticals, Inc. Gained Another 24% in September",2016-10-07 19:26:39 +0000,http://www.fool.com/investing/2016/10/07/the-key-reason-ionis-pharmaceuticals-inc-gained-an.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"The Key Reason Ionis Pharmaceuticals, Inc. Gained Another 24% in September"
BIIB,BIIB:UW,BBG000C18861,6 Healthcare Stocks Investors Can't Miss in Q3 Earnings,2016-10-07 18:43:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DZWZlJnc5pI/6-healthcare-stocks-investors-cant-miss-in-q3-earnings-cm690471,Controversies surrounding drug prices are again making it to the headlines this time spurred by the EpiPen price hike issue Generic drug maker Mylan N V drew flak from lawmakers for over pricing its epinephrine auto injector EpiPen severe allergic reactions around the end of Aug
BIIB,BIIB:UW,BBG000C18861,6 Healthcare Stocks Investors Can't Miss in Q3 Earnings,2016-10-07 16:22:04 +0000,http://finance.yahoo.com/news/6-healthcare-stocks-investors-cant-162204234.html,6 Healthcare Stocks Investors Can't Miss in Q3 Earnings
BIIB,BIIB:UW,BBG000C18861,Will Biogen Join Gilead in the Disappointment Club?,2016-10-07 15:51:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/07/will-biogen-join-gilead-in-the-disappointment-club/?mod=yahoobarrons&ru=yahoo,Will Biogen Join Gilead in the Disappointment Club?
BIIB,BIIB:UW,BBG000C18861,"Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc.",2016-10-05 18:44:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YSszC5Dongo/better-buy-anavex-life-sciences-corp-vs-ionis-pharmaceuticals-inc-cm689356,Image source Getty Images Recently Anavex Life Sciences Corp NASDAQ AVXL inked an an agreement with Biogen NASDAQ BIIB joining the ranks of several high profile drug developers with Biogen partnerships including Ionis Pharmaceuticals Inc NASDAQ IONS In
BIIB,BIIB:UW,BBG000C18861,"Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc.",2016-10-05 17:13:34 +0000,http://www.fool.com/investing/2016/10/05/better-buy-anavex-life-sciences-corp-vs-ionis-phar.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc."
BIIB,BIIB:UW,BBG000C18861,Biogen: On the Way to $386?,2016-10-05 16:09:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/05/biogen-on-the-way-to-386/?mod=yahoobarrons&ru=yahoo,Biogen: On the Way to $386?
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Summit Soars on Sarepta Deal, Regeneron Presents Data",2016-10-05 15:48:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-rcJwyaDxNo/biotech-stock-roundup-summit-soars-on-sarepta-deal-regeneron-presents-data-cm689126,It was an eventful week for the biotech sector with companies like Regeneron REGN and Intra Cellular Therapies ITCI presenting data while Summit SMMT shot up on a collaboration agreement with Sarepta SRPT Recap of the Week s Most Important Stories Summit Shoots Up on
BIIB,BIIB:UW,BBG000C18861,[$$] Samsung BioLogics IPO Could Value Firm at $8.2 Billion,2016-10-05 04:51:45 +0000,http://www.wsj.com/articles/samsung-affiliate-seeks-european-approval-for-near-replica-of-herceptin-1475546455?ru=yahoo?mod=yahoo_itp,[$$] Samsung BioLogics IPO Could Value Firm at $8.2 Billion
BIIB,BIIB:UW,BBG000C18861,Samsung Group Furthers Drug Push -- WSJ,2016-10-05 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2tEzh_LOljA/samsung-group-furthers-drug-push--wsj-20161005-00079,Samsung Group Furthers Drug Push -- WSJ
BIIB,BIIB:UW,BBG000C18861,[$$] Samsung BioLogics IPO Could Value Firm at $8.2 Billion,2016-10-04 16:56:47 +0000,http://www.wsj.com/articles/samsung-affiliate-seeks-european-approval-for-near-replica-of-herceptin-1475546455?mod=yahoo_hs,[$$] Samsung BioLogics IPO Could Value Firm at $8.2 Billion
BIIB,BIIB:UW,BBG000C18861,America’s 15 Fastest Growing Companies,2016-10-04 15:32:29 +0000,http://finance.yahoo.com/news/america-15-fastest-growing-companies-153229175.html,America’s 15 Fastest Growing Companies
BIIB,BIIB:UW,BBG000C18861,Correction to Samsung BioLogics story,2016-10-04 05:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v_ojdRExK7Y/correction-to-samsung-biologics-story-20161004-00125,Correction to Samsung BioLogics story
BIIB,BIIB:UW,BBG000C18861,Samsung BioLogics IPO Could Value Firm at $8.2 Billion -- 2nd Update,2016-10-04 01:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5WNOVkq6xC4/samsung-biologics-ipo-could-value-firm-at-82-billion--2nd-update-20161004-00037,Samsung BioLogics IPO Could Value Firm at $8.2 Billion -- 2nd Update
BIIB,BIIB:UW,BBG000C18861,Samsung Affiliate Seeks European Approval for Herceptin Copy,2016-10-03 22:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ev-KibnLbHk/samsung-affiliate-seeks-european-approval-for-herceptin-copy-20161003-01293,Samsung Affiliate Seeks European Approval for Herceptin Copy
BIIB,BIIB:UW,BBG000C18861,Samsung BioLogics IPO Could Value Firm at $8.2 Billion,2016-10-03 22:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qO4yZY97U7U/samsung-biologics-ipo-could-value-firm-at-82-billion-20161003-01301,Samsung BioLogics IPO Could Value Firm at $8.2 Billion
BIIB,BIIB:UW,BBG000C18861,Samsung Affiliate Seeks European Approval for Near-Replica of Herceptin -- Update,2016-10-03 22:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4mNh1Tf1auE/samsung-affiliate-seeks-european-approval-for-nearreplica-of-herceptin--update-20161003-01302,Samsung Affiliate Seeks European Approval for Near-Replica of Herceptin -- Update
BIIB,BIIB:UW,BBG000C18861,Forcerank Consensus Rankings- Week of 10/3,2016-10-03 22:40:27 +0000,http://finance.yahoo.com/tumblr/blog-forcerank-consensus-rankings-week-of-103-224033580.html,Forcerank Consensus Rankings- Week of 10/3
BIIB,BIIB:UW,BBG000C18861,Samsung Affiliate Seeks European Approval for Near-Replica of Herceptin,2016-10-03 22:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WpPo5lO3KUs/samsung-affiliate-seeks-european-approval-for-nearreplica-of-herceptin-20161003-01290,Samsung Affiliate Seeks European Approval for Near-Replica of Herceptin
BIIB,BIIB:UW,BBG000C18861,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results,2016-10-03 17:53:31 +0000,http://finance.yahoo.com/news/possible-trading-opportunity-presents-itself-175331766.html,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : October 3, 2016",2016-10-03 16:12:28 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-value-analysis-nasdaqbiib-october-3-2016/,"Biogen, Inc. – Value Analysis (NASDAQ:BIIB) : October 3, 2016"
BIIB,BIIB:UW,BBG000C18861,Gilead: Will New HIV Drugs Overshadow Hep C Worries?,2016-10-03 15:03:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/03/gilead-will-new-hiv-drugs-overshadow-hep-c-worries/?mod=yahoobarrons&ru=yahoo,Gilead: Will New HIV Drugs Overshadow Hep C Worries?
BIIB,BIIB:UW,BBG000C18861,Top 6 Biopharma Gainers of the Past Week,2016-10-02 14:05:42 +0000,http://247wallst.com/healthcare-business/2016/10/02/top-6-biopharma-gainers-of-the-past-week/,Top 6 Biopharma Gainers of the Past Week
BIIB,BIIB:UW,BBG000C18861,Big Pharma vs Big Pharma in court battles over biosimilar drugs,2016-10-02 09:00:01 +0000,http://finance.yahoo.com/news/big-pharma-vs-big-pharma-090001407.html,"[Reuters] - The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals' complex biological medicines. Biologics, manufactured in living cells, then extracted and purified, are more complex than traditional medicines and cannot be copied with precision, and so their knock-off versions are called biosimilars instead of generics. The allure of biosimilars is clear, with insurers and other payers counting on the steep discounts."
BIIB,BIIB:UW,BBG000C18861,Could Growing HIV Franchise Drive Gilead Sciences’ Valuation?,2016-09-30 22:03:44 +0000,http://marketrealist.com/2016/09/could-growing-hiv-franchise-drive-gilead-sciences-valuation/?utm_source=yahoo&utm_medium=feed,Could Growing HIV Franchise Drive Gilead Sciences’ Valuation?
BIIB,BIIB:UW,BBG000C18861,Two Stocks With Something To Prove: Biogen And Twitter,2016-09-30 19:37:08 +0000,http://www.investors.com/stock-lists/ibd-big-cap-20/two-stocks-with-something-to-prove-biogen-and-twitter/,Two Stocks With Something To Prove: Biogen And Twitter
BIIB,BIIB:UW,BBG000C18861,Stocks Roar Higher; Apple Still Strong; Will Facebook Break Out Again?,2016-09-30 16:15:48 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-roar-higher-apple-still-strong-will-facebook-break-out-again/,Stocks Roar Higher; Apple Still Strong; Will Facebook Break Out Again?
BIIB,BIIB:UW,BBG000C18861,"Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : September 30, 2016",2016-09-30 12:31:04 +0000,http://www.capitalcube.com/blog/index.php/biogen-inc-breached-its-50-day-moving-average-in-a-bearish-manner-biib-us-september-30-2016/,"Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : September 30, 2016"
BIIB,BIIB:UW,BBG000C18861,"Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure",2016-09-29 20:26:08 +0000,http://www.investors.com/news/technology/amgen-biogen-gilead-could-spike-va-pricing-to-skirt-california-measure/,"Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure"
BIIB,BIIB:UW,BBG000C18861,"Anavex Jumps on Biogen Testing Deal (AVXL, BIIB)",2016-09-29 19:09:00 +0000,http://www.investopedia.com/news/anavex-jumps-biogen-testing-deal-avxl-biib/?partner=YahooSA,"Anavex Jumps on Biogen Testing Deal (AVXL, BIIB)"
BIIB,BIIB:UW,BBG000C18861,"Biogen Submits NDA for SMA Drug (BIIB, IONS)",2016-09-28 23:13:00 +0000,http://www.investopedia.com/news/biogen-submits-nda-sma-drug-biib-ions/?partner=YahooSA,"Biogen Submits NDA for SMA Drug (BIIB, IONS)"
BIIB,BIIB:UW,BBG000C18861,Anavex Life Sciences Corp. (AVXL) Scores Big on Biogen Test,2016-09-28 21:22:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aOeqOuQfeEo/anavex-life-sciences-corp-avxl-scores-big-on-biogen-test-cm686235,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Anavex Life Sciences Corp 160 NASDAQ AVXL is up 44 on news that Biogen Inc 160 NASDAQ BIIB would test one of its compounds in a
BIIB,BIIB:UW,BBG000C18861,"Health Care Sector Update for 09/28/2016: ATHX, AVXL, BIIB, GALT",2016-09-28 20:21:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WMf1V5DEubI/health-care-sector-update-for-09282016-athx-avxl-biib-galt-cm686202,Top Health Care StocksTop Health Care Stocks JNJ 0 11 JNJ 0 11 PFE 0 43 PFE 0 43 MRK 0 05 MRK 0 05 ABT 1 25 ABT 1 25 AMGN 1 08 AMGN 1 08 Health care stocks were narrowly mixed this afternoon with the NYSE Health Care Index posting a less than 0 1 gain while shares of health
BIIB,BIIB:UW,BBG000C18861,Newbie Anavex Rockets On Testing Deal With IBD 50 Stock Biogen,2016-09-28 20:12:53 +0000,http://www.investors.com/news/technology/newbie-anavex-rockets-on-testing-deal-with-ibd-50-stock-biogen/,Newbie Anavex Rockets On Testing Deal With IBD 50 Stock Biogen
BIIB,BIIB:UW,BBG000C18861,Why Anavex Life Sciences Corp. Rocketed Higher Today,2016-09-28 19:22:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eXmlQ0M1Bg8/why-anavex-life-sciences-corp-rocketed-higher-today-cm686161,Image source Getty Images What happened Tiny biotech Anavex Life Sciences NASDAQ AVXL got a little bigger today after announcing 160 that Biogen NASDAQ BIIB 160 will test the company s lead drug candidate ANAVEX 2 73 in a preclinical assay Shares of Anavex
BIIB,BIIB:UW,BBG000C18861,"Health Care Sector Update for 09/28/2016: VSAR,AVXL,BIIB,GALT",2016-09-28 17:41:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6fxFGNrAdh8/health-care-sector-update-for-09282016-vsaravxlbiibgalt-cm686107,Top Health Care StocksTop Health Care Stocks JNJ 0 13 JNJ 0 13 PFE 0 27 PFE 0 27 MRK 0 81 MRK 0 81 ABT 0 46 ABT 0 46 AMGN 1 03 AMGN 1 03 Health care stocks were declining this afternoon with the NYSE Health Care Index posting a 0 2 retreat while shares of health care companies
BIIB,BIIB:UW,BBG000C18861,Instant Analysis: Biogen's Agreement With Anavex Life Sciences,2016-09-28 17:26:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FIk7mXte2PM/instant-analysis-biogens-agreement-with-anavex-life-sciences-cm686050,Image source Getty Images What happened This morning Anavex Life Sciences NASDAQ AVXL announced an agreement with Biogen NASDAQ BIIB concerning the latter s only clinical stage candidate Anavex 2 73 160 Biogen will conduct a laboratory study with 2 73 in cultures
BIIB,BIIB:UW,BBG000C18861,Why Anavex Life Sciences Corp. Rocketed Higher Today,2016-09-28 17:18:39 +0000,http://www.fool.com/investing/2016/09/28/why-anavex-life-sciences-corp-rocketed-higher-toda.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Anavex Life Sciences Corp. Rocketed Higher Today
BIIB,BIIB:UW,BBG000C18861,Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis?,2016-09-28 16:22:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hjoTupSpWlQ/will-celgene-depose-biogen-to-become-top-dog-in-multiple-sclerosis-cm685978,Image source 160 https www pexels com photo black and white people bar men 4417 In July 2015 Celgene NASDAQ CELG made headlines with its 7 2 billion acquisition of Receptos mainly in order to get its hands on Receptos lead autoimmune candidate ozanimod
BIIB,BIIB:UW,BBG000C18861,Instant Analysis: Biogen's Agreement With Anavex Life Sciences,2016-09-28 15:45:00 +0000,http://www.fool.com/investing/2016/09/28/instant-analysis-biogens-agreement-with-anavex-lif.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Instant Analysis: Biogen's Agreement With Anavex Life Sciences
BIIB,BIIB:UW,BBG000C18861,Anavex Soars on Biogen Agreement,2016-09-28 15:15:12 +0000,http://finance.yahoo.com/news/anavex-soars-biogen-agreement-151512804.html,Anavex Soars on Biogen Agreement
BIIB,BIIB:UW,BBG000C18861,Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis?,2016-09-28 15:01:00 +0000,http://www.fool.com/investing/2016/09/28/will-celgene-depose-biogen-to-become-top-dog-in-mu.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Will Celgene Depose Biogen to Become Top Dog In Multiple Sclerosis?
BIIB,BIIB:UW,BBG000C18861,"ETF’s with exposure to Biogen, Inc. : September 28, 2016",2016-09-28 13:39:55 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-biogen-inc-september-28-2016/,"ETF’s with exposure to Biogen, Inc. : September 28, 2016"
BIIB,BIIB:UW,BBG000C18861,Anavex Compound to be Tested in Biogen Neurological Protection Model,2016-09-28 11:00:00 +0000,http://finance.yahoo.com/news/anavex-compound-tested-biogen-neurological-110000078.html,"[GlobeNewswire] - NEW YORK, Sept. 28, 2016-- Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases ..."
BIIB,BIIB:UW,BBG000C18861,Ionis/Biogen Complete Nusinersen NDA Submission in U.S.,2016-09-27 16:25:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lIVWqGO71Iw/ionisbiogen-complete-nusinersen-nda-submission-in-us-cm685388,Ionis Pharmaceuticals Inc IONS announced that its partner Biogen Inc BIIB has completed the rolling submission of a New Drug Application NDA for nusinersen in the U S for the treatment of spinal muscular atrophy SMA In addition Biogen has requested the FDA for Priority Review of
BIIB,BIIB:UW,BBG000C18861,Ionis/Biogen Complete Nusinersen NDA Submission in U.S.,2016-09-27 14:12:02 +0000,http://finance.yahoo.com/news/ionis-biogen-complete-nusinersen-nda-141202017.html,Ionis/Biogen Complete Nusinersen NDA Submission in U.S.
BIIB,BIIB:UW,BBG000C18861,Short Sellers Increase Bets in Major Biotechs,2016-09-27 11:50:26 +0000,http://247wallst.com/healthcare-business/2016/09/27/short-sellers-increase-bets-in-major-biotechs-5/,Short Sellers Increase Bets in Major Biotechs
BIIB,BIIB:UW,BBG000C18861,"Notable ETF Outflow Detected - MOAT, BIIB, TIF, STT",2016-09-26 16:23:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ADvRfdDm1Uw/notable-etf-outflow-detected-moat-biib-tif-stt-cm684510,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Morningstar Wide Moat ETF Symbol MOAT where we have detected an approximate 35 8 million dollar outflow that s a 4 5 decrease week over week from 23 100
BIIB,BIIB:UW,BBG000C18861,The Implied Analyst 12-Month Target For IWL,2016-09-26 15:22:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TTQwJ6mw-K0/the-implied-analyst-12-month-target-for-iwl-cm684435,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the
BIIB,BIIB:UW,BBG000C18861,Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy,2016-09-26 12:39:05 +0000,http://www.publicnow.com/view/A6FEE5726FC279ED7F20778BF168DD10AA547805,"[at noodls] - CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) and Ionis (NASDAQ:IONS) today announced that Biogen has completed the rolling submission of a New Drug Application (NDA) to the ..."
BIIB,BIIB:UW,BBG000C18861,"[$$] Rodin Therapeutics, a Neurology Drug Firm, Expands Management Team",2016-09-23 23:35:33 +0000,http://www.wsj.com/articles/rodin-therapeutics-a-neurology-drug-firm-expands-management-team-1474673731?mod=yahoo_hs,"[$$] Rodin Therapeutics, a Neurology Drug Firm, Expands Management Team"
BIIB,BIIB:UW,BBG000C18861,"Top 5 profitable Biotech stocks : September 23, 2016",2016-09-23 15:38:52 +0000,http://www.capitalcube.com/blog/index.php/top-5-profitable-biotech-stocks-september-23-2016/,"Top 5 profitable Biotech stocks : September 23, 2016"
BIIB,BIIB:UW,BBG000C18861,"Biogen Bets on Nusinersen (BIIB, IONS)",2016-09-22 18:00:00 +0000,http://www.investopedia.com/news/biogen-bets-nusinersen-biib-ions/?partner=YahooSA,"Biogen Bets on Nusinersen (BIIB, IONS)"
BIIB,BIIB:UW,BBG000C18861,Moves in Cancer Therapeutics among Recent Developments for Ionis,2016-09-22 12:04:37 +0000,http://marketrealist.com/2016/09/moves-in-cancer-therapeutics-among-recent-developments-for-ionis/?utm_source=yahoo&utm_medium=feed,Moves in Cancer Therapeutics among Recent Developments for Ionis
BIIB,BIIB:UW,BBG000C18861,"Stock Market News for September 21, 2016",2016-09-21 16:25:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6tHh0bgiaSs/stock-market-news-for-september-21-2016-cm682704,Benchmarks finished slightly higher on Tuesday ahead of the two day policy meetings of the Fed and Bank of Japan BOJ ending today Inventors eagerly awaited any major policy decisions from the two central banks Moreover gains in healthcare stocks offset declines in energy stocks
BIIB,BIIB:UW,BBG000C18861,"Amazon (AMZN), Charter Communications (CHTR) And 3 Other Hot Stocks That Billionaire Ken Griffin Is Bullish On",2016-09-21 15:55:02 +0000,http://www.insidermonkey.com/blog/amazon-amzn-charter-communications-chtr-and-3-other-hot-stocks-that-billionaire-ken-griffin-is-bullish-on-475976/,"Amazon (AMZN), Charter Communications (CHTR) And 3 Other Hot Stocks That Billionaire Ken Griffin Is Bullish On"
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug",2016-09-21 14:25:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zMySh2T-KSs/biotech-stock-roundup-tobira-soars-on-acquisition-deal-fda-says-yes-to-sarepta-dmd-drug-cm682518,It was an exceptionally good week for the biotech sector with the market reacting positively to pharma company Allergan s acquisition deals with biotech stocks Expectations are that more such deals will be announced with biotech companies like ARIAD seeing their shares prices increasing
BIIB,BIIB:UW,BBG000C18861,Trade of the Day: iShares Nasdaq Biotechnology Index (ETF) (IBB) Is Turning Things Around,2016-09-21 14:22:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7IIqsxX6-Zk/trade-of-the-day-ishares-nasdaq-biotechnology-index-etf-ibb-is-turning-things-around-cm682508,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips iShares Nasdaq Biotechnology Index ETF NASDAQ IBB This exchange traded fund ETF tracks the NASDAQ Biotechnology Index It invests 90 of its assets in stocks of
BIIB,BIIB:UW,BBG000C18861,Gilead Sciences: Allergan's Next Target?,2016-09-21 13:38:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/21/gilead-sciences-allergans-next-target/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: Allergan's Next Target?
BIIB,BIIB:UW,BBG000C18861,Orphan Drug Designation among Latest Happenings at Ionis,2016-09-21 12:04:59 +0000,http://marketrealist.com/2016/09/orphan-drug-designation-among-latest-happenings-at-ionis/?utm_source=yahoo&utm_medium=feed,Orphan Drug Designation among Latest Happenings at Ionis
BIIB,BIIB:UW,BBG000C18861,Stocks Close Barely Higher Ahead Of Fed Announcement; Biotechs Aid Nasdaq,2016-09-20 19:01:44 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-higher-ahead-of-fed-surging-biotechs-give-nasdaq-a-boost/,Stocks Close Barely Higher Ahead Of Fed Announcement; Biotechs Aid Nasdaq
BIIB,BIIB:UW,BBG000C18861,"3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition",2016-09-20 18:01:38 +0000,http://www.fool.com/investing/2016/09/19/3-ways-ionis-pharmaceuticals-inc-is-beating-the-co.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition"
BIIB,BIIB:UW,BBG000C18861,"Perrigo Could Rake In $2.8 Billion in Tysabri Divestitures, Analysts Say",2016-09-20 14:20:00 +0000,https://www.thestreet.com/story/13744540/1/perrigo-could-rake-in-2-8-billion-in-tysabri-divestitures-analysts-say.html?puc=yahoo&cm_ven=YAHOO,"Perrigo Could Rake In $2.8 Billion in Tysabri Divestitures, Analysts Say"
BIIB,BIIB:UW,BBG000C18861,Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen,2016-09-20 13:05:00 +0000,https://www.thestreet.com/story/13744610/1/applied-genetic-technologies-is-an-attractive-acquisition-target-for-allergan-or-biogen.html?puc=yahoo&cm_ven=YAHOO,Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen
BIIB,BIIB:UW,BBG000C18861,"3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition",2016-09-20 11:21:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G9gnf7EerNs/3-ways-ionis-pharmaceuticals-inc-is-beating-the-competition-cm681515,Image source Getty Images There are quite a few players on the field developing RNA based therapies along with Ionis Pharmaceuticals NASDAQ IONS Its biggest competitors Alnylam Pharmaceuticals NASDAQ ALNY Arrowhead Pharmaceuticals and privately held
BIIB,BIIB:UW,BBG000C18861,Could This Alzheimer’s Disease Drug Really Be Worth $20 Billion?,2016-09-19 18:22:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AumUEQoW84E/could-this-alzheimers-disease-drug-really-be-worth-20-billion-cm681485,Biogen s NASDAQ BIIB 160 plaque busting Alzheimer s disease AD drug candidate aducanumab could represent a jaw dropping 20 billion peak commercial opportunity for the company and its shareholders Putting this monstrous figure into context this experimental medicine has
BIIB,BIIB:UW,BBG000C18861,Could This Alzheimer’s Disease Drug Really Be Worth $20 Billion?,2016-09-19 17:16:18 +0000,http://www.fool.com/investing/2016/09/19/could-this-alzheimers-disease-drug-really-be-worth.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Could This Alzheimer’s Disease Drug Really Be Worth $20 Billion?
BIIB,BIIB:UW,BBG000C18861,"Marijuana Could Be the Answer to Curing Alzheimer's Disease, Study Shows",2016-09-18 14:20:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fEXbPhnYUkc/marijuana-could-be-the-answer-to-curing-alzheimers-disease-study-shows-cm680993,Image source Getty Images The statistics associated with Alzheimer s disease are downright depressing The disease which typically affects the elderly and is characterized by a progressive decline in cognitive function currently afflicts 5 4 million Americans and the Alzheimer
BIIB,BIIB:UW,BBG000C18861,Is This New Market the Biggest Investment Idea of the Decade?,2016-09-17 17:20:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o9nhQMEtSno/is-this-new-market-the-biggest-investment-idea-of-the-decade-cm680951,Image source Stockmonkeys com via Flickr Over 100 billion in annual sales for top selling biologic medicines will soon be up for grabs and that s leading to a gold rush to develop biosimilars With the biosimilar market poised to eclipse 20 billion as early as 2020 you might
BIIB,BIIB:UW,BBG000C18861,Is This New Market the Biggest Investment Idea of the Decade?,2016-09-17 15:41:06 +0000,http://www.fool.com/investing/2016/09/17/is-this-new-market-the-biggest-investment-idea-of.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is This New Market the Biggest Investment Idea of the Decade?
BIIB,BIIB:UW,BBG000C18861,SPDR S&P Biotech (ETF) (XBI): The Bears Got Nothin’ on Biotech Stocks,2016-09-16 17:19:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DC-w683vvsQ/spdr-sp-biotech-etf-xbi-the-bears-got-nothin-on-biotech-stocks-cm680136,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Despite the recent drubbing in stock land buyers remain in control of a few select areas One place in which their dominance is undeniable is the biotech space Indeed biotech
BIIB,BIIB:UW,BBG000C18861,3 Stocks to Trade Now for New Year’s Profits,2016-09-16 17:19:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f0NLPD19sBE/3-stocks-to-trade-now-for-new-years-profits-cm680166,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Wall Street has been fretting about whether the Federal Reserve will raise rates a second time 160 The consensus on this matter has flip flopped from one extreme conviction to another taking markets
BIIB,BIIB:UW,BBG000C18861,Biogen: You Mean There's Hope?,2016-09-16 14:53:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/16/biogen-you-mean-theres-hope/?mod=yahoobarrons&ru=yahoo,Biogen: You Mean There's Hope?
BIIB,BIIB:UW,BBG000C18861,"Stock Market News for September 15, 2016",2016-09-15 16:19:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pi7P7pqwATE/stock-market-news-for-september-15-2016-cm680034,Both the Dow and the S amp P 500 closed in the red on Wednesday thanks to a slump in crude oil prices Rise in U S stockpiles of refined products and Libya s plan to resume oil shipments weighed on oil prices The Nasdaq however defied the declining trend and closed in the
BIIB,BIIB:UW,BBG000C18861,New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile,2016-09-15 11:38:05 +0000,http://www.publicnow.com/view/3D4CCDD1DE6F313D2C6086D2F1C296065896A46A,"[at noodls] - CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA (daclizumab) achieved ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Reveals Positive Result For Phase 3 Trial Of Zinbryta In MS Patients,2016-09-15 07:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CmRV9C9umAY/biogen-reveals-positive-result-for-phase-3-trial-of-zinbryta-in-ms-patients-20160915-00285,Biogen Reveals Positive Result For Phase 3 Trial Of Zinbryta In MS Patients
BIIB,BIIB:UW,BBG000C18861,"Biogen to Report Third Quarter 2016 Financial Results on October 26, 2016",2016-09-14 20:08:02 +0000,http://www.publicnow.com/view/BAE4437B32932F830960BE2D79AF6E1BE868A7CF,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2016 financial results on Wednesday, October 26, 2016, before the financial markets open. ... This ..."
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News",2016-09-14 14:50:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iabmjE1dFeI/biotech-stock-roundup-horizon-raptor-acquisition-deal-geron-down-on-pipeline-news-cm679340,The biotech sector is in the news for mergers and acquisitions with Horizon HZNP announcing that it will be acquiring Raptor RPTP Meanwhile companies like Geron GERN and Lexicon LXRX provided updates on key pipeline candidates Recap of the Week s Most Important Stories
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Stock Gains on Positive Multiple Sclerosis Drug Data,2016-09-14 13:47:00 +0000,https://www.thestreet.com/story/13728545/1/biogen-biib-stock-gains-on-positive-multiple-sclerosis-drug-data.html?puc=yahoo&cm_ven=YAHOO,Biogen (BIIB) Stock Gains on Positive Multiple Sclerosis Drug Data
BIIB,BIIB:UW,BBG000C18861,New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting,2016-09-14 11:48:07 +0000,http://www.publicnow.com/view/21291AD95DA7267B7DEBFBD2E8E33F2176068901,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--New real-world and clinical evidence demonstrates that TECFIDERA (dimethyl fumarate) consistently delivered strong, sustained efficacy in newly-diagnosed and previously ..."
BIIB,BIIB:UW,BBG000C18861,Biogen reports positive new data for multiple sclerosis treatment,2016-09-14 11:42:53 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=675C3B5C-76F8-4596-9CA7-F25F6B6F1E82&siteid=yhoof2,Biogen reports positive new data for multiple sclerosis treatment
BIIB,BIIB:UW,BBG000C18861,"Biogen Reveales Efficacy, Safety Data For Tecfidera In MS Trials",2016-09-14 08:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JFiSqFMAQh0/biogen-reveales-efficacy-safety-data-for-tecfidera-in-ms-trials-20160914-00364,"Biogen Reveales Efficacy, Safety Data For Tecfidera In MS Trials"
BIIB,BIIB:UW,BBG000C18861,"Perrigo Up as Starboard Reveals Stake, Changes Proposed",2016-09-13 22:46:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ivSdYdNg8lY/perrigo-up-as-starboard-reveals-stake-changes-proposed-cm679095,Perrigo Company plc s PRGO shares gained 7 4 after the New York based activist investor Starboard Value LP revealed in a letter its 4 6 stake in the company making it one of Perrigo s largest shareholders In a letter dated Sep 12 2016 Starboard Managing Member Jeffrey C Smith
BIIB,BIIB:UW,BBG000C18861,Applied Genetics’ stock suffers record plunge to record low,2016-09-13 20:10:08 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=778E110A-79DC-11E6-B4BF-3713D53E66F6&siteid=yhoof2,Applied Genetics’ stock suffers record plunge to record low
BIIB,BIIB:UW,BBG000C18861,Why Applied Genetic Technologies Corp. Is Tanking Today,2016-09-13 19:47:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ii2dLqia_MA/why-applied-genetic-technologies-corp-is-tanking-today-cm678989,Image source Getty Images What happened Shareholders of Applied Genetic Technologies NASDAQ AGTC a clinical stage biotech focused on genetic ophthalmologic diseases 160 are having a rough day The company s stock is being bludgeoned down more than 32 as of 11 15 a m
BIIB,BIIB:UW,BBG000C18861,Why Applied Genetic Technologies Corp. Is Tanking Today,2016-09-13 17:45:59 +0000,http://www.fool.com/investing/2016/09/13/why-applied-genetic-technologies-corp-is-tanking-t.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Applied Genetic Technologies Corp. Is Tanking Today
BIIB,BIIB:UW,BBG000C18861,Biogen Committed to Bolstering Its Strong Product Pipeline,2016-09-13 14:04:21 +0000,http://marketrealist.com/2016/09/biogen-committed-to-bolstering-its-strong-product-pipeline/?utm_source=yahoo&utm_medium=feed,Biogen Committed to Bolstering Its Strong Product Pipeline
BIIB,BIIB:UW,BBG000C18861,"Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for September 14, 2016",2016-09-13 13:16:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TEoM5SydGXs/gilead-sciences-inc-gild-ex-dividend-date-scheduled-for-september-14-2016-cm678549,Gilead Sciences Inc GILD will begin trading ex dividend on September 14 2016 A cash dividend payment of 0 47 per share is scheduled to be paid on September 29 2016 Shareholders who purchased GILD prior to the ex dividend date are eligible for the cash dividend payment This
BIIB,BIIB:UW,BBG000C18861,Product Launches Are Part of Biogen’s Plans to Boost Revenues,2016-09-13 12:04:31 +0000,http://marketrealist.com/2016/09/product-launches-are-part-of-biogens-plans-to-boost-revenues/?utm_source=yahoo&utm_medium=feed,Product Launches Are Part of Biogen’s Plans to Boost Revenues
BIIB,BIIB:UW,BBG000C18861,Short Sellers Run for Cover From Major Biotechs,2016-09-13 11:05:22 +0000,http://247wallst.com/healthcare-business/2016/09/13/short-sellers-run-for-cover-from-major-biotechs-9/,Short Sellers Run for Cover From Major Biotechs
BIIB,BIIB:UW,BBG000C18861,Traders pick biotech stocks as sector sees best day in months,2016-09-12 22:45:36 +0000,http://www.cnbc.com/id/103934092?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=103934092,Traders pick biotech stocks as sector sees best day in months
BIIB,BIIB:UW,BBG000C18861,Buying biotech: 5 trades in pharma,2016-09-12 21:00:00 +0000,http://finance.yahoo.com/video/buying-biotech-5-trades-pharma-210000476.html,Buying biotech: 5 trades in pharma
BIIB,BIIB:UW,BBG000C18861,How the Tides Are Turning in Alzheimer's Research,2016-09-12 20:10:00 +0000,http://www.fool.com/investing/2016/09/12/how-the-tides-are-shifting-in-alzheimers-research.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How the Tides Are Turning in Alzheimer's Research
BIIB,BIIB:UW,BBG000C18861,Biotech: Four Catalysts for Four Stocks,2016-09-12 19:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/12/biotech-four-catalysts-for-four-stocks/?mod=yahoobarrons&ru=yahoo,Biotech: Four Catalysts for Four Stocks
BIIB,BIIB:UW,BBG000C18861,How the Tides Are Turning in Alzheimer's Research,2016-09-12 18:32:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dq_227I0xcg/how-the-tides-are-turning-in-alzheimers-research-cm678162,Image source Getty Images Here s how James Lah the lead researcher for the Alzheimer s Research Center at Emory explains what s coming in Alzheimer s disease The baby boomers are now turning 65 at the rate of 10 000 a day And one in nine of that 10 000 is going to have
BIIB,BIIB:UW,BBG000C18861,"After Spinning Off Hemophilia Business, What’s Next for Biogen?",2016-09-12 15:04:29 +0000,http://marketrealist.com/2016/09/after-spinning-off-hemophilia-business-whats-next-for-biogen/?utm_source=yahoo&utm_medium=feed,"After Spinning Off Hemophilia Business, What’s Next for Biogen?"
BIIB,BIIB:UW,BBG000C18861,What’s behind Biogen Buyout Rumors?,2016-09-12 14:04:37 +0000,http://marketrealist.com/2016/09/whats-behind-biogen-buyout-rumors/?utm_source=yahoo&utm_medium=feed,What’s behind Biogen Buyout Rumors?
BIIB,BIIB:UW,BBG000C18861,Biogen To Present At Morgan Stanley Healthcare Conference; Webcast At 1:40 PM ET,2016-09-12 12:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WknVMjMZOxc/biogen-to-present-at-morgan-stanley-healthcare-conference-webcast-at-140-pm-et-20160912-00829,Biogen To Present At Morgan Stanley Healthcare Conference; Webcast At 1:40 PM ET
BIIB,BIIB:UW,BBG000C18861,Market Cheers FDA’s Fast Tracking of BIIB’s Alzheimer’s Treatment,2016-09-12 12:04:42 +0000,http://marketrealist.com/2016/09/market-cheers-fdas-fast-tracking-of-biibs-alzheimers-treatment/?utm_source=yahoo&utm_medium=feed,Market Cheers FDA’s Fast Tracking of BIIB’s Alzheimer’s Treatment
BIIB,BIIB:UW,BBG000C18861,Samsung Bioepis' SB4 (BRENZYS™) Becomes First Etanercept Biosimilar to Receive Regulatory Approval in Canada,2016-09-12 12:00:00 +0000,http://au.finance.yahoo.com/news/samsung-bioepis-sb4-brenzys-becomes-120000198.html,"[Business Wire] - INCHEON, Korea--(BUSINESSWIRE)-- Samsung Bioepis Co., Ltd. today announced that BRENZYS ™ – a biosimilar referencing Enbrel ® (etanercept), also known as SB4 – received regulatory approval in Canada for ..."
BIIB,BIIB:UW,BBG000C18861,Google Parent and Sanofi Name Diabetes Joint Venture Onduo,2016-09-12 02:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x2kBnDAmZ9U/google-parent-and-sanofi-name-diabetes-joint-venture-onduo-20160912-00040,Google Parent and Sanofi Name Diabetes Joint Venture Onduo
BIIB,BIIB:UW,BBG000C18861,Market Watches to See if Biogen Will Meet Its Raised Guidance,2016-09-09 19:04:10 +0000,http://marketrealist.com/2016/09/market-watches-to-see-if-biogen-will-meet-its-raised-guidance/?utm_source=yahoo&utm_medium=feed,Market Watches to See if Biogen Will Meet Its Raised Guidance
BIIB,BIIB:UW,BBG000C18861,Here Are the Latest Analyst Recommendations for Biogen,2016-09-09 18:04:12 +0000,http://marketrealist.com/2016/09/here-are-the-latest-analyst-recommendations-for-biogen/?utm_source=yahoo&utm_medium=feed,Here Are the Latest Analyst Recommendations for Biogen
BIIB,BIIB:UW,BBG000C18861,Biogen Launches Flixabi To Raise Stakes In Biosimilar Wars (BIIB),2016-09-09 16:53:00 +0000,http://www.investopedia.com/news/biogen-launches-flixabi-raise-stakes-biosimilar-wars-biib/?partner=YahooSA,Biogen Launches Flixabi To Raise Stakes In Biosimilar Wars (BIIB)
BIIB,BIIB:UW,BBG000C18861,Biogen’s Latest Valuation Compared to Its Peers,2016-09-09 15:37:10 +0000,http://marketrealist.com/2016/09/biogens-latest-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,Biogen’s Latest Valuation Compared to Its Peers
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: SWKS, STX",2016-09-09 15:31:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g9qb5hHYRGY/nasdaq-100-movers-swks-stx-cm676941,In early trading on Friday shares of Seagate Technology topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 0 Year to date Seagate Technology registers a 2 0 gain And the worst performing Nasdaq 100 component thus far on the day is
BIIB,BIIB:UW,BBG000C18861,Biogen: Be Like Celgene?,2016-09-08 18:53:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/08/biogen-be-like-celgene/?mod=yahoobarrons&ru=yahoo,Biogen: Be Like Celgene?
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Gilead Sciences,2016-09-08 17:23:42 +0000,http://www.fool.com/investing/2016/09/08/better-buy-biogen-inc-vs-gilead-sciences.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Biogen Inc. vs. Gilead Sciences
BIIB,BIIB:UW,BBG000C18861,Better Buy: Biogen Inc. vs. Gilead Sciences,2016-09-08 16:19:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N1FSF96Mc48/better-buy-biogen-inc-vs-gilead-sciences-cm676304,Image source Getty Images A closer look at Biogen s NASDAQ BIIB most exciting asset recently caught the attention of the wider public while Gilead Sciences NASDAQ GILD hepatitis C virus HCV treatment sales have been sliding Both have provided enormous returns to
BIIB,BIIB:UW,BBG000C18861,"IXJ, MDT, LLY, BIIB: Large Outflows Detected at ETF",2016-09-08 16:17:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dDjQ0tR2BLA/ixj-mdt-lly-biib-large-outflows-detected-at-etf-cm676269,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Global Healthcare ETF Symbol IXJ where we have detected an approximate 35 7 million dollar outflow that s a 2 2 decrease week over week
BIIB,BIIB:UW,BBG000C18861,Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio,2016-09-08 11:39:02 +0000,http://www.publicnow.com/view/CB28784242ADF3300C734750FCE0A25554C0FEAD,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--New research collected from more than 16,000 multiple sclerosis (MS) patients across Europe, in the largest study to capture the widespread impact of the disease, along ..."
BIIB,BIIB:UW,BBG000C18861,GW Pharmaceuticals PLC- ADR (GWPH) Boards the Buyout Rumor Mill,2016-09-07 23:17:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aHRi_zDMMpE/gw-pharmaceuticals-plc-adr-gwph-boards-the-buyout-rumor-mill-cm675939,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips GW Pharmaceuticals PLC ADR 160 NASDAQ GWPH finished 23 higher 160 on seven times its typical volume Wednesday after buyout rumors emerged
BIIB,BIIB:UW,BBG000C18861,Celgene’s Enterprise Value to Earnings in Line with Peers,2016-09-07 18:04:08 +0000,http://marketrealist.com/2016/09/celgenes-enterprise-value-to-earnings-in-line-with-peers/?utm_source=yahoo&utm_medium=feed,Celgene’s Enterprise Value to Earnings in Line with Peers
BIIB,BIIB:UW,BBG000C18861,5 Stocks to Buy for September,2016-09-07 17:20:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tMEXBQ2aoaQ/5-stocks-to-buy-for-september-cm675293,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips September is the market s cruelest month but that doesn t mean tactical investors can t find stocks to buy that are poised to deliver short term upside Since 1928 the S amp P 500 has logged an
BIIB,BIIB:UW,BBG000C18861,Understanding Celgene’s Premium PE Valuation,2016-09-07 15:41:18 +0000,http://marketrealist.com/2016/09/understanding-celgenes-premium-pe-valuation/?utm_source=yahoo&utm_medium=feed,Understanding Celgene’s Premium PE Valuation
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled",2016-09-07 15:21:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oik0MnvC884/biotech-stock-roundup-colucid-soars-on-migraine-data-dynavax-drug-fda-panel-meeting-cancelled-cm675560,It was a relatively slow week for the biotech sector though companies like CoLucid CLCD and Dynavax DVAX came out with important pipeline updates Recap of the Week s Most Important Stories CoLucid Hits 52 Week High on Positive Migraine Data CoLucid s shares shot up 123 6
BIIB,BIIB:UW,BBG000C18861,These Stocks are Predicted to Outperform this Week According to Forcerank,2016-09-07 15:10:42 +0000,http://finance.yahoo.com/tumblr/blog-these-stocks-are-predicted-to-outperform-this-week-151045724.html,These Stocks are Predicted to Outperform this Week According to Forcerank
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled",2016-09-07 13:30:01 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-colucid-soars-133001542.html,"Biotech Stock Roundup: CoLucid Soars on Migraine Data, Dynavax Drug FDA Panel Meeting Cancelled"
BIIB,BIIB:UW,BBG000C18861,"Activision Hits High On Analyst Call, Qualcomm PT Hiked, Intel Upgraded, Biogen Cut",2016-09-06 20:51:23 +0000,http://www.investors.com/news/qualcomm-activison-pt-raised-intel-upgraded-biogen-downgraded/,"Activision Hits High On Analyst Call, Qualcomm PT Hiked, Intel Upgraded, Biogen Cut"
BIIB,BIIB:UW,BBG000C18861,"3 Stocks to Watch Tuesday: Monsanto Company (MON), Biogen Inc (BIIB) and Navistar International Corp (NAV)",2016-09-06 19:18:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SLrw6N4auqs/3-stocks-to-watch-tuesday-monsanto-company-mon-biogen-inc-biib-and-navistar-international-corp-nav-cm675166,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Oil prices were the weekend s big news as Saudi Arabia and Russia made a deal to stabilize the market helping the commodity 160 surge as much as 5 It was also a good day for the yen
BIIB,BIIB:UW,BBG000C18861,SPDR Gold Trust (ETF) (GLD) Is Ready to Rally,2016-09-06 19:18:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f5whXVBCJlo/spdr-gold-trust-etf-gld-is-ready-to-rally-cm675163,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Last Friday s August jobs report came in below analyst expectations however 160 markets reacted in a fairly muted fashion 160 But gold as represented by the popular 160 SPDR
BIIB,BIIB:UW,BBG000C18861,"4 Stocks, 4 trades: GT, MDLZ & more",2016-09-06 16:31:00 +0000,http://finance.yahoo.com/video/4-stocks-4-trades-gt-163100575.html,"4 Stocks, 4 trades: GT, MDLZ & more"
BIIB,BIIB:UW,BBG000C18861,Gilead Sciences: Why is This Upgrade Different from All Other Upgrades?,2016-09-06 14:08:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/06/gilead-sciences-why-is-this-upgrade-different-from-all-other-upgrades/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: Why is This Upgrade Different from All Other Upgrades?
BIIB,BIIB:UW,BBG000C18861,Here's what you missed on your summer vacation in life science news,2016-09-06 13:30:11 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/09/heres-what-you-missed-on-your-summer-vacation-in.html?ana=yahoo,Here's what you missed on your summer vacation in life science news
BIIB,BIIB:UW,BBG000C18861,"Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Devon Energy, Gilead, Mondelez, Urban Outfitters and More",2016-09-06 12:55:24 +0000,http://247wallst.com/investing/2016/09/06/top-analyst-upgrades-and-downgrades-biogen-broadcom-devon-energy-gilead-mondelez-urban-outfitters-and-more/,"Top Analyst Upgrades and Downgrades: Biogen, Broadcom, Devon Energy, Gilead, Mondelez, Urban Outfitters and More"
BIIB,BIIB:UW,BBG000C18861,"Biogen (BIIB) Stock Lower, Downgraded at Jefferies",2016-09-06 11:50:00 +0000,https://www.thestreet.com/story/13694292/1/biogen-biib-stock-lower-downgraded-at-jefferies.html?puc=yahoo&cm_ven=YAHOO,"Biogen (BIIB) Stock Lower, Downgraded at Jefferies"
BIIB,BIIB:UW,BBG000C18861,Is Biogen's Rough Ride Over?,2016-09-06 11:40:00 +0000,https://www.thestreet.com/story/13694059/1/is-biogen-s-rough-ride-over.html?puc=yahoo&cm_ven=YAHOO,Is Biogen's Rough Ride Over?
BIIB,BIIB:UW,BBG000C18861,Why Pfizer’s Enbrel Faces a Sales Decline,2016-09-05 12:04:05 +0000,http://marketrealist.com/2016/08/why-pfizers-enbrel-faces-a-sales-decline/?utm_source=yahoo&utm_medium=feed,Why Pfizer’s Enbrel Faces a Sales Decline
BIIB,BIIB:UW,BBG000C18861,Is Biogen a Worthwhile Buyout Candidate?,2016-09-04 16:05:34 +0000,http://www.fool.com/investing/2016/09/03/is-biogen-a-worthwhile-buyout-candidate.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Biogen a Worthwhile Buyout Candidate?
BIIB,BIIB:UW,BBG000C18861,"Health Care Sector Update for 09/02/2016: BIIB,ATEC,GMED,ELTP",2016-09-02 17:56:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6SOwi1d_e08/health-care-sector-update-for-09022016-biibatecgmedeltp-cm674252,Top Health Care StocksTop Health Care Stocks JNJ 0 05 JNJ 0 05 PFE 0 16 PFE 0 16 MRK 0 69 MRK 0 69 ABT 0 14 ABT 0 14 AMGN 0 55 AMGN 0 55 Health care stocks were mostly trading on the plus side today with the NYSE Health Care Index climbing about 0 4 while shares of health
BIIB,BIIB:UW,BBG000C18861,Time to look at biotechs?,2016-09-02 17:03:00 +0000,http://finance.yahoo.com/video/time-look-biotechs-170300197.html,Time to look at biotechs?
BIIB,BIIB:UW,BBG000C18861,"Nasdaq 100 Movers: AVGO, BIIB",2016-09-02 16:19:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lrE4GRwDeyY/nasdaq-100-movers-avgo-biib-cm674103,In early trading on Friday shares of Biogen BIIB topped the list of the day s best performing components of the Nasdaq 100 index trading up 3 5 Year to date Biogen registers a 3 4 gain And the worst performing Nasdaq 100 component thus far on the day is Broadcom AVGO
BIIB,BIIB:UW,BBG000C18861,Biogen: On the Fast Track,2016-09-02 15:27:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/02/biogen-on-the-fast-track/?mod=yahoobarrons&ru=yahoo,Biogen: On the Fast Track
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.,2016-09-02 15:22:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kan0jl6ecWc/biogen-biib-aducanumab-gets-fast-track-status-in-the-us-cm673990,Biogen Inc BIIB announced that the FDA has granted Fast Track designation for its investigational therapy aducanumab for the treatment of early stage Alzheimer s disease AD We note that the FDA grants Fast Track status to facilitate the development and expedite the review process
BIIB,BIIB:UW,BBG000C18861,"Biogen (BIIB) Stock Climbs, Alzheimer's Treatment Gets Fast-Track Designation",2016-09-02 13:40:00 +0000,https://www.thestreet.com/story/13693223/1/biogen-biib-stock-climbs-alzheimer-s-treatment-gets-fast-track-designation.html?puc=yahoo&cm_ven=YAHOO,"Biogen (BIIB) Stock Climbs, Alzheimer's Treatment Gets Fast-Track Designation"
BIIB,BIIB:UW,BBG000C18861,Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.,2016-09-02 13:33:01 +0000,http://finance.yahoo.com/news/biogen-biib-aducanumab-gets-fast-133301919.html,Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status,2016-09-01 22:53:41 +0000,http://www.wsj.com/articles/biogens-alzheimers-therapy-granted-fda-fast-track-status-1472769993?mod=yahoo_hs,[$$] Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status
BIIB,BIIB:UW,BBG000C18861,Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation,2016-09-01 20:13:05 +0000,http://www.publicnow.com/view/D0E1655ACD7C7D0E53587494CDB6680DA81EC9ED,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Biogen (NASDAQ: BIIB) announced that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was granted Fast Track designation by the U.S. ..."
BIIB,BIIB:UW,BBG000C18861,Biogen to Present at the Morgan Stanley Global Healthcare Conference,2016-09-01 20:01:00 +0000,http://finance.yahoo.com/news/biogen-present-morgan-stanley-global-200100545.html,"[Business Wire] - Biogen Inc. announced today that it will present at the Morgan Stanley Global Healthcare Conference. The webcast will be live on Monday, September 12, 2016 at 1:40p.m."
BIIB,BIIB:UW,BBG000C18861,Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation,2016-09-01 20:01:00 +0000,http://finance.yahoo.com/news/biogen-investigational-alzheimer-disease-treatment-200100695.html,"[Business Wire] - Today Biogen announced that aducanumab, its investigational treatment for early Alzheimer’s disease , was granted Fast Track designation by the U.S. Food and Drug Administration ."
BIIB,BIIB:UW,BBG000C18861,Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status,2016-09-01 19:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1uoQ2hZvwsc/biogens-alzheimers-therapy-granted-fda-fasttrack-status-20160901-01261,Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status
BIIB,BIIB:UW,BBG000C18861,Biogen''s Alzheimer''s Therapy Granted FDA Fast-Track Status,2016-09-01 19:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hAR9XL4XB4o/biogens-alzheimers-therapy-granted-fda-fasttrack-status-20160901-01253,Biogen''s Alzheimer''s Therapy Granted FDA Fast-Track Status
BIIB,BIIB:UW,BBG000C18861,"Tesla Motors Inc (TSLA) Needs More Cash for Gigafactory, Model 3",2016-08-31 20:58:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dw-EiaZmSMU/tesla-motors-inc-tsla-needs-more-cash-for-gigafactory-model-3-cm673138,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Tesla Motors Inc 160 NASDAQ TSLA just announced a second round of financing to fund Model 3 production and equipment for its gigafactory which it s hoping to complete before the Model 3
BIIB,BIIB:UW,BBG000C18861,"Health Care Sector Update for 08/31/2016: BIIB,VEEV,ATOS",2016-08-31 20:27:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QxhatdAq6OA/health-care-sector-update-for-08312016-biibveevatos-cm673097,"Top Health Care Stocks JNJ 0.14% PFE 0.31% MRK 1.94% ABT +0.03% AMGN 0.36% Health care stocks were drifting lower today, with the NYSE Health Care Index sliding about 0.3% Wednesday afternoon while shares of health care companies in"
BIIB,BIIB:UW,BBG000C18861,Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab,2016-08-31 17:33:01 +0000,http://www.publicnow.com/view/B0FA9B8B1CE6DC9F915E308B44F0088DD7E0CFA8,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Results from pre-clinical research and PRIME, the Phase 1b study of Biogen's (NASDAQ: BIIB) investigational treatment for early Alzheimer's disease (AD), aducanumab, ..."
BIIB,BIIB:UW,BBG000C18861,[$$] Biogen predicts preventive drug for Alzheimer's disease,2016-08-31 17:00:55 +0000,"http://www.ft.com/cms/s/c1c6e708-6ef9-11e6-9ac1-1055824ca907,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - A senior scientist at Biogen, the large US biotech group, has predicted that potential Alzheimer's victims will be treated long before they develop symptoms, much as millions of people without heart problems ..."
BIIB,BIIB:UW,BBG000C18861,"Top 10 Biotech Stocks for 2016 (ALXN, ALNY)",2016-08-30 19:00:00 +0000,http://www.investopedia.com/articles/company-insights/083016/top-10-biotech-stocks-2016-alxn-alny.asp?partner=YahooSA,"Top 10 Biotech Stocks for 2016 (ALXN, ALNY)"
BIIB,BIIB:UW,BBG000C18861,Biogen Is Setting Up for a Rare Low-Risk Buying Opportunity,2016-08-30 12:27:00 +0000,https://www.thestreet.com/story/13688764/1/biogen-is-setting-up-for-a-rare-low-risk-buying-opportunity.html?puc=yahoo&cm_ven=YAHOO,Biogen Is Setting Up for a Rare Low-Risk Buying Opportunity
BIIB,BIIB:UW,BBG000C18861,Time to Shift Your Focus,2016-08-28 11:07:40 +0000,http://finance.yahoo.com/tumblr/blog-time-to-shift-your-focus-110745912.html,Time to Shift Your Focus
BIIB,BIIB:UW,BBG000C18861,What Should We Expect from BioMarin’s Kuvan in 2016?,2016-08-26 14:05:05 +0000,http://marketrealist.com/2016/08/expect-biomarins-kuvan-2016/?utm_source=yahoo&utm_medium=feed,What Should We Expect from BioMarin’s Kuvan in 2016?
BIIB,BIIB:UW,BBG000C18861,What’s BioMarin’s Expected Revenue Growth in 2016 and 2017?,2016-08-25 17:04:05 +0000,http://marketrealist.com/2016/08/whats-biomarins-expected-revenue-growth-2016-2017/?utm_source=yahoo&utm_medium=feed,What’s BioMarin’s Expected Revenue Growth in 2016 and 2017?
BIIB,BIIB:UW,BBG000C18861,AbbVie Expects to Launch Zinbryta in the US in August,2016-08-25 15:04:05 +0000,http://marketrealist.com/2016/08/abbvie-expects-launch-multiple-sclerosis-drug-zinbryta-u-s-august-2016/?utm_source=yahoo&utm_medium=feed,AbbVie Expects to Launch Zinbryta in the US in August
BIIB,BIIB:UW,BBG000C18861,Analysts Anticipate 12% Gains Ahead For RYH,2016-08-25 13:46:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I6BjXHvOHys/analysts-anticipate-12-gains-ahead-for-ryh-cm669955,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12 month forward target price, and computed the weighted average"
BIIB,BIIB:UW,BBG000C18861,"Allergan, Humana, Biogen: Billionaires’ Favorite Healthcare Stocks For Q3",2016-08-25 13:30:16 +0000,http://www.insidermonkey.com/blog/allergan-humana-biogen-billionaires-favorite-healthcare-stocks-for-q3-470339/,"Allergan, Humana, Biogen: Billionaires’ Favorite Healthcare Stocks For Q3"
BIIB,BIIB:UW,BBG000C18861,Short Sellers Increase Bets in Major Biotechs,2016-08-25 12:40:13 +0000,http://247wallst.com/healthcare-business/2016/08/25/short-sellers-increase-bets-in-major-biotechs-4/,Short Sellers Increase Bets in Major Biotechs
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review",2016-08-24 20:46:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ia7VRSpmnw/biotech-stock-roundup-medivation-to-pfizer-clovis-priority-review-cm669752,The big news this week in the biotech sector was Pfizer's announcement that it will acquire cancer focused Medivation MDVN for $14 billion. This announcement has revived acquisition chatter in the sector with much speculation regarding which
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review",2016-08-24 18:09:06 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-medivation-pfizer-180906503.html,"Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review"
BIIB,BIIB:UW,BBG000C18861,"Notable ETF Outflow Detected - QLD, TXN, CHTR, BIIB",2016-08-22 16:42:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zi8F-Q4xxFM/notable-etf-outflow-detected-qld-txn-chtr-biib-cm668483,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra QQQ (Symbol QLD) where we have detected an approximate $33.8 million dollar outflow that's"
BIIB,BIIB:UW,BBG000C18861,9 Stocks Smart Investors Put Their Money in Last Quarter,2016-08-20 12:34:00 +0000,https://www.thestreet.com/slideshow/13680539/1/9-stocks-smart-investors-put-their-money-in-last-quarter.html?puc=yahoo&cm_ven=YAHOO,9 Stocks Smart Investors Put Their Money in Last Quarter
BIIB,BIIB:UW,BBG000C18861,Genzyme Continued to Boost Growth for Sanofi in 2Q16,2016-08-18 13:06:08 +0000,http://marketrealist.com/2016/08/genzyme-continued-to-boost-growth-for-sanofi-in-2q16/?utm_source=yahoo&utm_medium=feed,Genzyme Continued to Boost Growth for Sanofi in 2Q16
BIIB,BIIB:UW,BBG000C18861,Ozanimod May Prove to Be a Strong Growth Driver for Celgene,2016-08-18 13:04:26 +0000,http://marketrealist.com/2016/08/ozanimod-may-prove-strong-growth-driver-celgene-future-years/?utm_source=yahoo&utm_medium=feed,Ozanimod May Prove to Be a Strong Growth Driver for Celgene
BIIB,BIIB:UW,BBG000C18861,Another Endorsement for Biotech ETFs,2016-08-17 21:56:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hYQcDdHfypE/another-endorsement-for-biotech-etfs-cm666016,"The iShares Nasdaq Biotechnology ETF (NasdaqGS  IBB ) , which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds, seem to have put the woes experienced earlier this year behind them and recently have"
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data",2016-08-17 21:51:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xwlv_yWF1Cc/biotech-stock-roundup-vertex-slips-on-study-halt-aurinia-plunges-on-lupus-data-cm666783,"With second quarter earnings season drawing to a close, focus is back on pipeline and regulatory updates. Companies like Vertex VRTX , OncoGenex OGXI and Aurinia AUPH were in focus this week with the companies losing ground on pipeline"
BIIB,BIIB:UW,BBG000C18861,Better Buy: Amgen Inc. vs. Biogen,2016-08-17 12:21:00 +0000,http://www.fool.com/investing/2016/08/17/better-buy-amgen-inc-vs-biogen.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Amgen Inc. vs. Biogen
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Inc Begins to Shift Focus,2016-08-16 21:35:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_ErtzAbUoQY/ionis-pharmaceuticals-inc-begins-to-shift-focus-cm666215,"Image source  Getty Images.  Ionis Pharmaceuticals '(NASDAQ  IONS) earnings conference calls are usually focused on what investors can expect from upcoming releases of clinical trial data, but with top line results in"
BIIB,BIIB:UW,BBG000C18861,Ionis Pharmaceuticals Inc Begins to Shift Focus,2016-08-16 19:48:00 +0000,http://www.fool.com/investing/2016/08/16/ionis-pharmaceuticals-inc-begins-to-shift-focus.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Ionis Pharmaceuticals Inc Begins to Shift Focus
BIIB,BIIB:UW,BBG000C18861,Sarah Ketterer Takes 3 Positions in 2nd Quarter,2016-08-16 05:33:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SKaqSHgBzZ8/sarah-ketterer-takes-3-positions-in-2nd-quarter-cm665674,"Sarah Ketterer ( Trades , Portfolio ), founder and CEO of Causeway Capital Management LLC, creates long term capital growth for her shareholders through value oriented investing. As discussed in the fundAAAs prospectus , Ketterer prefers stocks that have"
BIIB,BIIB:UW,BBG000C18861,Sarah Ketterer Takes 3 Positions in 2nd Quarter,2016-08-15 23:17:01 +0000,http://finance.yahoo.com/news/sarah-ketterer-takes-3-positions-231701572.html,Sarah Ketterer Takes 3 Positions in 2nd Quarter
BIIB,BIIB:UW,BBG000C18861,"Top 3 Research Reports for August 15, 2016",2016-08-15 22:37:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KTGSvN9V47w/top-3-research-reports-for-august-15-2016-cm665593,"Monday, August 15, 2016 Today's must read reports are for AstraZeneca (AZN), Caterpillar (CAT) and Exelon (EXC). AstraZeneca shares have rallied from the mid June lows, erasing most of the stock's earlier underperformance. The Pound weakness following the Brexit"
BIIB,BIIB:UW,BBG000C18861,"Amid takeover rumors, Biogen gives details on hemophilia spinoff",2016-08-15 21:00:11 +0000,http://www.bizjournals.com/triangle/news/2016/08/15/biogen-biib-bioverativ-spinoff-hemophelia.html?ana=yahoo,"Amid takeover rumors, Biogen gives details on hemophilia spinoff"
BIIB,BIIB:UW,BBG000C18861,"Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline",2016-08-15 14:39:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J7m9W9nNbww/allergan-to-buy-forsight-vision5-boost-glaucoma-pipeline-cm665348,"Late last week, Allergan plcAGN announced that it will be acquiring a privately held, clinical stage biotechnology company focused on eye care. ForSight VISION5 will be acquired by Allergan for an upfront payment of $95 million as well as"
BIIB,BIIB:UW,BBG000C18861,Post Earnings Coverage as Perrigo Doubles Profit,2016-08-15 13:15:11 +0000,http://news.investornetwork.com/2016/08/15/post-earnings-coverage-as-perrigo-doubles-profit/?1=1&1471266911,Post Earnings Coverage as Perrigo Doubles Profit
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen",2016-08-13 05:37:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-3EbIvzc6kQ/the-zacks-analyst-blog-highlights-regeneron-biomarin-abbvie-amgen-and-biogen-cm664678,"For Immediate Release Chicago, IL August 12, 2016 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks"
BIIB,BIIB:UW,BBG000C18861,Richard Snow Slashed Abercrombie & Fitch Stake in 2nd Quarter,2016-08-12 22:07:34 +0000,http://finance.yahoo.com/news/richard-snow-slashed-abercrombie-fitch-220734307.html,Richard Snow Slashed Abercrombie & Fitch Stake in 2nd Quarter
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen",2016-08-12 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-regeneron-133001795.html,"The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen"
BIIB,BIIB:UW,BBG000C18861,"Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2016",2016-08-12 13:16:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vhO_h1acUJw/amgen-inc-amgn-ex-dividend-date-scheduled-for-august-15-2016-cm664562,"Amgen Inc. ( AMGN ) will begin trading ex dividend on August 15, 2016. A cash dividend payment of $1 per share is scheduled to be paid on September 08, 2016. Shareholders who purchased AMGN prior to the ex"
BIIB,BIIB:UW,BBG000C18861,"Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat",2016-08-11 21:30:09 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-earnings-focus-213009456.html,"Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat"
BIIB,BIIB:UW,BBG000C18861,"ETF’s with exposure to Biogen, Inc. : August 11, 2016",2016-08-11 16:34:45 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-biogen-inc-august-11-2016/,"ETF’s with exposure to Biogen, Inc. : August 11, 2016"
BIIB,BIIB:UW,BBG000C18861,Valeant sinks on criminal probe,2016-08-11 16:28:00 +0000,http://finance.yahoo.com/video/valeant-sinks-criminal-probe-162800408.html,Valeant sinks on criminal probe
BIIB,BIIB:UW,BBG000C18861,Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming,2016-08-11 12:20:25 +0000,http://247wallst.com/healthcare-business/2016/08/11/why-jefferies-sees-3-big-biotechs-having-key-upside-catalysts-coming/,Why Jefferies Sees 3 Big Biotechs Having Key Upside Catalysts Coming
BIIB,BIIB:UW,BBG000C18861,Biogen Inc: BIIB Stock Is a Biotech Standout,2016-08-10 21:52:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/41EDlQGg5QQ/biogen-inc-biib-stock-is-a-biotech-standout-cm663695,"There's no question that the biotechnology industry has been under pressure since it peaked in July 2015. However, the  iShares Nasdaq Biotechnology Index (ETF) (NASDAQ"
BIIB,BIIB:UW,BBG000C18861,"Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook",2016-08-10 21:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qQ9rjB5yWNY/ionis-ions-q2-loss-narrower-than-expected-issues-outlook-cm663688,"Ionis Pharmaceuticals, Inc.IONS reported a loss of 47 cents per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 48 cents but wider than the year ago loss of 29 cents."
BIIB,BIIB:UW,BBG000C18861,"Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook",2016-08-10 19:49:07 +0000,http://finance.yahoo.com/news/ionis-ions-q2-loss-narrower-194907473.html,"Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook"
BIIB,BIIB:UW,BBG000C18861,"Perrigo (PRGO) Misses Q2 Earnings Estimates, Cuts '16 View",2016-08-10 16:49:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zG_PJNgXnp8/perrigo-prgo-misses-q2-earnings-estimates-cuts-16-view-cm663474,Perrigo Company plc 's PRGO second quarter 2016 earnings of $1.93 per share fell short of the Zacks Consensus Estimate of $2.00. Reported earnings also declined 11% from the year ago figure. Perrigo Company (PRGO) Street EPS & Surprise
BIIB,BIIB:UW,BBG000C18861,Short Sellers Run for Cover From Major Biotechs,2016-08-10 12:50:48 +0000,http://247wallst.com/healthcare-business/2016/08/10/short-sellers-run-for-cover-from-major-biotechs-8/,Short Sellers Run for Cover From Major Biotechs
BIIB,BIIB:UW,BBG000C18861,"QUAL, PEG, BIIB, NKE: Large Outflows Detected at ETF",2016-08-09 18:33:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V8flpxjQRRs/qual-peg-biib-nke-large-outflows-detected-at-etf-cm662689,"Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Quality Factor ETF (Symbol QUAL) where we have detected an approximate $30.7"
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Intel, Align Technology, Qorvo and Biogen",2016-08-09 15:38:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EquC7aZJSqs/the-zacks-analyst-blog-highlights-intel-align-technology-qorvo-and-biogen-cm662532,"For Immediate Release Chicago, IL August 09, 2016 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks"
BIIB,BIIB:UW,BBG000C18861,"The Zacks Analyst Blog Highlights: Intel, Align Technology, Qorvo and Biogen",2016-08-09 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-intel-133001743.html,"The Zacks Analyst Blog Highlights: Intel, Align Technology, Qorvo and Biogen"
BIIB,BIIB:UW,BBG000C18861,Biogen's hemophilia business spinoff planned for early 2017,2016-08-09 13:26:19 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=36ECC861-6230-4294-8537-10334338FD20&siteid=yhoof2,Biogen's hemophilia business spinoff planned for early 2017
BIIB,BIIB:UW,BBG000C18861,Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company,2016-08-09 13:10:08 +0000,http://www.publicnow.com/view/FEC3F0AA9904298B2F8742745DC74A367738775E,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch in early ..."
BIIB,BIIB:UW,BBG000C18861,What Do Analysts Recommend for Regeneron after 2Q16 Earnings?,2016-08-09 13:08:47 +0000,http://marketrealist.com/2016/08/what-do-analysts-recommend-for-regeneron-after-2q16-earnings/?utm_source=yahoo&utm_medium=feed,What Do Analysts Recommend for Regeneron after 2Q16 Earnings?
BIIB,BIIB:UW,BBG000C18861,How Shows Like Grey's Anatomy Influence Patient Perceptions of Healthcare,2016-08-09 12:38:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T9KFTfa9PyI/how-shows-like-greys-anatomy-influence-patient-perceptions-of-healthcare-cm662090,"While hospitals perform life saving work every day, patients are far more likely to be receiving treated for unexciting conditions like heart disease than they are to present with something as dramatic as the bubonic plague."
BIIB,BIIB:UW,BBG000C18861,Biogen Plans to Name Hemophilia Spinoff ''Bioverativ'',2016-08-09 12:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uw92jezRewc/biogen-plans-to-name-hemophilia-spinoff-bioverativ-20160809-00828,Biogen Plans to Name Hemophilia Spinoff ''Bioverativ''
BIIB,BIIB:UW,BBG000C18861,Biogen Says Bioverativ As Name Of New Hemophilia-Focused Company,2016-08-09 09:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WgReJZIKtwU/biogen-says-bioverativ-as-name-of-new-hemophiliafocused-company-20160809-00622,Biogen Says Bioverativ As Name Of New Hemophilia-Focused Company
BIIB,BIIB:UW,BBG000C18861,"Biogen, Eisai’s Alzheimer’s Drug E2609 to Enter Late-Stage Trial",2016-08-09 07:35:52 +0000,http://www.bloomberg.com/news/articles/2016-08-09/biogen-eisai-s-alzheimer-s-drug-e2609-to-enter-late-stage-trial?cmpid=yhoo.headline,"Biogen, Eisai’s Alzheimer’s Drug E2609 to Enter Late-Stage Trial"
BIIB,BIIB:UW,BBG000C18861,Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies,2016-08-09 07:01:08 +0000,http://finance.yahoo.com/news/eisai-fda-confirms-enough-data-070108610.html,Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies
BIIB,BIIB:UW,BBG000C18861,"[$$] Allergan Revenue Increases, Though Loss Widens",2016-08-09 04:08:35 +0000,http://www.wsj.com/articles/allergan-revenue-increases-though-loss-widens-1470658455?ru=yahoo?mod=yahoo_itp,"[$$] Allergan Revenue Increases, Though Loss Widens"
BIIB,BIIB:UW,BBG000C18861,"Botox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ",2016-08-09 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U5oYaEg-IAo/botox-maker-allergans-revenue-climbs-but-loss-more-than-doubles--wsj-20160809-00036,"Botox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ"
BIIB,BIIB:UW,BBG000C18861,Intercept (ICPT) Reports Narrower-than-Expected Q2 Loss,2016-08-08 16:16:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mAfw8_KJ3t0/intercept-icpt-reports-narrower-than-expected-q2-loss-cm661848,"Shares of Intercept Pharmaceuticals, Inc . ICPT were down 5% after the company reported second quarter 2016 results. The company posted a loss of $3.14 per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate"
BIIB,BIIB:UW,BBG000C18861,"Allergan Revenue Increases, Though Loss Widens--Update",2016-08-08 14:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y6ocCRVqxMA/allergan-revenue-increases-though-loss-widensupdate-20160808-00757,"Allergan Revenue Increases, Though Loss Widens--Update"
BIIB,BIIB:UW,BBG000C18861,"Allergan Revenue Increases, Though Loss Widens",2016-08-08 08:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8l0xeZ_HrgQ/allergan-revenue-increases-though-loss-widens-20160808-00413,"Allergan Revenue Increases, Though Loss Widens"
BIIB,BIIB:UW,BBG000C18861,Does Biogen's Latest Win Make Its Shares a Buy?,2016-08-07 04:14:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3UsNRBRsvac/does-biogens-latest-win-make-its-shares-a-buy-cm661460,"Image source  Biogen, Inc.  Biogen, Inc. (NASDAQ  BIIB) and partner Ionis Pharmaceuticals, Inc. (NASDAQ  IONS) reported this week that an interim look at a study evaluating the companies' nusinersen as a"
BIIB,BIIB:UW,BBG000C18861,Biogen: Not Your Grandmother's M&A Target,2016-08-05 16:10:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/05/biogen-not-your-grandmothers-ma-target/?mod=yahoobarrons&ru=yahoo,Biogen: Not Your Grandmother's M&A Target
BIIB,BIIB:UW,BBG000C18861,"Zacks.com featured highlights: AngloGold Ashanti, Biogen, QUALCOMM, Tallgrass Energy GP and Steel Dynamics",2016-08-05 15:38:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7McFzG2Nm8w/zackscom-featured-highlights-anglogold-ashanti-biogen-qualcomm-tallgrass-energy-gp-and-steel-dynamics-cm661146,"For Immediate Release Chicago, IL August 05, 2016 Stocks in this week's article include AngloGold Ashanti Ltd. ( AU ), Biogen Inc. ( BIIB ), QUALCOMM Inc. ( QCOM ), Tallgrass Energy GP, LP ( TEGP ) and Steel"
BIIB,BIIB:UW,BBG000C18861,Biogen’s MS Drugs: Deadly Cash Cows?,2016-08-05 14:10:03 +0000,http://finance.yahoo.com/tumblr/blog-biogens-ms-drugs-deadly-cash-cows-141008534.html,Biogen’s MS Drugs: Deadly Cash Cows?
BIIB,BIIB:UW,BBG000C18861,"Zacks.com featured highlights: AngloGold Ashanti, Biogen, QUALCOMM, Tallgrass Energy GP and Steel Dynamics",2016-08-05 13:30:01 +0000,http://finance.yahoo.com/news/zacks-com-featured-highlights-anglogold-133001811.html,"[Zacks] - Zacks.com featured highlights: AngloGold Ashanti, Biogen, QUALCOMM, Tallgrass Energy GP and Steel Dynamics"
BIIB,BIIB:UW,BBG000C18861,The Race To Cure Spinal Muscular Atrophy,2016-08-05 06:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oFrvWa6kz24/the-race-to-cure-spinal-muscular-atrophy-20160805-00108,The Race To Cure Spinal Muscular Atrophy
BIIB,BIIB:UW,BBG000C18861,"Why Sangamo Biosciences, Inc. Fell 29% Today",2016-08-05 00:51:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HburwE2z930/why-sangamo-biosciences-inc-fell-29-today-cm660835,Image source  Getty Images.  What  Sangamo Biosciences (NASDAQ  SGMO) fell 29% today after releasing second quarter earnings after the bell on Wednesday.  So what  It wasn't the earnings
BIIB,BIIB:UW,BBG000C18861,Allergan Plc: Will the Downtrend Continue for AGN Stock?,2016-08-04 21:52:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_k77NE-6Kio/allergan-plc-will-the-downtrend-continue-for-agn-stock-cm660743,"Specialty pharma giant Allergan Plc (NYSE  AGN ) reports earnings Monday morning. But in front of the quarterly release, are there clues as to"
BIIB,BIIB:UW,BBG000C18861,"Exelixis (EXEL) Posts Narrower Loss in Q2, Beats on Revenues",2016-08-04 21:52:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nSEKcLjQvdQ/exelixis-exel-posts-narrower-loss-in-q2-beats-on-revenues-cm660731,"Exelixis, Inc . EXEL posted a second quarter 2016 loss of 16 cents, narrower than both the Zacks Consensus Estimate of a loss of 27 cents and the year ago loss of 22 cents. Net revenue came in at"
BIIB,BIIB:UW,BBG000C18861,Amyris Enters Partnership with Biogen to Develop Alternative Cell Lines Supporting Production of Therapeutics,2016-08-04 12:12:05 +0000,http://www.publicnow.com/view/8AAF062658642F34A2F48B1E891B2A03944D1AAD,"[at noodls] - EMERYVILLE, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has entered into a funded partnership with Biogen, Inc. (Nasdaq:BIIB). ..."
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Energy, financial stocks give Wall St modest lift",2016-08-03 20:10:50 +0000,http://uk.finance.yahoo.com/news/us-stocks-energy-financial-stocks-201050479.html,"US STOCKS-Energy, financial stocks give Wall St modest lift"
BIIB,BIIB:UW,BBG000C18861,Biogen not pursuing a sale - source,2016-08-03 18:55:10 +0000,http://in.finance.yahoo.com/news/biogen-not-pursuing-sale-source-185510909.html,Biogen not pursuing a sale - source
BIIB,BIIB:UW,BBG000C18861,"In Quest to Grow, Rivals Woo Biogen -- WSJ",2016-08-03 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6uWr2Ug4SF8/in-quest-to-grow-rivals-woo-biogen--wsj-20160803-00055,"In Quest to Grow, Rivals Woo Biogen -- WSJ"
BIIB,BIIB:UW,BBG000C18861,WSJ : Biogen Draws Takeover Interest From Rival Drugmakers,2016-08-02 22:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TZBTunmi-zY/wsj--biogen-draws-takeover-interest-from-rival-drugmakers-20160802-01686,WSJ : Biogen Draws Takeover Interest From Rival Drugmakers
BIIB,BIIB:UW,BBG000C18861,"Biogen draws takeover interest from Merck, Allergan - WSJ",2016-08-02 22:12:44 +0000,http://sg.finance.yahoo.com/news/biogen-draws-takeover-interest-merck-221244544.html,"Biogen draws takeover interest from Merck, Allergan - WSJ"
BIIB,BIIB:UW,BBG000C18861,Biogen Draws Takeover Interest from Rival Drugmakers--2nd Update,2016-08-02 19:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JQZ0wh9GuTo/biogen-draws-takeover-interest-from-rival-drugmakers2nd-update-20160802-01135,Biogen Draws Takeover Interest from Rival Drugmakers--2nd Update
BIIB,BIIB:UW,BBG000C18861,Rivals Woo Biogen in Search for Growth,2016-08-02 15:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C4GNNr0Q7a4/rivals-woo-biogen-in-search-for-growth-20160802-01655,Rivals Woo Biogen in Search for Growth
BIIB,BIIB:UW,BBG000C18861,Rivals Woo Biogen in Search for Growth,2016-08-02 15:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b7IXcMq7cNo/rivals-woo-biogen-in-search-for-growth-20160802-01656,Rivals Woo Biogen in Search for Growth
BIIB,BIIB:UW,BBG000C18861,Biogen Attracts Takeover Interest From Two Rivals,2016-08-02 15:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gcDGpifgjms/biogen-attracts-takeover-interest-from-two-rivals-20160802-01139,Biogen Attracts Takeover Interest From Two Rivals
BIIB,BIIB:UW,BBG000C18861,Biogen Draws Takeover Interest from Rival Drugmakers--Update,2016-08-02 15:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QT9jy1Hfcj4/biogen-draws-takeover-interest-from-rival-drugmakersupdate-20160802-01134,Biogen Draws Takeover Interest from Rival Drugmakers--Update
BIIB,BIIB:UW,BBG000C18861,Biogen Draws Takeover Interest from Rival Drugmakers,2016-08-02 14:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4F5-0ulBkeU/biogen-draws-takeover-interest-from-rival-drugmakers-20160802-01108,Biogen Draws Takeover Interest from Rival Drugmakers
BIIB,BIIB:UW,BBG000C18861,Dow Heads for Seventh Session of Losses,2016-08-02 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vrix7li5tLM/dow-heads-for-seventh-session-of-losses-20160802-01136,Dow Heads for Seventh Session of Losses
BIIB,BIIB:UW,BBG000C18861,Dow Logs Seventh Session of Losses,2016-08-02 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BRLsP17PdGU/dow-logs-seventh-session-of-losses-20160802-01411,Dow Logs Seventh Session of Losses
BIIB,BIIB:UW,BBG000C18861,Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy,2016-08-01 11:51:04 +0000,http://www.publicnow.com/view/BC09EE09DE49B83A15D884AF99DCABCF094E5A70,"[at noodls] - CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) today announced that nusinersen, their investigational treatment for spinal muscular atrophy ..."
BIIB,BIIB:UW,BBG000C18861,BUZZ-U.S. stocks weekly: Don't drink and drive,2016-08-01 11:16:42 +0000,http://uk.finance.yahoo.com/news/buzz-u-stocks-weekly-dont-111642923.html,BUZZ-U.S. stocks weekly: Don't drink and drive
BIIB,BIIB:UW,BBG000C18861,Biogen rises after 2nd-quarter results surpass forecasts,2016-07-21 15:22:41 +0000,http://sg.finance.yahoo.com/news/biogen-beats-street-2q-forecasts-111144595.html,Biogen rises after 2nd-quarter results surpass forecasts
BIIB,BIIB:UW,BBG000C18861,Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress,2016-07-18 11:30:00 +0000,http://uk.finance.yahoo.com/news/biogen-sobi-showcase-long-term-113000661.html,Biogen and Sobi to Showcase Long-Term Efficacy and Safety Data from Extended Half-Life Hemophilia Therapies at World Federation of Hemophilia 2016 World Congress
BIIB,BIIB:UW,BBG000C18861,"SB5, An Adalimumab Biosimilar Referencing Humira®, Accepted for Review by European Medicines Agency",2016-07-18 03:18:03 +0000,http://www.publicnow.com/view/C003AAD845292075E23E259D08707359419F6D08,"[at noodls] - ZUG, Switzerland--(BUSINESS WIRE)--The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira, has been accepted for review by the European Medicines Agency ..."
BIIB,BIIB:UW,BBG000C18861,Samsung Bioepis' Marketing Authorization Application for SB5 Adalimumab Biosimilar Candidate Accepted for Review by the European Medicines Agency,2016-07-18 01:00:00 +0000,http://au.finance.yahoo.com/news/samsung-bioepis-marketing-authorization-application-010000400.html,"[Business Wire] - INCHEON, Korea--(BUSINESSWIRE)-- Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB5, ..."
BIIB,BIIB:UW,BBG000C18861,Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis,2016-07-05 12:21:07 +0000,http://www.publicnow.com/view/295BE01DE3B1CBE57ACAC2B372AA4157CE5AC11B,"[at noodls] - CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Selects Cognizant's SmartTrials Platform,2016-06-28 10:11:02 +0000,http://www.publicnow.com/view/A3C8D3F8AF18407327487F93274D80A527C78D7D,"[at noodls] - TEANECK, N.J., June 28, 2016/PRNewswire / -- Cognizant (NASDAQ: CTSH) today announced that Biogen (NASDAQ: BIIB) has selected Cognizant's SmartTrials™ platform to aggregate and store clinical trial operational ..."
BIIB,BIIB:UW,BBG000C18861,"Biogen Names Paul McKenzie Executive Vice President, Pharmaceutical Operations & Technology",2016-06-21 15:09:05 +0000,http://www.publicnow.com/view/A64E939DF2D5C1CA047FA6565DE6720CC57806CD,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the appointment of Paul McKenzie, Ph.D., as executive vice president, Pharmaceutical Operations & Technology, effective July 1, ..."
BIIB,BIIB:UW,BBG000C18861,"Biogen to Report Second Quarter 2016 Financial Results on July 21, 2016",2016-06-20 20:19:06 +0000,http://www.publicnow.com/view/61D83CCA219D725759AF8D58E7374E08DF903069,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2016 financial results on Thursday, July 21, 2016, before the financial markets open. ... This ..."
BIIB,BIIB:UW,BBG000C18861,New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio,2016-06-09 11:29:06 +0000,http://www.publicnow.com/view/112FD9F8BB949B35FE0DFC36F332DA0D07209D27,"[at noodls] - ZUG, Switzerland--(BUSINESS WIRE)--Data demonstrating long-term comparable efficacy, safety and immunogenicity of BENEPALI (etanercept) and FLIXABI (infliximab) were presented by Samsung Bioepis, the joint ..."
BIIB,BIIB:UW,BBG000C18861,New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio,2016-06-09 11:08:00 +0000,http://uk.finance.yahoo.com/news/data-presented-annual-european-congress-110800921.html,New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen’s Anti-TNF Biosimilars Portfolio
BIIB,BIIB:UW,BBG000C18861,US STOCKS-S&P edges closer to record high; energy shares lead,2016-06-07 20:29:40 +0000,http://uk.finance.yahoo.com/news/us-stocks-p-edges-closer-202940190.html,US STOCKS-S&P edges closer to record high; energy shares lead
BIIB,BIIB:UW,BBG000C18861,Biogen's MS drug fails to meet goals in study,2016-06-07 14:52:02 +0000,http://sg.finance.yahoo.com/news/biogens-ms-drug-fails-meet-145202344.html,Biogen's MS drug fails to meet goals in study
BIIB,BIIB:UW,BBG000C18861,Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis,2016-06-07 11:48:12 +0000,http://www.publicnow.com/view/F904D0400DA35508492153243A8B20430ED0AE26,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Biogen (NASDAQ: BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal ..."
BIIB,BIIB:UW,BBG000C18861,Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Accepted into European Medicines Agency’s PRIME Program,2016-06-01 16:15:04 +0000,http://www.publicnow.com/view/7719DA5DA96CF79649341A919C7D7EF0D8674BD1,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Biogen (NASDAQ:BIIB) announced that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was accepted into the European Medicines Agency's ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy,2016-05-31 11:42:05 +0000,http://www.publicnow.com/view/47BB1A362AEA53B6757FBC84907B998C7C07AEE4,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--The Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a variation to ..."
BIIB,BIIB:UW,BBG000C18861,"FLIXABI®, Biogen’s Infliximab Biosimilar Referencing Remicade®, Approved in the European Union",2016-05-30 07:00:01 +0000,http://www.publicnow.com/view/38A3D5553208871AF7B0AAB7DC63464624718B72,"[at noodls] - ZUG, Switzerland--(BUSINESS WIRE)--The European Commission (EC) today granted marketing authorization in the European Union (EU) for FLIXABI, an infliximab biosimilar referencing Remicade. FLIXABI was ..."
BIIB,BIIB:UW,BBG000C18861,Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis,2016-05-28 01:57:07 +0000,http://www.publicnow.com/view/BD6788EC6018138A11B35C6788ABAD218E566365,"[at noodls] - CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) approved ZINBRYTA (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for relapsing ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Announces Webcast of Virtual Annual Meeting of Stockholders,2016-05-19 20:52:04 +0000,http://www.publicnow.com/view/CD0410C7FFBDEBAEF63D351EBF7BDAD7247B562D,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that the webcast of the Company's 2016 Annual Meeting of Stockholders will be held on Wednesday, June 8, 2016 at 9:00 a.m. ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Announces Collaboration with University of Pennsylvania on Multiple Gene Therapy Programs,2016-05-16 11:32:10 +0000,http://www.publicnow.com/view/5BACA84021125F30B1A412FC0EF077019D84AE0A,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) today announced a broad collaboration and alliance with the University of Pennsylvania ('Penn') to advance gene therapy and gene editing technologies. ..."
BIIB,BIIB:UW,BBG000C18861,Biogen Announces Intent to Spin off Its Hemophilia Business,2016-05-03 11:40:12 +0000,http://www.publicnow.com/view/7F89C4DC4F63CD07B67B6503DF6DF8573EC8E944,"[at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) today announced that it intends to spin off its hemophilia business as an independent, publicly traded company. The strategic goal of this ..."
BIIB,BIIB:UW,BBG000C18861,"ADAM KOPPEL, EXECUTIVE VICE PRESIDENT, STRATEGY AND BUSINESS DEVELOPMENT, TO RETURN TO BAIN CAPITAL",2016-04-29 15:23:35 +0000,http://www.publicnow.com/view/42DF2B06BE22AD2C32E7288214EBC4B9CDC18404,"[at noodls] - Cambridge, Mass. - Biogen (NASDAQ: BIIB) today announced that Adam Koppel, M.D., Ph.D., executive vice president, strategy and business development, will depart the company on June 2, 2016, to return to ..."
BIIB,BIIB:UW,BBG000C18861,Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis,2016-04-29 12:18:27 +0000,http://www.publicnow.com/view/67C14E8BB3C1E9E08CF33A73DD887655AE295DC0,"[at noodls] - CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the ..."
BIIB,BIIB:UW,BBG000C18861,Biogen beats 1Q profit forecasts,2016-04-21 11:49:24 +0000,http://sg.finance.yahoo.com/news/biogen-beats-1q-profit-forecasts-114924543.html,Biogen beats 1Q profit forecasts
BIIB,BIIB:UW,BBG000C18861,Samsung brings in the lawyers for biosimilars push,2016-04-03 23:11:11 +0000,http://sg.finance.yahoo.com/news/samsung-brings-lawyers-biosimilars-push-231111794.html,Samsung brings in the lawyers for biosimilars push
BIIB,BIIB:UW,BBG000C18861,Biogen Joins Pioneering Target Validation Collaboration,2016-02-08 12:00:00 +0000,http://uk.finance.yahoo.com/news/biogen-joins-pioneering-target-validation-120000604.html,Biogen Joins Pioneering Target Validation Collaboration
BIIB,BIIB:UW,BBG000C18861,"Biogen 4Q profit falls on costs, but tops forecasts",2016-01-27 15:28:45 +0000,http://sg.finance.yahoo.com/news/biogen-beats-street-4q-forecasts-123947567.html,"Biogen 4Q profit falls on costs, but tops forecasts"
BIIB,BIIB:UW,BBG000C18861,"In the Caribbean, a stinking seaweed menace spurs invention",2015-11-17 10:22:44 +0000,http://uk.finance.yahoo.com/news/caribbean-stinking-seaweed-menace-spurs-102244494.html,"In the Caribbean, a stinking seaweed menace spurs invention"
BIIB,BIIB:UW,BBG000C18861,Biogen to cut 11% of its workforce,2015-10-21 19:43:02 +0000,http://sg.finance.yahoo.com/news/biogen-cut-11-workforce-194302166.html,Biogen to cut 11% of its workforce
BIIB,BIIB:UW,BBG000C18861,Biogen cutting 11 percent of its workforce,2015-10-21 17:39:00 +0000,http://sg.finance.yahoo.com/news/biogen-cutting-11-percent-workforce-123801094.html,Biogen cutting 11 percent of its workforce
BIIB,BIIB:UW,BBG000C18861,US open: Stocks edge higher as investors analyse raft of mixed earnings,2015-10-21 14:46:00 +0000,http://uk.finance.yahoo.com/news/us-open-stocks-edge-higher-144600421.html,US open: Stocks edge higher as investors analyse raft of mixed earnings
BIIB,BIIB:UW,BBG000C18861,Biogen tops Street 3Q forecasts,2015-10-21 11:41:34 +0000,http://sg.finance.yahoo.com/news/biogen-tops-street-3q-forecasts-113946073.html,Biogen tops Street 3Q forecasts
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Wall St slides to end rough week on macro, earnings concerns",2015-07-24 20:46:36 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-slides-204636767.html,"US STOCKS-Wall St slides to end rough week on macro, earnings concerns"
BIIB,BIIB:UW,BBG000C18861,Biogen cuts 2015 profit outlook as key MS drug sales slow,2015-07-24 14:59:17 +0000,http://sg.finance.yahoo.com/news/biogen-cuts-2015-profit-outlook-145917657.html,Biogen cuts 2015 profit outlook as key MS drug sales slow
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Wall St set to extend selloff,2015-07-24 13:11:30 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-set-131130838.html,US STOCKS-Wall St set to extend selloff
BIIB,BIIB:UW,BBG000C18861,Biogen beats 2Q profit forecasts,2015-07-24 11:30:48 +0000,http://sg.finance.yahoo.com/news/biogen-beats-2q-profit-forecasts-105755225.html,Biogen beats 2Q profit forecasts
BIIB,BIIB:UW,BBG000C18861,"BUZZ-U.S. STOCKS ON THE MOVE-Apple, Intuitive Surgical, Biogen",2015-07-22 13:05:15 +0000,http://uk.finance.yahoo.com/news/buzz-u-stocks-move-apple-130515822.html,"BUZZ-U.S. STOCKS ON THE MOVE-Apple, Intuitive Surgical, Biogen"
BIIB,BIIB:UW,BBG000C18861,"US STOCKS-Nasdaq hits 15-year high, propelled by Amazon, Microsoft",2015-04-24 17:16:04 +0000,http://uk.finance.yahoo.com/news/us-stocks-nasdaq-hits-15-171604741.html,"US STOCKS-Nasdaq hits 15-year high, propelled by Amazon, Microsoft"
BIIB,BIIB:UW,BBG000C18861,Biogen misses Street 1Q forecasts,2015-04-24 11:22:02 +0000,http://sg.finance.yahoo.com/news/biogen-misses-street-1q-forecasts-112202144.html,Biogen misses Street 1Q forecasts
BIIB,BIIB:UW,BBG000C18861,FDA approves generic version of top-selling MS drug Copaxone,2015-04-17 17:17:20 +0000,http://sg.finance.yahoo.com/news/fda-approves-generic-version-top-165255415.html,FDA approves generic version of top-selling MS drug Copaxone
BIIB,BIIB:UW,BBG000C18861,U.S. prescription drug spending rose 13 pct in 2014-IMS report,2015-04-14 04:00:01 +0000,http://uk.finance.yahoo.com/news/u-prescription-drug-spending-rose-040001106.html,U.S. prescription drug spending rose 13 pct in 2014-IMS report
BIIB,BIIB:UW,BBG000C18861,"US stocks lifted by Shell, pharma deal news",2015-04-08 20:59:44 +0000,http://uk.finance.yahoo.com/news/us-stocks-lifted-shell-pharma-201225174.html,"US stocks lifted by Shell, pharma deal news"
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Wall Street down for 2nd straight day; energy weak,2015-03-24 20:23:32 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-street-down-202332366.html,US STOCKS-Wall Street down for 2nd straight day; energy weak
BIIB,BIIB:UW,BBG000C18861,US STOCKS-Wall St drifts lower; Google buoys Nasdaq,2015-03-24 19:18:23 +0000,http://uk.finance.yahoo.com/news/us-stocks-wall-st-drifts-191823371.html,US STOCKS-Wall St drifts lower; Google buoys Nasdaq
BIIB,BIIB:UW,BBG000C18861,"Exclusive - Biogen shortens name, expands ambitions in Alzheimer's, ALS",2015-03-23 05:04:17 +0000,http://sg.finance.yahoo.com/news/exclusive-biogen-shortens-name-expands-050417968.html,"Exclusive - Biogen shortens name, expands ambitions in Alzheimer's, ALS"
BIIB,BIIB:UW,BBG000C18861,Biogen shares soar on optimistic Alzheimer's drug study data,2015-03-20 18:13:09 +0000,http://sg.finance.yahoo.com/news/biogen-shares-soar-optimistic-alzheimers-181309227.html,Biogen shares soar on optimistic Alzheimer's drug study data
BIIB,BIIB:UW,BBG000C18861,Biogen releases Alzheimer's drug data,2015-03-20 11:41:41 +0000,http://sg.finance.yahoo.com/news/biogen-releases-alzheimers-drug-data-114141842.html,Biogen releases Alzheimer's drug data
BIIB,BIIB:UW,BBG000C18861,"GLOBAL MARKETS-U.S. stocks slip, dollar gains day after Fed view",2015-03-19 20:32:03 +0000,http://uk.finance.yahoo.com/news/global-markets-u-stocks-slip-203203648.html,"GLOBAL MARKETS-U.S. stocks slip, dollar gains day after Fed view"
BIIB,BIIB:UW,BBG000C18861,Biogen tops 4Q profit forecasts,2015-01-29 22:27:47 +0000,http://sg.finance.yahoo.com/news/biogen-tops-4q-profit-forecasts-222139355.html,Biogen tops 4Q profit forecasts
BIIB,BIIB:UW,BBG000C18861,Insight - Big Pharma faces up to new price pressure from aggressive insurers,2015-01-15 06:08:41 +0000,http://sg.finance.yahoo.com/news/insight-big-pharma-faces-price-060841578.html,Insight - Big Pharma faces up to new price pressure from aggressive insurers
BIIB,BIIB:UW,BBG000C18861,Biogen to buy private U.K. company with chronic pain drug,2015-01-12 01:02:36 +0000,http://sg.finance.yahoo.com/news/biogen-buy-private-u-k-010236187.html,Biogen to buy private U.K. company with chronic pain drug
BIIB,BIIB:UW,BBG000C18861,Biogen beats Street 3Q forecasts,2014-10-22 11:24:36 +0000,http://sg.finance.yahoo.com/news/biogen-beats-street-3q-forecasts-112436615--finance.html,Biogen beats Street 3Q forecasts
